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Cervical cancer is the fourth most common cancer in women worldwide. An estimated 
62,000 cases of cervical cancer occur annually in China, accounting for 12% of global 
incidence. Virtually all cervical cancers are related to infection by Human Papilloma Virus 
(HPV): effective HPV vaccines have been developed and vaccination programmes 
introduced in many countries over the last decade. Given the burden of cervical cancer in 
China, it is imperative that effective primary and secondary prevention strategies are 
introduced. Effective introduction of HPV vaccination programmes will require education 
and information strategies that are informed by a comprehensive understanding of the 
knowledge, attitudes and beliefs about HPV infection and its relationship to cervical cancer 
in the Chinese population.  
 
Aims and objectives 
The aims of my thesis are: 1) to systematically review the evidence from the Chinese-
language literature in relation to knowledge of and attitude towards HPV infection and HPV 
vaccination, and 2) to explore knowledge and attitudes about HPV infection, HPV 
vaccination and cervical screening amongst teenagers in Heilongjiang province in China.   
 
Methods 
I undertook a systematic literature review using two electronic Chinese databases – the 
‘Chinese National Knowledge Infrastructure’ (CNKI) database and the ‘Wanfang’ database. 
These were searched from inception through November 30th 2012: MeSH terms were 
applied to both Chinese databases. Manual searching of relevant online journals was also 
undertaken. Following selection of papers based on pre-determined inclusion and exclusion 
criteria, quality assessment was carried out using a modified quality assessment checklist, 
and included studies were classified as good, fair or poor quality. Due to heterogeneity of 
populations and survey instruments a narrative approach was adopted for data synthesis. 
 
I also undertook a questionnaire survey of high-school students in China. Questions were 
designed based on the Health Belief Model, informed by findings from my systematic 
review, and refined through cognitive interviews prior to field work in early 2014. The 
survey targeted students in five public high schools in one middle-income city (Mudanjiang 
city) and two small counties (Ning’an and Hailin) of Heilongjiang province; 3788 young 
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people aged 14-22 years participated. Descriptive statistical analysis was used to summarise 
demographic characteristics; initially differences were identified using the chi-square test. 
Factor analysis was applied to identify attitude patterns and logistic regression analysis 
models were applied to determine the association between attitude (potential predictors) and 
acceptability, attitude and levels of knowledge. 
 
Results 
Forty seven articles met my inclusion criteria and were included in the systematic review.  
All included studies were published between 2006 and 2011; all were cross-sectional 
questionnaire surveys with sample sizes ranging from 100 – 9,865. The quality of included 
studies varied considerably. Included populations ranged from the general public, to young 
people, and health professionals. Awareness of HPV and knowledge of the relationship 
between HPV and cervical cancer, and of the sexually transmitted nature of HPV, were the 
main issues examined. Awareness of HPV was low among all non-health professionals 
groups. Similarly, understanding of the relationship between HPV infection and cervical 
cancer and of the sexually transmitted nature of HPV was low. However, significant 
differences in awareness and knowledge were found, based on urban/rural status, ethnicity 
and age. Uighur women had the lowest awareness and knowledge levels, followed by rural 
women adults, and teenagers.  
 
Acceptability of HPV vaccination varied in terms of the vaccine target recipients (whether 
adult women, or for their daughters), and between health professionals and the general 
public). Reported levels of HPV vaccine acceptability (for women adults themselves and for 
their daughters) were higher in North China compared to South China. Health professionals 
were less willing to accept the vaccine for their daughters than they were to receiving it 
themselves. The cost, source and appropriate age for HPV vaccination were also frequently 
examined issues. Importantly, a high proportion of the health professionals believed that the 
appropriate age for vaccine was over 18 years old for girls.  
 
3788 participants aged 14-22 years were included in the questionnaire survey, with 54% 
females and 20% urban students. Overall awareness of HPV was 13.2% and acceptability of 
the HPV vaccine was 68%. Knowledge levels varied in different content areas; for example 
74% of respondents knew that HPV vaccination is not 100% effective against cervical cancer 
while only 6% knew that poor personal hygiene did not increase the risk of contracting HPV 
infection. Attitudes towards HPV infection and vaccination were also interesting and novel; 
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the greatest concern about HPV vaccination was minor side effects (72%). The highest-rated 
source of recommendations about HPV vaccination was parents (66%), while there were 
concerns expressed about ‘gossip’ in relation to HPV vaccination (51%). No urban/rural 
differences were found in knowledge and attitudes - gender differences existed, but 
depended on specific circumstances. Participants who were willing to accept HPV 
vaccination were more likely to be influenced by others, to report high perceived severity of 
HPV and cervical cancer, to perceive benefits of HPV vaccination and to score well on 
knowledge questions. Participants with high knowledge scores for HPV infection and 
vaccination were more likely to consider HPV infection and cervical cancer to be serious, 
and were less likely to associate HPV infection with stigma. Participants who had high levels 
of awareness of HPV infection were more likely to be influenced by others in relation to 
accepting HPV vaccination.  
 
Discussion 
My thesis has produced new and novel findings in relation to HPV vaccination knowledge, 
attitudes and beliefs in China. Low levels of awareness and knowledge amongst Chinese 
people may be influenced by traditional Chinese culture, which perhaps makes people more 
reluctant to consider issues related to sexual practices. Another possible explanation is that 
people tended to under-report knowledge of HPV when answering the questions in the 
survey in order to conform to social norms in China - these topics are highly sensitive in 
China.  
 
High levels of acceptability of HPV vaccines may have also been influenced by ‘ways of 
thinking’ among Chinese people; their natural inclination is to accept all recommendations 
for vaccination from government agencies – so they may not have thought hard about this 
choice. There is optimism in the Chinese population that cancer can be prevented by 
vaccination – indeed, they are inclined to believe it will prevent disease that can generate 
serious health impacts in the future. Nevertheless, some Chinese people have conservative 
attitudes towards the effectiveness of HPV vaccination and some suspicion of the drug 
companies which produce these vaccines. 
 
There were significant methodological issues in my comparisons of Western and Chinese 
literature. Western literature is more likely to comprise good quality studies – typically there 
are better-defined sampling frames, more valid and reliable instruments and robust 
theoretical frameworks. The difference in quality between Chinese and Western literature 
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arises from the stricter rules for reporting and evaluation in western publications and the 
relatively low publishing standards in Chinese literature. 
 
My thesis also details a number of methodological issues which arose in conducting my 
questionnaire survey – ideally, I would like to follow up the work I have done with a multi-
centre population-based study among teenagers in China (an idea which I will pursue once I 
return to China). This would hopefully provide better quality information on the influences 
of factors such as socio-economic status and family background in determining acceptability 
of HPV vaccination. Nevertheless, my relatively modest, school-based study has, I believe, 
produced results which add to the information available to health care planners and policy 
makers in the field of HPV vaccination in China. 
 
Conclusion 
My systematic review is, to my knowledge, the first to identify and synthesise findings about 
knowledge of and attitude towards HPV infection and vaccination in the Chinese literature – 
as such, it addresses a gap in currently available evidence. Although there are 
methodological limitations in Chinese literature (with more poor quality studies), the results 
still have implications for further health education intervention programmes and health 
policy.  
 
My questionnaire survey was also a ‘first’ in many ways – it explored attitudes towards HPV 
vaccines based on Health Belief Model among Chinese teenagers and examined HPV related 
stigma among mainland Chinese teenagers. Low levels of awareness and knowledge and 
conservative attitudes towards sexually related infections suggest the impact of Chinese 
traditional culture and a range of other social and financial constraints in China. Hence, there 
is a great deal to be done before HPV vaccination can be implemented in China – there are 
educational needs, and in many areas societal and cultural attitudes need to be challenged. 
Significant changes are also need in government policy and investment – these are major 
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1 Chapter 1 Introduction/Background 
1.1 Cervical cancer 
My thesis examines HPV vaccination, cervical cancer and cervical screening in China. I 
begin with an overview of cervical cancer in China and internationally. Cervical cancer is the 
fourth most common cancer among women worldwide [1] and is usually classified into two 
main types: squamous cell carcinoma (SCC),which contributes to 75% of all cervical cancer 
cases, and adenocarcinoma (ACC) [2].  
 
Before invasive cervical cancer (ICC) (commonly called cervical cancer) develops, 
precancerous lesions occur including different grades of dysplasia, ranging from mild to 
severe [2, 3]. Dysplasia, diagnosed based on histology, is a term describing the cell changes 
in epithelium[4]. Grades of dysplasia are defined in terms of the location of cell changes in 
the various layers of epithelium[4]. The nearer the dysplasia occurs to the basal layers, the 
higher the risk of the development of cervical cancer. If the lesions are found in the basal 
membrane, invasive cancer is diagnosed [2-4].  
 
There are two precursor phases of cervical cancer: cervical intraepithelial neoplasia (CIN; 
diagnosed histologically by biopsy) and squamous intraepithelial lesions (SIL; defined by 
cytology screening) [2]. CIN1 (cervical intraepithelial neoplasia grade 1) and LSIL (low-
grade squamous intraepithelial lesions) normally occur in the superficial layers of epithelium; 
CIN2 and HSIL (high-grade squamous intraepithelial lesions) in the intermediate layers; and 
CIN3 and HSIL in the basal layers[4, 5]. Figure 1-1 shows different grades of CIN occurring 
in various layers of epithelium.  
1.1.1 Classification of cervical cancer 
Four systems of classification of cervical cancer are used worldwide [3]. Two systems (the 
Papanicolaou system and the Bethesda system) based on cytology are used for cervical 
screening; two others (the Richart system and the Reagen/WHO system) based on histology 
are used for diagnosis of cervical lesions and cancer[3]. Table 1-1 shows the classification 
systems for cervical screening and diagnosis [3]. Precancerous lesions are often 





Table 1-1:  Classification systems for cervical screening and diagnosis 
Cytological classification (for screening) Histological classification (for diagnosis) 
Papanicolaou system Bethesda system* Richart system* Reagen/WHO system 
I Normal Normal Normal 




Mild dysplasia  
CIN1 
HSIL 
CIN2 Moderate dysplasia 
CIN3 
Severe dysplasia 
IV Carcinoma in situ (CIS) 
V Invasive carcinoma Invasive carcinoma Invasive carcinoma 
ASC-US: atypical squamous cells of undetermined significance; ASC-H: atypical squamous 
cells where it is not possible to exclude a high-grade squamous epithelial lesion.  
* Both the Bethesda system and the Richart system are used in China for cervical screening 
and cervical cancer diagnosis.  
Reproduced from World Health Organization Guide: Comprehensive cervical cancer 
control [5] with a slight adaptation. 
1.1.2 Natural history of cervical cancer 
Precancerous lesions normally exist for an extended period of time, during which regression 
and progression can occur, depending on the various grades of lesions [2, 3] (see Figure 1-1 
and Table 1-2). 
 




Regress  Progress to CIN3 Progress to ICC 
CIN1 57–90% 11% 1% 
CIN2 43–55% 22% 5% 
CIN3/CIS 32%  >12% 
Reproduced from Cervical Cancer Studies on Prevention and Treatment [6]with a slight 
adaptation 
 
Figure 1-1:  Natural history of cervical cancer 
 
Reproduced from World Health Organization Guide: Comprehensive cervical cancer 




Regression: Most precancerous lesions regress spontaneously without treatment [5, 8]. The 
respective likelihood of regression and progression depends on the CIN grade [6, 8]. Up to 
80% of CIN1 lesions will regress, reaching up to 90% in adolescents and young women 
under 25 years old [6, 8]. Up to 55% of CIN2 will regress within 4–6 years [6, 8]. CIN3 will 
regress in one third of the cases [6, 8].  
 
Progression: If precancerous lesions are not treated appropriately, they may progress and 
eventually lead to invasive disease. But prior to the occurrence of invasive cancer,  
precancerous lesions are entirely reversible[5]. The link between HPV infection and cervical 
cancer is now well established; there are four stages in the progression from Human 
Papillomavirus (HPV) infection to cervical cancer, they are: HPV transmission, acute HPV 
infection, persistent HPV infection leading to precancerous lesions, and ICC (invasive 
cervical cancer) [5]. The risk and the time taken for progression to cervical cancer largely 
depend on the persistence of specific HR-HPV (high-risk HPV) types and the grade of CIN 
[8]. The average total time from HR-HPV infection to the development of ICC is 25–30 
years. CIN3 have a 90% likelihood of progressing to ICC, and it is estimated that more than 
12% of CIN3 cases progress to ICC if not properly treated[9]. However, the rate of 
progression to ICC is low for CIN1 (1%) and CIN2 (5%)[4, 6]. Positive cases of HPV 16 and 
18 with low-grade lesions are more likely to progress to high-grade disease and ICC than 
other HPV types [8].  
 
1.1.3 Cervical cancer epidemiology 
An estimated 62,000 new cases of cervical cancer occur annually in China, accounting for 12% 
of the total new cases worldwide, which stands at approximately 528,000 women in 2012[1, 
10]. Around 30,000 deaths from the disease occur annually in China, out of 266,000 deaths 
worldwide in 2012 [1]. As predicted by the World Health Organisation [2], if the incidence 
rates do not drop and instead remain constant over time in China, the annual number of new 
cases of cervical cancer will increase by 85% in the over-65 age group by 2025; a similar 
projection is given in relation to the annual number of deaths by 2025. However, the 
projected burden is smaller in developed countries such as the UK. By 2025, the annual 
number of new cases and deaths is predicted to increase by 27% in the over-65 age group in 
the UK [2]. Figure 1-2 presents the age-standardised incidence and mortality rates in selected 




Figure 1-2:  Age-standardised incidence and mortality rates for cervical cancer in 
selected countries in 2014  
 
 
Adapted from WHO report: Human Papillomavirus and Related Diseases 2014 [1] 
 
Incidence  
WHO and IARC Report 
The WHO reported in 2010 that the age-standardised rate (ASR) of incidence of cervical 
cancer was 7.5 per 100,000 women in China, compared with 14.0 per 100,000 women 
worldwide [1]. However, no national cancer registry exists in China, and the incidence rate 
of cervical cancer is estimated by modelling from sample surveys, which may not be 
representative of China overall. In the WHO report, of 36 Chinese cancer registries, fifteen 
registries (Hong Kong, Macao and Taiwan are excluded because of potential bias) were able 
to monitor cervical cancer incidence rate between 1993 and 2007 with any degree of 
reliability [1]. The age-standardised incidence rate ranged from 0 per 100,000 women in 
Changle to 71.8 per 100,000 women in Yangcheng [1]. The data were also reported in 
Cancer incidence in five continents IX  by the International Agency for Research on Cancer 
(IARC) [10-12]. However, seven of the fifteen registries are Tier one cities (capital city in 
the province or municipalities such as Beijing and Shanghai) where the annual income of 



















































per capita is also higher than average) [1, 10, 11]. The remainder were less-developed 
counties. Incidence of cervical cancer by histology in China have been reported in only five 
cancer registry between 1998-2002, four of which are Tier one city [1]. Thus, direct 
comparisons of the incidence rate between cancer registries and other unavailable regions 
should be made with caution due to limitations on the accuracy and availability of data.  
 
National Centre for Cancer Registries Report 
The incidence rate reported by the National Centre for Cancer Registries of China was 
obtained from 1998 to 2006 based on more than 30 sites (the number of sites varied each 
year). But the proportion of the total population covered was consistently small, standing at 
less than 6% of the national population. In the last three reports (2004, 2005 and 2006), the 
overall cervical cancer incidence rate was 6.0–9.1/100,000 women reported, and no 
substantial difference between urban and rural areas was identified [10, 13-15] .  
 
Cancer Registries Latest Report 
The most recent report on the cervical cancer incidence rate was published in 2014 in 
Chinese[16]. It analysed the trend of cervical cancer incidence and mortality rates among 
Chinese women during 1989–2008, and is considered to be the most comprehensive and 
objective study assessing the burden of cervical cancer in China in the recent decades. The 
overall ASR incidence reported between 2007 and 2008 was 8.53/100,000 women, 
8.11/100,000 in urban areas and 8.89/100000 women in rural areas [16-18].  
 
The data came from 41 cancer registries, which were established in China to record the 
cancer incidence rate and mortality rate up to 31 December 2008[16]. They covered 31 
provinces/autonomous regions/municipalities, including 32,798,187 Chinese women, 
accounting for only 5% of national population in the whole country[16]. Population data 
were obtained from the local police department, where information about citizens’ identity 
was stored[16]. Further, 9 of 41 cancer registries have continuous data through 1989–2008, 
covering approximately 22 million people. The sub-analysis of the trends of the cervical 
cancer burden based on the nine cancer registries was equivalent to the trends from the 41 
cancer registries [16-18].  
 
Differences exist between the people covered by these registries and the national Chinese 
population in terms of the proportion of urban and rural residents[16]. Thus, adjustments 
were made when the incidence and mortality rates were estimated. But economic status (ie 
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annual income), social status, ethnicity, and education levels were not adjusted, suggesting 
that the composition of the population covered by the cancer registries could not be 
considered representative of the national population as a whole. Although bias may exist, the 
estimate of cervical cancer burden provided by this study is thought to be the most reliable in 
China due to the data integration of national cancer registries and the adjustment made to the 
proportion of urban/rural residents[16]. The 41 cancer registries were the selected qualified 
registries based on the requirement of registration quality in Cancer incidence in five 
continents IX  [12, 16]. Figure 1-3 presents the trends in ASR of cervical cancer during 
1989–2008 [16-18].   
 
Figure 1-3:  Trends in age-standardised incidence rate for cervical cancer by 
urban/rural regions in China 
 
 
Reproduced from Tables 1 and 2 of Trend Analysis of Cervical Cancer Incidence and 
Mortality Rates in Chinese Women During 1989–2008. [16] 
 
Trends of ASR in cervical cancer 
The incidence dropped before 1997, but a significant increase was observed from 1999 to 
2008, with an annual increase rate of 8.7% (crude incidence rate) nationally; the increased 
rate was higher in rural regions than urban regions [16-18]. In the contrast, most countries 


















Developed countries have seen an annual decrease rate of 2–4% over the past two decades, 
largely attributable to screening activities[19]. For example, the US [19] had an annual 
decrease rate of 1.8–3.6% (Black and White) during the period of 1975–2009; the UK [19] 
reported that incidences of cervical cancer declined by 4.1% annually from 1983–2007.  
 
A downward trend was generally observed in most developing countries during the period of 
1980–2002, with the exception of Thailand and Uganda; the average annual drop in 
incidence was 1.5–4.1%[19]. However, the data comprised only partial information from 
limited cancer registries, and was thus not representative of large and heterogeneous 
countries such as India and China. During the last decade, data have been unavailable or 
have not been summarised in countries such as Brazil, Philippines, Thailand, India, and 
China [19]. Thus, comparisons cannot be made between developing and developed countries. 
There are difficulties in identifying a typical pattern of cervical cancer incidence in 
developing countries over the last decade.  
 
The potential factors contributing to the trend in the cervical cancer burden in China during 
the period 1989–2008 are as follows. First, the diagnostic criteria for the pathology of 
cervical cancer did not change over the period, and before 2009 no large national cervical 
screening programmes were undertaken. Hence, theoretically, the detection rate would not 
have changed significantly. Second, the downward trend before 1997 may be attributable to 
the improvement in overall health conditions, along with a growing economy in the whole 
country after the Reform and Opening Up policy (major social reform initiative in China, 
which started in 1978). Third, the remarkable upward trend after 2000 may be partly a 
reporting effect, but also potentially due to the cumulative result of exposure to risk factors. 
These include changes in sexual attitudes and behaviours (becoming sexually active at a 
younger age, multiple sexual partners, and unprotected sexual activity, etc.), brought about 
by the social change that followed the Opening Up. Also, the establishment of a primary care 
system is still lacking progress (inadequate primary and secondary prevention, including 
health awareness, education, and screening, etc.). The Reform and Opening Up policy 
brought better health care, but, on the other hand, lifestyle changes led to higher-risk 







The pattern among different age groups 
Age-specific incidence rates comprised fewer than 10 cases per 100,000 women aged under 
44, which is similar to global rates. One peak was observed in most developed countries at 
about 50–60 years after the rise from the age of 30–35 [3]. Two such peaks were observed in 
rates in China[18]. The first one was observed between the age of 40–44 years (18.7/ 
100,000), and the second was at 80–84 year old (13.9/100,000); the rates then dropped 
immediately after the peak. The data were obtained from 1990 to 1992 and reported by the 
National Office for Cancer Prevention and Control in 2008 [18]. Another two-peak pattern 
was reported in 2008, with data from 1998 to 2002. The first peak was seen at age 35–54 
years (6.7–7.3/100,000) and the second one was in women aged over 65 years (8.8–
21.3/100,000) [18]. Geographically limited data sources and a variety in cancer reporting and 
registration systems may explain the different patterns. Most developing countries have the 
pattern of the two peaks of ASR of incidence, with one peak at approximately 45 years old 
and another peak at 55 years old, but not equivalent to those of China [2]. Figure 1-4 
presents the age-specific incidence rate of cervical cancer with two peaks, based on 5 cancer 
registries from 1998 to 2002 [17].  
 
Figure 1-4:  The age-specific incidence rate of cervical cancer in 1998-2002  
 
Reproduced from Epidemiology and Prevention of Human Papillomavirus and Cervical 
Cancer in China and Mongolia [17] 
The data was obtained from on 5 cancer registries.  
 
It is difficult to explain why two peaks in the rates occurred in China. The data came from 5 















31 provincial regions. Thus, the two-peak pattern generated is probably not reliable or 
representative.   
 
Geographical differences  
Incidence rates are also affected by geographic area – although again there are limitations on 
the accuracy of the data. Yangcheng of Shanxi Province in China has a very high incidence 
rate—81 cases per 100,000 women in 2008 [17]. Kashi Prefecture in Xinjiang Uyghur 
Autonomous Region had an increase in the prevalence of cervical cancer from 459 
cases/100,000 women in 1991 to 622 cases/100,000 women in 2007. Between 2010 and 
2011, the prevalence of cervical cancer was 407 cases/100,000 among low-income Muslim 
Uyghur women aged 30–59 years [20]. As an incidence rate of cervical cancer in Xinjiang 
region cannot now be obtained, it is more difficult to make comparisons between Xinjiang 
region and other regions in China and to estimate the level at which Xinjiang stands.  
 
Mortality 
WHO and IARC Report 
The WHO reported in 2010 that the age-standardised mortality rate for cervical cancer was 
4.5 per 100,000 women in China and 7.8 globally. It interpreted data on China obtained from 
the Third National Death Survey from 2004 to 2005 for rural and urban populations in three 
regions (East, Middle, and West) [2]. The Third survey used multistage stratified cluster 
sampling with proportional allocation, covering 11% of total population in 31 provinces, 
autonomous regions, and municipalities [10, 16]. The mortality rate in the 2014 WHO report 
was lower (3.4) - an estimation for 2012 by modelling using data in 23 cancer registries 
(covering 6% of the population) between 2004 and 2010 [1]. 
 
Cancer Registries Latest Report 
The recently published Chinese-language study (2014) summarised the crude and age-
standardised mortality rate of cervical cancer in the period 1989–2008[16]. The study was 
based on 41 cancer registries in China, covering 5% of the total Chinese population. The 
urban ASR mortality rate was 1.58 per 100,000 women, and the  rural ASR mortality rate 
was 2.82 per 100,000 women in 2008; the overall ASR was 2.25/100,000 women [16].  
 
ASR trends in cervical cancer 
The cervical cancer mortality rate initially experienced a downward trend, followed by an 
upward trend during the period 1989–2008. Evidence suggested [10] the downward trend of 
10 
 
mortality occurred between 1987–1989 and 1997–1999. In rural areas the decrease in 
mortality was found to be 34% in women aged over 50 years, although the average rate 
remained constant over the period. In urban areas, the mortality reduction in women aged 
over 50 years was greater, at 61%, but remained low and stable for women younger than 50 
[10]. After 2000, an upward trend in mortality rates was found, which was an 8.1% annual 
increase in crude mortality rates (7.3% annual increase in urban areas after 2001, and the 
rural annual increase was not significant after 2001) [16]. Figure 1-5 presents the trends in 
mortality ASR of cervical cancer.  
 
Figure 1-5:  Trends in age-standardised mortality rate of cervical cancer by 
urban/rural regions in China 
 
Reproduced from Tables 1 and 2 of Trend Analysis of Cervical Cancer Incidence and 
Mortality Rates in Chinese Women During 1989–2008. [16] 
 
The factors contributing to the mortality pattern are generally the same as those for the 
incidence pattern. The Reform and Opening Up policy starting from 1978 was the major 
influencing factor. It is thought to have been associated with the reduction of incidence and 
mortality in the earlier years, but potentially increased the likelihood of exposure to risk 
factors without an ability to access prevention programmes in time.   
 
Geographical difference  
Mortality rates vary by geographic area [11]. Western and central China had the highest 
mortality rates for cervical cancer (36/100,000 women in Wudu County, Gansu Province and 













geographic comparisons are shown in Figure 1-6. Generally, western and central China are 
deprived regions compared to eastern China, and regional inequalities in health exist in 
China [21, 22]. Western regions (e.g. Xinjiang, Qinghai) in China are lacking of adequate 
health recourses and health services, which may make residents less likely to have constant 
access to health care than residents in eastern more developed regions. Further, deprived 
people (in rural regions) tend to have intercourse for the first time and give birth at a younger 
age - generally three and four years earlier than people in urban regions [11]. These factors 
may explain the regional differences in incidence and mortality rate.  
 
Figure 1-6:  Age-standardised mortality rate for cervical cancer in different regions of 




There are also variations in cervical cancer mortality between different ethnic groups. The 
three ethnic groups with the highest mortality rates are the Uygur ethnic group in Xinjiang 
(17.2 per 100,000), the Mongolian ethnic group (15.7), and the Hui ethnic group (12.2) [18]. 
These three groups mostly reside in specific autonomous regions. They are very closely 
related to geographical areas and socio-economic conditions. For example, Xinjiang 
autonomous region, located in the West China, is a deprived area with less developed health 
care and education systems.  
 
Five-year survival 
Some data suggest the five-year relative survival rate for cervical cancer in the period 2000–
2002 in China was higher (67%) than in most developed countries, such as the UK (58.6–
63.5%) and the US (65.8%) [23]. But the 95% confidence interval is too wide to be reliable, 
the reliable range being 48–79%. Access to the latest data in China (covering the last decade) 
is not yet available. The lack of registries and incomplete health informatics systems may 















stage of cervical cancer. The earlier the stage of cervical cancer, the higher the five-year 
survival rate. A worldwide multicentre study [24] (37 countries) of 11,775 patients treated 
between 1999 and 2001 reported that Stage I (the carcinoma is strictly confined to the cervix) 
cervical cancer patients had an over 75% overall survival rate at five years, and rate was over 
65% for Stage II (the cervical carcinoma has invaded beyond the uterus, but not to the pelvic 
wall).  
1.1.4 Summary 
The incidence pattern typically seen in many countries around the world (one peak of 
incidence ASR) is not so recognisable in China. Although the two-peak pattern was observed 
in many developing countries (in Asia and Africa), the pattern in China is not typical of a 
developing country, as it was different from other countries (India and Africa) in terms of the 
age range of each peak [2]. Developed countries in America, Europa, and Oceania have 
generally the same incidence pattern, with only one peak at approximately 45 years old [2].  
 
The mortality trend (first downward, then upward from the year 2000) in China appears to 
relate to the economic impact and social transition of the recent decades.  
 
The transition of demography and economy in the last two decades in China may explain the 
different pattern of incidence and mortality of cervical cancer from that of other countries. 
The Reform and Opening Up policy (market economy reform) lead to the growth of the 
economy, the improvement of health conditions, and the migration of people for better jobs 
in big cities. It also contributes to the changes in sexual attitudes: having sexual intercourse 
at an earlier age, multiple sexual partners, and less monogamous relationships long-term 
separation from families (because of the migration for work).   
1.2 Human Papillomavirus (HPV) 
Given the focus in my PhD on HPV vaccination, I report some background information on 
HPV. HPV infection is one of the most common sexually transmitted diseases. Worldwide, 
the estimated age-adjusted global prevalence of HPV is 11.7% [25]. Prevalence will be up to 
30% in women under 25 years old [4]. The overall HPV prevalence among women is higher 
in developing regions (14.3%) than developed regions (10.3%). But, since data concerning 
HPV prevalence cannot be obtained for most developing countries - especially in Africa, 
Central Asia and East Europe (See Figure 1-7), it is difficult to examine differences between 
low-resource and high-resource countries[2]. China has an overall HPV prevalence of 12.2%, 
13 
 
but this is likely to be an underestimate because of the lack of available and reliable data 
sources in China (the available data were obtained from research-based studies in various 
parts of China, mostly in the developed regions)[2].  
 
Figure 1-7:  World prevalence of HPV among women with normal cytology 
 
Reproduced from WHO 2014 on Human Papillomavirus and Related Diseases [1] 
 
A trend was reported in the female age-specific distribution of HPV. HPV prevalence peaks 
among young women under 25 years old in most geographical regions worldwide [2]. 
Further, a second peak of prevalence, in women aged 45 years or older, is found in Central 
America, South America, and Africa. In contrast, HPV prevalence in males generally 
remains stable or declines slightly after the peak [26]. 
 
Chinese studies [11] also reported two peaks of HPV prevalence among Chinese women 
(discussed later in this chapter). But the pattern is unlike the one in developed countries, 
where a general downward trend was observed. The social transition in China over the past 
decades along with the Reform and Opening Up policy may explain the difference from 
other countries in the world.  
 
The age-specific overall HPV prevalence in China follows an expected pattern, especially 
when taking into account the pattern of ASR incidence of cervical cancer. Similarly, two 
peaks were observed and the peak of HPV prevalence occurs slightly earlier than ASR 
incidence of cervical cancer. The first peak is among 15–24-year-old women, with a 16.2% 
prevalence, and the second peak is at 35–39 years, with a prevalence of 18.6% [11]. The 
differences from developed countries are explained by the new acquisition or reactivation of 
latent HPV infections [27]. 
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1.2.1 The natural history of HPV infection 
Most HPV infections are transient and asymptomatic. Between 60 and 80% of new HPV 
infections clear within 12 months, and 90% within 24 months [4]. Only 10–30% of 
infections will persist over 1 or 2 years and thus have the potential to lead to the 
transformation of epithelium in cervix. Studies have shown that the average duration of 
infection is usually 4–20 months (the median duration is 8 months), and HR-HPV types will 
persist longer than LR-HPV types[28]. Between 1 and 10% of persistent HPV infection 
cases may develop dysplasia in 0.5–5 years and finally progress to cancer through several 
stages[4].  
1.2.2 Virology and immunology of HPV  
Structure of the HPV virus 
The HPV virus is a non-enveloped, double-stranded segment of DNA in the Papovaviridae 
family, with the DNA wrapped by two capsid proteins: the major protein is L1, and the 
minor one is L2. Apart from structural genes (L1 and L2), several early genes (E1, E2, E4, 
E5, E6 and E7) help to interact with the host genome [6]. These genes and proteins are used 
for virus transcription and replication, are expressed in various layers of epithelium, 
stimulate the proliferation of infected basal cells, and are internalised by host cells, finally 
leading to invasive disease [6]. 
 
Clearance of HPV virus 
Most HPV infections are transient and are automatically cleared by the host immune 
response without causing lesions [29]. But the mechanism behind this is still not well 
understood. Two possible explanations are: complete viral clearance and extremely low 
levels of virus replication with incomplete viral expression. HPV infections that are not 
cleared can persist for a long period in the infected epithelium, which can progress to low-
grade lesions (LSIL, CIN1) or directly to high-grade lesions (HSIL, CIN2, CIN3) and in turn 
progress to invasive cancer [29]. 
 
Immunology and integration with host cells 
Two pathways can be identified which are involved in the immunology of HPV infections of 
host cells [29]. First is a humoral immune response, taking approximately 6–18 months and 
producing neutralising antibodies against a type-specific L1 epitope. The antibodies are 
useful to prevent an initial HPV infection but not sufficient to fight against new infections 
[29]. Second, the HPV makes contact with the basal membrane and starts integration with 
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the epithelial cell and basal membrane by L1 of the HPV virus. However, the integration 
process is still unclear [29]. After integration, L1 and L2 are shed from the epithelial cell and 
the L1 antibody does not work. Then cytotoxic T cells start to react, recognising the 
expressed viral proteins (E6 and E7) and in turn fight against HPV epitopes. The 
effectiveness of the host’s immune response affects how well the HPV infection is cleared. 
People with HIV are at higher risk of getting persistent HPV infections [29].  
 
Influencing factors of HPV virus persistence 
Several factors affect the persistence of the HPV virus in the human body. They are: specific 
types of virus (HR-HPV, LR-HPV), co-infection with multiple HPV types, and HPV viral 
load [30]. First, HR-HPV, such as HPV 16 and 18, present a higher risk of progressing to 
high-grade lesions. Epidemiological studies have shown HPV 16-positive women had a 17% 
cumulative incidence rate of developing high-grade lesions; the rate is 13% for HPV 18-
positive women. In contrast, the 10-year risk for LR-HPV-positive women is 3% [30]. 
Second, co-infection with multiple HPV types is another factor in HPV viral persistence, but 
the mechanism for this is not clear. It is difficult to determine whether it is the modification 
of the persistence of a given HPV type or of the progression to high-grade lesions/invasive 
cancer that contributes to the persistence of the HPV virus by co-infection with multiple 
HPV types[30]. Third, the HPV viral loads, defined by the number and size of HPV, are 
considered to be one of the factors of HPV viral persistence. Studies have shown low viral 
loads have a low risk of developing precancerous lesions/invasive cancer. However, high 
viral loads have not been clearly confirmed to be associated with a high risk of development 
of cervical cancer, as some of the highest viral loads have been found to contribute to the 
regression of low-grade lesions [30].  
1.2.3 HPV and cancer (especially cervical cancer) 
The 2008 Nobel Prize [31] was awarded to Harald zur Hausen for his discovery of “human 
papilloma viruses causing cervical cancer”. He assumed in the 1970s that HPV caused 
cervical cancer, found novel HPV-DNA in cervical cancer biopsies, and thus discovered 
HPV 16 type in 1983 and cloned HPV 16 and 18 from cervical cancer patients in 1984 [31]. 
Figure 1-8 presents the structure of the HPV virus and how it integrates into tumour cell 




It has been 40 years since the initial hypothesis that HPV causes cervical cancer. Many 
biological and epidemiological studies have confirmed the association between HR HPV and 
cervical cancer.  
 
Biological evidence 
There are no confirmed biological mechanisms that completely explain how HR HPV causes 
cervical cancer, but the most accepted one is that the first step of HPV infection - the 
interaction between the capsid protein of HPV (eg L1) and the membrane of cells at the basal 
layer of the epithelium [32]. The viral particles are thought to bind to another component of 
the cellular membrane. E6 and E7 oncoproteins have been found to play a key role in the 
cervical cancer carcinogenesis by altering the immune-response-related pathways and 
cellular transformation [32]. E6 and E7 are found to deregulate fundamental cellular evens, 
such as cell cycle, apoptosis, DNA repair, senescence, and differentiation. They also 
facilitate damage to DNA and the progression towards malignancy [32].  
 
Figure 1-8:  The structure of HPV and the integration with epithelial cells.  
 
 







Epidemiological evidence  
A systematic review and meta-analysis [33] published in 2008 suggested a strong and 
consistent association between persistent HPV DNA and CIN2-3/HSIL+. Forty-one studies 
(36 from Europe and North America) of over 22, 500 women were included in the review. 
The RRs (relative risks) ranged from 1.3 (95% CI: 1.1–1.5) to 813.0 (95% CI: 168.2–3229.2) 
for CIN2-3/HSIL+ compared with <CIN2-3/HSIL+; 92% RRs were above 3.0. The variation 
in the magnitude and precision of RRs was influenced by the reference group - uninfected 
women, women with mixed HPV infections, and women with transient HPV infections. The 
magnitude of association was stronger with a longer duration of infection (12 months), wider 
testing intervals, and the use of an HPV-negative reference group [33]. 
 
There are more than 100 types of HPV. Eighteen of these types are carcinogenic (HR HPV), 
(eg HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82) [34]. 
The remaining genital types (LR HPV) (eg HPV types 6,11,42,43, etc.) are of low or no 
carcinogenic risk [34]. HR-HPV is estimated to cause 99.9% of cervical cancer cases, 90% 
of anal cancer cases, and 40% of external genital cancers cases (of the vulva, vagina, and 
penis) [34] [35]. It is possible for multiple HPV types (LR HPV and HR HPV) to be 
identified in one infected person. But the risk of developing cervical cancer with multiple 
HPV infections is not clear [4].   
 
The means of HPV transmission currently known are: penile-vaginal intercourse, penile-anal 
intercourse, skin-to-skin genital contact (eg oral-genital, penile-vulvar, although this is less 
common than transmission through penetrative intercourse), and transmission to a new-born 
baby from the cervix of an infected mother (uncommon) [34]. 
1.2.4 Cofactors of HPV infection and cervical cancer 
There are multiple factors influencing HPV acquisition and persistence as well as the 
development of cervical cancer. Three groups of cofactors are identified as playing an 
important role in the etiology and development of cervical cancer [36]. They are:  
 environmental factors [36], including hormonal contraceptives, tobacco smoking, 
multiple sexual partners, and co-infection with other STI agents;  
 viral factors [36], including viral load and viral integration;  




Viral and host factors were discussed above in the section on HPV virology and immunology, 
and the evidence for environmental factors is mainly shown in this section.  
 
The mechanism by which environmental factors influence cervical cancer development in 
terms of virology, immunology, hormone response and genetic susceptibility, etc is not 
clearly understood; the identified mechanisms are plausible rather than certain. Further 
studies are ongoing to explore stronger biological evidence of this mechanism. 
 
The last decade experienced a rapid growth in epidemiological studies [3] [36] [37, 38] 
addressing the role of oral contraceptives, multiple lifetime sexual partners, smoking, etc. on 
the acquisition of HPV infection and the development of cervical cancer. Due to the 
increasing number of epidemiological studies, a series of systematic reviews and meta-
analyses [39-43] were conducted to summarise the pooled effects, which provide sound 
evidence in this area.  
 
Since 2005 the International Collaboration of Epidemiological Studies of Cervical Cancer 
(ICESCC) has conducted a series of collaborative reanalyses (meta-analysis) regarding the 
role of environmental factors in cervical cancer [39-42]. It provides solid evidence in terms 
of an epidemiological perspective. The environmental cofactors related to HPV infection and 
cervical cancer are listed and discussed below. 
 
Sexual behaviours (the lifetime number of sexual partners, age of sex debut, condom use) 
ICESCC organised a collaborative analysis from 21 epidemiological studies [39], assessing 
the role of lifetime number of sexual partners and age at first sexual intercourse on cervical 
cancer. Half of the studies were from less developed countries. The meta-analysis included 
15,461 women with cervical cancer and 29,164 controls. The RRs was 2.78 (95% CI: 2.22–
3.47) times higher among women who had had 6 or more lifetime sexual partners compared 
with those who had had only 1 partner. The RRs was 2.05 (95% CI: 1.54–2.73) times higher 
among women whose first had sexual intercourse at 14 years old or under compared with 
those aged 25 years or older. The adjustment included age, study, reproductive factors, and 
sexual behaviours [39]. But HPV status cannot be obtained from all included studies, which, 
to some extent, undermines the strength of the association. 
 
There are no consistent results to suggest whether condom use is associated with the risk of 
HPV infection (either increased or reduced). But recent data showed that consistent condom 
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use reduces the risk of male-female genital HPV infection. Further, condom use is associated 
with regression of dysplasia [4, 28]. 
 
Reproductive factors (number of full-term pregnancies, age at first full-term pregnancy) 
ICESCC conducted a meta-analysis in 2006 [41] of 16,563 women with cervical cancer and 
33,542 controls in order to assess the association between reproductive factors and cervical 
cancer. Twenty-five epidemiological studies were included, half of which were from less 
developed countries (such as Nigeria, Philippines, Mexico, Thailand,etc) [41]. Associations 
were found between the number of full-term pregnancies and age at first full-term pregnancy 
and cervical cancer. The relative risk (RR) was 1.76 (95% CI: 1.53–2.02) for 7 or more full-
term pregnancies compared with 1–2. The RR was 1.77 (95% CI: 1.42-2.23) for those aged 
under 17 years at their first full-term pregnancy compared with those aged 25 years or under 
[41]. The adjustment on the potential confounding included study, age, lifetime number of 
sexual partners, and age at first sexual intercourse.  
 
The hypothesised mechanisms include: high concentrations of oestrogen and progesterone 
during pregnancy, leading to columnar epithelium ectopy (equamo-columnal), thus 
increasing the likelihood of exposure to HPV infection [36]; hormonal changes during 
pregnancy may accelerate cervical carcinogenesis (by enhancing gene expression)[36]; and 
immune depression caused by pregnancy, which may affect the effectiveness of the immune 
response in clearing HPV infections [36].  
 
HIV infection 
High-risk and multiple HPV types are more prevalent among HIV-positive people, 
especially among men who have sex with men (MSM) [37, 38]. Biological studies suggest 
that immune response is involved in the clearance of HPV infections [32]. Epidemiological 
studies found that the incidence of cervical cancer was higher in immune-compromised 
individuals than normal ones[32]. However, it is unclear whether it is the 
immunosuppression caused by HIV infection or the higher-risk sexual behaviours among 
HIV-infected people that increase the risk of HPV infection acquisition and persistence.  
 
Long-term use of oral contraceptive pill (OCP) 
Epidemiological studies [40, 43] have shown that the long-term (more than 5 years) use of 
OCP is associated with HPV infection. A systematic review and meta-analysis in 2003 [43], 
including 28 studies (16 of developed countries) with 12,531 women with cervical cancer 
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and 26,711 controls, reported 5 or more years’ use of OCP led to a 1.6 times increased risk 
of cervical cancer compared with those who had never used an OCP (RR=1.6, 95% CI:1.4–
1.7). The relative risks were identified as similar for women with ACC and SCC. Another 
collaborative analysis (ICESCC) in 2007 of 24 studies worldwide (half of which were from 
less developed countries) confirmed the association [40]. The analysis included 16,573 
women with cervical cancer and 35,509 controls, and confirmed that 5 or more years’ use of 
OCP increases the risk of invasive cervical cancer to 1.90 times that of those who had never 
used OCP (RR=1.90, 95% CI: 1.69–2.13); while the risk declined when use stopped [40]. 
The possible mechanism [36] of the effect of oral contraceptives is that oestrogens or 
progestagens enhance HPV gene-expression in the cervix through hormone response in the 
viral genome and hormone receptor route.  
 
Although long-term OCP use is responsible for HPV infection (1.5% of Chinese women use 
OCP)[2], tubal ligation and the use of intrauterine contraceptive devices are the most 
commonly used contraceptive methods in China, and neither has been found to be associated 
with HPV infection [17].  
 
Smoking 
Smoking is another risk factor for HPV infection, as it is thought to suppress immune 
function, reducing the immune response in the cervix as well as affecting the metabolism of 
female hormones [36]. The tobacco-related carcinogens are also thought to damage gene 
expression in the cervix [36]. Epidemiological studies [42] confirmed the association 
between tobacco smoking and cervical cancer. A meta-analysis (ICESCC) of 23 studies (half 
from less developed countries) including 13,541 women with cervical cancer and 23,017 
controls in 2005, reported that increased relative risks of SCC were identified as 1.6 times 
higher among current smokers than among those who had never smoked (RR=1.60, 95%CI: 
1.48–1.83) [42]. However, an association between smoking and ACC was not found. No 
clear risk trend was found from when smoking ceased. However, due to heterogeneity 
between studies as well as the potential confounding effect of HPV infection status, the risks 
of smoking in relation to cervical cancer and the worldwide burden still need to be accurately 
explored and quantified. 
 
Nutrition 
A 2005 review [44] examined the potential role of diet and nutrition in cervical cancer. It 
included 33 studies in all, but 2 studies were conducted in developed countries. The evidence 
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was classified as convincing, probable, possible, and insufficient based on the World Cancer 
Research Fund and American Institute for Cancer Research, taking account to the strength of 
both epidemiologic studies and mechanistic or laboratory evidence [44]. There was no 
convincing evidence that diet and nutrition played a role in cervical carcinogenesis. There is 
a possible protective effect [44] of certain diets on HPV persistence, principally those diets 
rich in fruits, vegetables, vitamins C and E, beta-and alpha-carotene, lycopene, 
lutein/zeaxanthin, and cryptoxanthin. The probable protective effects [44] of diets on 
cervical cancer pertain to  diets rich in folate, retinol, and vitamin E, and possibly vegetables, 
vitamins C and B12, alpha-carotene, beta-carotene, lycopene, lutein/zeaxanthin, and 
cryptosanthin [44].  
 
The plausible mechanisms [36] here are that dietary factors may prevent HPV infection from 
progressing (transient to persistent). For instance, vitamins A and E regulate cell 
differentiation and proliferation. Vitamins C and E and other dietary constituents, acting as 
antioxidant nutrients, scavenge free radicals and oxidants, and could also modulate immune 
response and decrease viral replication and gene expression. 
 
Summary  
The association between environmental factors and cervical cancer has been explored 
through biological mechanisms and epidemiological studies. No confirmed mechanisms 
have been identified. In terms of epidemiological evidence, outputs from meta-analyses have 
provided more convincing evidence than individual studies. But the strength of the 
association is undermined by some uncontrollable factors. Regarding the ICESCC [39-42] 
study design, of the 25 epidemiological studies, 9 were cohort studies (all were in developed 
countries), 12 were population-based case control studies (10 were of developed countries), 
and the rest were hospital-based case control studies (all except two of which were in 
developing countries). It is said that the ICESCC [39-42] results could represent 85% of 
known published epidemiological studies worldwide and those not included due to their very 
small sample size had similar findings. But more prospective cohort studies are needed, 
especially in developing countries, to reduce the selection or recall bias that occurred in the 
case control studies. The heterogeneity between ICESCC studies [39-42] in the meta-
analysis (which is difficult to avoid) is another potential factor undermining the findings 
relating to risks from environmental factors. Thus, the magnitude of the overall risk is 
uncertain and the possible subsequent cervical cancer burden and public health implications 
generated by the risk cofactors worldwide remain unclear.  
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1.2.5 HPV prevalence and type distribution in China 
HPV prevalence in the general population 
In 2012, a pooled analysis [11] based on 17 population-based studies of 30,207 women was 
conducted in China. The overall age-standardised HR HPV prevalence was 16.8%, and there 
was no significant difference between rural and urban regions. HPV 16 was the most 
common type in the survey, followed by HPV 58 and 52 [45-47].  
 
The 17 cross-sectional population-based studies were conducted in five urban and nine rural 
regions of China (covering 9 provincial regions) from 1997 to 2008 [11]. The study locations 
included the Province of Shanxi, Guangdong, Liaoning, Jiangsu, Xinjiang, Henan, Jiangxi, 
and big cities like Shanghai and Beijing. The studies were supported by the Cancer 
Institute/Hospital of the Chinese Academy of Medical Sciences (CICAMS), in collaboration 
with the Cleveland Clinic (Cleveland, Ohio, USA), IARC, (Lyon, France), and PATH 
(Seattle, Washington, USA) [11, 48]. The participants were women who had never been 
screened for cervical cancer. They were tested by using Hybrid Capture Assay (HC2) and 
GP5+/6+ mediated PCR and PCR (MY09/11 primer) to detect the presence of HPV. [49] 
[45-47]. The HPV prevalence reported in China was largely dependent on the target 
population, study location, and the lab methodology (the DNA detection methods). 
 
In 2007, a multi-centre study was conducted by the Chinese Academy of Medical Sciences 
to determine the distribution of types of HPV among women from seven areas in China [48, 
50]. Around 1,200 women were included in the study; HR HPV DNA was detected by using 
the SPF10 LiPA25 version 1 assay, and histological diagnosis was used to confirm the type 
of invasive cervical cancer. In terms of SCC, HPV 16 (76.7%) and HPV 18 (7.8%) were the 
most common, together accounting for 84.5% of SCC, followed by HPV 31 (3.2%), HPV 52 
(2.2%), and HPV 58 (2.2%). As for CIN 2/3, HPV 16, 58, 31, 52, and 18 were common, 
accounting for 68.7%, 12.5%, 7.4%, 6.5%, and 3.3% of cases respectively [50]. So, the two 
HPV vaccines would theoretically prevent 84.5% of SCC and 72% of CIN 2/3 for Chinese 
women. The results were similar those produced by the WHO report. The HPV 16/18 
prevalence among women with normal cytology was 2.3%; it was 31.9% in women with 
low-grade lesions, 45.7% in women with high-grade lesions, and 71.0% in women with 
cervical cancer [2]. 
 
The HR reported HPV prevalence in China was higher than in the WHO report (12.2%), 
which was from five cancer registries a decade ago. This may be explained by the population 
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and the time period selected. A systematic review on the HR HPV prevalence conducted by 
IARC in the WHO report included studies on Taiwan and Hong Kong [2] and did not 
include all the literature pertaining to mainland China. To avoid bias, Taiwan and Hong 
Kong studies have been excluded in this review due to their different cancer registry system 
and preventive strategies. The WHO report of 2010 updated previous Chinese data from 
2002[2]. The HR HPV prevalence was similar to that in southern India (16.9%) [51], but 
higher than in many other low-resource countries in Asia, such as Thailand (3.9–9.1%) [52], 
Vietnam (1.6–11.4%), [52] and Pakistan (2.8%) [53]. Mongolia has a substantially higher 
HR HPV prevalence than most of Asia, at 35% [11].  
 
 HPV prevalence in different age groups 
With regard to the age-specific prevalence of HR HPV, two Chinese studies (a pooled 
analysis of 17 studies [11] and a multi-centre study [54]) reported their results in terms of 
different regions. Only one peak was identified in high-risk HPV prevalence from 15–59 
year old women in urban and rural residence. The peak was observed in urban women at age 
of 15–24 while in rural women at age of 35–49 [11]. Figure 1-9 shows the trends. However, 
two peaks were found in the HR HPV prevalence, one in the under-25 age group, and the 
other in the 40–44 age group [54]. Among four regions selected for the study, Shanghai had 
a relatively high overall prevalence of HPV (HR and LR) while a lower overall HPV 
prevalence was found in Xinjiang [54] (Figure 1-10).  
 
Figure 1-9:  Age-specific prevalence of high-risk HPV by urban/rural residence  
 
Reproduced from Prevalence of human papillomavirus and cervical intraepithelial 














HPV prevalence in high risk groups 
Female sex workers and HIV-positive men and women have a significantly higher 
prevalence of HR HPV in China [38, 55, 56]. A study in Zhejiang in 2012 involving 288 
female sex workers (FSW) reported an HR-HPV prevalence of 66.7% among FSW. The 
most frequent HR HPV types are HPV 16, 58, and 52. Rates of cervical abnormalities of 
20.8% were found among FSW [55]. A Hubei province study in 2012 reported a 36.5% HR-
HPV infection rate and a 33.5% rate of multiple HPV infection in HIV-positive Chinese 
women. HPV 16, 52, and 18 were the types most frequently found among HIV-infected men 
and women [56]. A study carried out in Beijing in 2013 with 212 HIV-infected participants 
reported that a prevalence rate of 61.3% for anal HR-HPV was found in HIV-infected men 
who have sex with men (MSM), and 45.8% of MSM had more than two HPV types [38]. All 
the studies were cross-sectional, regional (more developed regions) research-based ones, and 
the reported sample collection and laboratory tests were performed by trained and 
experienced physicians in local CDC and hospitals, so the data should have been accurate. 
However, the study design and the target population limited the representativeness of the 
results.  
 
Figure 1-10:  Age-specific overall HPV prevalence in four regions of China in 2006-
2007  
 
Adapted from figures in Prevalence of type-specific human papillomavirus and pap results 
in Chinese women: a multi-center, population-based cross-sectional study [54] 
The four regions are from West to East China (Xinjiang, Shanxi, Henan and Shanghai) 





















Challenges in obtaining accurate data in China 
There are some challenges in attaining accurate information about HPV prevalence in China. 
They are listed below: 
 
Current cancer registries do not cover the whole population of China. Up until 2008, 41 
cancer registries were available in China, covering 5% of the total population, including 
urban and rural regions[16]. The registries have expanded in the last few decades, but there 
are differences regarding the number of registries points, the number of people reached, and 
the quality of the data reported every year. Only nine cancer registries have continuous data 
(incidence and mortality rate) for the period 1989–2008[16].  
 
Lack of national screening programme. No national screening programme exists to record 
data relating to cervical cancer, including HPV prevalence.  
 
Selection bias in research-based studies. This arises from opportunistic screening and short-
term (2–3 years) research-based studies. They are usually multi-centre studies, which are 
more representative than individual studies. But the target population may be confined to 
some specific areas of China where the prevalence (or incidence or mortality) is either high 
or low. HPV prevalence would be either overestimated in rural regions or underestimated in 
urban regions[48].  
 
Selection bias of urban/rural sites. Researchers reported that no urban/rural difference in 
terms of HPV prevalence have been found. This may be due to the selection bias of urban 
sites and rural sites. The urban women were only from big cities, and the rural women came 
from high-burden counties[48].  
 
HPV detection methods differ between urban and rural regions. GP5+/6+ mediated PCR 
detection is used in urban areas, and HC2 assay is used in rural areas. HC2 assay has higher 
sensitivity and is more standardised and easily controlled than PCR detection [48, 57]. 
 
The delay in reporting and lack of updates. The most recent data on HPV prevalence in 
China is from 2008, but the report became available only in 2012. Currently there are no data 
available on HPV from 2009–2013. The delay in reporting and updates may impede policy 
making as well as the implementation of prevention programmes.  
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1.2.6 HPV in China: Summary 
The public health burden caused by HPV infection in China is high among the low- and 
intermediate-resource countries in Asia, but not the highest. The best estimate of HPV 
prevalence is 16.8% based on 17 studies of approximately 30,207 women. No time trend or 
geographical pattern has been identified until now. Since the source of the data is currently 
limited in terms of geographical regions, time period, study design, target population, and 
detention methods, it is possible that some trends or patterns might be found later when more 
accurate and reliable data is available. The challenges for establishing accurate information 
regarding HPV prevalence and the potential public health burden have been identified, and 
they mainly concern defects in the health system. But any national prevention approach will 
not be established in the near future and thus, the most possible and realistic way might be to 
combine research-based studies and current cancer registries together to get the reliable 
disease burden and achieve prevention goals. High-burden areas and high-risk groups might 
be the priority of the prevention strategy, but issues like how to access high-risk groups such 
as female sex workers pose another challenge.  
1.3 Cervical cancer prevention 
An ideal national cervical cancer programme should include four stages:[5] 
 Primary prevention (education, HPV vaccination, male circumcision, etc.)[58]  
 Secondary prevention (cervical screening) 
 Diagnosis and treatment (follow-up of positive patients, treatment on precancer and 
ICC)[5] 
 Palliative care (symptomatic relief, compassionate care, and involvement of the family 
and community)[5] 
 
From the public health perspective, primary and secondary prevention are the most effective 
way to reduce incidence and mortality rates of cervical cancer at the population level, but the 
provision of vaccines or screening should not be non-organised and opportunistic[5].   
 
The WHO has created a checklist [58] for cervical cancer prevention and control at the 








Table 1-3:  Checklist for cervical cancer prevention and control programme  
Prevention and control Target population 
National policy or plan General population 
National guidelines Health workers 
Financial and technical resources  
National or local cancer registry Women (incidence and mortality) 
Health education and promotion programme General population (males and females) 
HPV vaccination 9–13 year old girls* 
Cervical cancer screening with follow-up treatment 30–49 year old women 
Referral system  Screening women (precancerous lesions and 
ICC) eg HPV triage in England. colposcopy 
referral indications: cytology>=low-grade 
lesions or HPV positive[59] 
Monitoring system  Women at any of the stage of HPV 
vaccination, screening, and treatment 
Adapted from WHO guidance [58] 
* The age identified is generally based on western countries. The appropriate age to 
vaccinate girls varied across countries due to differences in age at sexual debut, and for 
China, it may extend to 13–15-year-olds [60]. 
1.3.1 Primary prevention 
Primary prevention of cervical cancer mainly targets HPV infection and related risk factors 
and aims to prevent cervical cancer. It includes: health education and awareness raising, 
intervention on behaviours posing a risk to health (smoking, risk sexual behaviours, etc.), 
and HPV vaccination.  
 
Health education and awareness raising 
As demonstrated by controls on tobacco smoking for lung cancer and campaigns for condom 
use for acquired immune-deficiency syndrome (AIDS) [61, 62], health education 
intervention can reduce the risk of disease and, accordingly, save lives. The risk reduction of 
cervical cancer occurs through raising awareness of HPV infection, using methods of 
protection in sexual activities, and avoiding high-risk sexual behaviours [63]. Raising 
awareness of early detection through cervical screening is also useful, especially integrated 
with prevention and appropriate treatment of precancerous lesions. This would help reduce 
mortality in low-resource regions like China, Middle and Far East regions, and sub-Saharan 
Africa, where other methods like HPV vaccination will soon cease to be affordable and 
manageable on a national scale. IARC estimated that health education and awareness raising 






Targeting health risk behaviours 
Condom use 
Consistent condom use may reduce the risk of HPV infection and cervical cancer. The recent 
(2014) systematic review of eight longitudinal studies (two randomised control trials (RCT) 
and six cohort studies) reported that those who consistently used condoms had a significantly 
lower risk of HPV infection, a higher chance of clearing existing infections (eg hazard ratio 
(HR) =0.58, 95% confidence interval (CI): 0.35–0.97), and a higher chance of regression 
from high-grade CIN (eg HR=3.1, 95% CI: 1.4–7.1; OR=5.28, 95% CI: 1.68–16.62). 
Potential confounding factors include the number of sexual partners, history of STIs, and 
‘social desirability’ (by which respondents provide answers which they consider to be the 
most socially desirable) in reporting the information on condom use.  
 
Male circumcision (MC) 
The mechanism through which circumcision might protect people against HPV infection is 
not well understood. One plausible reason is that the removal of the foreskin could minimise 
the chance of viral entrance, and the smaller mucosal surface would lead to less HPV 
infection and mucosal trauma [66]. A systematic review and meta-analysis of 21 studies 
(involving 8,046 circumcised and 6,336 uncircumcised men) suggested a significant 
association between MC and reduced genital HPV prevalence (odds ratio (OR) = 0.57, 95% 
CI: 0.42–0.77) [66]. Weak evidence from cross-sectional studies (only two were RCTs) and 
potential selection bias undermine the strength of the epidemiological evidence. Further, the 
impact of MC on the prevalence of HPV in women is equivocal.  So, safe sex (protected sex 
and low-risk sex) is still one possible strategy by which sexually active people could prevent 
further HPV infections[6].  
 
HPV vaccination 
In 2006, the US Food and Drug Administration (FDA) approved the quadrivalent vaccine 
(Gardasil) for use against HPV 6, 11, 16, and 18; it is estimated to prevent 70% of cases of 
cervical cancer and 90% of genital warts cases [67]. In 2009, the bivalent HPV vaccine 
(Cervarix) was approved by the FDA for use against HPV 16 and 18 and is estimated to 
prevent 70% of cervical cancer cases [67]. Both of the vaccines have been proved to be 
tolerated and efficacious in large-scale clinical trials [68], but the burden of cervical cancer 
will be reduced only when uptake of the vaccines is widespread. Table 1-4 summarises the 





Table 1-4:  Summary of two types of HPV vaccine  
 Gardasil (quadrivalent) Cervarix (bivalent) 
HPV types 6, 11, 16, 18 16, 18 
Prevention of disease  70% cervical cancer,  
90% anal cancer,  
40% external genital cancer 
(vulvar, vagina and penis),  
90% genital warts,  
CIN1, 2, 3 
70% cervical cancer, 
CIN1, 2, 3 








96% for precancerous lesions, 
vulva and vaginal and genital warts 
90% high-grade CIN 
75% HPV 16, 18 
Duration of 
protection  
5 years 8.4 years 
Cross-
protection 
46% for HPV 31 77.7% for HPV 31,45 
6.4 years 
Safety  One serious adverse reaction in  
0.8% vaccine recipients vs. 1.0% 
placebo recipients 
One serious adverse reaction in 
5.3% vaccine recipients vs. 
5.9 % placebo recipients 
Administration  0,2, and 6 months 0,1, and 6 months  
Coverage 82% in Belgium (2010), 
71% Australia (2009), 
63% in Norway (2011), 
32% in the US (2010) 
84% in UK(>90% in Scotland) 
(2009), 
56% in Italy (2012), 
33% in the US (2010) 
Adapted from Prevention of human papillomavirus (HPV) infection and cervical cancer in 
China: How does HPV vaccination bring about benefits to Chinese women?[1, 69] 
 
By 2010, over 120 countries in the world had approved one of the HPV vaccines (either 
Cervarix or Gardasil) [70], 62 of which have included HPV vaccination in the national 
immunisation programmes [70]. Table 1-5 presents these countries. Neither of the HPV 
vaccines has been licensed in China, although Phase III clinical trials had finished by the end 





















Table 1-5:  Cervarix and Gardasil approvals worldwide by 2010  
 Cervarix (bivalent) (110 countries) Gardasil (quadrivalent) (120 countries) 
America Canada, USA, Mexico 
 
Argentina, Aruba, Brazil, Chile, 
Colombia, Costa Rica, Curacao, 
Dominican Republic, Ecuador,  
El Salvador, Guatemala, Guyana, 
Honduras, Jamaica, Nicaragua, Panama, 
Peru, Surinam, Trinidad and Tobago, 
Uruguay 
Canada, USA, Mexico 
 
Aruba, Bahamas, Barbados, Bermuda, 
Cayman Islands, Costa Rica, Curaçao, 
Dominican Republic, El Salvador, 
Guatemala, Honduras, Jamaica, Nicaragua, 
Panama, Puerto Rico, Trinidad/Tobago 
 
Argentina, Bolivia, Brazil, Chile, Colombia, 
Ecuador, Peru, Uruguay 
Europe EU (27)*, Iceland, Switzerland 
 
Albania, Armenia, Azerbaijan, Belarus, 
Bosnia, Croatia, Georgia, Kazakhstan, 
Macedonia, Moldova, Russia, Serbia, 
Ukraine 
Albania, Austria, Belarus, Belgium, Bosnia, 
Bulgaria, Croatia, Cyprus, Czech Republic, 
Denmark, Estonia, Finland, France, 
Germany, Greece, Herzegovina, Hungary, 
Iceland, Ireland, Italy, Latvia, Liechtenstein, 
Lithuania, Luxembourg, Macedonia, Malta, 
Montenegro, Netherlands, Norway, Poland, 
Portugal, Romania, Russia, Serbia, Slovakia, 
Slovenia, Spain, Sweden, Switzerland, 
Turkey, UK, Ukraine 
Africa Burkina Faso, Congo, DRC, Gabon, 
Ghana, Ivory Coast, Kenya, Mali, 
Namibia, Nigeria, Senegal, South Africa, 
Tanzania, Uganda 
Botswana, Burkina Faso, Cameroon, Central 
African Republic, Chad, Congo 
(Brazzaville), Cote d’Ivoire, Equatorial 
Guinea, Ethiopia, Gabon, Guinea (Conakry), 
Kenya, Malawi, Mali, Mauritania, 
Mauritius, Namibia, Nigeria, South Africa, 
Tanzania, Togo, Uganda 
Asia 
Pacific 
Bangladesh, Cambodia, Hong Kong SAR, 
India, Indonesia, Japan, Macau SAR, 
Malaysia, Myanmar, Pakistan. 
Philippines, Singapore, South Korea, Sri 
Lanka, Taiwan, Thailand, Uzbekistan, 
Vietnam 
 
Australia, New Zealand 
Bhutan, Georgia, Hong Kong SAR, India, 
Indonesia, Kazakhstan, Korea, Kyrgyzstan, 
Macau SAR, Malaysia, Philippines, 
Singapore, Taiwan, Thailand, Uzbekistan, 
Vietnam 
 
Australia, Fiji, New Zealand 
Middle 
East 
Bahrain, Egypt, Israel, Kuwait, Lebanon, 
Mauritius, Morocco, Oman, Saudi Arabia, 
Tunisia, Turkey, United Arab Emirates 
Bahrain, Egypt, Israel, Jordan, Kuwait, 
Morocco, Pakistan, Saudi Arabia, Tunisia, 
United Arab Emirates 
*The data were obtained from Human Papillomavirus Vaccines: Current status and future 
prospects [70], but I was unable to obtain further details of the EU countries approving 
Cervarix. 
 
Adapted from the figure of Human Papillomavirus Vaccines: Current status and future 





HPV vaccine mechanism  
The HPV vaccines use virus-like particles (VLPs), containing viral capsid proteins—the 
major one (L1)—of different virus types (6, 11, 16, 18) to induce an immune response. The 
DNA of the virus is not contained in the vaccine, so the virus cannot replicate through it.  
 
Experiments on animals have proved that the vaccines invoke an antibody response, which is 
much stronger than the natural immune response due to the adjuvants used in the vaccines. 
The L1 antibody is expressed in the cervical mucus, immediately neutralising the virus. As 
the efficacy of the vaccines against the internalised virus is not well understood, the vaccines 
are considered to be more effective before sexual debut [4].  
 
HPV vaccine efficacy and safety 
Efficacy 
The most recent systematic review and meta-analysis [72] invoved seven unique 
randomised-controlled trials worldwide of 44,142 females were conducted in 2011, assessed 
the efficacy and safety of the two vaccines. Evidence suggested that both the vaccines were 
most efficacious (75–95%), depending on which sub-cohorts were enrolled) against a 6-
month persistent infection with HPV 16 and 18 [72]. Regarding CIN1+ with HPV 16 and 18, 
the efficacy was 57–98% and 50–90% for CIN2+. Per-protocol population cohort (vaccine 
HPV type naive) tended to have higher efficacy than the intention-to-treat cohort (regardless 
of HPV status in the enrolment) [72].  
 
The vaccines provide 100% protection against HPV 16 infection over 17 months and 94% 
after 3.5 years [4, 73]. In terms of precancerous lesions, vulval and vaginal cancer, and 
genital warts, a Phase Ш clinical trial of 17,000 women showed that for unexposed (to 
relevant HPV types) women, the efficacy of the quadrivalent vaccine is over 96% [74]. 
Phase Ш clinical trials also showed that the efficacy of the bivalent vaccine was over 90% in 
preventing high-grade cervical lesions and over 75% in preventing persistent infection (HPV 
16 and 18) [74]. But so far the clinical trial studies do not have strong evidence for 
protection beyond 5 years – although the period of protection is likely to be much longer. It 
is estimated that the duration of protection for the bivalent vaccine is 8.4 years, and 5 years 
for the quadrivalent vaccine [34, 74]  
  
The efficacy of HPV vaccine for different stages of dysplasia and ICC has to be available 
until 2020 due to the long-term development of cancer and very rare incidence [4]. However, 
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some preliminary findings reported the efficacy in some high-income countries where HPV 
vaccines have been introduced for 4-5 years, such as Australia [75], Scotland [76] and 
Denmark [77]. The results showed 48% reduction in CIN3 in the quadrivalent vaccinated 
group in Australia [75], 29%, 50% and 55% of reduction in CIN1, 2, and 3 respectively in 
bivalent vaccinated group in Scotland [76] and 44-73% reduction of CIN2-3 in vaccination 
cohorts in Denmark [77]. Further, as neither all HR-HPV nor already present HPV infection 
are protected by the vaccines, implementation of cervical screening needs to be continued, 
but HPV vaccination offers the prospect of less intensive screening - the intervals between 
screening tests could potentially be widened.[4]. 
 
Cross-protection 
Both the vaccines provide cross-protection against other HPV types. It is inferred that there 
are some phylogenetic similarities between L1 genes of the vaccines and other types. The 
bivalent vaccine is found to have 59.8% and 77.7% efficacy with HPV 31 and HPV 45 
respectively for up to 6.4 years [29].  
 
There is a possibility that if natural competition exists among HPV types, HPV type 
replacement (strain-replacement) would occur after vaccination. However, HPV 16 and 18 
are the dominant types in the development of cervical cancer; other HPV types would carry a 
lower risk of developing cancer and in turn have fewer implications for public health [29]. 
 
Adverse effects 
The most common adverse event seen in trials of HPV vaccination has been local discomfort 
at the injection site, including pain, swelling, and redness, headache, and low-grade fever, 
but this is usually of short duration. People who received the bivalent vaccine were more 
likely to report these local symptoms than those who received the quadrivalent vaccine [74]. 
In terms of serious adverse reactions, the most commonly reported was abnormal pregnancy 
outcomes[72]. However, there was not a significant difference in vaccine-related serious 
adverse events between the vaccine and control groups[72].   
 
Health impact of HPV vaccines 
Vaccine coverage, efficacy, and duration of protection are expected to influence the health 
impact of HPV vaccines [78]. As HPV vaccines have only recently been introduced, the 
health impact cannot be directly observed. Thus, models have been used in high-, middle- 
and low-income countries [78] to predict the incidence reduction for cervical cancer and 
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precancerous lesions (CIN2/3). The estimated cancer reductions of vaccine-related HPV 
types (HPV 6,11,16, and18 in Cervarix and Gardasial) vary from 43% to 98% in Asia [78], 
America, [78] and GAVI-eligible countries [79, 80]. This variation may be attributable to the 
different model estimations of cervical screening frequency, vaccine coverage, inclusion of 
boys, and vaccination age range.  
 
Delivery of HPV vaccine 
Age and gender 
To achieve the maximum effectiveness of the vaccines, and due to their prophylactic nature, 
the target population for vaccination should be those who are not sexually active. While the 
median age of sexual debut varies across different populations, most countries recommend 
girls aged between 10 and 14 years should take the HPV vaccine[74].  
 
 HPV-related burden is low among males and due to the efficacy and price of the vaccines, 
adolescent boys were not considered as the target population in most countries. However, the 
vaccination has been introduced in the all the states in US [81] and Australia [82, 83]. 
Studies showed HPV infection would be much more reduced by further increasing the 
vaccine uptake of girls rather than including boys in the programmes [29]. But if the 
coverage amongst girls is less than 50%, involving boys in the programmes may be cost-
effective [29]. Involving boys in the vaccination programmes also offers some advantages to 
both men (particular high risk group, eg MSM) and women in the prevention of genital warts, 
oral cancer, and anal cancer, as well as providing herd immunity benefits to men’s female 
partners [74].   
 
Delivery and administration 
Several strategies of HPV vaccination have existed worldwide, and China needs to find one 
appropriate for its current conditions. Below are the potential strategies.  
 national free programmes, adding to the existing national immunisation system or EPI 
system (ie UK, Australia, US, Singapore, Malaysia) [84] 
 national semi-free programmes, in which recipients pay for a proportion (ie France, 35% 
no reimbursement) [84] 





In terms of delivery venue, the WHO recommended several possible vaccine delivery 
strategies: school-based immunisation programmes, EPI (Expanded Programme on 
Immunisation) campaigns, adolescent-friendly health programmes, and community-based 
sexual and reproductive health programmes (eg family planning). [34]. Most developed 
countries (Canada, UK, and Australia) [74] deliver the vaccine through school-based 
programmes (school-based health services can reach more adolescents than community-
based ones), while in some developing countries where the school attendance among girls is 
relatively low, school-based services would not achieve this optimal benefit and coverage. 
Thus, further studies are required to explore which delivery strategies would be most feasible 
and achievable in developing countries.  
 
The two vaccines are administered according to a standard protocol, which means the 
quadrivalent vaccine is given at 0, 2, and 6 months, and the bivalent vaccine is given at 0, 1, 
and 6 months [74]. The possibility of reducing the number of doses from three to two is 
being discussed, and the schedule will become more flexible. It is expected to greatly reduce 




School-based HPV vaccination programmes have achieved high coverage in some developed 
countries. In terms of the three doses, the coverage is over 70% in Australia (71%) (Gardasil, 
the quadrivalent vaccine, is used in Australia) [86], higher in Belgium (83.2%)[29], and was 
even higher in the United Kingdom in 2013 (86.1% in England, over 90% in Scotland) 
(Cervarix, the bivalent vaccine, is used in the UK immunisation programme, against 
HPV types 16 and 18)[87]. But in the US, coverage is only 33% for the three-dose series 
(both types of HPV vaccines are currently used in the US)[88]. In Australia, the national 
school-based HPV Vaccination Program has been extended to males. From February 2013, 
both males and females aged 12–13 years will receive the HPV vaccine (the quadrivalent 
vaccine) at school [82]. 
 
Cost-effectiveness of the HPV vaccines 
A number of studies have employed cost-effectiveness models to assess whether the 
intervention (HPV vaccination) combined with other prevention strategies (eg cervical 
screening) is cost effective [78]. These studies typically use cost-effectiveness ratios to 
express the results, and no global standardised ratios are available currently [78]. The 
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commonly used parameters to calculate the ratios include GDP, quality-adjusted life years 
(QALYs), and disability-adjusted life years (DALYs); the ratios are expressed as Cost per 
QALY, or Cost per DALY [78] [89]. The threshold of GDP is widely used as the evaluation 
criteria: a strategy (eg HPV vaccination) which has a ratio less than the average per capita 
GDP is viewed as very cost effective, and less than three times GDP is viewed as cost 
effective [78] [89]. In terms of the cost-effectiveness of the HPV vaccination, a number of 
factors influence the results, including vaccine cost, efficacy, coverage, duration of 
protection, health impact and frequency of cervical screening [89]. But it is still difficult to 
assume that measures of cost-effectiveness (of the HPV vaccine or HPV vaccine plus 
cervical screening) truly reflect the affordability of national health care or social willingness 
[90]. 
 
Ongoing issues of the HPV vaccines 
The vaccine type: 1) Three-dose vaccines to two-dose vaccines: the antibody response, 
cross-protection, and duration of protection with two-dose vaccines need to be explored 
further [29]. 2) Nine-valent vaccine: studies are ongoing to add nine HPV types (HPV31, 33, 
45, 52, and 58) to the quadrivalent vaccine. Trials showed the vaccine may provide 90% 
protection against SCC [29]. 3) Therapeutic vaccines: this kind of vaccine intends to increase 
the T-cell immune response using viral vectors. But issues of safety and administration need 
to be studied further [29].  
 
Regarding the need for the full coverage of the HPV vaccines, several factors must be 
considered.  
 
Disease burden: the HPV vaccines aim to prevent cervical cancer as well as genital warts. 
Compared to other cancers (lung cancer) and communicable diseases (HIV), cervical cancer 
and HPV infection are unlikely to be a priority in a national cancer or communicable disease 
prevention programme.  
 
Natural history of the disease: Unlike other vaccines which aim to prevent infectious disease 
(measles, smallpox, hepatitis B virus (HBV), etc.), cervical cancer is a chronic disease which 
takes a long time to develop, during which screening could play a role in prevention and 
accordingly lower the risk of getting cervical cancer. Thus, the government would probably 
delay the introduction of vaccines due to the existent screening programmes and their long-




Protection duration and efficacy: the protection mechanism is not well understood, and 
studies need to explore it further.  
 
Cost-effectiveness and affordability: it would be a big financial burden for a large country 
such as China to afford whole population coverage for HPV vaccines.  
 
HPV vaccination in China    
Summary of HPV vaccines in China  
HPV vaccines have not been licensed in China—although there is some availability of the 
vaccine in Hong Kong, Macau, and Taiwan—but Phase Ш clinical trials are ongoing. These 
involve the Gardasil (Merck) quadrivalent HPV 16/18/6/11 vaccine and the Cervarix 
(GlaxoSmithKline Biologicals, GSK) bivalent HPV 16/18 vaccine (Table 1-6). They have 
been working to investigate the safety and efficacy of HPV vaccination in Chinese 
women[91]. A randomised double-blind trail among 100 males and 500 females was 
conducted in China to evaluate the efficacy and immunogenicity of the quadrivalent HPV 
vaccine produced by Merk. It showed that high antibody levels of the four HPV types were 
observed and that the vaccine is well tolerated, highly immunogenic, and has no serious 
adverse effects [92].  
 
There are two Chinese vaccine manufacturers developing HPV vaccines for licensure in 
China, starting in 2014. INNOVAC (name of a Chinese pharmaceutical company) has an 
HPV vaccine in Phase III clinical trials, and Walvax has an HPV vaccine that is about to go 
into Phase III clinical trials (Table 1-6). No further details of the HPV vaccines of the 
Chinese manufacturers are yet known. The clinical trials will take many years to conduct, 
because the endpoint of the trials is the presence of precancerous cervical lesions. (WHO has 
recognised that these clinical trials could be accelerated by modifying the clinical endpoint, 












Table 1-6:  Status of HPV vaccines in China  
Status of HPV vaccine 





Endpoint for clinical trials 
International 
companies 
Merck(Gardasil) Finished (2013) precancerous cervical lesions 
(>=CIN II) 
GSK (Cervarix) Finished (2013) precancerous cervical lesions 
(>=CIN II) 
Chinese companies INNOVAC Ongoing (2014) precancerous cervical lesions 
(>=CIN II) 
Walvax Plan to (2014) precancerous cervical lesions 
(>=CIN II) 
Data was obtained from APEC Conference in Beijing in 2014 [93] 
 
The appropriate age for HPV vaccines in China 
To determine the appropriate age for HPV vaccines, a Chinese multi-centre cross-sectional 
study [60] assessed the sexual debut of 11,852 women aged from 15 to 59 years in 2009. It 
found that 4.5% of rural and 10.8% of urban respondents aged 15–19 years had engaged in 
sexual activity. In the 20–24 age group, 62.2% and 44.4% of rural and urban women 
reported engagement in sexual activity. The study accordingly employed standard frequency 
calculation and cohort analysis by age and urban/rural residence to estimate the median age 
of sexual debut. It was 17 years old in the 15–19 age group and 19 years old in the 20–24 age 
group for both urban and rural women [60, 94] 
 
When the two age groups were split into students and non-students, the prevalence of sexual 
activity was significantly different. In the 15–19 age group, 23.1% versus 0.6% of rural 
participants (non-students versus students) and 38.8% versus 4.0% of urban participants 
(non-students versus students) had experienced sexual activity [60]. In the 20–24 age group, 
more pronounced difference were found: 71.7% difference (non-students versus students) for 
rural women and 46.7% difference for urban women (non-students versus students) [60]. 
Thus, finally, the study suggested that HPV vaccination would better starting between the 
age of 13–15 years, because of the potential earlier age of sexual debut among non-student 
women as well as the downward trend in the age of sexual debut [60, 94].   
 
Lessons from Hepatitis B virus (HBV) vaccination in China 
There has been a long time between the introduction of the HBV vaccine and full coverage 
via a free vaccination service in China—approximately 20 years from 1986 universal 
neonate immunisation to the free neonate vaccination in 2005 [95, 96]. A rough estimate on 
the delay of universal vaccination programmes showed that 64.000 carcinoma cases, 
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2.131.000 chronic cases, and 8,524,000 chronic HBV carriers should have been prevented 
during the period, but were not because of the slow speed of implementation of HBV 
vaccine [96].  Based on the experience of the implementation of the Hepatitis B Virus (HBV) 
vaccination in China, the HPV vaccination should be introduced across the whole country as 
early as possible, otherwise excess morbidity and mortality caused by HPV will substantially 
increase the disease burden and, in turn, the financial burden of the government. As 
estimated, in developing countries, every 5-year delay of the HPV vaccination leads to more 
than 1.5 million deaths from cervical cancer worldwide [20]. In China, a 7-year delay (2006–
2012), would lead to 380,000 new cases and 210,000 deaths within the female population 
who should have been vaccinated during this period [97].  
 
Challenges to the implementation of HPV vaccination in China 
There are several challenges and recommendations concerning the implementation of the 
HPV vaccination in China.  
 
First, it is necessary to determine if cervical cancer (together with HPV infection) is 
currently a health priority amongst adolescents and adults in China in terms of disease 
burden. It is also important to discover whether the reported burden has taken into account 
the relevant factors of the variability and mobility of the Chinese population. If this is not 
done, selection and information bias may exist and the burden will not represent the national 
estimates. For example, lack of data from rural residents and immigrants to cities would lead 
to an underestimation of the disease burden, thereby delaying it being made a priority in the 
schedule.  
 
Second, publicity and education need to be widely carried out as soon as possible. Evidence 
showed that women who have less HPV and cervical cancer knowledge and do not think 
they would be infected by HPV [98] are be more likely to worry about the quality and safety 
of HPV vaccine and have lower acceptability [91].  
 
Third, in terms of the high cost of HPV vaccination, cost-effectiveness studies should be 
conducted in China to help the government make a finance plan. A study [91] conducted in 
2010 in China has suggested it would be cost effective to have a cervical cancer preventive 
strategy combining screening and vaccination approaches together. It indicated strategies 
including vaccination would cost US$50–54 per girl vaccinated, but if costs rose to over 
US$54, there would be no need to include vaccination in the preventive strategy [91]. 
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Optimal strategies of the HPV vaccination combined with screening should be studied 
further in China in different socio-economic areas. The affordability to the government and 
the distributional equity also need to be explored [99].  
 
Fourth, the different priorities among diverse stakeholders are considered to be a potential 
impediment to implement HPV vaccination in China. The stakeholders include sexual and 
reproductive health, adolescent health, immunisation, and cancer prevention departments, 
which are such mixed groups that it is difficult to coordinate them all together. Plus, due to 
the delayed impact of the HPV vaccination (rather than the immediate impact brought by the 
measles vaccination), stakeholders need to make decisions regarding whether it is important 
to save lives now or in the future [99].  
 
Finally, a persistent HPV infection of over 6 months, recommended by WHO, should be 
used as the efficacy endpoint for Phase III clinical trials in China rather than precancerous 
lesions (CIN 2+). The current efficacy endpoint in China (CIN 2+) would require a large 
amount of people to reach an acceptable sample size, as well as long-term observation 
(maybe over 10 years) to get the relevant data. If the WHO-recommended endpoint is not 
used, the approval process in China will be delayed another 10 years (2016 will mark 10 
years since the introduction of the vaccine [96].  
 
Expanded programme on immunisation in China 
Current immunisation programmes in China 
The Expanded Programme on Immunisation (EPI) was established in 1978 in China [100]. 
By 1995, China had achieved its universal childhood immunisation goals of over 85% 
coverage in the whole country from the provincial level to county and village levels [100]. In 
2007, the expansion of the National Immunisation Plan (NIP) [100] was announced by the 
central government, and a few vaccine-preventable contagious disease were added. The 
number of the NIP vaccines had increased from 6 to 14 by 2014, contributing to the 
prevention of 15 contagious disease [100] (Table 1-7). The primary goals of the NIP is to:  
 maintain poliomyelitis-free status 
 eliminate measles by 2015 
 reduce chronic hepatitis B infection 
 
Two categories of vaccines are provided in China [100]. The first category of vaccines are 
provided free of charge by the government for the citizens; they include NIP vaccines and 
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vaccines for emergency immunisation. The second category of vaccines are paid for by 
citizens themselves and provided on a voluntary basis (Table 1-7). 
 
Likely future scenarios of HPV vaccine availability in China 
The Merck and GSK vaccines will be most likely licensed first in China, but they would be 
put into market as self-pay vaccines based on the current EPI and NIP systems in China, in 
line with the priority of vaccine-preventable disease of the government. Even after HPV 
vaccines are licensed by Chinese manufacturers, they will not likely be automatically made 
available free of charge to the target girls and boys (at no cost to their parents) in the EPI and 
NIP systems. To implement the HPV vaccines in China at no cost or low cost to the potential 
recipients, an agreement has to be reached between the National Health and Family Planning 
Commission (NHFPC) and the Ministry of Finance. GAVI purchases HPV vaccines for 
GAVI-eligible countries, but China is not eligible in terms of the economic conditions and 
potential affordability. Plans for the prequalification of the Chinese HPV vaccines are not 
detailed on the official NHFPC website or even known by the public via mass media. To 
speed up the licensure of HPV vaccines in China, a faster endpoint for clinical trials may be 
viewed as a way to help the Chinese manufacturers as well as the policy makers and other 
stakeholders.  
 
The potential strategy of HPV vaccines in China 
Several strategies of HPV vaccination exist worldwide, and China needs to find one 
appropriate for its current condition. It would not be realistic to implement a vaccination 
programme free of charge in the whole country due to the affordability to the government 
and logistical issues. The programme would initially target high-risk people (those who are 
more likely to have unsafe sex, be unaware of protection methods, start early sex, etc.) and 
high-burden cervical cancer regions. For example, Xinjiang Uyghur Autonomous Region, 
where the illiteracy rate is 29% (compared with a national average of 4.1% in 2010) and 93% 
of residents live on $1.0 or less per day, there is a very high prevalence of cervical cancer 











Table 1-7:  China expanded NIP vaccines and target diseases since 2007  
NIP Vaccines Target diseases 
Child immunisation plan vaccines  
1 Hep B 1 Hepatitis B  
2 Bacilli Chalmette Guérin (BCG) 2 Pulmonary Tuberculosis (PTB) 
3 OPV 3 Poliomyelitis 
4 Diphtheria and Tetanus toxoid with a cellular 
Pertussis vaccine (DTaP) 
4 Pertussis 
 
5 Diphtheria and Tetanus toxoid Vaccine (DT) 
5 Diphtheria 
6 Tetanus 
6 Measles Containing vaccine (MV) 7 Measles 
7 measles, mumps and rubella (MMR) 
8 Rubella  
9 Mumps 
8 Japanese encephalitis vaccine (JapEnc) 10 Japanese encephalitis 
9 Meningococcal A vaccine (Men A) 11 Epidemic cerebrospinal 
meningitis DCSM 10 Men AC 
11 HepA 12 Hepatitis A 
Vaccines for susceptible people 
12 Haemorrhagic fever vaccine 13 Haemorrhagic fever 
13 Anthrax vaccine 14 Anthrax 
14 Leptospira inactivated Vaccine 15 Leptospirosis 
Reproduced from The National immunisation plan: China 2010 [100] 
1.3.2 Secondary prevention (cervical screening) 
Evidence [19] [101] has proven that cervical screening offers a protective impact on the 
reduction of cervical cancer incidence and mortality. A recent (2013) systematic review and 
meta-analysis [101] of 24 studies reported cervical screening has substantial protective 
effects when screening is offered to women aged 30 years and over and at intervals of 5 
years or less intervals. Due to the heterogeneity of different studies, the review reported its 
findings based on the study design and screening method. An Indian RCT in 2009 including 
131,746 women suggested a single lifetime screening could significantly reduce the risk of 
mortality and incidence compared to non-screening. The RR for mortality was 0.65 (95% CI: 
0.47–0.90), and was 0.56 for incidence (95% CI: 0.42–0.75)[102]. A UK cohort study in 
1996 including 116,022 women showed cytology screening significantly decreased the risk 
of being diagnosed with CC compared with non-screening (RRs 0.38, 95% CI: 0.23–
0.63)[103]. The findings were also confirmed by 12 case-control studies involving 4,800 
cases and 18,000 controls. (OR 0.35, 95% CI: 0.30–0.41). However the heterogeneity 
statistics were significant and can be explained by the inclusion of diverse countries 






Cervical screening methodology 
There are several screening methods (Table 1-8) available for both developed and 
developing countries, although the cervical screening is almost non-existent at the national 
level in resource-constrained countries.  
 
Table 1-8:  Major characteristics of the screening methodologies for cervical cancer  
Characteristics 
VIA* Cytology testing HPV DNA 
test Pap smear LBT 
Sensitivity 50.0–89% 50–80% 70–85% 83–100% 
Specificity 67–90% 86–90% 78–90% 65–99% 
Quality control No standardised Second reader Repeat test 
Result Subjective  Subjective  Quantitative  
Training Weeks (eg 3–14-day 
training courses) 
Months Weeks  
Personnel & technique 
requirement 
Lower personnel and 
lab requirements 






Overall  Inexpensive  Expensive (more for follow-ups) Expensive  
CN¥/test per person 10 30 200 300 
US$/test per person  1.5 4.5 30 45 
Per 1,000 $1,500 $4,500 $30,000 $45,000 
Per 1 million $1.5 million $4.5 million $30 million $45 million 
Suitable regions Low-resource High- and low-resource High-resource 
Currency exchange rate was US$1=CN¥6.623 on 31 December 2010 (Bank of China) 
*VIA: Visual inspection with acetic acid; LBC: Liquid-based testing 
Data was obtained from three papers [69, 97, 104]  
 
VIA: Visual inspection with 3–5% acetic acid (VIA) is commonly used in low-resource 
areas, as it is an inexpensive, simple test. The examiner uses acetic acid on the cervix, and 
when the testing areas turn white, the result is positive. It requires a low level of 
infrastructure and can be performed by a wide range of personnel. Its sensitivity and 
specificity are relatively low in comparison with other screening methods shown in Table 1-
8 [105]. One meta-analysis indicated that region, capacity of screener (health worker, nurse, 
or physician), place of screening, study period, and size of study population had no effect on 
VIA accuracy, which suggests that VIA is reliable [106].  
 
Cytology testing: Cervical cytology testing (ie the Papanicolaou (Pap) smear and liquid-
based test) is also a commonly used cervical cancer screening method in both high- and low-
resource areas. The Pap smear aims to detect cytological abnormalities and to classify the 
cancer risk (PAP I–IV). The classification is now used together with epithelial dysplasia or 
CIN 1/2/3 to present the level of abnormalities of cervical cells in terms of cytology and 
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histology. Table 1-8 shows the classification based on different methods. The advantage of 
the Pap smear is its overall high specificity. However, its sensitivity is low [107] (Table 1-8). 
Low sensitivity leads to a great many false negative results and requires the need for frequent 
screening. Human errors in sampling and interpretation (the specimen is stained and 
inspected by cytologists for abnormalities) lead to the low sensitivity of the Pap smear [4, 
107]. Liquid-based testing has higher sensitivity and lower specificity compared to the Pap 
smear. The results of the liquid-based test are easier to read, and HPV can be tested in the 
residual specimen when cytological abnormalities are found [107].  
 
HPV test: The human papillomavirus test (HPV DNA test) is used to identify high-risk HPV. 
Its sensitivity and specificity are shown in Table 1-8 [105]. HPV testing has been shown to 
have 30–40% higher sensitivity than cytology but lower (5–10%) specificity for detecting 
high-grade lesions[108].  
 
It has been found that when combined with cytology, ie Pap testing, the HPV test can attain 
nearly 100% clinical sensitivity and nearly 93% specificity in women age 30 years or older 
[107]. Unfortunately, the test is expensive, requiring advanced technology to perform, so it 
could not be used widely in low-resource areas. The advantages of the HPV test compared 
with cytology are as follows: the process can be completely automated; it has quality-control 
procedures; it can be performed by self-sampling; it has a higher sensitivity for detecting 
HSIL in women aged 30 years or older[105].  
 
Screening interval 
One recent (2014) study [4] used the Markov model to evaluate the effectiveness of 17 
strategies for cervical screening. Varying the screening interval between one to three years 
(for Pap testing or combined HPV testing) does not have a significant impact on the risk 
reduction (all are over 70%) in cervical cancer incidence or mortality, compared with a non-
screening policy [4]. Even having Pap testing once every 5 years would achieve a risk 
reduction of almost two thirds for cervical cancer [4]. The US Preventive Services Task 
Force recommended in 2012 [109] that the interval for cervical screening using cytology 
(Pap smear) should be three years for women aged 21–65 years, and five years for the 
screening combining cytology and HPV testing together. England assessed the screening 
interval for the use of HPV testing as the primary screening method and found that HPV test 
screening could safely extend the screening interval from 3 (cytology screening interval) to 6 




A study [111] on when screening should stop found that by the age of 65, 80% of the benefit 
of cervical cancer screening is achieved. By the age of 75, 3 days in life at the most would be 
lost due to the non-attendance for screening, and by the age of 80, it would be 1.5 days [111].  
 
Screening coverage 
From a public health perspective at a population level, greater efficacy would be achieved 
through targeting more women who have never had cervical screening than through offering 
more frequent screening to those women who have already been screened [112]. The UK has 
the highest screening coverage (approximately 80% with a 5-year interval). Even so, the 
significant reduction of incidence (estimated 35%) was not seen until 20 years after 
screening began (eg from 15/100,000 in 1986 to 8.7/100,000 in 2005 in England) [113].  
 
The following provides information on cervical screening coverage in the UK [114]. In 
England in 2003, the coverage (<3.5 years from last test) was 71% among women aged 25–
49, and 81% (< 5 years) among those aged 50–64. It gradually dropped to 77.5% among 50–
64-year-old women (< 5 years) and remained generally the same for 25–49-year-old women 
(<3.5 years) at 71.5%. For the younger group (25–29 years) in England, the 3.5 year 
coverage was low, standing at 62.0% in 2013.  
 
Scotland [115] has a similar cervical screening uptake to that of England. Three-year uptake 
was 71.2% among women aged 20–60, and 5-year uptake was 78.1% in 2013. The uptake 
among the younger group was 53.5% (3 years) and 55% (5 years) among women aged 20–24 
years, and 66.2% (3 years) and 73.5% (5 years) for women aged 25–29.  
 
Of the non-attendees, women with low socio-economic status account for the majority [3]. 
These women tend to have a higher risk of HPV infection and cervical cancer (because of a 
lack of sexual knowledge and awareness of self-protection) [3]. Thus, increasing uptake 
targeting of the non-attendees would reduce health inequalities to some extent.  
 
Swedish studies [6] reported several methods—telephone invitations, interviews, and media 
promotion—that can be applied to increase the compliance rate in the cervical screening 
programmes. However, the use of such methods will be dependent on their financial 
affordability in local regions, as such management will as least triple the screening costs, 




Ongoing issues of cervical screening  
Low screening coverage (especially in developing countries): There is evidence that at least 
50% of cervical cancer worldwide can be attributed to the lack of cervical screening [116-
118]. In most regions, including rural China, cervical screening is used as an opportunistic 
tool for cervical cancer prevention. Even in the US, 25% of women have not received 
cervical screening in the last 3 years [118].  
Screening errors: It is estimated that one-third of cervical cancer cases are attributable to 
errors in Pap screening [117, 118]. Results are more accurate when Pap testing and HPV 
testing are combined, yet the high cost of this is not affordable in most developing regions.  
Lack of follow-up for the screening: It has been found that the lack of follow-up screening 
and treatment leads to the occurrence of at least 12.5% of cervical cancer cases [118]. This 
problem is particularly prevalent in low-resource settings where a systematic cervical cancer 
prevention strategy has not been developed.  
 
Cervical screening in China 
National cervical screening programmes in China 
The national health and family planning commission (NHFPC) has launched a free national 
breast and cervical cancer screening programme, targeted rural middle-aged women (35–59 
years old) from 2009, covering 1,140 counties across 31 provinces in China. The 
accumulative total investment has reached 1.09 billion yuan, and 37.15 million rural women 
have been screened and 46,000 women diagnosed. In 2013, China invested 370 million yuan 
in conducting cervical screening for a total of 10.14 million rural middle-age women, thus 
the women were able to get early detection and early treatment (partly paid for by NRCM 
and insurance).  An HPV screening pilot will be started by NHFPC for around 546,000 
women in September 2014. The current available cervical screening methods are cytology 
screening and VIA, in urban and in rural areas, respectively. The colposcopy examination 
will be provided for women who have positive results from the gynaecological and cervical 
cytology examination (about 10%). The project has played an important role in reducing the 
disease burden, reaching the objective of early discovery, early diagnosis, and early 
treatment. (Data were obtained from NHFPC official website).  
 
The NHFPC national screening programmes have brought about a great improvement in the 
primary care of women’s cancers in China. The central government has made great efforts 
through the provision of financial and human resources to support the prevention of cervical 
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cancer. The future plans of the NHFPC national programmes are not yet known, and their 
long-term effect and success largely depends on timely surveillance and follow-up treatment.  
 
Cervical screening health impact  
Available data suggest the mortality rate for cervical cancer dropped by 68% from the early 
1970s (10.3/100,000) to early 1990s (3.3/100,000) in China, and this achievement was 
mostly attributable to the numerous organised cervical screening programmes in the rural 
regions of many provinces before the 1980s [18]. However, when China’s market economic 
reform started in the early 1980s, public attention and interest turned towards high-profit 
industries, and, accordingly, funding for public health, including primary prevention 
(cervical screening) for cervical cancer, was no longer sufficient due to the profit-driven 
environment.  
 
In the last decade, even though some sporadic cervical cancer control programmes have been 
implemented in many provinces in China, their effectiveness was not satisfactory (suggested 
by the mortality increased to 4.3/100,000 in 2008) [16].  Three main issues exist in the 
current cervical cancer control programmes in China. First, these programs are for a short 
period (3 years), and they are grant-supported in a few rural regions. If the grant runs out, the 
programmes stop. Second, these programmes were designed for research purposes to collect 
data on incidence and mortality or to conduct trials on screening methods. When the research 
finishes, the programmes stop as well. Third, screening effectiveness would be enhanced by 
the integration of health education and follow-up treatment [16, 97]. Yet, Chinese short-term 
research programmes are usually independent of a sustained screening provision, and do not 
involve the continued education and subsequent treatment of recipients – screening which is 
disconnected from appropriate treatment and follow-up tends to be ineffective [97].  
 
Coverage of cervical cancer screening 
There is not an established national screening programme for cervical cancer in China. The 
World Health Survey reported by WHO in 2003 indicated that the overall coverage of 
cervical cancer screening (by Pap smear) in China is 16.8% among women aged 18–69 and 
that the coverage varied in urban (21.5%) and rural areas (14.8%) [2]. It was a sample survey, 
and 2,036 women were selected through multistage cluster sampling. These women self-





Cervical cancer programmes in China 
In 2006, China’s government implemented a project to provide low-cost, low-technology 
screening - visual inspection with 5% acetic acid stain (VIA)/visual inspection with Lugol’s 
iodine (VILI) screening to six counties in China. Now 42 clinical sites that provide screening 
services have been established in China (at least one clinical site for each province), and 
3,500 women aged 30–59 have received screening at each site [17]. In 2009, China’s 
government launched a cervical cancer screening programme for 10 million women living in 
rural China and provided visual inspection or Pap smears over three years. However, the 
majority of the women who need to be screened do not have the chance, because 70% of the 
whole population lives in rural areas - a total of 350 million women aged over 15 [2, 119]. 
 
Several cervical screening projects were undertaken from 1998 to 2008 by the Cancer 
Institute and Hospital of Chinese Academy of Medical Sciences (CICAMS) and Cancer 
Foundation of China (CFC), in collaboration with various international organisations. These 
international organisations included the Cleveland Clinic Foundation (CCF, Cleveland, Ohio, 
USA), IARC, (Lyon, France), PATH (Seattle, Washington, USA), GSK (Belgium), and the 
University of North Carolina (UNC, USA). Nearly 40,000 women were screened as part of 
these projects in four urban and ten rural areas of China, throughout nine provinces. For 
many women, it was probably the only occasion on which they received screening in their 
lifetime [17, 119]. These projects have explored a range of aspects of screening; rapid 
screening tests for HPV DNA detection, screening characteristic evaluation, health 
economics evaluation on screening programmes, population-based HPV prevalence, and 
HPV type distribution in urban and rural areas [17] (see Table 1-9). 
 
Further, the Bill and Melinda Gates Foundation provided US$1.68 million from the 
Programme for Appropriate Technology in Health to implement a 5-year project (2003–
2007), developing three biochemical screening tests [120]. 
 
Now three sets of cervical cancer screening are considered to apply to different regions of 
China. The optimal set of screening strategies is suggested in the developed regions, 
combining HPV-DNA testing with liquid-based cervical cytology, which might be the best 
screening model with sensitivity and specificity of up to 98% and 84%, respectively (79). 
However, such an approach is too expensive to implement nationally, and only a small 
number of women in non-deprived regions may be able to access it - for example, those in 
Shenzhen (US$7162 GDP per capita); the general method of screening is suggested in the 
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medium-developed regions, combining HPV-DNA testing with Pap smear test. The primary 
screening method in the most deprived regions of China, at present, is low technology - 
combining visual inspection with acetic acid (VIA) /visual inspection with lugol (VILI) (79). 
It costs only CN¥5 but has low sensitivity and specificity [95, 120]. Therefore, none of the 
three screening models currently in use in China meet the requirements exactly, and it is 
necessary to establish a cost-effective and affordable preventive strategy as well as HPV 
triage tailored to different geographical regions.  
 
Table 1-9:  Selected projects [17] on HPV and cervical cancer in China  
Project Title Location Age (years) Number  Year 
Shanxi Province Cervical 













Prevalence Survey of HPV 
infection and cervical cancer  
Shanxi, Liaoning 
Guangdong 
15–59 2,226 2004–2005 
Screening Technologies to 
Advance Rapid Testing  
Shanxi,  30–54 9,057 2003–2007 
HPV Type-distribution Study N/A 20–86 1,234 2006–2007 
Health Economics Evaluation Shanxi, Jiangsu, 
Guangdong 
30–59 15,750 2006–2008 
1.4 Summary 
Cervical cancer and HPV 
Cervical cancer is ranked as the fourth most prevalent female cancer in the world, with 
530,000 new cases and 275,000 deaths every year. China, as a large and heterogeneous 
country, contributes 14.2% of new cases and 12% of deaths to the annual global figures. The 
incidence rates in China are similar to those of developed countries (such as US and UK), 
but the lack of availability of national cancer prevention programmes and the ongoing 
upward trend in both incidence and HPV prevalence in recent years could lead to a greater 
public health and financial burden for the country. The current situation is mainly 
attributable to the social and economic transition ongoing in China, which produces a highly 
profit-driven environment, a growing gap between the rich and the poor, and delays in the 
implementation of a national health care system – a more public health approach is required 
if appropriate investments are to be made in cervical screening.  
 
HPV vaccines 
As one of the biggest research achievements in the recent years, HPV vaccines have the 
potential to prevent 70% of cervical cancer cases worldwide. More than 120 countries (both 
developing and developed countries) have implemented at least one of the HPV vaccines 
49 
 
nationally throughout the five continents, and the meta-analysis of RCTs I previously 
described has confirmed the efficacy and safety of the two vaccines. The immediate effect is 
protection against 6-month persistent infections of HPV 16 and 18 (75–95%), and in the 
future, the efficacy should be 50–90% for CIN1+ and CIN2+. The efficacy studies are still 
ongoing. Although Phase III clinical trials finished in 2013 in China, the introduction of 
HPV vaccines to China has not been made a priority in health care. Two main obstacles to 
the vaccines are the unrealistic endpoint for the clinical trials (CIN2+) and the big financial 
burden caused by the large number of potential recipients (0.3 billion).  
 
Cervical screening and prevention programmes 
The cervical screening coverage reported in China is 16.8% - that is, available data (from 
2003) indicate that 16.8% of women (aged 18-69) had had a smear in the previous 3 years. 
However, this was only a sample survey of 2,036 women. As I’ve indicated, all the other 
cervical screening programmes are mostly research-based and short-term (usually 3 years) 
screening initiatives, without subsequent education and treatment. Some issues need to be 
solved before implementing national screening programmes in China. First, HPV triage 
should be set up for women according to different geographical regions and socio-economic 
groups. Second, given the large and heterogeneous nature of China, the optimal path would 
be to first implement screening programmes in high-risk groups or high-burden areas. But 
some issues must first be addressed regarding how to access high-risk groups and how to 
ensure health inequity. Third, a complete cervical cancer prevention programme should be 
developed for China’s current circumstances. This would include education, vaccination, 
screening, diagnosis, and treatment. It is critical for the success of cervical screening 
programmes to have adequate follow-up procedures (for example, colposcopy and treatment 
services) and an information infrastructure. At present these critical elements of successful 
screening are lacking. Further, as an essential part of the prevention strategy, education 
programmes would be critical, and thus, knowledge and beliefs of people regarding HPV 
vaccination and cervical screening should be assessed, providing the necessary information 
for any future policy.  
 
A brief international comparison of cervical cancer prevention programmes in some 
countries involving cervical screening and HPV vaccination has provided in Table 1-10. It 
could be the background on which my following studies would be based and I hope it might 




In this chapter I hope I have provided thorough background and contextual material for my 
thesis. Clearly there are significant challenges ahead if China is to develop an appropriate 
strategy for reducing the burden from cervical cancer. International evidence suggest that 
HPV vaccination needs to be an integral part of that strategy. Hence, in the following 
chapters I examine key implementation issues for HPV vaccination in China – focusing on 
knowledge, attitudes and beliefs in the population.  
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Table 1-10 A brief comparison of cervical cancer prevention programmes in selected countries 
 
Region Country Cervical screening HPV vaccination  
Age (years) Interval$ 
(years)  








Europe France >=25 3   11 12-20 25-29% 
(2012) 
national 
Italy 25-64 3 HPV test pilot 12 11-24 52% (2012) national 
Norway 25-69 3   12  63% (2011) national 
Belgium 25-64 3   12 13-18 82% (2010) national 
United Kingdom 20-60/25-64 3   12-13 13-17 84-92% 
(2009) 
national 
America United States 21-65 3 HPV test national 11-12 13-26 32% (2010) national 
Canada* 18-69 2 HPV test pilot 9-14 14-26 50-86% national 
Mexico >=25 3 HPV test  national 11-13  67% (2010) national 
Brazil 25-60 3 HPV test pilot 10-11   pilot 
Asia China#   VIA national     
  HPV test pilot     
India 18-69 3 VIA & HPV test pilot    pilot 
Japan >=20 1   13   national 
Korea >=30 2       
Singapore 25-69 3   9-26   national 
Malaysia 20-65 3   13 13-18  national 
Oceania Australia 18-69 2   12-13 13-26 71% (2009) national 
New Zealand 20-69 3   12  40 (2010) national 
Africa South Africa >=30 10 VIA pilot     
Kenya   VIA national    pilot 
Uganda   VIA national 10   pilot 
  HPV test pilot     
*the screening age and interval varies slightly in different regions of the country 
$the interval refers to those who have had 2-3 annual negative smears 
# China is lack of specific national cervical screening strategy (including HPV triage) 






2 Chapter 2 Literature review—Systematic review 
2.1 Background 
HPV vaccines have the potential to lower the incidence of cervical cancer, and they have 
been shown to be both biologically effective, and cost-effective from a health economic 
perspective when used with a combination of screening approaches in China [91].   
 
Even when HPV vaccines are licensed in China, it is unlikely that HPV immunisation will be 
introduced free of charge to all because of the high financial burden associated with the large 
population in China (approximately 1.3 billion overall, with 200 million teenage girls), so it 
is likely individuals would have to choose to have the HPV vaccine themselves—a decision 
affected by individual perceptions of the HPV vaccine. Hence, before vaccination is initiated 
in mainland China, there is a need to understand the knowledge and acceptability that might 
affect the implementation of future HPV vaccination strategies. 
 
English-language systematic reviews of knowledge and attitudes towards HPV vaccines 
have been mostly based in Western countries [67, 121, 122]. Seven studies carried out in 
mainland China [123-129] and written up in English are available on online databases (such 
as PubMed), but only one of these studies [124] has been included and the results 
synthesised in English-language systematic reviews. Two of the seven studies were English-
language publications [125, 126] of existing studies in Chinese literature. Given the limited 
amount of English-language literature available from mainland China, there is a need to 
explore the Chinese-language literature to obtain a comprehensive understanding of 
knowledge of and attitudes towards HPV vaccines among Chinese populations. 
 
In the past few years, great progress has been made in China towards providing full-text 
access to the large amount of information reported in Chinese-language academic journals. 
More than 1,000 academic periodicals biomedical and health journals are published, 
providing a large amount of health evidence that Western literature does not often report. 
Several databases [130] are available, for example, the China National Knowledge 
Infrastructure (CNKI), Wanfang, and Chinese Medical Current Content. There is a 
considerable literature relevant to the knowledge of and attitudes towards HPV infection and 
vaccination available online in many Chinese academic journals; many studies [124, 131, 
132] have reported the findings from different regions of China. However, as yet there is no 
synthesis of the literature from across China, looking at all populations within the country. 
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Thus, there is a need to carry out a systematic review of the Chinese literature to synthesise 
findings from different regions of China.  
 
The English-language papers provide some indicative evidence. Li’s study [124]—the most 
influential study of HPV and vaccination in China—was the first one to comprehensively 
present knowledge of and attitudes towards HPV from a Chinese population, and is the only 
study included in the English-language systematic review [124]. The questionnaire used in 
this study has been widely adopted in other Chinese studies since 2008. It was a population-
based study including 6,024 respondents, conducted in 2008 in 6 community clusters in three 
major cities and three rural areas [124]. The main findings of the study were that Chinese 
women had a poor knowledge of HPV (15.5%) [124], but a high acceptability of HPV 
vaccines (84.6%) (it did not mention the type of HPV vaccine) [124], although they have 
health and safety concerns. The percentage of knowledge varied between urban (21.6%) and 
rural areas (9.3%) [124]. The source of the HPV vaccine and its safety were the major 
concerns for women who were unwilling to be vaccinated. Women would, however, accept 
the HPV vaccine if it was offered by the government [124].  
 
In order to more comprehensively understand what the Chinese population thinks and how 
they view the HPV vaccine, my review focuses on Chinese-language literature examining 
knowledge and attitudes of people in China about HPV infection and vaccination, ultimately 
aiming to improve understanding of how to implement HPV vaccination in China in the 
future. My synthesis of findings will likely be of interest to health policy makers, public 
health officials, and health practitioners seeking to introduce HPV vaccination uptake among 
the populations across China.  
2.2 Aims and research questions 
The aim of my systematic review is to better understand the knowledge of and attitudes 
towards HPV infection and vaccination in the Chinese population, as well as among health 
care providers in China.  
My research questions are: 
 What are the levels of knowledge about and attitudes towards HPV infection and 
vaccination among the general population, and among health care providers?  
 Do awareness, knowledge, and attitudes differ by the age, gender, rurality, and ethnicity 
in China, and if so, in what ways? 
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 What are the predictors of HPV vaccination acceptability (such as awareness, knowledge, 
or attitudes in terms of cost concern or worries about safety)?  
2.3 Methods 
I followed standard systematic literature review methodology in carrying out my literature 
review: search strategy, study selection, quality assessment, data extraction, and data 
synthesis. I describe below how I carried out the survey and the rationale for why I chose the 
specific methods I did.  
2.3.1 Search strategy 
Databases 
Two Chinese databases—the Chinese National Knowledge Infrastructure (CNKI) and the 
Wanfang database—were used, and searched from inception through to 30 November 2012. 
CNKI and Wanfang are the first and most widely used electronic databases in the academic 
field in China. Chinese researchers are trained to use both of these databases as soon as they 
begin academic work.  
 
Chinese National Knowledge Infrastructure CNKI (http://www.cnki.net/) is the most 
comprehensive source of academic information in China and represents the Chinese 
equivalent of the “Web of Knowledge” or “Pubmed”. It is the first internet publishing 
platform approved by the State Press and Publication Administration. Publications include 
secondary publications from traditional publishing methods, and first-time internet 
publishing, including text, images, audio, video, animation, online courses, and scientific 
data. Currently, CNKI has assembled more than 8,000 kinds of journal, nearly 1,000 
newspapers, 180,000 Doctoral/Master's theses, 160,000 conference papers, 300,000 books, 
and more than 1,100 specialized databases. Doctoral/Master's theses, conference papers, and 
part of the database is secondary publishing, while periodicals, books, newspapers are first-
time publications. 
 
Based on detailed literature content indexing, the CNKI literature search provides title, 
author, keyword, abstract, and full-text search capabilities with exact match (displaying 
papers with exactly the same key words) and blur matches (displaying all the terms 
containing the key words); the literature search also provides a variety of intelligent sorting 
methods. Relevance ranking takes into account a variety of factors: citation relations, full 
text, and literature sources, to make results more relevant. “Times Cited” is sorted in 
56 
 
ascending or descending order of publication date for each item; author index sorting is 
based on the amount of literature the author has published, the number of times that literature 
has been cited, and the impact factor of the academic influence of the author, and sorts the 
literature accordingly. I used keyword literature search with blur match in CNKI, and 
relevance ranking of the literature was applied: the literature was ranked based on the 
publishing time (those put in the front were the most recent ones).  
 
Wanfang database Wanfang (http://www.wanfangdata.com.cn/) is another comprehensive 
database, which includes full-text papers published since 1998 from Chinese academic 
journals (the number of journals included is 4,529), PhD/Master’s dissertation theses, and 
conference proceedings. It also provides title, author, keyword, abstract, and full-text search 
capabilities, as well as relevance ranking based on publishing time, impact factor, etc. The 
literature is ranked by the publication date, listed in descending or ascending order. 
 
I considered using additional Chinese academic databases in my search, such as Chinese 
Scientific Journals Database (Weipu Database) and the Chaoxing Electronic Library. These 
two databases have unique features, but also have some weakness. The former is the oldest 
e-database in China, having been started in 1989, but it is not the most comprehensive one. It 
only includes journal articles and is not interface-friendly. Some recent journals are missing 
from Weipu, especially in the medical category. The latter database provides millions of e-
books, 5 million papers, and over 80,000 academic videos. But the academic searching 
strategy (e.g. keyword searching) in the e-library is not developed. Based on the above 
reasons, these two databases were excluded from my search.  
 
I used manual searches to go through relevant online journals in CNKI and the Wanfang 
database, scanned a reference list of identified studies, and included articles that met the 
inclusion criteria.   
 
Search terms 
MeSH search terms were applied to both Chinese databases included in my research (CNKI 
and Wanfang). I used the search terms (in the Chinese language) “HPV”, “human 
papillomavirus” (renrutouliu bingdu), “HPV vaccination” (HPV yimiao), ”HPV 
immunisation” (HPV mianyi) AND “knowledge” (zhishi), “perception” (renzhi), “awareness” 
(zhixiao), “attitude” (taidu),  “acceptability” (jieshoudu), “will” (yiyuan),  and “health 
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behaviour” (jiankang xingwei). All the keywords used in the literature search are displayed 
in Table 2-1.  
2.3.2 Study selection 
Here I describe the criteria for eligibility and the selection procedure of the identified studies.  
 
Inclusion criteria 
I included all relevant study designs in the search strategy (although only cross-sectional 
studies with quantitative results were finally included in my review). The inclusion criteria 
are based on the following study characteristics. 
 
Article publication type 
 Peer-reviewed journal articles 
 Conference articles 
 Doctoral/master’s dissertation theses 
These are the main types of publication and are the types I was able to access through 
Chinese academic databases (CNKI and Wanfang). CNKI has three sub-databases based on 
these types, and Wanfang put them together in one database. They include almost all the 
literature published in the Chinese language.  
 
Study setting (but not restricted to) 
 Community-based setting,  
 Hospital-based setting  
 College- or school-based setting.  
Based on the review of Western and Chinese literature in the preparation phase, it was found 
that studies of HPV knowledge were usually set in the hospitals, colleges or schools, and 
communities in cities or towns. But for included studies, restrictions on the study setting 
were not defined.  
 
Study location  
 Mainland China (because there are different health systems in Hong Kong, Macao, and 
Taiwan.)  
Although Hong Kong, Macao, and Taiwan share similar Chinese culture and ideologies with 
mainland China, due to the social transformation in modern and contemporary society in 
these four locations, different social and health care systems are in place. This leads to 
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different levels of knowledge and acceptability of HPV vaccines, and accordingly 
compromises the reliability of pan-China comparison. An organized cervical screening 
programme has been implemented in Hong Kong, and the coverage was over 40% in 2008 
[133]. The Hong Kong government is considering bearing some of the cost of the vaccine in 
the near future [133]. However, cervical screening is still opportunistic in mainland China, 
and the HPV vaccine has not yet been licensed. The gap between the places increases the 
difficulty and complexity of comparison in terms of knowledge of and attitude towards HPV 
vaccines.  
 
Furthermore, studies in Hong Kong and Taiwan usually publish in English through 
international peer-reviewed journals or conferences. If they were to publish in Chinese, it 
would be traditional written Chinese which Chinese databases (like CNKI and Wanfang) 
would not include. Mainland China uses Simplified written Chinese (Mandarin and 
Cantonese are the categories of oral Chinese; Traditional and Simplified Chinese are the 
categories of written Chinese). The two types of written Chinese share the same grammar 
and sentence structure, but the characters are so different that I am not able to read them.  
 
Study population (but not restricted to) 
 Students (high school and college students of all the grades) 
 Parents 
 Patients 
 Health professionals (including physicians, nurses, other)  
 
Instruments (not restricted to): 
 Questionnaire survey 
 Interview survey 
 Interview-administrated questionnaire survey 
 
Sampling methods (not restricted to): 
 Cluster sampling 
 Random sampling 






Examples of outcomes may include  
 Knowledge of HPV infection and vaccination, such as symptoms, transmission of HPV 
infection, and risk factors of cervical cancer;  
 Attitude towards HPV, cervical screening, and HPV vaccination;  
 Factors affecting people’s intentions to be vaccinated, such as knowledge regarding 
cervical cancer and STIs, perceived risk and severity of cervical cancer, and perceived 
barriers to vaccination.  
 
No limitations were applied to study size.  
 
Exclusion criteria 
Exclusion criteria were: 
 Studies that were not based on the original data, such as opinion pieces and general 
reviews (non-systematic reviews);  
 Studies in which the knowledge and attitudes of respondents were not discussed in the 
result;  
 Sample populations not selected in mainland China.  
 
Selection procedure 
The selection process had three stages. First, I reviewed the titles and authors of studies on 
the CNKI and Wanfang databases. The three types of papers are located across four 
databases: three are CNKI sub-databases categorized by peer-reviewed journal articles, 
conference articles, and doctoral/master’s dissertation theses, and one is the Wanfang 
database. Second, I pooled the included studies from each database together to exclude 
duplicates. Third, I screened studies by titles and abstracts and followed the steps of the 
PRISMA flow chart [134] to screen studies for inclusion. Finally, I read the full text of 
screened papers and decided which would be included in my systematic review.  
2.3.3 Quality assessment 
Quality assessment is viewed as a critical part of the systematic review process before data 
synthesis takes place, and can help the reviewer to evaluate the strength of the evidence 
[134]. It assesses the risk of bias of individual studies in terms of method and outcome level, 
indicating the influence of bias and the study in the synthesis [134]. Moreover, it assesses 
bias across studies as well, suggesting the potential publication bias, for example, in the 
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report of the synthesis of results [135]. Hence, for this step I sought to find an appropriate 
tool to undertake a quality assessment of the selected papers.  
 
A number of challenges have to be addressed in planning for quality assessment of the 
Chinese literature. There are no standard guideline for conducting studies and reporting 
findings in China. There are a large number of quality assessment tools available in the 
Western literature, but are many designed for clinical trials carried out in a specific setting. 
My systematic review includes surveys carried out in diverse settings across China. No 
quality assessment tools have been specifically designed for studies carried out in China and 
compared to using quality assessment tools in the Western literature for Western research 
methodology.  In choosing a quality assessment tool to use in my systematic review I had to 
compare existing tools in the Western literature and chose one that may be most appropriate 
for my review, recognising the need to find a tool that could accommodate the cultural 
setting in which the primary research was carried out. Details are presented below.  
 
Quality assessment tools for use in systematic review of observational studies 
Many quality assessment tools (of the number of checklists and scales is over a hundred) 
have been reported in the literature [136-141]. But no agreed “gold standard” quality 
assessment tool exists currently for widespread use. For my systematic review, I chose the 
tool based on the need to include key characteristics. Some reviews [136, 138] focusing on 
quality assessment tools provided the evidence needed to guide my choice (see the flow 
diagram in Figure 2-1 of the selection procedure for quality assessment tools).  
 
Sanderson 2007 [136] reviewed 86 tools for observational studies and provided 
recommendations for assessing their quality: “The tool should 1) include  key domains; 2) be 
as specific as possible in terms of study design and topic, for example whether it is about 
economic impact, health outcomes, or patient reported outcomes, whether it is a prospective 
study (e.g. cohort study), a retrospective study (e.g. case-control study), a cross-sectional 
study (the type mostly found in my review), or randomised control trials; 3) be a simple 
checklist rather than a scale; 4) show evidence of development, of validity and reliability”. 
The key domains include: methods for selecting study participants; measurement of variables; 
other bias; confounding control; and statistical methods [136, 138]. Moreover, the purpose of 
the assessment tool purpose needs to be considered as well [136], for example, whether it 
was intended for single use in a specific systematic review (e.g. cost effectiveness or clinical 
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trial), or was a generic tool for systematic reviews (e.g. for all the cross-sectional studies), or 
was only for use in critical appraisal. 
 
Deek’s review, recommended by York University Systematic Review Handbook, identified 
nearly 200 tools used for the non-randomised studies [138]. Fourteen of them were viewed 
as the “best tools”, as they covered at least five out of six internal validity domains and three 
out of four core items—the indicators that are used to assess the quality of the tool. Of these 
14, six were recommended as being suitable for use in the systematic review of non-
randomised studies.  
 
I listed the recommended quality assessment checklists and scales based on these two 
reviews. Below are the names of the reports featuring quality assessment tools: 
 EPHPP, “Quality assessment tool for quantitative studies” [139]; 
 Newcastle-Ottawa quality assessment scale (for case-control and cohort studies)[140]; 
 Downs, “Feasibility of creating a checklist for both of the randomised and non-
randomised studies of health care intervention” [137]; 
 Zaza’s “Data collection instrument and procedure for systematic reviews in the ‘Guide to 
Community Preventive Services’”[141] ; 
 Cowley, “Prostheses for primary total hip replacement. A critical appraisal of the 
literature” [142] 
 SIGN (Scottish Intercollegiate Guidelines Network)’s handbook [143] 
 
Figure 2-1 presents the flow diagram for the selection of quality assessment tools.  
 
The inclusion/exclusion of quality assessment tools for my systematic review  
In consideration of the tool’s key domain, purpose, ease of use, and development, I chose 
Zaza’s checklist as the quality assessment tool for my review. The comparisons of the 
characteristics of the 7 tools are listed in Table 2-2. 
 
Exclusions  
 Topic-specific use of reviews: Cowley’s checklist [142] and Reisch’s checklist [144] are 
for use in the systematic review of therapeutic studies and other topics. Reisch’s checklist 
is considered to be difficult to use.  
 Development not described: Cowley’s checklist [142], EPHPP [139], Newcastle-Ottawa 
[140], and Reisch’s checklist [144] showed a lack of evidence of the tool’s development.  
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 Unclear tool purpose: SIGN [143] can be used in a lot of situations and its ambiguous and 
all-purpose features made it difficult to use for my chosen purpose.  
 Use of critical appraisal: my aim was to choose a tool to critically appraise the studies 
included in my review. The tools [137, 139, 144] that are used only for critical appraisal 
would not take the context of the systematic review into consideration. They could have 
been used for my review, as this feature was not among the most significant criteria for 
exclusion, but would not have been the most appropriate ones.  
 
Inclusion  
Down’s checklist [137] and Zaza’s checklist [141] were included. I chose Zaza’s checklist 
for the following reasons.  
 It covered the key domains, including methods for selecting study participants, the 
measurement of variables; confounding control, statistical methods, and other sources of 
bias.  
 To avoid subjective answers to questions about quality, clear rules and specific examples 
of answers were provided for a range of circumstances.  
 The forms could be adjusted to suit different study designs (experimental studies and 
observational studies). I was able to choose the one most suitable for my studies.  
 It described how it developed, which involved independent assessment by several 
evaluators.  
 It was easy to use and had clear descriptions of how to score items.  
 
Zaza’s checklist  
Zaza’s quality assessment checklist was first reported in the paper “Data collection 
instrument and procedure for systematic reviews in the Guide to Community Preventive 
Services”[141], which described the development of the tool, including data collection and 
instrument evaluation. In terms of the content, six categories (descriptions, sampling, 
measurement, analysis, interpretation of results, and other) with 23 questions were 
formulated [141].  
 
Zaza’s checklist has been cited by approximately 50 systematic reviews (sometimes together 
with meta-anlaysis) in last decade (2002–2014). Due to the large amount of work involved, I 
checked the 50 systematic reviews by abstract instead of full text. Four of the reviews 
mentioned in the abstract that Zaza’s checklist was used for the quality assessment of the 
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study, three of which were reviews of interventional studies [145-147]; one was a review of 
an observational study [148].   
 
Modifications of Zaza’s checklist  
I performed quality assessments of the included studies according to Zaza’s checklist [141], 
with modifications for my systematic review. Zaza’s checklist was created for general use, 
and not specific to any study design. My quality assessment tool was made up of five 
components: description, sampling, measurement, data analysis, and interpretation of results. 
The tool is shown in Table 2-3.  
 
The modifications to Zaza’s checklist were as listed below: 
 One component was excluded: one of the six components of Zaza’s checklist was 
excluded in my quality assessment tool, which was “Others”. This category was intended 
for researchers who wanted to add something else based on the specific circumstances of 
their study. In the “Others” component of Zaza’s checklist, no specific items were 
described. 
 Eleven items remained the same: 11 items (items 1, 2, 4, 5, 7–10, and 15–17 of my 
checklist) out of 23 Zaza’s items were cited in my quality assessment tool in the same 
form as they originally were.  
 Five items were adapted: 5 items (items 3, 6, 11, 12, 14 of my checklist) out of 23 of 
Zaza’s items were generated based on the instruction of Zaza’s checklist, but their 
wording was adapted in my quality assessment tool.  
 One item was added: item 13 in my checklist (was the power calculation provided) was 
added.  
 Six items were excluded: Based on the study design—a cross-sectional study—items of 
Zaza’s checklist that were related only to intervention or cohort studies were excluded 
from my checklist.  
 
Scoring of Zaza’s checklist for my systematic review 
I gave each item in the checklist a score. As items were weighted differently in terms of the 
importance of the quality in question, I gave them different scores. The rating for the items 
on the checklist is provided in Table 2-4. Description, sampling, and interpretation of results 
were given higher scores (a score of 2 for each item), and data analysis and measurement 




Based on the scores generated by the tool, included studies were classified into three 
categories (good, fair, and poor). Below are the boundaries for the different quality levels of 
the studies.  
 Good: A score of 18–23; 
 Fair: A score of 14–17;  
 Poor: A score of 8–13.  
2.3.4 Data extraction 
I extracted data in terms of variables and the relationship between variables identified in the 
individual studies. These variables were based on the outcomes of the studies. The common 
numerical variables I extracted were the reported levels of knowledge and the attitudes 
towards and acceptability of the vaccine. The results of the relationship between variables 
were extracted as text.  
  
I set up a data extraction form to summarize the characteristics of the included studies.  
These included study date the study was carried out, study setting, participant characteristics, 
and measurements of knowledge, attitudes, and acceptability. The data extraction form also 
summarised the main results of each study, including participants’ awareness of HPV and 
the HPV vaccine, knowledge of HPV and cervical screening, and intention to be vaccinated 
(or to vaccinate their child). Where reported, the predictors of acceptability and attitude were 
included as well. The data extraction form is provided in Appendix 1.  
2.3.5 Data Synthesis 
I used a narrative synthesis approach to synthesise the data for my systematic review. The 
studies included in my systematic review were quantitative ones, but the following factors 
made it difficult to undertake specific quantitative synthesis such as meta-analysis—pooling 
the findings of multiple studies in a statistical way. 
 The heterogeneous findings reported in the individual studies (some focused on 
knowledge, others on attitudes) 
 The inconsistent questions and indicators used to assess the knowledge and attitudes 
 The population variation of study participants (see below for description of included 
populations) 




Based on these conditions, the approach I took to data synthesis was narrative synthesis- 
summarising and explaining findings by using words, text, and tabulation. The techniques I 
chose to use for my synthesis are listed below. They include textual description, groupings, 
tabulation, common statistic, graphics, plots, sub-group analysis, and a critical discussion. 
The common statistic I chose to use was the median, given that the distribution of my 
findings (such as the percentage of knowledge level) was not symmetrical and that there 
were outliers (described later in this chapter). The median was thus preferred to present the 
average percentage, due to the heterogeneity of the studies and findings. 
 
In the preliminary synthesis, I grouped the studies into sub-groups in terms of study location, 
the rurality of participants, age group, ethnic group, and health professionals. In the 
exploration of relationships between the groups, I analysed the data based on these groups 
and then synthesised the results to see whether there was a pattern within or across them. 
Then, I used exploratory data analysis (EDA), which is a way to assess the population 
distribution of the variables. I used multivariate graphical EDA—a boxplot, barchart, and a 
map of China—to present the findings. In the assessment of synthesis, I decided to discuss 
the limitations at the individual study level and at review level. Limitations may include the 
selection bias, publication bias, and single reviewer bias. 
 
R statistical programming 3.0.1 (free online) was used to produce the boxplot and barchart. 
The map of China was generated online (http://www.dituhui.com/favorites/data).  
2.4 Results 
2.4.1 Study selection 
The database searches were run in December 2012. Studies were first reviewed by title and 
author(s) in each database, and duplicates were excluded. The search identified 251 articles 
at this stage and their abstracts were then reviewed. I excluded studies whose topic was not 
relevant to HPV infection and HPV vaccination or to knowledge of and attitudes towards 
HPV, whose methodology was not a survey, and which were not research reports. Fifty full-
text articles were included, and 3 were excluded because of difficulties in data extraction 
(their results were not clearly presented). Therefore, a total of 47 articles met the inclusion 
criteria and were therefore included in the systematic review. The selection process for 
studies is summarised in a Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram [134], see Figure 2-2. The excluded studies and the 




2.4.2 Study characteristics 
The included studies have been listed by study period, location, setting, instrument, sampling, 
and characteristics of participants in Table 2-5. 
 
Study period, location, and setting 
The study period was 2006–2011, with the majority (65.8%) of the studies being conducted 
in 2008 (19.1%), 2009 (17.0%), and 2010 (29.8%). The regions included in the studies 
covered 17 provinces out of 31 provincial regions (22 provinces, 4 municipalities, and 5 
autonomous regions) in China, from the west, the north, and the south. The definition of 
West, North and South China comes from China Statistical Yearbook [149], which provides 
information for central government reporting in China.  
 
Study settings (overlap exists in the categories below, Table 2-5 presents the details) 
 Hospital-based setting: 27 studies (57.4%)  
 Community-based setting:  9 studies (19.1%) 
 College/high school-based setting: 5 studies (18.5%) 
 Rural region setting (village-based): 9 studies (19.1%)  
 Urban region setting: 22 studies (46.8%) 
 Unknown/ not described: 5 studies (18.5%), 4 of which were in West China [150-152] 
 
Study sample size and participants 
All of the included studies were quantitative, cross-sectional studies, with sample sizes 
ranging from 100 to 9,865. Over half of the studies (55.3%) had a sample size greater than 
500; one third of studies had a sample size of 1,000 or more.  
 
Study participants 
 Gender: Most participants were female, and 5  studies (18.5%) [153-157] included male 
participants; but only two studies[153, 154] assessed the knowledge and attitudes of both 
genders.  
 Age: Seven (14.9%) included teenagers (13-18 year old) and young adults (18-26 year 
old) aged between 14 and 26 years old, and 4 of them [153-156] reported the awareness 
and knowledge in this group separately.  
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 Ethnicity: Five studies (18.5%) [150, 157-160] examined knowledge and attitudes among 
minority populations: 4 among the Xinjiang Uyghur people [157-160], 1 among Tibetan 
women [151], and 1 among Hui women[150].  
 Cervical cancer patients: two studies carried [160] out in Xinjiang recruited cervical 
cancer patients as their study participants.  
 Health professionals: Three studies [161-163] explored the issues among health 
professionals including doctors and nurses.   
 
Study instrument 
 Interview: one study used telephone interviews [164]  
 Questionnaire surveys: Eleven studies (23.4%) used interview-administrated 
questionnaires conducted by trained researchers (Table 2-5); the majority (31) of the 
remaining studies employed self-administrated questionnaires with closed questions. Of 
these studies, 4 were completed by health professionals (i.e. gynaecologists) on behalf of 
the participants [158-160, 165]; 3 were completed by health professionals giving their 
own knowledge and attitudes [161-163]; the others were filled in by the non-professional 
participants (women, young adults, and teenagers).  
 
Wording of the questions 
Different wording of the same question was used in the instruments of the studies in my 
review. Details are provided in Table 2-6. A summary is presented below. 
Thirty-one (66.0%) studies examined the awareness of HPV infection and the wording was 
different:  
 Have you had heard of HPV infection? 
 Do you know what HPV is? 
 
Thirty-six (76.6%) studies explored the knowledge of cervical cancer, and the wording again 
varied:  
 Is HPV the main cause of cervical cancer? 
 Can HPV lead to cervical cancer? 
 Is HPV an essential element in cervical cancer?  
 Is HPV related to cervical cancer?  





Sixteen studies (34%) reported on knowledge of STIs, and the wording was the same: 
 Is HPV sexually transmitted? 
 
Study sampling methods 
Over half of the included studies used probability sampling methods, and fewer than half did 
not describe their methods. Details are provided in Table 2-5. A summary is presented below. 
 Twenty-six  studies (55.3%) used cluster or random sampling methods  
 One study employed a convenience sampling method  
 Others did not describe the sampling method used 
 
 
2.4.3 Study quality 
Overview of the studies’ quality  
The quality assessment checklist included 17 items in total and except for 4 items (multiple 
comparisons, multivariate techniques, reliable measurement, and potential bias), the 
remaining items in the checklist were met by approximately 50% of the studies. Details are 
presented below and are also provided in Figure 2-3. 
 Eight of the criteria were met by 38 (approximately 80%) of the studies. These criteria 
included: description of the study population, outcomes, statistical tests, and study 
instruments.  
 Five criteria were met by 23 (approximately 50%) of the studies. These criteria included: 
inclusion/exclusion criteria for the study population, the assessment of confounding, at 
least 80% of enrolled participants completing the study.  
 Four criteria were met by 5 (10.6%) of the studies. These criteria included: multiple 
comparisons, detailed descriptions of the instrument’s development, and descriptions of 
potential bias.  
 
Based on the scores given to each paper, the included studies were categorized into good, 
fair, and poor quality. Eleven studies were ranked as good quality studies (having scored 18–
22) [98, 131, 132, 165-172], the majority of my included studies, 25 in total, were ranked as 
fair quality studies (having scored 14–17), and the remaining 11 studies were ranked as poor 
quality (having scored 8–13) [152, 155, 157, 159, 164, 173-178]. Details of the distribution 
of the different quality studies (with scores) are provided in Tables 2-7 and 2-8, and Figure 




Characteristics of good quality studies 
Good quality studies were good at sampling, measurement, data analysis, and the 
interpretation of results:  
 Description: The study population was well described in terms of its demographics.  
 Sampling: The sampling frame was specifically provided in terms of the date, location, 
participants, and study instrument.  
 Measurement: The measurement was mostly valid and had clearly defined outcomes.  
 Data analysis: The statistical methods were described, and the power calculation provided. 
Confounding was assessed and controllable variables were corrected when necessary. 
 
The most common feature of good quality studies was larger sample sizes. Eight out of 11 
good quality studies had over 1,000 participants. The most common weaknesses among good 
quality studies were a lack of assessment of the measurements’ reliability, and of evidence 
(i.e. theory-based model) of the instrument’s development. Hence, it is difficult to identify 
how these studies generated the questions and the extent to which participants’ responses 
reflected their real knowledge and attitudes. 
 
Furthermore, geographical patterns were found in the quality of the studies (See Table 2-9 
and Figures 2-5, 2-6 and 2-7). No studies carried out in West China (Xinjiang, Sichuan, 
Yunnan and Qinghai) (12 studies) were of good quality, and 5 (41.7%) were of poor quality. 
Studies carried out in North China were mostly of good quality, with one exception [177]. 
Descriptions of the poor studies are presented below. 
 
Moreover, there was no clear pattern in terms of the settings of the studies, given the lack of 
evidence of studies. None of the college/school-based studies were of good quality. There 
was no relation between date of publication (2008–2012) and whether or not a study was 
rated as good quality. 
 
Characteristics of fair quality studies 
The methodological strengths and weaknesses of the studies rated as ‘fair quality’ varied 
considerably. Some of them described a specific sampling frame, assessed the confounding, 
and made stratifications on the basis of demographics to adjust controllable variables. 
However, some did not provide inclusion/exclusion criteria for study groups, mention what 
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percentage of the enrolled participants complete the study, or have a reliable measurement 
method.  
 
There was no evident association of fair quality studies with sample size, geographical 
locations, study setting, or date of publication.  
 
Characteristics of poor quality studies 
The 11 studies rated as ‘poor quality’ studies shared some common weaknesses. Details are 
presented in the Table 2-7 and in the table in Appendix 3 
 Sampling methods were not described in the poor quality studies, including: 
o How they collected the sample (Was it a random or a convenient sampling?)  
o How the participants were recruited 
o What the representativeness of the population was  
 
 The instrument (questionnaire) was not evidence-based. Most studies reported the 
questions included in the questionnaire in a table, but the following issues regarding 
instrument development were not clear:  
o What the questions were based on  
o Whether there was a theoretical model for the development of the questionnaire  
o Whether there was a pilot study or cognitive interview to validate the instrument  
 
 No controllable variables were corrected or bias was limited. The 11 poor quality studies 
did not conduct any stratification or statistical adjustment to correct controllable variables 
(such as age, gender, and education). Even in the data-collection process, measures for 
confounding control had not been considered. Study results were mostly presented by 
descriptive analysis rather than association analysis.  
 
There is some evidence of a geographical pattern in the poor quality studies. Half of the poor 
quality studies were from West China—four from Xinjiang [152, 157, 159, 176] and one 
from Sichuan [174].  
 
Small sample size may be a factor in the poor quality studies. The typical sample size of the 
poor quality studies was 100–500, with the exception of one study, which recruited 
approximately 800 participants. Compared with sample size of the fair and good quality 
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studies—1,000 to 9000—the smaller sample size may imply limited research resources and 
poor quality fieldwork.  
2.4.4 Results of individual studies 
The main results of the individual studies are summarised in Tables 2-5 and 2-6. Awareness 
and knowledge of HPV and cervical cancer, and of the sexually transmitted nature of the 
HPV infection, and information on the acceptability of HPV vaccines are listed, as well as a 
comparison of study quality and the wording of questions. Additional findings (e.g. 
knowledge of HPV and genital warts, influencing factors in acceptability of the HPV vaccine) 
from included studies are detailed in Appendix 1.  
 
Of the 47 studies included in my review, a few of them need to be highlighted.  
 
M. He’s study in 2011 [169] is the only cross-regional (seven regions of China) study in my 
review with a relatively robust methodology (rated as a good quality study) and had the 
biggest sample size (9,865 adult women and 780 health professionals). Although no 
geographical pattern of knowledge and attitudes was reported in this study, this particular 
feature was not actually examined and the study’s findings were not displayed based on 
different locations. Hence, He’s study was not included in the later synthesis because of its 
cross-regional participants. The recruitment of participants in urban hospitals of tier-one 
cities suggested the findings (participants had a moderate level of knowledge, and a high 
level of acceptability) be more generalised to wealthy and well-educated people. Population 
migration may compromise the conclusion, although this information was not explored in the 
study.  
 
A. Guzhalinuer’s study [159] in 2007, together with A. Gulinuer’s study [160] in 2009, were 
the earliest papers (both surveys were carried out in 2006) included in my review, and did 
not explore the acceptability of HPV vaccines. These two studies were also the only ones in 
which the questionnaires were filled in by the gynaecologists on behalf of participants. The 
lowest knowledge (0%) of HPV infection was found in Guzhalinuer’s study of Uyghur 
cervical cancer patients in urban hospitals in Xinjiang. The poor quality and early date of this 
study may compromise the findings. C.L. Ren’s study [150] in 2010 was the only one to 
compare differences between ethnic groups in the level of knowledge of HPV causing 
cervical cancer: in this study Uyghur women had the lowest level of knowledge (5.2%), then 
72 
 
Hui (11.5%), then the Han population (20.6%). The lack of information on the study setting 
and details of recruitment limit the generalisability of results.  
 
L.N. Xu’s study [166] from 2009 and B. Cui’s studies [131] in 2010 and in 2008 were good 
quality studies which recruited participants from a wide age range (15–59 years in the first 
two, 15–54 years in the latter): teenagers, young adults, and adults. Their methodology was 
of a good quality, and differences were found between urban and rural areas in the former 
two studies. Nevertheless, no findings were reported in terms of specific age groups in these 
studies. A further five fair quality studies had the same feature, they are: D. Song’s 
study[179] in 2007 (15–54), J. Li’s study [167] in 2008, D.J. Zhao’s study[180] in 2010 (16–
54), L.X. Zhou’s study[181] in 2011 (16–55), and Y. Zhou’s study[177] in 2011 (17–59).  
2.4.5 Synthesis of results 
Awareness of HPV and knowledge of the relationship between HPV and cervical cancer, and 
of the sexually transmitted nature of HPV were the main issues examined in the studies 
included in my review. Figures 2-8 and 2-9 show the number of studies that explored 
individual items relating to knowledge, awareness, and the acceptability of the HPV vaccine. 
Outliers of data estimates existed in poor quality studies (Figure 2-10). Hence, the results 
from poor quality studies were less reliable when they were synthesised together with other 
included studies, and they were excluded accordingly when the median level of awareness 
and knowledge was calculated. The data presented below relates to the median estimate of 
the percentage and range of awareness and knowledge of HPV and the HPV vaccine. Studies 
of all levels of quality are shown in Table 2-9. The findings of the data synthesis are 
presented below. 
 
The overview of awareness and knowledge of HPV 
Thirty-two good  and fair quality studies and 7 poor quality studies included in my review 
reported on awareness, and two examined mainly knowledge (see above) among different 
groups of people in West, North, and South China. Figures 2-10 and 2-11 show the overview 
of awareness and knowledge in terms of differences in rurality, region, and study quality in 
boxplot of synthesis of results.  
 
The overall awareness was 31% (11–46%) for urban adult women and 9% (6–27%) for rural 
adult women. Awareness varied across different population sub-groups, Uyghur women had 
the lowest awareness (3.5%; 0–7%), followed by teenagers (10%, no range available as only 
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one study undertaken among teenagers), and young adults (29%, 17–50%), and the health 
professionals had the highest awareness at 90.5% (85–92%). See Tables 2-10 and 2-11.  
 
The knowledge of HPV among the participants in the included studies showed a similar 
pattern to awareness levels. The two most commonly identified knowledge items are listed in 
Tables 2-10 and 2-11 (knowledge of relationship between HPV and cervical cancer, and 
knowledge of the sexually transmitted nature of HPV). Other knowledge items were also 
examined. For example, ‘Do you know that HPV is asymptomatic? ‘or ‘Do you know that 
having multiple sexual partners could increase the risk of getting HPV infection?’, but the 
low number of studies (< 8) with a diverse study population limited the possibility for further 
data synthesis. Hence, these findings are summarised later in this chapter in text form. 
Figures 2-12 and 2-13 compare the two main knowledge criteria in different groups of 
people. 31% (9–57%) of urban adult women were aware of the relationship between HPV 
and cervical cancer; the percentage was 6% (3–49%) for rural adults, 7% (0–14%) for  adult 
Uyghur women. , 19% for teenagers (no range available as only one study undertaken among 
teenagers), 55% (53–75%) for young adults, and 79% (66–84%) for health professionals. 36% 
(20–55%) among urban adult women were aware of the sexually transmitted nature of HPV, 
19.5% (1–38%) for rural adults, 0% for adult Uyghur women, 16% for teenagers (no range 
available as only one study undertaken among teenagers), 60% (46–76%) for young adults, 
and 85% (78-92%) for health professionals.  
 
Differences by demographic of participants  
As a wide range of groups of participants were included in the systematic review, in order to 
report the results with less confounding, comparison was made between similar categories in 
terms of demographies. Seven poor quality studies were excluded from the estimate of 
median and comparison (see Tables 2-10 and 2-11). 
 
Differences by location and rurality  
Twenty-four good and fair quality and five poor quality studies reported differences of 
awareness and knowledge of HPV and cervical cancer according to rurality. The awareness 
and knowledge varied according to the regions from which the sample was collected. People 
from South China tended to be more aware and knowledgeable about HPV than those from 
North and West China, while people from West China had the lowest awareness. This 
geographical trend was observed among urban and rural adults (participants excluded 
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teenagers, young adults, health professionals, and minority ethnic groups). Rural adults 
showed less awareness of HPV than those from urban areas.   
 
Figure 2-12 shows clearly the pattern among urban and rural adults in different parts of 
China, in terms of the awareness and knowledge. From West, North, and South, the 
awareness was 23.5% (11–45%), 27.5% (12–46%), and 37.5% (21–41%) for urban adults, 
and 9% (6–17%) and 15.5% (4–27%) for north and south rural adults (no data was reported 
from West China). The knowledge of HPV and cervical cancer and the sexually transmitted 
nature of HPV are also presented in the figure.  
 
Differences by ethnicity  
Two fair  [158, 160] and one poor quality [159] study reported levels of knowledge among 
Uyghur people. Two of them recruited cervical cancer patients as their participants [159]; 
these were the only two studies of my review that were carried out among cervical cancer 
patients. Of the Uyghur respondents, 3.5% (0–7%) had heard of HPV [158, 160]; this figure 
was lower than in all the other studies. The knowledge of the link between HPV and cervical 
cancer and of the sexually transmitted nature of HPV were low, at 7% (0–14%) and 0% [158, 
160]. Figure 2-13 presents these results graphically in Uyghur people compared to other 
population sub-groups.  
 
Differences by age  
Three fair  [153, 154, 156] and one poor quality[155] study were carried out among 
teenagers and young adults—school/college-age students. Teenagers [156] had the lowest 
awareness (10%) and knowledge (19% knew of cervical cancer, 16% knew about its 
sexually transmitted nature); this was generally the same as for rural adults in North China, 
but lower than rural adults in South China.   
 
Young adults had relatively high awareness (21%; range of 17–50%) and knowledge (55% 
with a range of 53–75% for the link between HPV and cervical cancer; 60% with a range of 
46–76% for the sexually transmitted nature of HPV)[153, 154]. The level of knowledge was 
even higher than that of urban adults. Figure 2-13 presents these results graphically in 






Differences by gender 
Two fair quality studies [153, 154] conducted in colleges reported the influence of gender on 
knowledge. They indicated that male students know more (35.5%, range: 21–37%) about 
HPV than female students (27%, range: 17–37%) [153, 154]. However, the significance of 
these results is unclear due to the limited available evidence. 
 
Knowledge and awareness among health professionals 
Three fair quality studies [161-163] reported that health professionals (referring to 
obstetricians, gynaecologists, and nurses) had the highest awareness (89%; range: 85–92%) 
and knowledge (79% with a range of 66–84%; and 85% with a range of 78–92%). Figure 2-
13 presents these results graphically in health professionals in contrast to other population 
sub-groups.  
 
Other findings: misconceptions about the HPV infection and vaccine 
The asymptomatic nature and self-clearing nature of HPV infection 
One fair quality and two poor quality studies explored knowledge about HPV infection. Few 
participants knew that HPV infection could disappear spontaneously or be asymptomatic. 
Among obstetricians and gynaecologists, 34.3% knew that HPV infection could be self-
clearing [163], compared to 17.1% among adult women [177]. In terms of the asymptomatic 
nature of HPV, 15.6% of adult women [177] and 62.2% of college students [155] knew this 
fact.  
 
Risk factor of HPV: having multi-sexual partners  
One good quality [168] and two fair quality studies [153, 156] explored the increased risk of 
being infected with HPV by having multiple sexual partners, but they focused on different 
populations. These studies suggested that more male college students (76.2%) answered 
correctly than females (71.7%), but the result was not statistically significant [153]; 63% of 
teenagers[156] and 90% of urban women adults reported knowing about this risk factor 
[168].  
 
The general acceptability of the HPV vaccine 
Twelve good and fair quality studies and one poor quality study included in my review 
explored respondents’ willingness to be vaccinated, and 8 of them examined the willingness 
related to the participants’ daughters (See Figure 2-14 and Table 2-12). For adult women, the 
acceptability of the HPV vaccination both for themselves and for their daughters were 
76 
 
generally the same in North China (76.5% and 75%), and both figures were lower in South 
China (48% and 59%). Health professionals in North China tended to have lower 
acceptability for their daughters (28%), although the acceptability for themselves is higher 
(74%). No data was reported in West and South China for health professionals. These results 
are presented in Table 2-12.  
 
Eight studies explored the influencing factors in the acceptability of HPV vaccination, and 
Table 2-13 presents the results of these studies. The appropriate age, cost of the vaccine, and 
the source through which the vaccine was offered were presented in a descriptive way in 
these individual studies in my review; concerns about the vaccine’s adverse effects, 
effectiveness, and changes to future sexual behaviour are examined in the multivariate 
analysis of the individual studies. Details are shown below.  
 
The acceptable cost that people would be willing to pay  
Two good  [167, 169] and 6 fair quality [163, 179, 180, 182-184] studies examined the cost 
issues related to the HPV vaccine. A total of 55.2% (41.5–67.2%) of the participants wished 
the government could cover the whole cost of the vaccine. W. Xiao’s study and D.J. Zhao’s 
study reported that 84.2% and 93.9% of the participants would be willing to pay up to ¥100 
($16) for the vaccine. Y. Wu’s study found 71.2% of respondents indicated they wished to 
pay less than ¥500 ($80) for the vaccine. 
 
Acceptable sources for vaccine in the future 
Two good  [167, 169] and 5 fair quality [179, 180, 182-184] studies examined participants’ 
preferred source for the HPV vaccine in the future. Overall, 56.2% (55.4–82%) of the 
respondents would prefer to receive the vaccine if it was offered by the government, and 
35.7% would prefer to receive vaccines offered by medical institutions.  
 
The appropriate age for vaccination 
Three good and fair quality studies and one poor quality study explored the vaccination age. 
The fair quality study found that 72.4% of the health professionals believed the appropriate 
age for vaccination to be over 18 years old for girls [163]. The same results were also found 
among adults in two other good quality [167, 169] and one poor quality study [177]. M. He’s 
study [169] found that 10.7% of health professionals believed that married people should be 




Factors affecting willingness to accept HPV vaccine 
Two good  [167, 169] and four-fair quality [163, 180, 183, 184] studies examined the 
potential factors that might inhibit participants’ acceptance of HPV vaccines. These studies 
all explored the following two issues with a closed question using the same wording. Details 
are shown in Table 2-13. 
 No perceived risk of cervical cancer: 37.2% (4.9–68.6%) of respondents did not perceive 
they were at risk of cervical cancer.  
 Concerns about vaccines not being used on a large scale: 43.6% (12.3–63.9%) of 
respondents worried that the vaccines were not being used on a large scale.  
The other factors included: 
 Concerns about vaccine’s adverse effects: How many people worried about the safety of 
the vaccine in the studies in my review? 
o 61.8% of adult women and 69.0% of health professionals [169] 
o 67.3% of health professionals [163] 
o 26.6% adult women [183] 
o 24.1% of adult women [167] 
 Concerns about the vaccine’s effectiveness: How many people believe HPV vaccines 
could effectively protect humans from cervical cancer in these studies or hope it to be 100% 
effective? (‘Hope the HPV will be 100% effective’ is one of the options respondents can 
choose in the questionnaire used in these studies.) 
o 54.8% of health professionals [163] 
o 19.2% of adult women [183] 
o 63.3% of urban adults hoped the HPV vaccines would be 100% effective [180] 
o 65.9% of women adults believed the vaccine would be 100% effective[167] 
 Concerns about changes of future sexual behaviours: How many people were concerned 
that HPV vaccines would increase high-risk sexual activity?  
o 54.1% of the health professionals were concerned about this [163] 
 
No further stigmatising attitude towards HPV infection was explored in the studies included 
in my review. 
2.5 Discussion 
2.5.1 Key findings and interpretation 
My systematic review is the first I am aware of to examine and synthesise the awareness and 
knowledge of HPV in different geographical areas of China (West, North, and South China), 
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and also the first to make comparisons among different groups of Chinese people—Uyghur 
compared to the rest of the population (teenagers and adults), teenagers compared to young 
adults, urban compared to rural adults, and adult women compared to health professionals. 
Based on my review, differences of location and diversity in demographics might account 
for the different level of awareness, knowledge, and acceptability of HPV and vaccination.  
 
Awareness, knowledge, and acceptability 
In general, the awareness of HPV varied across different regions of China and groups of 
people in my review. The main contributors to the significant differences were location 
(West, North, and South), rurality, ethnicity, age, and whether or not the participants were 
health professionals. But rurality and ethnicity might be partially explained by the lower 
socioeconomic status of those groups. Uyghur and rural people live mostly in deprived 
regions with lower socioeconomic status and limited health resources. Details of the 
interpretation are discussed later in this section.  
 
The most frequently examined knowledge items were the relationship between HPV and 
cervical cancer, and the sexually transmitted nature of HPV. One weakness which might 
undermine the level of knowledge in the studies in my review was the difficulty in 
discriminating between participants in the studies who were already aware of HPV, and 
those who were not just prior to answering the knowledge questions. If the participants did 
not know about HPV, their knowledge of the relationship between HPV and cervical cancer 
and the sexually transmitted nature of HPV would not be accurate. But another possibility 
was that people would be more aware of HPV when it is related to cervical cancer and 
sexually transmitted disease rather than when they were asked about HPV alone. Hence, the 
results may have underestimated or overestimated the level of knowledge among participants.  
 
In general, the acceptability of HPV vaccines varied in terms of the vaccines’ target 
recipients (for oneself or for one’s daughter) and the participants’ health knowledge 
background (i.e. whether from the general population, or a health professional). The cost, 
source, and appropriate age for the HPV vaccines were the most examined issues in the 
studies.  
 
The impact of the demographic of participants on knowledge and attitudes 
Findings for some specific populations highlight the need to implement tailored HPV 
vaccination information campaigns. The first group of people that needs to be emphasised is 
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the Uyghur population, who had very limited knowledge of HPV. The second is health 
professionals, who displayed a lack of specialised knowledge regarding the HPV vaccine. 
The third group is female students in schools and colleges, who had a lower level of 
knowledge than males. Details are presented below.  
 
Ethnicity: Uyghur people 
The Uyghur population had the least awareness and knowledge compared to the majority 
Han population in China. A number of factors likely contribute to this. The Uyghur 
population resides in West China—a remote and less developed area. They have a 
completely different culture (most of them are Muslim) from the majority Chinese 
population, live in low economic conditions, receive a low level of education, and speak 
Uyghur and low levels of Mandarin; however, Mandarin is the language used for health 
education. These cultural and socioeconomic factors might contribute to the low levels of 
health-related knowledge among the Uyghur population.  
 
Moreover, three Uyghur studies were conducted through convenience sampling. Hence, 
limited sampling methods might be responsible for the less reliable results and thus limit 
their generalisability to the wider Uyghur population. Further, acceptability of the HPV 
vaccine was not examined in four Uyghur studies, and the predictive factors were not known, 
but there is some evidence [185, 186] that ethnicity is an important factor affecting the 
acceptability of HPV vaccination in the UK, where Muslim individuals were less likely to 
accept the vaccination. The extent to which specific religious or cultural beliefs may affect 
the acceptability of the HPV vaccine in Uyghur Muslim populations is unknown.   
 
Health professionals 
The health professionals lacked some specialised knowledge of HPV infection and vaccines 
(e.g. the type-specific outcomes of HPV, the optimal age for vaccination, and the purpose of 
screening) [187]. The reported low levels of acceptability of the HPV vaccine for their 
daughters (28%) may reflect the uncertainty of health professionals about the vaccine’s 
effects and safety. This lack of knowledge and uncertainty about the vaccine among health 
professionals might affect the advice they give to patients and the public. However, it is 
important to note that this low acceptability of health professionals of HPV vaccination for 
their daughters was only reported in one study (fair quality), carried out in one province with 
approximately 200 health professionals. Therefore the external validity of this finding is 
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limited, and further studies with health professionals are needed before any firm conclusions 
can be made.   
 
Age, rurality, gender, and other factors  
Teenagers in school, young adults in college, and adult women in rural areas had a similar 
level of awareness and knowledge, which was lower than that of adult women in urban areas. 
There is some indication that male students had more knowledge than female students, but 
confidence in these results is limited because this finding appeared in only two of the studies 
[153, 154]. Differences in knowledge by age may be attributed to differences in the level of 
education; rurality differences may be associated with socioeconomic status and limited 
health care services; and gender difference may be due to the conservative culture in China, 
where female students might feel embarrassed more often than males when inquiring about 
sexual issues in public and thus, have less knowledge. Very few studies (<8) in my review 
explored attitudes and acceptability, and the limited evidence prevented me from finding 
patterns in age, gender, and rurality.  
 
The findings of my review suggest demographical variations in knowledge about and 
attitudes towards HPV and vaccination. They also imply the health disparity existing in the 
diverse groups in China. Participants’ demographic characteristics might be associated with 
access to health care; for example, ethnic minority groups and rural adults may have a low 
level of socioeconomic status, live in deprived regions, and accordingly have less health care 
facilities and personnel. Hence, the implementation of a widespread vaccination programme 
needs to take health inequality into account. 
2.5.2 Methodological issues 
My systematic review has some methodological strengths and weaknesses in relation to 
search strategy, study quality, selection bias and instrument development. See below for 
detailed discussion.  
 
Search strategy 
The generalizability of my systematic review may be limited by my search strategy 
(determined by the objective of my review and feasibility of obtaining papers) – the time 
period covered, language included and locations covered. My search in the Chinese literature 
in the two databases (CNKI and Wanfang) finished by December in 2012, so literature 
published after this date would not have been included. However, my review provides 
81 
 
evidence of synthesis of results in the areas of knowledge and attitudes up to 2012, from 
which time point further updates would be valuable. There are language and location 
limitations in my search: , the search strategy was limited to  studies located Mainland China 
increase the comparability of results across studies. 
 
I have identified approximately twenty additional publications in the Chinese literature that 
may match my inclusion criteria in the two databases since 2012. Although not part of my 
systematic review, my initial scope of these new papers has found that more geographical 
regions are included, and more areas of attitudes towards HPV vaccination were discussed, 
than were included in the papers included in my systematic review. As my systematic review 
reported in this chapter was completed in 2013 I have not included these updated papers in 
my thesis. However, I plan to review these papers in more detail and will include relevant 




It is difficult to identify whether the study quality had an influence on differences in 
awareness and knowledge. For example, it seemed that the difference of study quality had an 
impact on the reported awareness of HPV. The level of awareness of HPV was 26% (6–
39%), 21% (-646%), and 12% (8–45%) respectively for good, fair, and poor quality studies 
[173, 175, 176]. But when the study location is taken together with the study quality it 
becomes clear that poor quality studies were mostly performed in West China, and good 
quality ones were carried out in North and South China. I may thus conclude that the factors 




Selection bias likely exists in the included studies due to the lack of evidence and description 
of recruitment, sampling methods, and response rate. It is difficult to conclude if the results 
of the studies can be generalised to the wider population.  
 
Except for two studies which recruited participants from local register agencies, the others 
did not provide details about the recruitment process, although the study setting was mostly 
reported. Five studies did not describe the study setting [150-152, 183]. The following 
questions are unanswered in most studies: 
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 Was the sample collected by door-to-door interviews or household registration? 
 Were the participants contacted by post, telephone, or another means? 
 Was there a reminder sent to the participants to improve the response rate? 
 
Out of a total 47 studies, 27 reported they had used convenience, cluster, or random 
sampling in the selection of participants, but none described the details of the sampling 
methods, such as:  
 How clusters were selected 
 How elements were identified in each cluster in the cluster sampling? 
Twenty of 47 studies did not report which sampling method they had used. 
 
Half of the studies (24) did not report on the following issues regarding response rate.  
 What was the response rate in the survey?  
 How many people approached, agreed to attend, and finally completed the survey? 
 
Sample size 
A larger sample size may suggest sufficient research resources and networks and the 
capacity to carry out big fieldwork projects. My review indicates that sample size might be 
related to study quality and study setting. Approximately 80% of the good quality studies 
had a sample size greater than 1,000, and all the poor quality studies had a sample size 
smaller than 500, with one exception, which had a sample size of 800. Twelve out of the 21 
population-based studies had a sample size greater than 1,000, most (24/27) of the hospital-
based studies had a small sample size (<1000). Bigger samples may be more generalisable to 
the wider population, but the sampling methods should also be taken into account regarding 
the representative.  
 
Instrument  
Lack of an evidence-based instrument: All the included studies lacked descriptive evidence 
of the instrument’s development. None of the studies used a theory-based model to formulate 
the questions. Questions generated from Li’s study’s instrument [124] were commonly used 
in other studies.  
 
Closed questions with dichotomous choice: Closed questions were employed in all the 
included studies, with a dichotomous choice response (participants were asked to choose 
“yes” or “no”). Compared to the 5- or 7-point Likert scale of response, commonly found in 
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Western literature, a dichotomous option might reflect limited details of the participants’ 
attitude toward HPV infection and vaccines. Open-ended questions were found in the only 
interview study in my review, but detailed descriptions of participants’ responses were not 
provided. 
 
Wording of the questions: It is difficult to identify whether the wording of the questions had 
any impact on levels of awareness and knowledge. For example, among Uyghur people, in 
terms of knowledge of the relationship between HPV and cervical cancer—with the 
exception of one study, which reported 14% of participants had the relevant knowledge (the 
same wording of the question was used in another Uyghur study revealing 0% knowledge)—
no Uyghur participants answered correctly no matter what the wording of question was [150, 
158-160].  
 
Interpretation of results 
Brief discussion: The Chinese literature in my review usually had a very short discussion 
section (which usually reported some methodological limitations and limited comparisons 
with Western literature). The requirement of a word limit in Chinese academic journals may 
contribute to this. Furthermore, Chinese studies were less likely to criticise on both 
themselves and other studies. Comparisons were made between studies (Chinese-Chinese, 
Chinese-Western), but critique was rarely found in these papers; for example, discussion on 
bias and confounding were ignored by most of the studies in my review.  
 
Single reviewer 
An additional limitation is that all steps in this systematic review of the Chinese language 
literature is, of course, that it was carried out by only one reviewer. I recognise that normally 
study selection based on review of abstracts and titles, reading of full text papers, quality 
assessment and data extraction steps are carried out by at least two reviewers. Given the 
language barrier inherent in this review, this was not possible. The objective of my 
systematic review was to review Chinese-language literature. The two databases I searched 
had English-language versions, but these were at very rudimentary level, not equivalent to 
the Chinese-language version in terms of the extent of the included Chinese literature, or the 
structure and layout of the databases. Moreover, there were no researchers including my 
supervisors in my Centre who were able to read and understand Chinese literature at the time 
I was doing my systematic review. Hence, it was not possible to have two reviewers reading 
the papers. However, I discussed each step and the content of included papers in detail with 
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my supervisors at each stage (study selection, data extraction and data synthesis) to reduce 
the single reviewer bias as much as possible.  
2.5.3 Comparisons with previous similar literature 
Comparison of findings 
Some of my findings were confirmed by a few systematic reviews, published since 2007, 
regarding knowledge of and attitudes towards HPV and vaccination. They are: 
 The low-moderate level of awareness and knowledge of HPV in China, comparable with 
other Asian and sub-Saharan African countries [188] [189] 
 The high level of acceptability of HPV vaccines in China, the same as in sub-Saharan 
Africa[188] [189] 
 The difference of awareness and knowledge among young adults and teenagers, the same 
as in Europe [190] 
 The high level of knowledge among health professionals [68] 
 The impact of ethnicity, similar to a review among people in the US [191] 
 The most examined (most concerned or not) predictors of HPV vaccines [191] 
[192] 
 
However, some of my findings were not consistent with the published studies: 
 The difference in awareness and knowledge between males and females [68] [190] 
The diversity of results described in published systematic reviews may limit reliable direct 
comparisons. Some further details and interpretation is given below.  
 
A. Young’s systematic review [188] was the first to examine HPV awareness, knowledge, 
and acceptability among Asians, including the Chinese (4 studies), Malaysians (1), South 
Koreans (1), and Thai populations (1) from 2006 to 2010. Mainland Chinese had the lowest 
level of awareness (16%), a moderate level of knowledge of HPV and cervical cancer (48%), 
and the highest level of acceptability of HPV vaccines (85%). The findings were generally 
similar to those in my review, but the comparison is less reliable as considerable variation  
(the survey methods, age groups of participants, and measure of awareness, knowledge, and 
acceptability) was found in the individual studies included in the Asian-Pacific review [188]. 
Perlman’s systematic review, carried out among Sub-Saharan African populations [189] in 
2014, had some similar findings to mine, i.e. that Africans from 6 sub-Saharan countries had 
a high level of HPV vaccine acceptability but low levels of knowledge and awareness of 




Marlow’s systematic review of studies among UK ethnic minorities carried out from 2006 to 
2009 reported different levels of acceptability of HPV vaccination—Chinese, 40%; other 
Asians, lower than 25%; and white and black, higher than 50% [185]. These findings suggest 
that Chinese people have relatively high acceptability among Asians, but still lower than the 
white and black groups. The sense of identity of Chinese people living abroad might partly 
explain the relatively low acceptability, even lower than the Chinese living in China.  
 
Samkange-Zeeb’s systematic review of studies carried out among European school-going 
adolescents from 1990 to 2010 [190] assessed awareness and knowledge of sexually 
transmitted diseases (STDs). Two studies included in the review, by M. Gottvall M [193] 
and C. Pelucchi [194] in 2008, found that young adults (71.6%) had a higher awareness of 
HPV than teenagers (16.4%). Males (young adults: 47.4%; teenagers: 5.4%) were less 
knowledgeable than females (young adults: 64.9%; teenagers: 12.1%) in terms of the 
sexually transmitted nature of HPV infection. The same gender pattern was also reported in 
an early systematic review in which studies on people in the US and UK formed the majority 
[68]. The review also found a high level of knowledge (of the link between HPV and 
cervical cancer, and of the asymptomatic nature of HPV) among health professionals (nurse 
practitioners, general practitioners, gynecologists, and physicians), which was 59–100% [68]. 
My review showed a similar pattern of awareness of HPV in young adults and teenagers, but 
difference between the two sub-groups was not that huge, and a similar high level of 
knowledge among health professionals.  
 
Nevertheless, the differing level of knowledge between males and females was found to be 
opposite in my review, and this might be explained by the lack of robust evidence in my 
review—there were very few good quality studies. It might also be explained by the social 
desirability bias. Female students in China would be more inclined to present themselves in a 
socially acceptable way to gain the approval of others. A conservative attitude towards 
sexual practices still exists in China, and female Chinese students might think that being 
knowledgeable on matters relating to sex is not good or acceptable for girls, so they may be 
more likely to conceal their knowledge when answering the questions in the survey. Male 
students may have fewer such considerations. But the limited evidence of the studies in my 




S. Klug’s systematic review, which reported on studies carried out in Western countries 
(mostly in the US) and published in 2012 [191], explored the predictors of HPV vaccine 
uptake. Ethnicity, the place of vaccination, and the age at vaccination were found to have 
impact on both the initiation and completion rates of HPV vaccination. But this study  was 
conservative in describing the impact of ethnicity, considering that it may be related to 
socioeconomic status and health insurance [191]. My review also found differences among 
ethnicities (Uyghur) in the knowledge of HPV and vaccines, and explored the potential 
health inequality that might be caused by the related location, culture, education, and health 
access. Hence, the impact of ethnicity on knowledge and acceptability of HPV vaccines 
requires exploration through further studies. 
 
L. Garcini’s systematic review [192] of studies among US residents and also published in 
2012 found that demographics and access-related issues (health providers’ recommendation 
and insurance coverage) were the most recognised factors influencing acceptability of HPV 
vaccines from a parental perspective. My review found the most frequently examined factors 
thought to be associated with HPV vaccine acceptability were the cost, followed by the 
source through which HPV vaccines were offered, and the vaccination age. However it is 
important to note that this is not a definitive ranking of the predictors of vaccine uptake 
among Chinese populations - I am not able to draw any conclusions on the relative 
importance of these due to the very limited evidence.    
 
To summarise, it is difficult to draw any definite conclusions based on the comparisons 
between my review among Chinese populations and other reviews carried out among other 
population groups. As several factors may influence the recipients’ knowledge and 
acceptability, and these included the study period (prior to or after the introduction of the 
vaccine), the vaccination campaigns in the country, the health insurance coverage, the 
demographics of participants, etc. Some similarities are seen though: in terms of the 
differences by the participants’ key demographics (i.e. age, rurality, or social-economic 
status) and the potential predictors of vaccination acceptability (i.e. cost-related issues), the 
findings were generally the same regardless of the ethnicity of participants and the country in 







Comparison of methodology 
Comparison of knowledge questions: Compared with Western literature, only a few the 
knowledge questions were used in the Chinese literature, both in surveys among the general 
population, and also in surveys among health professionals. In Western literature, apart from 
the basic knowledge (the health consequences of the HPV infection, and the transmission 
mode), knowledge questions also included:  
 Whether wart- and cancer-related HPV types differ  
 Whether there is a need for continued Pap screening after vaccination  
 Whether poor personal hygiene may lead to HPV infection.  
The knowledge of health professionals on these topics may affect the care they deliver and 
indirectly affect the uptake of screening and the acceptability of the vaccines. 
 
Comparison of acceptability questions: Some studies in the Western literature created 
hypothetical scenarios for the participants to rate the acceptability [122]. The scenarios 
included age of the recipient, severity of infection, vaccine efficacy, and the cost of the 
vaccine. In the Chinese literature, the method used to examine the acceptability were 
questions such as “Would you vaccinate your daughter or yourself?” regardless of the cost, 
efficacy, and various health outcomes of the vaccines. 
 
Comparison of attitude questions: Some studies in the Western literature formulated 
questions regarding attitudes towards the HPV vaccine based on the concept of the Health 
Belief Model [121]. But these were absent from Chinese literature. Moreover, attitudes on 
stigma were not explored in Chinese literature. Evidence [187] showed that a biased attitude 
(a perception of dirtiness and promiscuity for HPV positive people) from health 
professionals would affect the health care service uptake and create stigma among patients 
when receiving HPV testing or HPV vaccines. This illustrates the need of education to 
reduce stigma about HPV infection among health professionals.  
 
Instrument: All but two of the Chinese studies in my review lacked a description of the 
development of the survey instrument used in the report, whereas studies in the international 
literature more commonly describe the use of a validated instrument or conducted a pilot 
study to develop the survey instrument [195-197]. Chinese researchers might have done this 
and simply not described it in the literature due to the word limit. Because of the logistical 
issues and limited academic network in China (most Chinese researchers would not reply to 
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unknown academics via Chinese-language email), I did not contact each author to confirm 
this possibility.   
 
Data analysis: Four studies conducted multivariate analysis to take the confounding 
(demographics, socio-economic status, etc.) into account. The remainder carried out 
descriptive or bivariate analysis, ignoring the effect of age, gender, and rurality. Studies in 
the Western literature were more likely to use multivariate analysis, i.e. logistic regression 
[198-200], to examine whether there were independent factors influencing the acceptability 
of the HPV vaccines.  
 
To summarise, the methodological differences between Western and Chinese literature may 
be explained by the strict rules of reporting and the peer-review process in academic 
publication in Western literature, as well as the relatively low standard for publishing a paper 
in China. Failure to contact the authors of studies in my review may have resulted in the loss 
of some information.  
2.6 Conclusion 
This is the first systematic review of the Chinese-language literature examining the 
knowledge of and attitudes towards HPV and vaccination among Chinese populations that I 
am aware of. It is also the first study to assess the level of knowledge and acceptability from 
a general geographical perspective—West, North, and South China. Regional variations are 
commonly used by the government in China to allocate resources rationally. The variation in 
demographics also offers insight to health professionals and related stakeholders to take 
account of the potential health inequality and priority when implementing a national 
vaccination programme.  
 
My review is also among the first to assess the quality of Chinese literature based on a 
standardised quality assessment tool. Methodological issues raised in the comparison of 
Western and Chinese literature indicate that Western literature more often has good quality 
studies. Thus, in the future, Chinese surveys with clear recruitment and sampling frame, 
theoretical framework, valid instrument, and multivariate analysis should be developed to 
reduce the potential bias and provide more robust evidence in this field. This review 
facilitated the next stage of my PhD work, in which I carried out a questionnaire survey in 






















Box.  Summary of knowledge of and attitudes towards HPV and vaccination among 
Chinese 
Awareness 
A low level of awareness of HPV (<10%) was found:  
 in West China 
 among Uyghur women adults, rural women adults and teenagers. 
A moderate level of awareness of HPV (approximately 30%) was found:  
 in North and South China 
 among young adults and urban women adults. 
A high level of awareness of HPV (>85%) was found:  
 among health professionals. 
 
Knowledge 
The knowledge that HPV causes cervical cancer and HPV is sexually transmitted are the 
two most examined issues. The level of knowledge showed a similar trend to awareness. 
 
Acceptability 
A low level of acceptability of HPV vaccine (<30%) was reported:  
 among health professionals, for daughters. 
A moderate level of acceptability of HPV vaccine (50–60%) was reported:  
 in South China.  
A high level of acceptability of HPV vaccine (>70%) was reported:  
 in North China. 
 
Predictors of HPV vaccine 
The most examined predictors of HPV vaccine: 
 cost of the vaccine 
 source through which the vaccine would be offered 




Table 2-1:  Keywords used for literature search 
 
No. English keywords Chinese keywords (Pinyin) 
1 HPV HPV 
2 Human papillomavirus 人乳头瘤病毒 (renrutouliu bingdu) 
3 HPV vaccination HPV 疫苗 (HPV yimiao) 
4 HPV immunisation HPV 免疫 (HPV mianyi) 
5 knowledge 知识 (zhishi) 
6 perception 认知 (renzhi) 
7 awareness 知晓 (zhixiao) 
8 attitude 态度 (taidu) 
9 acceptability 接受度 (jieshoudu) 
10 will 意愿 (yiyuan) 
11 health behaviour 健康行为 (jiankangxiangwei) 
Search  #1 AND #5 
#1 AND #6 
#1 AND #7 
#1 AND #8 
#1 AND #9 
#1 AND #10 
#1 AND #11 
#2 AND #5 
#2 AND #6 
#2 AND #7 
#2 AND #8 
#2 AND #9 
#2 AND #10 
#2 AND #11 
#3 AND #5 
#3 AND #6 
#3 AND #7 
#3 AND #8 
#3 AND #9 
#3 AND #10 
#3 AND #11 
#4 AND #5 
#4 AND #6 
#4 AND #7 
#4 AND #8 
#4 AND #9 
#4 AND #10 













Cowley’s[142] Y For systematic review of observation 




Y For critical appraisal of observational studies Y Y 
EPHPP[139] Y For critical appraisal of observational studies Y N 
Newcastle-
Ottawa [140] 
Y For systematic reviews of observational 
studies 
Y N 
Reisch’s[144] N Specific for critical appraisal of therapeutic 
studies 
N N 
SIGN[143] Y The tool purpose is ambiguous and could be 
used in a few situations, e.g. guideline 





Y For systematic reviews of observational 
studies, specific for case-control and cohort 
studies 
Y Y 
Y: Yes; the tool included the key domain, was easy to use, and showed evidence of 
development. 






Table 2-3:  Quality assessment tool for systematic review  
 
 Questions  Yes No N/A 
Description 
1. Was the study population well described (including sample 
size justification)? 
   
Sampling 
2. Was there a specific sampling frame for the study population?    
3. Were there specific inclusion/exclusion criteria for all groups?    
4. Was the study population used as a probability sample?    
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
   
Measurement 
6. Were the primary/ secondary outcomes clearly defined?    
7. Was the measurement method valid?    
8. Was the measurement method reliable?    
Data analysis 
9. Did the researchers conduct statistical testing?    
10. Did the researchers report which statistical tests were used?    
11. Were multiple comparisons taken into consideration?    
12. Were the modelling and multivariate techniques appropriate?    
13. Was the power calculation provided?    
14. Was there an assessment of confounding?    
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study?    
16. Did the researchers correct for controllable variables to limit 
bias appropriately (randomisation, stratification or statistical 
adjustment)? 
   









Table 2-4:  The scores for each item on the checklist 
 Questions  Score  
Description 1. Was the study population well described? 2 
2: well described, including demographics (age, gender, etc.) and sample size 
1: some population characteristics were missing 
0: did not describe population 
Sampling 
2. Was there a specific sampling frame for the study 
population? 
2 
2: sampling frame, including recruitment context (when, where, who, and how) 
1: some characteristics were missing 
0: did not describe the sampling  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
2 
2: sampling criteria, including inclusion and exclusion criteria 
1: some criteria were missing 
0: did not describe the criteria 
4. Was the study population served as a probability sample? 2 
2: described sampling method, and it was a random sample 
1: described sampling method, but it was not a random sample 
0: did not describe the sampling method 
5. Was there other selection bias (low participation rate, all-
volunteer sample, or inappropriate control)? 
1 
1: no other selection bias 
0: there was other selection bias 
Measurement 
6. Were the primary/secondary outcomes clearly defined? 2 
2: outcomes were clearly defined 
1: outcomes were defined, but not very clearly 
0: outcomes were not described 
7. Was the measurement method valid? 1 
1: questions were provided and fulfil the objectives of the study 
0: questions were not provided 
8. Was the measurement method reliable? 1 
1: reliability test was conducted 
0: no reliability test was conducted 
Data analysis 
9. Did the researchers conduct statistical testing? 1 
1: statistical analysis was conduced 
0: statistical analysis was not conduced 
10. Did the researchers report which statistical tests were 
used? 
1 
1: statistical tests were used 
0: statistical tests were not used 
11. Were multiple comparisons taken into consideration? 1 
1: multivariate analysis was conducted 
0: multivariate analysis was not conducted 
12. Were the modelling and multivariate techniques 
appropriate? 
1 
1: multivariate analysis was appropriate 
0: multivariate analysis was not appropriate 
13. Was the power calculation provided? 1 
1: power calculation was provided 
0: power calculation was not provided 
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Table 2-4:  Continued 
 Questions  Score  
 14. Was there an assessment of confounding? 1 
1: confounding was assessed 
0: confounding was not assessed 
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study? 
1 
1: the response rate was over 80% 
0: the response rate was less than 80% 
16. Did the researchers correct for controllable variables to 
limit bias appropriately (randomisation, stratification, or 
statistical adjustment)? 
2 
2: the researchers corrected the controllable variables and reported the method  
1: the researchers did not clearly report the correction of variables 
0: the researchers did not correct the variables 
17. Did the researchers describe all potential bias or 
unmeasured confounders? 
1 
1: the researchers described potential bias or confounders 
0: the researchers did not describe potential bias or confounders 
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Table 2-5:  Characteristics of included studies 
 






Study setting Study instrument Age 
(years) 
Study population 
Chen J 2011 Zhejiang 2010 123 Urban hospital Telephone interview with HPV-positive 
women at home  
17-79 HPV-positive women who took the HPV test from 
March to April in 2010 at one hospital 
Cui B 2010 Liaoning 2010 1160 Urban hospital 
village 
Self-administered questionnaire filled in at 
one room in the selected hospitals and 
villages  
15-59 Outpatients, inpatients, and female relatives of the 
patients in seven urban hospitals; women residents 
in the selected villages 
Fu FH 2010 Beijing 2008 2952 Urban 
community 
Interview-administered questionnaire 
conducted by trained researchers 
40-95 Women residents in three communities in 
Shijingshan district from 7 –18April  2008 
Fan XF 2011 Xinjiang 2011 242 N/A Self-administered questionnaire filled in at  
the same time  at one place   
28-60 Women with low medical insurance 
Fan BJ 2010 Liaoning  2009 962 Urban hospital  Interview-administered questionnaire  
conducted by the researchers 
19-72 Women outpatients selected from a hospital 
within one year 
Feng SW 
2010 
Zhejiang  2010 1432 Urban and 
rural hospital 
Self-administered questionnaire filled in at 
selected hospitals  
20-50  782 women from urban hospitals, 650 women 
from rural hospitals within six months 
Gao L 2012 Yunnan 2008 2648 Village Interview- administered questionnaire  
conducted by the researchers 




Xinjiang 2008 560 Village Interview- administered questionnaire  
conducted by the researchers 
N/A 90%  Uyghur men were from rural regions, 10%  
Uyghur men were from urban regions in Hetian 
district 
Gulinuer A  
2010 
Xinjiang 2006 248 Urban hospital  Self-administered questionnaire filled in at 
the selected hospital by the gynaecologists 
20-65 Women outpatients between March and June in 
2006 at Bozhou hospital in Xinjiang 
Guzhalinuer 
A 2007 
Xinjiang 2006 400 Urban hospital  Self-administered questionnaire filled in at 
five hospitals by the gynaecologists 
23-76 Uyghur Cervical cancer patients in five hospitals 
in Xinjiang  
Huang GF 
2011 
Guangdong 2008 196 Urban hospital  Self-administered questionnaire filled in at 
the selected hospital  
20-58 Women during a certain time period at the 
selected hospital 








Urban hospital Self-administered questionnaire filled in at 
14 hospitals in seven regions of China   
18-82 Women outpatients and health professionals 
outpatients at 14 hospitals from 2007 to 2009 
He X 2010 Henan 2009 2102 College Self-administered questionnaire filled in 
during class  
16-26 1093 female and 1009 male students from two 







Self-administered questionnaire filled in at 
one place in the community 
20-65 Women residents in one community of Hong Kou 
district of Shanghai city in 2010 
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Table 2-5:  continued  
 






Study setting  Study instrument Age (years) Study population 
Lu KN 2008 Beijing 2008 104 Urban hospital Self-administered questionnaire filled in at 
the selected hospitals   
19-69 Outpatients and inpatients selected from 3 
hospitals from Sep to Dec in 2007 
Li J 2008 Beijing 2008 1013 Urban 
community 
Interview-administrated questionnaire 
conducted by the trained researchers 
15-54 Women residents in Zhanlanlu community of 
Beijing city from June of 2006 to June of 2007 
Li JM 2008 Guangdong 2008 304 Urban 
community 
Self-administered questionnaire filled in at 
one place in the community  
18-60 Women residents in one community in Baoan 
district of Shenzhen city 
Li XP 2007 Zhejiang 2007 300 Urban 
community 
Self-administered questionnaire filled in at 
one place in the community 
20-50 Women residents in Nanpu community of 
Wenzhou city  
Li J 2011 Liaoning 2011 160 Urban and 
rural hospital 
Self-administered questionnaire filled in at 
one place in the hospital 
36.6±9.6 Doctors and government officials 
Li CT 2011 Xinjiang 2011 960 N/A Self-administered questionnaire  20-39 Women residents in Tianshan district in Urumqi 
city 
Liu ZH 2012 Hunan 2011 848 High school Self-administered questionnaire filled in 
during class 
14-18 396 male and 452 female high school  students 
in Xiangtan city 
Long XE  Zhejiang N/A 286 College Self-administered questionnaire filled in 
during class  
>18 Medical testing major students from selected 
college 
Ma D 2012 Hebei 2011 198 Urban hospital Self-administered questionnaire filled in at 
the selected hospital 
20-54 49 doctors and 149 nurses from selected 
hospital in Tangshan city 
Ma D 2010 Beijing 2010 249 Urban 
community 
and hospital 
Self-administered questionnaire filled in at 





100 community women residents from a 
selected community and  149 women 
outpatients from a selected hospital 
Ren CL 
2011 
Xinjiang 2010 1005 N/A Interview-administered questionnaire 
conducted by researcher 
18-58 355 Han, 328 Uyghur, and 322 Hui women 
from Malan district in Xinjiang region 
Song D 2007 Shanxi  2007 957 Village Self-administered questionnaire filled in at 
selected villages  
15-54 Women from 26 villages in Xiangyuan county 
in Shanxi province 
Sun J 2010 Liaoning 2010 310 Urban hospital Self-administered questionnaire filled in at 
selected hospital  
21-60 Women from one hospital in Dalian from Feb to 
Mar in 2010 
Shi YY 2011 Heilongjiang 2010 1200 Village and 
urban hospital 
Self-administered questionnaire filled in 
by health professional researchers 
20-60 600 women residents from three selected 




Table 2-5:  continued  
 
 






Study setting  Study instrument Age 
(years) 
Study population 
Wang HQ 2011 Hebei 2011 257 Urban hospital Self-administered questionnaire filled in  at 
the four selected hospitals  
20-53 Obstetricians and Gynaecologists from four 
hospitals in Tangshan city 
Wen LZ 2010 Xinjiang 2009 400 Urban hospital Self-administered questionnaire filled in  at 
the selected hospital  
22-48 Women outpatients at one hospital selected 
from Jan to June in 2009 
Wang QL 2011 Sichuan 2010 886 Village Interview-administrated questionnaire 
conducted by the trained researchers 
41.9 
(mean) 
Women residents from 3 counties in north 
Sichuan mountain areas 
Wu Y 2011 Zhejiang 2010 489 N/A Self-administered questionnaire filled in at 
one place  
>15 Women residents in Hangzhou city 
Wang XM 2012 Shanxi 2010 2269 Urban hospital 
and village 
Interview-administered questionnaire by 
researcher 






245 Urban hospital Self-administered questionnaire filled in at 
the selected hospitals by the gynaecologists  
23-85 Uyghur cervical cancer patients selected from 
five hospitals from Jan of 2004 to Jul of 2006 
Xiao W 2010 Beijing 2008 368 Urban hospital Self-administered questionnaire filled in  at 
the selected hospital  
21-74 Women outpatients selected from one hospital 
from Jan to Apr in 2008 
Xing YX   Qinghai 2009 200 N/A Self-administered questionnaire filled in by 
local doctors 
18-63 136 Tibetan women residents and 64 Han 
women population 
Xu CY  2010 Beijing 2007–
2008 
6339 Urban and 
rural 
community 
Self-administered questionnaire filled in at 
one place in the community 
25-54 Women residents from four districts of city, 
four districts of inner suburbs and four 
districts of outer suburbs 
Xu LN   Beijing, 
Tianjin, 
Shanxi 
2009 1666 Urban hospital 
and village 
Self-administered questionnaire filled in at 
one place in the hospital and  selected 
villages 
15-59 640 from urban residents and 1026 from rural 
residents in the three provinces from June to 
November in 2009 
Xie Y 2011 Sichuan  2010 2000 Village Interview-administered questionnaire at 
selected villages 
30-59 Women from 3 counties in August in 2010 
Ye JR 2011 Guangdong  2010 1120 Village Self-administered questionnaire filled in at 
selected villages 
23-51 560 married women from two villages from 
January of 2010 to January of 2011 
Zhang LJ 2009 Guangdong 2006–
2007 
100 Urban hospital Self-administered questionnaire filled in at 
one place in the hospital 
18-54 Women patients from on hospital from 
December of 2006 to September of 2007 
Zhao DJ 2010 Shanghai  2009 997 Urban 
community 
Self-administered questionnaire filled in at 
one place  
16-54 Women residents in two selected 
communities in Shanghai 
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Table 2-5:  continued  
  






Study setting  Study instrument Age 
(years) 
Study population 
Zhou JY 2010 Beijing 2008 2000 Urban and 
rural 
community 
Self-administered questionnaire filled in at 
one place 
30-59 Women residents in urban and  rural 
community from April to December in 2008 
Zhou LX 2011 Guangdong 2010 752 Urban 
community 
and hospital 
Interview-administered questionnaire at 
selected community and hospital 
16-55 Women residents from selected community 
and women outpatients from selected hospital 
Zhou Y 2010 Hunan  2009 207 College Self-administered questionnaire filled in 
during class 
17-21 64 male and 143 female first-year students 
from  selected college 
Zhou Y 2012 Hunan  2009 2239 College  Self-administered questionnaire filled in the 
dormitory 
17-25 1428 male and 865 female students from  
selected college 
Zhou Y 2011 Shanxi  2010 500 Village  Interview-administered questionnaire at 
selected village 




Table 2-6:  Main results of included studies in the comparison of study quality and wording of questions  














Cui B 2010 Good  17 





HPV can lead to CC 
64-68 (rural-
urban) 
Are you willing 














HPV can lead to CC   
He M  2011 Good  33 
Have you heard 
of HPV 
  90 (HPs) HPV is the essential element of CC 
70-72 (urban 
F-HPs) 
Are you willing 
to be vaccinated 
Jiang SY  
2010 
Good  25-42 N/A   
34 
HPV is the main cause of CC   
Li J  2008 Good  31 
Have you heard 
of HPV 
  
52 When referring to HPV, your first 
thought is… 
76 
Are you willing 
to be vaccinated 
Li JM  2008 Good    55 
HPV is sexually 
transmitted 
31 
HPV is the main cause of CC   
Ma D  2010 Good  
  
15-29 
HPV is sexually 
transmitted 
24-33 HPV is the main cause of CC  
 
Sun J 2010 Good  
 
 20 
HPV is sexually 
transmitted 
24  HPV is the main cause of CC  
 
Shi YY 2011 Good  
  
  13  HPV is related with CC   






HPV is sexually 
transmitted 
   
 
Xu LN   Good  
12-33 (rural-
urban) 
Have you heard 
of HPV   
63 HPV can lead to CC 
73-79 (rural-
urban) 
Are you willing 
to be vaccinated 
Fu FH  2010 Fair  16 
Do you know 
what HPV is 
  7 
When referring to HPV, your first 
thought is… 
  
Fan BJ 2010 Fair  24 
Have you heard 
of HPV 
  57 
When referring to HPV, your first 
thought is… 
88 
Are you willing 
to be vaccinated 
Gao L  2012 Fair      3 (rural) HPV is the essential element of CC   
Gulinuer A  
2010 
Fair  7 (Uyghur) 
Do you know 
what HPV is 
  14 (Uyghur) HPV is related with CC   
Huang GF  
2011 
Fair        32 
Are you willing 
to be vaccinated 
He X  2010 Fair  37-50 (F-M) 
Have you heard 
of HPV 
60-76 (F-M) 
HPV is sexually 
transmitted 
53-55 (M-F) HPV can lead to CC   
STI: sexually transmitted infection; CC: cervical cancer. 
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Table 2-6:  Continued 










Wording of questions Acceptance 
(%) 
Wording of questions 
Lu KN 2008 Fair  46 




   












Li CT  2011 Fair  11 
Do you know 
what HPV is 
     
 
Liu ZH  2012 Fair  10 
Have you heard 
of HPV 
16 
HPV is sexually 
transmitted 
19 
HPV can lead to CC 
 
 
Ma D  2012 Fair  
77-92 
(HPs) 




HPV is sexually 
transmitted 
50-82 









HPV is the main cause of CC  
 
Song D 2007 Fair  6 (rural) 





When referring to HPV, your 
first thought is… 
97 (rural) 
Are you willing to be 
vaccinated 
Wang HQ  
2011 
Fair  92 (HPs) 
Have you heard 
of HPV 
92 (HPs) 
HPV is sexually 
transmitted 
84 (HPs) 




Wu Y 2011 Fair     
 
  48 
Are you willing to be 
vaccinated 
Xiamixinuer A  
2010 
Fair  0 (Uyghur) 
Do you know 
what HPV is 
0 (Uyghur) 
HPV is sexually 
transmitted 
0 (Uyghur) HPV is a risk factor of CC  
 
Xiao W  2010 Fair  46 




  73 
Are you willing to be 
vaccinated 
Xing YX   Fair  
2 (Han, 
Tibetan) 
Do you know 
what HPV is 
 
 
   
 
Xu CY  2010 Fair      27 HPV is a risk factor of CC   
Xie Y  2011 Fair    1 (rural) 
HPV is sexually 
transmitted 
   
 
Ye JR  2011 Fair  4 (rural) 
Do you know 
what HPV is 
 
 
3 (rural) HPV is related with CC  
 
Zhao DJ  2010 Fair  21 




  66 
Are you willing to be 
vaccinated 
STI: sexually transmitted infection; CC: cervical cancer.  
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Table 2-6:  Continued 










Wording of questions Acceptance 
(%) 
Wording of questions 
Zhou JY  
2010 
Fair      16 HPV is the essential element 
of CC 
  
Zhou LX  
2011 
Fair  36-46 Have you 
heard of HPV 
      
Zhou Y  2012 Fair  17-21 (F-
M) 
Have you 
heard of HPV 
46 HPV is sexually 
transmitted 
75 HPV can lead to CC   
Chen J  2011 Poor     70 (HPV P) HPV is related with CC   
Fan XF  2011 Poor    25 HPV is sexually 
transmitted 
22  HPV is the main cause of 
CC 
  
Guzhanuer A  
2012 
Poor  0 (Uyghur 
M) 
Do you know 
what HPV is 
  0 (Uyghur 
M) 




A  2007 
Poor  0 
(Uyghur) 
Do you know 
what HPV is 
  0 (Uyghur) HPV is related with CC   
Li XP  2007 Poor  8 Have you 
heard of HPV 
12 HPV is sexually 
transmitted 
22 HPV is related with CC   
Long XE   Poor  3-74 Do you know 
what HPV is 
81 HPV is sexually 
transmitted 
    
Wen LZ  
2010 
Poor  45 Do you know 
what HPV is 
  30 HPV is related with CC   
Wang QL  
2011 
Poor      0.2 (rural) HPV is related with CC   
Zhang LJ  
2010 
Poor    28 HPV is sexually 
transmitted 
11 HPV is related with CC   
Zhou Y  2010 Poor  18 Have you 
heard of HPV 
30 HPV is sexually 
transmitted 
86 HPV can lead to CC   
Zhou Y  2011 Poor  12 (rural) Have you 
heard of HPV 
  70 (rural) HPV can lead to CC 82 (rural) Are you willing to be 
vaccinated 
STI: sexually transmitted infection; CC: cervical cancer   
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Table 2-7:  Scores of each items of each individual study based on the scoring standard in the checklist 
 
Quality Study Score 











MC* MT* PC* C* RR* CC* bias 
Good 
Feng SW 2010 22 2 2 2 2 1 2 1 1 1 1 1 1 1 1 0 2 1 
Cui B 2010 20 2 2 2 2 1 2 1 0 1 1 0 0 1 1 1 2 1 
Xu LN  20 2 2 2 2 1 2 1 0 1 1 1 1 1 1 1 1 0 
Jiang SY 2010 19 2 2 2 2 1 2 1 0 1 1 0 0 1 1 1 2 0 
Li J 2008 19 2 2 2 2 1 2 1 0 1 1 0 0 1 1 0 2 1 
Li JM  2008 19 2 2 2 2 1 2 1 0 1 1 0 0 1 1 0 2 1 
Shi YY 2011 19 2 2 2 2 1 2 1 0 1 1 0 0 1 1 1 1 0 
He M 2011 18 2 2 0 2 1 2 1 0 1 1 1 1 1 1 0 1 1 
Ma D 2010 18 2 2 2 1 1 2 1 1 1 1 0 0 1 1 0 2 0 
Sun J 2010 18 2 2 2 1 1 2 1 1 1 1 1 1 1 0 1 0 0 
Wang XM 2012 18 2 2 2 2 1 2 1 0 1 1 0 0 1 1 0 2 0 
Fair 
Fan BJ 2009 17 2 2 0 2 1 2 1 0 1 1 0 0 1 1 1 2 0 
Gao L 2012 17 2 2 1 0 0 2 1 0 1 1 1 1 1 1 0 2 1 
He X 2010 17 2 2 0 2 1 2 1 0 1 1 0 0 1 1 1 2 0 
Liu ZH 2012 17 2 2 0 2 1 2 1 1 1 1 1 1 1 0 1 0 0 
Wang HQ 2011 17 2 2 0 2 1 2 1 0 1 1 0 0 1 1 1 2 0 
Zhou Y 2012 17 2 2 0 2 1 2 1 0 1 1 0 0 1 1 1 2 0 
Li CT 2011 17 2 1 2 1 1 2 1 0 1 1 0 0 1 1 0 2 0 
Lu KN 2008 16 2 2 0 1 1 2 1 0 1 1 0 0 1 1 1 2 0 
Li J 2011 16 2 1 1 2 1 2 1 0 1 1 0 0 1 0 1 2 0 
Ma D 2012 16 2 2 0 1 1 2 1 1 1 1 0 0 1 1 1 1 0 
Xu CY 2009 16 2 2 2 2 1 2 1 0 1 1 0 0 1 0 1 0 0 
Xie Y 2011 16 2 2 2 2 1 2 1 0 1 1 0 0 1 0 1 0 0 
Ye JR 2011 16 2 2 2 2 1 2 1 0 1 1 0 0 1 0 1 0 0 
Gulinuer A 2009 15 2 2 1 0 1 2 1 0 1 1 0 0 1 1 0 2 0 
Ren CL 2011 15 2 1 2 1 1 2 1 0 1 1 0 0 1 0 0 2 0 
Song D 2007 15 2 2 2 0 1 2 1 0 1 1 0 0 1 1 1 0 0 
Wu Y 2011 15 2 0 0 2 1 2 1 0 1 1 0 0 1 1 1 2 0 
*Abbreviations of words are used due to the limited space in the table.  
SP: study population; SF: Sampling frame; I/E: inclusion/exclusion; P: probability; SB: selection bias; VM: valid measurement; RM: reliable measurement; ST: statistical 
testing; MC: Multiple comparison; MT: Multivariate techniques; PC: Power calculation; C: confounding; RR: response rate; CC: correct for controllable variables 
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Table 2-7: continued 
Quality Study Score 











MC* MT* PC* C* RR* CC* bias 
Good 
Xiao W 2009 15 2 2 0 0 1 2 1 0 1 1 0 0 1 1 1 2 0 
Zhou JY 2010 15 2 1 2 2 1 2 1 0 1 1 0 0 1 0 1 0 0 
Zhou LX 2011 15 2 1 2 2 1 2 1 0 1 1 0 0 1 0 1 0 0 
Fu FH 2010 14 2 2 1 0 1 2 1 0 1 1 0 0 1 1 1 0 0 
Huang GF 2011 14 2 1 2 0 1 2 0 0 1 1 0 0 1 1 0 2 0 
Xiamixinuer A 2009 14 2 2 1 0 1 2 1 0 1 1 0 0 0 1 0 2 0 
Xing YX  14 2 2 0 0 1 2 1 0 1 1 0 0 1 1 0 2 0 
Zhao DJ 2010 14 2 2 0 2 1 2 1 0 1 1 0 0 1 1 0 0 0 
Poor 
Chen J 2011 13 2 2 1 0 1 2 1 0 1 1 0 0 1 0 1 0 0 
Zhang LJ 2009 13 2 2 2 0 1 2 1 0 1 1 0 0 1 0 0 0 0 
Guzhanuer A 2012 12 1 2 1 0 0 2 1 0 1 0 0 0 1 1 0 2 0 
Wang QL 2011 12 2 2 0 2 1 2 1 0 1 1 0 0 0 0 0 0 0 
Zhou Y 2010 12 2 2 0 0 1 2 1 0 1 1 0 0 1 0 1 0 0 
Fan XF 2011 11 2 0 2 0 1 2 1 0 1 1 0 0 1 1 1 0 0 
Li XP 2007 11 2 2 0 0 1 2 1 0 1 1 0 0 1 0 0 0 0 
 Wen LZ 2009 11 2 2 0 0 1 2 1 0 1 1 0 0 1 0 0 0 0 
 Guzhalinuer A 2007 10 2 2 1 0 1 2 1 0 1 0 0 0 0 0 0 0 0 
 Zhou Y 2011 10 2 0 0 0 1 2 1 0 1 1 0 0 1 1 0 0 0 
 Long XE  8 1 1 0 0 1 2 1 0 1 0 0 0 0 0 1 0 0 
*Abbreviations of words are used due to the limited space in the table.  
SP: study population; SF: Sampling frame; I/E: inclusion/exclusion; P: probability; SB: selection bias; VM: valid measurement; RM: reliable measurement; ST: statistical 






Table 2-8:  Quality level of included studies 
 
Scores Number of studies Quality of studies 
18-23 11 Good  
14-17 25 Fair  
8-13 11 Poor  
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Good Wang XM et al 2012   Shanxi 2269 
Xu LN et al   Beijing, Tianjin, Shanxi 1666 
Cui B, 2010  Liaoning 1160 
Shi YY, 2011  Heilongjiang 1200 
Li J et al, 2008  Beijing 1013 
Sun J, 2010  Liaoning 310 
Ma D et al, 2010  Beijing 249 
Fair Xu CY et al, 2009  Beijing 6339 
Fu FH et al, 2010  Beijing 2952 
He X et al, 2010  Henan 2102 
Zhou JY et al, 2010  Beijing 2000 
Song D, 2007  Shanxi 957 
Fan BJ, 2009  Liaoning 962 
Xiao W et al, 2009  Beijing 368 
Wang HQ et al, 2011  Hebei 257 
Ma D et al, 2012  Hebei 198 
Li J, 2011  Liaoning 160 
Lu KN, 2008  Beijing 104 
Poor Zhou Y et al, 2011  Shanxi 500 
South 
China 
Good Feng SW, 2010  Zhejiang 1432 
Jiang SY et al, 2010  Shanghai 944 
Li JM et al, 2008  Guangdong 304 
Fair Zhou Y et al, 2012  Hunan 2239 
Ye JR et al, 2011  Guangdong 1120 
Zhao DJ et al, 2010  Shanghai 997 
Liu ZH et al, 2012  Hunan 848 
Zhou LX et al, 2011  Guangdong 752 
Wu Y et al, 2011  Zhejiang 489 
Huang GF et al 2011  Guangdong 196 
Poor Li XP et al, 2007  Zhejiang 300 
Long XE et al  Zhejiang 286 
Zhou Y et al, 2010  Hunan 207 
Chen J et al, 2011  Zhejiang 123 
Zhang LJ et al, 2009  Guangdong 100 
West 
China 
Fair Gao L et al, 2012  Yunnan 2648 
Xie Y et al, 2011  Sichuan 2000 
Ren CL et al, 2011  Xinjiang 1005 
Li CT et al, 2011  Xinjiang 960 
Gulinuer A et al, 2009  Xinjiang 248 
Xiamixinuer A et al, 2009  Xinjiang 245 
Xing YX et al  Qinghai 200 
Poor Wang QL et al, 2011  Sichuan 886 
Guzhanuer A et al, 2012  Xinjiang 560 
Guzhalinuer A et al, 2007  Xinjiang 400 
Wen LZ et al, 2009  Xinjiang 400 




















Urban adult women 
North 
China 
Good Xu LN et al   Beijing, Tianjin, Shanxi 33     
Li J et al, 2008  Beijing 31 52   
Wang XM et al 2012   Shanxi 24     
Cui B, 2010  Liaoning 17 9   
Sun J, 2010 Liaoning   24 20 
Ma D et al, 2010  Beijing   28  22  
Fair Lu KN, 2008 Beijing 46     
Xiao W et al, 2009  Beijing 46     
Fan BJ, 2009 88 Liaoning 24 57   
Fu FH et al, 2010  Beijing 16 7   
South 
China 
Good Feng SW, 2010  Zhejiang 39  40  50  
Jiang SY et al, 2010  Shanghai 34 34  
Li JM et al, 2008  Guangdong  31 55 
Fair Zhou LX et al, 2011 Guangdong 41   
Zhao DJ et al, 2010  Shanghai 21    
Poor Li XP et al, 2007  Zhejiang 8  22 12 
Zhang LJ et al, 2009  Guangdong  11 28 
West 
China 
Fair Li CT et al, 2011  Xinjiang 11    
Poor Wen LZ et al, 2009  Xinjiang 45  30  
Rural women adults 
North 
China 
Good Cui B, 2010  Liaoning 17  6   
Xu LN et al   Beijing, Tianjin, Shanxi 12    
Wang XM et al 2012   Shanxi 6    
Fair Song D, 2007  Shanxi 6  35   
Poor Zhou Y et al, 2011  Shanxi 12  70  
South 
China 
Good Feng SW, 2010  Zhejiang 27  49  38  
Fair Ye JR et al, 2011  Guangdong 4  3   
West 
China 
Fair Gao L et al, 2012  Yunnan  3   
Xie Y et al, 2011  Sichuan   1  
Poor Wang QL et al, 2011  Sichuan  0.2   





















Uyghur adult women  
 West 
China 
Fair Gulinuer A et al, 2009  Xinjiang 7  14   
Xiamixinuer A et al, 2009  Xinjiang 0 0 0 
Poor Guzhalinuer A et al, 2007  Xinjiang 0  0   
Teenagers (14-18 years) 
South 
China 
Fair Liu ZH et al, 2012  Hunan 10 19 16 
Young adults (16-26 years) 
North 
China 
Fair He X et al, 2010  Henan 37 (F*) 55 (F*) 60 (F*) 
50 (M*) 53 (M*) 76 (M*) 
South 
China 
Fair Zhou Y et al, 2012  Hunan 21 (M) 75 46 
17 (F)   




Fair Li J, 2011  Liaoning 89  79   
Ma D et al, 2012  Hebei 85 66 78 
Wang HQ et al, 2011  Hebei 92  84 92 


























Good Cui B, 2010  Liaoning 66   
Li J et al, 2008  Beijing 76 63   




77   
Fair Xiao W et al, 
2009  
Beijing 
73 75   
Song D, 2007  Shanxi 97 97   
Fan BJ, 2009  Liaoning 88   
Ma D et al, 2012  Hebei  34 28  
Li J, 2011  Liaoning  74  
Poor Zhou Y et al, 
2011  
Shanxi 
82 63   
South 
China 
Fair Wu Y et al, 2011  Zhejiang 48 64   
Huang GF et al 
2011  
Guangdong 
32   
Zhao DJ et al, 
2010  
Shanghai 
66 54   
*GP: general population; HPs: health professionals 
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The source for the vaccine people would 
prefer if it is offered 
The cost people agree or would 
like to pay 
Have not 
been used 

















cover all the cost 
% 
Would like to 




Good Li J et al, 2008 Beijing GP* 55.8 41.8 2.0 57.1  61.5 58.2 
Fair 
 
Fan BJ, 2009 Liaoning GP* 55.4   46.6     
Song D, 2007 Shanxi GP*   60.7  67.2     
Xiao W et al, 
2009 
Beijing GP* 71.0 25.8 2.9 55.8 84.2 31.9 37.2 
Wang HQ et al, 
2011 
Hebei HPs*    54.5    
South 
China 
Fair Wu Y et al, 2011 Zhejiang GP* 82.0    71.2 pay <¥500 12.3 4.9 
Zhao DJ et al, 
2010 





Good He M et al, 2011 Seven 
regions of 
China 
GP* 56.2  38.7  5.0  41.5   43.6 26.2 
HPs* 40.4 45.3 13.7 35.8   39.8 38.3 
*GP: general population; HPs: health professionals 
**CC: cervical cancer 























Quality assessment tools for use in 
systematic review of observational studies 
Sanderson’s review of 86 tools 
Cover at least 5/6 internal validity domains 
Cover 3/4 core items 
Include key domains 
Be specific to study design and topic 
Show evidence of development 
Meet the tool purpose 
 
 
Scoring Zaza’s checklist for my review 
Deek’s review of 200 tools 
Modification of 
Zaza’s checklist 
Zaza’s checklist is chosen for use 
6 tools included 
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Titles and abstracts screened 
                    251 
Duplicates 512 
Full articles reviewed 
50 
 
Excluded 201  
Review                          14 
Not a research report      6 
Knowledge, attitude not 
discussed                       180 
Not in mainland China    1 
 
Articles included 
            47 
Excluded 3 
Can’t extract information on 
knowledge and attitude    3 
Titles and authors screened 
251 
Studies excluded after evaluation 
of full text from electronic search 
Studies excluded from electronic search 
Narrative synthesis of the included studies  
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47 47 46 45 45 44 43
38
28 27 26 26
23






















Green: good quality; Blue: fair quality; Yellow: poor quality  
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The scores of each study in the quality assesment tool
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Knowledge of CC: the knowledge of the relationship between HPV and cervical cancer 
Awareness of HPV: the awareness of HPV infection 
Knowledge of STI: the knowledge of the sexually transmitted nature of HPV infection 
Knowledge of GW: the knowledge of the relationship between HPV and genital warts 
Knowledge of MS: the knowledge that having multiple sexual partners could increase the risk of 
being infected with HPV 
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Figure 2-9:  Distribution of number of studies in the exploration of influencing factors 
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Figure 2-10:  Boxplot of results’ synthesis: the overview of awareness and knowledge in 






Figure 2-11:  Boxplot of results’ synthesis: the overview of the awareness and 











Dark blue/green, medium blue/green, light blue/green mean ‘awareness’, ‘knowledge of CC’, 
and ‘knowledge of STI’ respectively; 
Data is shown by median percentage of studies 
Knowledge of CC: Knowledge of the relationship between HPV and cervical cancer 
Knowledge of STI: Knowledge of the sexually transmitted nature of HPV 







































The awareness and knowledge of HPV among urban/rural women
(24 good&fair studies included, 5 poor studies excluded)
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Figure 2-13:  The pattern of awareness and knowledge of HPV and vaccination among 
different groups of participants 
 
 
Data is shown by median percentage of studies 
Knowledge of CC: Knowledge of the relationship between HPV and cervical cancer 


































The awareness and knowledge of HPV among HPs, teenagers, 
young adults, and Uyghur
(8 fair studies included, 3 poor studies excluded, no good studies)
The awareness The knowledge of CC The knowledge of STI
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Figure 2-14:  The pattern of acceptability of HPV vaccines among the general 
population and HPs 
 
 
Data is shown by median percentage of studies  
N: no data was reported among health professionals in South China 
No data on the acceptability of HPV vaccines was reported in West China 
The data on the acceptability of HPV vaccines among health professionals for their 
daughters (28%) was based on only one study (fair quality) in my review. The validity of the 
finding is therefore limited and not comparable with other data generated from a greater 
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3 Chapter 3 HPV and cervical screening survey: 
Background and methods 
 
In this chapter I describe the questionnaire survey I undertook in China in 2013. First, I 
present a brief overview of the 3 key components of my survey, and associated timings:   
1. Preparatory work: this was undertaken in Edinburgh (August, 2012-January, 2013) 
 I chose a sample, determined the sample size and the mode of survey distribution 
 I developed a questionnaire suitable for my survey and the potential participants  
 I refined the instrument by conducting cognitive interviews among Chinese students in 
Edinburgh 
 I obtained ethical approval from the University of Edinburgh 
 
2. Data collection: this was undertaken in Heilongjiang, China (March, 2013-May, 2013) 
 I travelled to China and conducted the survey in Mudanjiang city, Heilongjiang 
province between end of March and end of May in 2013 
 I obtained ethical approval in Mudanjiang Medical University. 
 I recruited schools, grades, classes and students in 5 high schools 
 I distributed questionnaires and collected them from participants in class. I supervised 
the whole process 
 
3. Data management and analysis: this was undertaken in Edinburgh (June, 2013-Dec, 2013) 
 I sent back questionnaires to Edinburgh 
 I undertook data coding, entry and analysis. 
3.1 Background 
The objective of my thesis is to explore knowledge of and attitudes towards HPV vaccines 
among Chinese teenagers. My systematic review of Chinese literature has identified relevant 
issues in China among a wide range of people; a few studies from the English literature have 
also examined issues in China, but the perceptions of teenagers have not been examined 
thoroughly. Moreover, existing studies in the Chinese literature are mostly hindered by 
poorly described methods – particularly in terms of instrument development, recruitment, 
and sampling processes; this may compromise the validity of the findings. Hence, I intended 
to carry out a study based on a robust methodology among high school students, aiming to 




3.1.1 Overview of HPV vaccine knowledge and attitudes in China 
Findings of my systematic review of Chinese literature 
My review showed that variation in study location and the diversity of participants’ 
demographics are associated with different levels of awareness of HPV infection. For 
example, adult Uyghur women and rural adult women and teenagers had a low level (<10%) 
of awareness of HPV. Young adults and urban women adults had a moderate level 
(approximately 30%), and health professionals had a high level of awareness (>85%). A 
similar pattern (rural adult women knew least while health professionals knew most) was 
also found in the knowledge of the relationship between HPV and cervical cancer, and of the 
sexually transmitted nature of HPV—the two most examined areas of knowledge in my 
systematic review (Chapter 2 presents the findings).   
 
The level of acceptability of HPV vaccination varied from 28% to 77% - influenced mainly 
by levels of knowledge. For example, if HPV vaccination is targeted to oneself, acceptability 
is high, but if the target is one’s daughter, acceptability is low. The factors most commonly 
explored which can influence acceptability are the vaccine’s cost, the venue at which it 
would be offered, and the age at which it would be given.   
 
Review of the English literature studies conducted in China 
A small number of studies in the English literature have examined HPV vaccine knowledge 
and attitudes in China, survey participants in these studies were mostly female adults 
(including parents of adolescents) [123, 124, 201] and young adults (college students) [128, 
129]. Awareness of HPV differed from a low, moderate level to a high level, depending on 
age of respondents and date of study [123, 124, 128, 129, 201]. The acceptability of HPV 
vaccines varied from a moderate to a high level, influenced by the population sub-groups (eg. 
female adults or young adults). No clear pattern has been observed due to the limited 
existing data in the English literature [123, 124, 128, 129, 201].   
 
The gaps in evidence and methodology I want to address 
The findings of my systematic review and studies in the English literature carried out in 
China highlighted the need for further work in this area. Below are the gaps in evidence and 
methodology weaknesses in existing studies which I want to address in my survey: 
 Content: very few studies examined issues of acceptability and attitudes among Chinese 
teenager populations; some issues identified in western literature were largely absent 
from Chinese literature, for example:  
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 ‘Do people know there is a need for continued Pap screening after vaccination?’  
 ‘Would attitudes surrounding the perceived benefits of HPV vaccination affect its 
acceptability?’ 
 Quality: The instruments used in studies carried out in China are typically not evidence- 
and theory-based; methods of recruitment and sampling are not well described, and the 
interpretation of results typically lacks assessments of confounding and potential bias. 
 
Hence I decided to develop a methodologically robust questionnaire-based survey to address 
these gaps in knowledge.  
3.1.2 Methods commonly used in Chinese studies on these topics  
Commonly used methods of studies in China 
In western literature, multi-centre population-based studies were the most common (over 
three quarters of studies) [123, 124, 128, 129, 201], and in my review hospital-based studies 
were the main mode of survey in these studies (approximately 60%). College/school-based 
studies did not feature prominently in China, in both English and Chinese published 
literature. With respect to study instruments, only one study in my review used telephone 
interviews - the remainder used questionnaire surveys, either interview-administrated (23%) 
or self-administrated. Cluster and random sampling methods were mostly reported in both 
English and Chinese literature [123, 124, 128, 129, 201], but insufficient descriptions of key 
methodological elements, such as sampling processes, places limitations on the interpretation 
of findings from these studies. 
 
Background of high school sampling  
I considered that a high school-based survey might be the best choice for my survey as my 
intended participants are school-age young people. But the variety of types of high school in 
China makes it difficult to choose, in a rigorous way, a representative sample of high-school 
students. Hence I intended to choose a sample that would be representative of the majority of 
them.  
 
There are public and private high schools in China. Private high schools are viewed as 
informal, and they have a completely different education system, preparing students to attend 
Western universities. The majority of Chinese students attend public high schools and 
choose to go to Chinese universities. My intention was to undertake sampling in public high 
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schools. Middle school graduates are allowed to attend a range of public high schools, which 
are divided into the following categories  
 Ordinary independent high school  
 Key independent high school  
 Vocational high school  
 Combined middle and high school  
 Minority high school  
 
The categories may vary between individual provinces – for example, in Heilongjiang 
province, the minority high school is a Korean ethnic high school. The education system is 
generally the same in all the categories of high schools. Apart from vocational high schools, 
all high school graduates are required to sit a national college entrance exam prior to 
attending university. Korean ethnic high school graduates have different subjects in the exam.  
 
Public high schools recruit students based on their academic ranking in the high school 
entrance exam. In Heilongjiang, approximately the top 60–75% of middle school graduates 
go to public independent high schools, and the remaining students go to vocational schools 
or stop school and look for jobs. Hence, students at vocational schools may have the lowest 
academic performance and records.   
 
Difficulty in obtaining data on sexual behaviours 
One of the factors affecting HPV infection and cervical cancer is sexual behaviours (eg age 
of sexual debut, number of partners, condom use etc), and I wanted to include questions on 
this topic in my survey. But considering of the difficulty in obtaining valid information in 
these areas in China, I omitted questions on these topics. Difficulties include:  
 Findings of self-reported sexual behaviour might be undermined by the accuracy of self-
reporting among school-age young people 
 Findings from parents’ reports of their children’s sexual behaviour might be 
underestimated 
 Chinese culture and societal customs do not encourage discussing sexual issues with 
others (eg friends, parents). 
 
A few western literature studies have reported sexual behaviours in China, but still the data 
might be underestimated due to the cultural factors and social norms. Three multi-centre 
studies (3–28 provincial units) carried out between 2005 and 2008 in China [202-204] have 
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explored factors relating to sexual behaviours amongst high school and college students 
(12,313–224,770 students). The main findings include the prevalence of sexual activity  
(4.5–5.9% of high school students [202-204], 11.3% of college students [202]), the 
unintended pregnancy rate (24.2% of college students) [202], and the prevalence of condom 
use (49.7% in college students[202]; 11.9% of high school students [204] reported consistent 
condom use). Nevertheless, because of the lack of methodological detail in the studies and 
lack of updated information for the years after 2008, it is difficult to make comparisons with 
studies based on young people in other Asian countries and Western countries.  
3.2 Aims and objectives 
The objective was to develop and implement a population-based survey which explored 
knowledge of and attitudes towards HPV infection and vaccines amongst teenagers in China. 
Specifically, the survey addressed the following questions: 
1. What is the level of knowledge of, acceptability of, and attitudes towards HPV and 
vaccination among school-age young people in Heilongjiang? 
2. How do demographics affect knowledge of, acceptability of, and attitudes towards HPV? 
3. What are the predictors for the acceptability of HPV vaccination and how do they act as 
predictors?  
3.3 Choice of methodological approach for my survey 
Based on the objectives of my survey and my review of the literature, I chose to undertake a 
school-based, self-administrated questionnaire survey in Heilongjiang province. 
Considerations are presented later in this section.  Figure 3-1 provides a graphical 
representation of key elements of my survey. 
3.3.1 Generating a representative sample  
China has 31 provincial regions. The diversity in geography, demography, economy, and 
education makes it difficult to choose a sample which is representative of the whole country. 
A one-province study must be less generalisable than multi-centre studies in China, but 
given my available academic network and budgets, I decided to choose Heilongjiang 
province as my survey location. The study was conducted in one middle-income city 
(Mudanjiang city in Heilongjiang province) and two small counties (Ning’an county and 
Hailin county in Heilongjiang province). The characteristics and representativeness of the 
study region are described later in this chapter. 
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3.3.2 Mode of survey distribution and data collection 
In deciding upon the best approach to this survey, a number of design issues and 
methodological approaches were taken into account - bearing in mind the unique social, 
cultural, and organisational factors that prevail in China.   
 
Table 3-1 summarises a number of modes of administration of the questionnaire and the pros 
and cons of each approach based on the prevailing local context in China. While a large 
postal questionnaire survey might have been desirable in terms of numbers of responses, 
there are logistical issues in conducting such studies in China, particularly relating to the use 
of the postal system by the Chinese population. The most desirable option thus seemed to be 
one in which I accessed populations through health and educational institutions. As indicated 
in the table, these kinds of approaches, in which sampling might be considered to be based 
on a ‘convenience sample’, have their own set of limitations; my principal concern is 
sampling bias (which I will address later in this chapter).  
 
Ultimately I decided on a school-based survey - I considered this to be feasible, given my 
available time and resources, and I considered school-based samples to have significant 
potential to provide results that are representative of the wider population. While recognising 
the caution required in using school-based sampling approaches, the reasons for choosing 
this method were: 
 it is logistically very difficult to conduct postal surveys in China 
 schools offer an accessible sampling frame with students from a broad cross-section of 
Chinese society 
 my existing connections with regional health and educational networks facilitated my 
access to schools for the purposes of conducting surveys 
 many existing surveys on HPV vaccination in the international literature have been 
undertaken in schools, increasing the potential for international comparisons. 
3.4 Development of the questionnaire 
I developed a self-administered questionnaire by reviewing both Chinese and international 
literature. I adopted a few steps to develop my questionnaire. First, I decided what the 
structure of the questionnaire and the response format would be. Second, I formulated the 
questions based on the theory I had chosen from my literature review. Finally, I performed a 
cognitive review process to refine the draft questions. Figure 3-2 presents the key elements 
of my questionnaire development process. The questionnaire is in Appendices 4 and 5.  
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3.4.1 Structure of questionnaire 
I based the development of the questionnaire on the objective of my survey and my literature 
review of international and Chinese studies. Two main topical issues (knowledge and 
attitudes) were of interest to me, and hence, the survey instrument comprises 3 sections:  
 Section 1: knowledge of HPV infection and vaccines  
 Section 2: attitudes towards HPV infection and vaccines 
 Section 3: background characteristics 
 
The broad range of areas of enquiry in the questionnaire meant that different response types 
were needed for different questions. For example, knowledge questions required a 
‘categorical’ true/false/don’t know response, while attitudinal questions required scoring on 
a 5-point Likert scale (with, for example, responses ranging from strongly disagree to 
strongly agree).  
 
A rudimentary level of knowledge about HPV infection and vaccination was required to 
complete the knowledge section of questionnaire. There would be little point in asking 
detailed knowledge questions in areas where there was no basic understanding of the topic. 
Therefore, the questionnaire started with a ‘screening’ knowledge question, asking 
participants if they have ever heard of the HPV. If not, they were instructed to skip over the 
remainder of the knowledge questions. Nevertheless, I still considered, after some 
deliberation, that it was reasonable to collect data on attitudes towards vaccination amongst 
those who indicated no knowledge of HPV infection. 
 
In order to assist participants whose knowledge of HPV infection and vaccination may be 
limited and who would otherwise find it difficult to answer attitudinal questions, an 
information box with key facts about HPV and vaccination was provided before the attitude 
questions were asked. Information was provided in areas including risk factors for HPV 
infection, the transmission mode of HPV infection, the target population, and the transient 
nature of HPV infection. Of course, the information box would have helped respondents 
complete the knowledge questions in Section 1, so I needed to take steps to prevent 
participants from changing answers after reading the information box. A sentence was put in 
front of the information box stating ‘Please do NOT change your answers in Section 1 after 
reading the information box.’ Further, this point was emphasised in front of the class after 
the questionnaires were distributed by stating: ‘We value your honest answers rather than the 
correct ones - please don’t change your answers once you’ve read the information in the 
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knowledge box.’ Splitting the questionnaire and distributing the knowledge and attitude 
sections separately was also considered, but, this would have been logistically difficult and 
may have compromised the distribution process and the rate of return.  
3.4.2 Sources of questions 
Items in the questionnaires were drawn from a number of sources, including studies in the 
previous review of western [121, 122, 205-207] and Chinese literature [123, 124, 187, 201] 
(some of which provided sample survey instruments). Details are described below. 
 
Section 1: Knowledge 
The main questions concerning knowledge were generated by reviewing several relevant 
studies conducted in Italy [206], the US [207], Germany [205], Korea [198], and Hong Kong 
[187, 208, 209]. These areas of knowledge included:  
 risk factors in HPV infection 
 protective factors in HPV infection 
 symptoms of HPV infection 
 the most suitable people to receive HPV vaccination 
  
The wording of the questions extracted from the literature (and the order in which they were 
presented) was modified to make them more appropriate for a survey of teenagers.  
 
Through consideration of the characteristics of the target population (young teenagers, who 
tended to have less health knowledge) and the setting (Heilongjiang province of China, 
where HPV vaccines have not been introduced and cervical screening has not been carried 
out extensively) some of the questions were excluded, such as knowledge of the HPV DNA 
test, HPV treatment, and HPV health consequences. Further, I aimed to explore basic 
knowledge and understanding of concepts relating to HPV rather than more technical aspects 
and medical knowledge of HPV among my sample; in-depth knowledge questions (eg ‘Pap 
smear’ is more technical than ‘cervical screening’ for teenagers) were also excluded.  
 
Section 2: Attitudes 
To formulate attitude questions, I found, in international literature, a number of health 
behaviour theories that could guide the development of my questionnaire. Below are the 




Health behaviour theories  
Numerous health behaviour theories have been developed since the 1950s [210-214]. 
Theories are used to guide practitioners to understanding behaviour change in a systematic 
way and provide evidence for further health interventions. By reviewing literature [210-212], 
I found five health behaviour theories that are currently widely used:  
 Health Belief Model (HBM) [210-212] 
 Theory of Reasoned Action (TRA) [210-212] 
 Theory of Planned Behavior (TPB) [210-212] 
 Social Cognitive Theory (SCT) [210-212, 215] 
 Transtheoretical Model (TTM) [210-212] 
 
The theories can be categorised based on individual, interpersonal, and community levels 
[210] or theory purpose – there are both explanatory theories and change theories [210, 211]. 
As the level name implies, individual-level theories (eg HBM, TTM) are used to help people 
adopt healthy behaviours or eliminate unhealthy behaviours [210]; interpersonal theories  (eg 
TRA, SCT) focus on support and control [210]; community theories (eg ecological 
approaches) mostly offer information to promote community-level behaviour change and 
guide community interventions [210]. As the purpose indicates, explanatory theories (eg 
HBM, TRB, SCT ) provide an explanation for why people have certain behaviours, and 
change theories (eg TTM) help to find what factors will influence future intervention 
programmes (and how).  
 
To identify the most appropriate theory for my survey, I looked at each theory’s key 
elements and constructs. Noar 2005 [212, 214] reviewed the similarities and differences of 
the elements of the five theories. The similar elements were the general ones for predicting 
health behaviour: positive/negative aspects of the behaviour, other people’s support, one’s 
ability to perform the behaviour, one’s risk if not engaged in the behaviour (Table 3-2 
presents the details of each theory). And the different elements of theories related mostly to 
their application to different scenarios [212-217]. A summary of the application of these 
theories is described below, and a comparison of these theories is listed in Table 3-2. 
 HBM mostly applies to assessing illness avoidance and asymptomatic prevention-based 
health concerns (eg cancer screening, injury prevention) [212];  
 TRA/TPB mostly applies to more rational behaviours and those that have a potentially 
strong intention-behaviour link (eg addictive behaviours: tobacco use) [213];  
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 SCT mostly applies to reciprocal relationships between individuals and their environment 
(eg eating habits, contraception) [215]; 
 TTM mostly applies to deliberate behaviours (eg drug use, weight management) [216, 
217].  
 
Hence, factors such as whether one has strong intentions or commitment, or even plans to 
engage in the behaviour are not included in HBM compared with other theories – but these 
factors were not my key concern. In terms of theory level, purpose, and applied scenarios, 




Many of the attitudinal questions were drawn from the concepts of the HBM [198, 199]. 
There are five such concepts, described below. Nevertheless, some areas of attitude were not 
covered (eg stigma). Hence, questions on the stigma of HPV infection were generated from 
the literature review [187, 199, 208, 209, 218]; again, relevant changes were made to the 
wording, order, and phrasing of the questions. These concepts were adapted as follows:  
 Perceived susceptibility/risk (eg ‘how likely is it you will be infected with HPV in the 
future?’)  
 Perceived severity (eg ‘do you agree that HPV infection will have a serious impact on 
your physical health?’)  
 Perceived effectiveness/benefits (eg ‘do you agree that the vaccine may help you avoid 
cervical cancer?’)  
 Perceived barriers (eg ‘do you agree or disagree with the statement “I am concerned that 
HPV vaccines may have major side effects such as long term illness’)  
 Cues to action (eg ‘I would get vaccinated if doctors or nurses recommend me to do so’). 
 
Regarding HPV-related stigma, questions such as ‘Do you agree people will think someone 
who is infected with HPV is likely to have been promiscuous?’ were included in my survey 
instrument. Details of the questionnaire are in Appendices 4 and 5. 
 
Section 3: Background 
The third section of the questionnaire comprised background data: age, gender, rurality, high 
school, and self-reported lifestyle behaviours. The lifestyle question concerned smoking 
behaviour. The reason for this is that I assumed that teenagers who engaged in high risk 
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health behaviours would have different attitudes towards HPV, and smoking acted as a proxy 
for this. So I was interested in whether smoking behaviour was associated with teenagers’ 
knowledge and attitudes towards HPV and vaccines.  
3.4.3 Refinement of draft questions: Cognitive interviews 
The process of cognitive interviewing is an important technique in refining draft 
questionnaires, testing their capacity to be understood and eliciting valid responses in the 
chosen target population [219].  
 
Approaches to the cognitive interview 
From interview goal perspectives, cognitive interview can be categorised into three types 
[219]:  
 concept elicitation,  
 cognitive debriefing (which I chose to use in my cognitive interviews) 
 a combined elicitation/debriefing interview.  
 
Concept elicitation interviews are generally used to identify constructs generated from 
participants’ perception and provide evidence of the validity of the instrument. Cognitive 
debriefing interviews are used for the development and modification of the questionnaire to 
reduce measurement error – I chose this approach for my cognitive interview, based on the 
interview objectives (to obtain the most accurate, or valid, responses).  
 
Various techniques are employed in conducting cognitive interviews [219]. They include 
(but are not restricted to): 
 think-aloud interviewing (used in my interview) 
 verbal probing techniques  
 concurrent verbal probing (used in my interview) 
 retrospective verbal probing. 
 
Based on my available resources and interview scenarios, I chose concurrent probing and 
think-aloud interviewing techniques for my interviews. This meant that participants were 
required to read the questions in the questionnaire and verbalise their thinking process during 
the interview. Issues raised by this method include:  




 The response selection (categories): either mutually exclusive or social desirability bias.  
 The reference period for information recall: either too long or too short. 
 
Conduct of the cognitive interview 
While it was not feasible to undertake interviews among teenage high school students living 
in China, I considered Edinburgh-based Chinese students to be a reasonable proxy; they 
were only marginally older than my survey participants, and were likely to hold reasonably 
similar knowledge and attitudes in my key survey domains (although, of course, their 
exposure to Western culture and the educational environment at Edinburgh would have had 
some impact). I undertook ten cognitive interviews with 21–24-year-old Chinese students 
based in Edinburgh. While the age range of interviewees was not ideal for the questionnaire 
survey, I felt  21–24-year-old Chinese students were young enough to be able to recall from 
their own experiences what kind of wording and sentence was suitable for high school 
students. Interviewees were identified through class lists and informal networks, and on each 
occasion I sat with the respondent at a convenient location while he/she completed the 
questionnaire and simultaneously offered feedback on whether the questions were clear or 
difficult to understand.  
 
A number of changes relevant to the wording and structure of the questionnaire were made 
based on these interviews: 
 
1. Comprehension: There were a couple of instances of misunderstanding of the wording. 
Since the Chinese translation of HPV involves the word ‘nipple’, two female respondents 
mistakenly thought the infection was related to the breast. To minimise confusion between 
HPV and breast conditions, an explanation of the name HPV was added to the information 
box before participants answered the attitude questions: ‘the word HPV is based on a 
pathological description, it  can cause common warts or genital warts showing 
papillomatosis, and has nothing to do with the nipple or breast’. 
 
One male student could not differentiate between ‘risk factors for cervical cancer’ and ‘one 
cause of the cervical cancer’ – that is, he felt a little confused about the meaning of the terms 
‘risk factor’ and ‘cause’. To address this, the words ‘increase/reduce the risk of cervical 




2. Difficulty in remembering or recalling information to provide answers: most of the 
interviewees thought the question ‘Compared to others of your age, how likely is it you will 
get HPV infection/cervical cancer in the future?’ was difficult to answer. This was because 
they needed to consider information relevant to risk or protective factors for HPV 
infection/cervical cancer in relation to their own behaviours (which some found challenging). 
Further, most interviewees had limited knowledge of risk and protective factors, and hence 
they found it difficult to assess their own risk. Some also could not understand the statement 
‘HPV infection usually disappears without treatment’.  
 
Based on these responses and the suggestions of interviewees, a number of changes were 
made, including changes in wording and the provision of more information in the 
information box - for example, ‘High-risk HPV infection is very common among young men 
and women, but 70% of infections will be got rid of by the immune system within 1 year’; 
‘5–10% of infected women are at risk of developing cervical cancer’; ‘The risk factors for 
cervical cancer are multiple sexual partners, early pregnancy, multiple pregnancies’, etc. 
Identification of these extra pieces of information was assisted by a literature review of these 
topics [220]. Details are presented in the questionnaire (Appendices 4 and 5). 
 
3. Response categories: One male student suggested that friends’ recommendation would be 
different from parents’, so the question should not combine the two recommendations 
together into one sentence – so I split the question into two parts.  
 
Two students gave the response ‘unsure’ to the question ‘How likely is it you will get 
vaccinated?’ – they suggested that not using the neutral option would push participants to 
think more carefully before choosing the response categories and also avoid participants 
tending to choose the easiest option unconsciously (which may, indeed, be ‘unsure’). But I 
wanted know how many people were genuinely unsure or didn’t know about the statement. I 
found it difficult to respond to this feedback without making this section overly cumbersome. 
After some deliberation, I simply inserted a sentence at the top of these questions: ‘Please 
think carefully before answering the following questions.’  
3.4.4 Summary 
I’ve described, in the preceding paragraphs, the process I undertook in developing the 
instrument for use in my survey. It is, of course, preferable to use validated instruments for 
surveys – this leads to greater consistency and comparability of findings between surveys, 
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and gives greater confidence in the validity of survey findings. However, no such instrument 
existed – my areas of enquiry included knowledge of and attitudes towards cervical cancer 
and HPV vaccination and the instrument needed to be culturally, and cognitively appropriate 
for school-age Chinese people; that is, the wording of questions should be tailored to this 
young group. Survey instruments often need considerable adaptation if they are to be used in 
different settings and culture. Chinese people may, for example, have relative conservative 
attitudes towards sex related topics. 
 
Nevertheless, I drew on existing literature wherever possible - I generated the knowledge 
and attitude questions drawing on the international literature. I generated questions about 
stigma drawing on studies carried out in Hong Kong where many attitudes and cultural 
characteristics are similar to those found in mainland China. I also carried out cognitive 
interviews to refine the questionnaire (all the steps in the development of questionnaire and 
the measures I have taken were discussed with my supervisors). Hence, I undertook an 
instrument development process using rigorous questionnaire development techniques – I 
consider that having a ‘bespoke’ questionnaire for my survey provided benefits which 
outweighed the disadvantages of not having a pre-validated instrument.  
 
3.5 Sample size considerations in my survey 
This is the stage at which I determined how many participants I should recruit in my survey 
to achieve the best estimate of the proposed finding on the basis of the available resources 
and network.  
3.5.1 Considerations in the estimation of sample size  
Sample size was determined based on the research hypothesis, difference of proportions of 
the outcome (estimated via prior studies), and the parameter estimates (α: the significance 
level and β: the statistic power) – that is, the level of precision and certainty I wanted to 
achieve. Table 3-3 shows all the elements used for sample size estimation, and Table 3-4 
shows how these factors affect sample size estimation [221].  
 
Formulae that are used to estimate sample size vary, but there are common general principles. 
The available formulae comprise of the following parameters [221] (Table 3-3):  
 Difference in proportions of the outcome: p1-p2 
 Statistical power (β) and significance level (α) based on Z scores: Zβ and Zα/2 
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 The ratio of larger group to smaller group: r =1 means the number of males equals to the 
number of females in my survey. 
I used G*Power software (free online: http://www.gpower.hhu.de/) to calculate the sample 
size by entering the above parameters.  
3.5.2 Sample size estimation 
Two main research aims determined the sample size calculation: (1) to estimate the level of 
awareness in the sample with a reasonable level of precision, and (2) to identify associations 
between a. gender and knowledge, and b. knowledge and acceptability. My calculations 
indicated the required sample size would be 3,500–4,000 - the justifications for this are 
below. Figure 3-3 presents the key elements of the estimation. 
 
Estimate of level of awareness 
The level of awareness about HPV infection is low amongst Chinese teenagers (around 15% 
of people know about HPV [131, 155, 222]). With a 95% confidence level (95% probability 
of the precision of the result) and 80% power (80% probability of finding a significant result), 
the estimated sample size needed to measure a proportion of 15% of people who know about 
HPV would be 196. The level of awareness is examined by asking ‘Have you ever heard of 
HPV?’, which is also the screening question (used to filter people who were not aware of 
HPV infection). As I intended to undertake a number of comparisons between variables, a 
sample size much greater than 196 (around 4,000) was required (see below).  
 
Associations between variables 
Hypothesis tests are used to examine associations. The sample size must be large enough to 
achieve sufficient statistical power to correctly reject the null hypothesis. In questionnaire 
surveys the usual requirement is to detect a difference in proportions – and to do so with a 
high level of precision and confidence.  
 
Two central questions needed to be answered in the study; because multiple associations 
were being examined, there was an increased risk of falsely rejecting the null hypothesis 
(type І error) - finding a significant result by chance because of the large number of 
statistical tests taken. Therefore, the Bonferroni correction was used to reduce the likelihood 





1. Gender difference in the level of knowledge was the first comparison.  A different 
measure of level of knowledge was used here compared with the estimate of awareness 
above. The sample size estimation is described below. 
 The research hypothesis: Gender difference existed in knowledge of the association 
between HPV and cervical cancer (the main measure I used to examine knowledge of 
HPV).  
 Difference of proportions: The gender difference in the knowledge of HPV was 15% (eg 
50% males know that HPV causes cervical cancer, and 35% females do not [153]).  
 Parameter estimates: The significance level was 2.5%, and the statistical power (a 
probability of correctly detecting a difference of 15%) was 80%.  
 Other factors: Assuming male and female participants were equally distributed in the 
sample. 
 The sample size required would be 412 
 
2. The association between the level of knowledge of HPV and of HPV vaccination was the 
second comparison. Below is the sample size estimation. 
 The hypothesis: The level of knowledge would influence the acceptability of HPV 
vaccination. Knowledge was measured by asking the question ‘Does HPV cause cervical 
cancer?’  
 Difference of proportions: I aimed to detect a 15% acceptability difference (60% vs. 75%) 
between people who demonstrated knowledge and those who did not [166, 198]. 
Evidence showed that the level of knowledge of HPV and cervical cancer was around 30% 
[170, 175]. 
 The parameter estimates: Assuming the statistical power was 80% to truly detect a 15% 
acceptability difference and the p value was 0.025.  
 Other factors: There were potential confounders to adjust for (i.e. age, gender, and 
rurality).  
 The sample size required would be 500. 
 
However, as I expected that approximately 15% of the population would respond ‘yes’ to the 
screening question based on my literature review [131, 155, 222], I needed more than 500 
respondents - only those who answered yes got the opportunity to answer the knowledge 
questions. Hence, it transpired that 2,800–3,500 respondents should be sufficient to produce 
the required number of people (420–500). Previous similar surveys in China have achieved 
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response rates between 80 and 90% [152, 153]; thus I assumed that questionnaires needed to 
be provided to a sample of 3,500–4,000.  
 
To summarise, for associations between Section 2 variables (attitudes, beliefs etc) and 
Section 3 variables (patient characteristics), I used all the respondents’ questionnaires. 
Whereas, for associations between detailed knowledge and other variables, I used 
approximately 15% of the questionnaires - those from respondents who were aware of HPV. 
3.6 Representativeness of my sample (School children in 
Heilongjiang province) 
Selection bias almost always exists in surveys from regions which are small compared to the 
whole country. Nevertheless, I wanted my findings to be as representative as possible of 
most adolescents in ‘middle-developed’ provinces in China. To look at how representative 
my sample was, I assessed the status of school-age young people in Heilongjiang in the 
following terms. 
 
The representativeness of Heilongjiang province of the whole country 
 Demographics, economic status, education, etc. 
 Health care expenditure  
 Potential affordability  
 Cervical cancer and HPV epidemiology 
 
The representativeness of school-children of all people of the same age in the chosen region 
 Demographics 
 Academic performances in the chosen region 
 
The data presented later are from China Statistics Yearbook [149], and China Health 
Statistical Yearbook [223], which are recognised as a reliable and well-acknowledged 
health-related databases in China. The data are obtained from multiple levels of government 
(village, county, township, and provincial), and updated every year by the local government 
[223]. They have also been used as evidence for the annual central government official 




3.6.1 How representative is Heilongjiang province of the wider Chinese 
population? 
Demography  
Heilongjiang province, in the northeast of China, has a population of 38.34 million, and is 
ranked the 15th most populated province (in the middle) (see Table 3-5 and Figure 3-4) in 22 
provinces, 4 municipalities, 5 autonomous regions of China [149, 223]. The proportion of the 
population that is urban is 55.5%, higher than most provinces of China [149, 223]. There are 
53 ethnic groups within the province, and 94.3% of the population is Han, followed by the 
second and third largest population, of Man and Hui ethnicity respectively [149]. The 
minority ethnic groups lead a very similar life to the Han population, having no major 
differences in lifestyle, education, and health conditions (access to health services and health 
insurance coverage). Thus, Heilongjiang province is viewed as a medium-sized, urbanised 
province in China.  
 
Economic status of Heilongjiang in China 
Gross domestic product (GDP) per capita and household income per capita are the main 
indicators I used to assess Heilongjiang’s economic status in China.   
 GDP per capita: ¥32,615, ranked the 16th (in the middle) of 31 provincial regions in China 
[149, 223] (See Table 3-6, Figure 3-5).  
 Average household income per capita:  ¥15,696.2 in urban regions, ranked 28th in China; 
and ¥7,590.7 in rural regions, ranked 10th in China [149, 223]. (Data from other provinces 
is not shown.) 
 
Hence, Heilongjiang province is viewed as a medium-wealthy province in China and most 
inner land provinces have roughly similar levels of wealth (8 provincial regions have a 
similar level of GDP per capita, ¥30,000–40,000; see Table 3-6). The low urban and high 
rural average household income might indicate the rurality difference of household income is 
small in Heilongjiang province.  
 
Health care expenditure in China and Heilongjiang province 
In China, three components are involved in total health expenditure: Government health 
expenditure [224], social health expenditure [224], and individual out-of-pocket payment 
[224]. The average total health expenditure per capita in China was ¥1889 in 2011 [223]. It 
included  
 Government health expenditure (¥554) [223] 
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 Social health expenditure (¥625) [223] 
 Out-of-pocket payment (¥710) [223] 
 
The out-of-pocket payment (health care spending per capita) and its proportion of the total 
consumption per capita (health consumption proportion) are the two indicators used to assess 
the affordability of health care for residents. Below are the data for Heilongjiang province. 
 Out-of-pocket payment: 978.8 RMB (9th highest in China)  in urban residents and 434.3 
RMB (5th highest in China) in rural residents [149, 223]. (See Table 3-7) 
 The health consumption proportion: 10.2% in urban residents in 2010; 10.2% in rural 
residents in 2010 [149, 223]. (See Table 3-7).  
 
When the health consumption proportion is over 10%, it indicates a heavy financial burden 
on households [225]. The health consumption proportion is high in Heilongjiang province in 
comparison with most other provinces [223] (Figures 3-6 and 3-7), which implies the likely 
high health financial burden of Heilongjiang residents. Four provincial regions of China (see 
Table 3-7) had a health consumption proportion of over 10%, which would be comparable to 
Heilongjiang province.  
 
Demography and economic development of Mudanjiang city 
Mudanjiang city is the third largest city in Heilongjiang province, and has emerged as a 
medium-wealthy and urbanised city (55% are urban residents) in Heilongjiang [226]. 
 
Six counties are scattered around the central region of Mudanjiang; Ning’an and Hailin 
counties are located in the southwest and west of Mudanjiang city, with a population of 
440,000 in each (Figures 3-8 and 3-9). 
 
Attendance rate at school 
Attendance rates for primary school, middle school, and college in Heilongjiang provinces 
are generally high—over 95% [223]—but the attendance rate for high school is very low, 
only 68.1%[223]. Some provincial/municipalities like Beijing and Shanghai have attendance 
rates of over 100% [223]. No interpretation is available in the statistical yearbook of 






Cervical cancer statistics in Heilongjiang province 
No provincial cancer census is available in Heilongjiang province regarding the incidence 
rate of cervical cancer. A study carried out in Shangzhi county in 2009 reported the crude 
incidence rate at 15.94/100,000 (ranked 4th among the most common female cancers in the 
county) [227] and the crude death rate at 3.32/100,000 (ranked the 7th highest death rate of 
female cancers in the county[227]. Based on the national cancer census in 2004–2005 [17], 
the standardised death rate for cervical cancer in Heilongjiang province is 2.12/100,000, and 
the highest death rate is in Xinjiang province (10.69/100,000); the lowest death rate is in 
Chongqing (1.02/100,000) [11, 17]. (Table 3-8) It was reported that a death rate of 1.5-
2.5/100,000 was found in ten provincial regions of China, similar to Heilongjiang province. 
No geographical pattern was identified in the incidence and mortality rate of cervical cancer.  
 
Variation in economics, ethnic groups, and measurement may contribute to the gap in the 
death rate and mortality between national census and research-based studies. Death rates are 
thought to be underestimated by the national cancer census as most cancer registries in China 
have not established an electronic system, and entirely manual sorting, storage, and 
organisation may lead to human errors (eg records being defaced, incomplete, or even lost).  
 
Hence, the cervical cancer burden in Heilongjiang might be similar to the other ten 
provincial regions, but as the upward trend of cervical cancer incidence was observed in the 
whole country during the last decade (described in Chapter 1), the disease burden might 
become heavier over the years as well.  
 
HPV prevalence 
Difficulties also exist in estimating HPV prevalence in Heilongjiang province (in common 
with other provincial regions). Provincial regions in China have not set up efficient 
monitoring systems for HPV infection, though HIV and HBV have been monitored by local 
Centres for Disease Control (CDC). Data on HPV prevalence can only be obtained from 
research studies. The same situation prevails in other parts of China, making it difficult to 
assess the representativeness of HPV prevalence among Heilongjiang residents. Below are 
the findings from two research-based studies in Heilongjiang province.   
 
A study of 1,759 subjects on HPV prevalence in Daqing city, Heilongjiang [228] reported 
the positivity of HPV as 8.64% in 2010, while two studies conducted in Harbin hospitals 
have found higher HPV positivity (21.5%[229] and 31.2%[230]). The difference in HPV 
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positivity may be due to the variation in the selected population. The Daqing study chose 
women from among government employees, and the Harbin study selected women from 
among hospital patients.  
 
HPV prevalence might be either underestimated or overestimated in these studies. Hospital 
patients would have more HPV positivity than ordinary people, but it is difficult to assess the 
estimates of HPV prevalence among government employees, a distinct group generally with 
better education and living conditions. 
3.6.2 How representative is my sample of school-children? 
Senior high schools have been chosen on the basis of both convenience and their potential to 
provide representative samples. Hence, No. 1, 2, and 3 high schools (schools are typically 
given numbers to identify them in China), and high schools in Ning’an and Hailin were my 
sample schools. Details of the selection of schools are given later in this chapter. Here I 
examine the representativeness of my sample in terms of the students’ demographics, 
academic performances, and their likely family background. 
 
Rurality: No.1, 2, and 3 senior high schools recruit students only from urban regions of 
Mudanjiang city. Ning’an and Hailin senior high schools recruit students equally from urban 
and rural regions of the county. The ratio of urban to rural students among the selected 
schools could influence my results. Based on the estimated enrolment ratio of urban/rural 
students in the five schools, approximately one fifth of all the participants would have come 
from rural regions.  
 
Age: I tried to ensure the same proportion of students per age group by selecting an equal 
number of classes in each grade. These classes were distributed between Grades 10, 11, and 
12, with an age range of 15 to 18 years (although a small number of teenagers aged younger 
than 15 or older than 18 were also included). 
 
Gender: The male/female ratio is approximately 1 in these five schools. Involving both girls 
and boys in the survey was important - it carried the potential to avoid stigmatising females 
as the source of STIs and improve the social acceptability of HPV vaccine.  
 
Academic performance: Chinese students are required to undertake senior high school 
entrance exams to attend high school. They are recruited to school based on their academic 
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rankings in the corresponding region (rather than being recruited to the nearest high school). 
No.1, 2, and 3 senior high schools recruited the top 60.2% of students in the central regions 
of Mudanjiang city; students in Ning’an senior high school are in the top 74.3% of Ning’an 
county; and Hailin senior high school recruits the top 66.7% of students in Hailin county. 
These data comes from a local government report in 2013 [231]. Hence, the results from the 
five chosen schools could not be generalised to all teenagers at high schools, but ‘good 
students’ of the target region in Heilongjiang province. 
 
Family background: High school students in my survey come from diverse family 
backgrounds. Because the selected schools were all public high schools recruiting students 
based on the entrance exam, there should not be significant over-representation of any 
specific social class. Ideally, access to high school education is almost equal to all the 
students regardless of their backgrounds. Nevertheless, those who achieve better academic 
records are usually from relatively wealthy families or highly educated families. Hence, my 
sample of students would be more likely to have wealthy and well-educated parents.  
 
Some students in Chinese high schools have financial problems due to family circumstances. 
For students who are unable to pay tuition fees, state-funded programmes help to subsidise 
them, covering all their tuition fees and some part of their living expenses. The proportion of 
funded students is 20% in each public high school in Mudanjiang city, including affiliated 
counties (again, this is fairly consistent with other regions of China). Due to the difficulty in 
obtaining information about family income from high school students (it is sensitive, and/or 
they may be too young to know the details), I did not request this information in the 
questionnaire. Parents’ background may, of course, play an influential role in students’ 
perspectives when acquiring knowledge related to sex, but it was not my primary research 
question in the survey.  
3.6.3 Conclusion  
I have attempted, in this section, to assess how representative my sample is – by examining 
both the characteristics of Heilongjiang province, and of my school-based sample. I’ve 
examined factors including demography, economy, education, and health care. Based on the 
China Statistical Yearbook (summarised in Table 3-9), Heilongjiang is viewed as being in 
the top third of urbanised provinces in China, with a middle-size population. Five central 
provinces (Hebei, Shaanxi, Hunan, Shanxi, Liaoning) share a similar index (in terms of 
economy and health care expenditure) to Heilongjiang (Figures 3-4, 3-5, 3-6 and 3-7). It is 
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not an especially wealthy province (ranked in the second half) but has higher health 
expenditure than average, and residents, on average, spend more out-of-pocket money than 
two-thirds of Chinese people for their health, irrespective of whether they are urban or rural. 
It may be inferred from this that Heilongjiang residents would be more likely to experience 
financial burden related to health than most of other provinces (around two thirds) in China.  
 
The potential selection bias of the students in my survey relates to their greater likelihood of 
having a higher level of academic performance, and parents from wealthier, better-educated 
backgrounds. I will discuss these issues further in the next chapter.  
3.7 My recruitment process 
I decided on a school-based survey in Mudanjiang city of Heilongjiang and chose my sample 
at multiple levels, starting from schools to grades, classes, and students. The recruitment 
process is presented in Figure 3-1. 
3.7.1 Selection of schools and eligible criteria 
Due to the variety of high school systems in China, I established inclusion and exclusion 
criteria for the selection of the schools. The inclusion criteria were: 
 public high schools 
 schools with Grades 10, 11, and 12 
 
The exclusion criteria were: 
 ethnic minority high schools (in Mudanjiang city, this refers to the Korean ethnic high 
school) 
 vocational high schools (to prepare students for specific jobs) 
 private high schools 
 international high schools 
 
The chosen schools were:  
 Numbers 1, 2, and 3 senior high schools in Mudanjiang city 
 Ning’an senior high school in Ning’an county of Mudanjiang city 
 Hailin senior high school in Hailin county of Mudanjiang city 
148 
 
3.7.2 Selection of grades, classes, and students 
Within the five high schools, students were randomly allocated to different classes based on 
their student identity number (student ID) when they started school at Grade 10. The 
selection method for classes reflects both convenience and representativeness. I selected 13 
or 14 classes in each school, and four or five classes from each grade. The average number 
per class is around 60.  
 
In Grade 10, four or five classes in each school were chosen by convenience (depending on 
whether teachers were available at my first visit). In Grades 11 and 12 of all the high schools, 
classes are categorised into two types: science and arts. The ratio of science classes to arts 
classes of all the selected schools is approximately 2:1. I chose one or two arts classes and 
two or three science classes in Grades 11 and 12 of each school. Therefore, more science 
students were included in the survey than arts students. Differences may exist in terms of 
knowledge of HPV between science and arts students, but considering the difficulty in 
logistics and the priority of my research questions, I did not collect information on the class 
type (no questions were asked in the questionnaire about the class categories).  
 
I decided to distribute around 780–850 questionnaires in each school, based on my sample 
size calculations. The students were those from classes whose teachers had given their prior 
approval before conducting the survey. During the negotiation process with each class, a 
teacher of one class in Grade 12 from No. 1 high school rejected my request to let her 
students participate in the survey because students in the class had very busy schedules, so 
no survey was conducted in this class. No other students asked for leave from the classroom 
before the survey started. Questionnaires were given to all the students sitting in the 
classrooms of the chosen classes. Students who declined to participate after they had read the 
questionnaire did not return their questionnaire. No relevant information was obtained from 
them. For privacy and ethical reasons, I did not ask who the non-responders were in the class.  
3.8 My survey administration process 
Official approval was obtained from the Educational Departments in Mudanjiang city to 
carry out the questionnaire survey in the five high schools. Ethical approval was obtained 
from the ethics committee of Mudanjiang Medical University (Appendix 6, the Chinese 
document of ethical approval). 
The survey took me two months to administer (from end of March to end of May 2013), 




I visited each school three times to conduct the survey.  
 
Visit 1: 20 March–5April. I contacted the headmaster of each school by telephone and 
gained approval. I visited each school and talked to the director of each grade about the 
project. These directors helped me to confirm the teachers of the selected classes. Then when 
teachers were available, I talked to them about the study and arranged a mutually agreeable 
time (a period of self-study rather than a didactic teaching lesson) to speak to the whole class 
about the survey. On average, I took two days to talk to the teachers, arranging the time to 
visit each school. All but a teacher of Grade 12 in No. 1 high school agreed to let their 
students participate in the survey. 
 
Visits 2 & 3: Visits 2 and Visit 3 were conducted close together in each school (within two 
weeks). Only once I had finished the survey in one school did I start the survey in another 
school (the timeline of visits to each school is presented in Table 3-10). In each school, I 
came to each class accompanied by the class teacher, explaining why and how the study 
would be carried out and to clarify some common areas of confusion around HPV infection - 
such as the difference between HPV and HIV. Care was taken to limit the amount of direct 
information given about HPV, as this could have influenced the participants’ responses.  
 
I spent about 5 minutes speaking with each class. During this time I covered the following 
points: 
 I introduced myself, typically along the lines of: ‘thanks for giving me the opportunity to 
speak with you. I’m originally from Mudanjiang city; I am now a PhD student at the 
University of Edinburgh in the UK, working in the area of public health. I am carrying 
out a questionnaire survey to learn more what young people like you know and think 
about the introduction of HPV vaccination’  
 Summarised key points from the information sheet (eg clarified that the survey was about 
HPV, not HIV/AIDS) 
 Gave out the invitation letter and information sheets (Appendices 7, 8, 9 and 10), assured 
students that if they took part in the survey, their responses would be confidential  
 Encouraged them to read these documents before my next visit (and told them the time of 
Visit 3) 
 Told them they could discuss this with their parents if they wished 
 Told the class that in the final phase of my PhD (one year and a half later), I would send a 
project summary and copies of academic papers to the head teacher so that they would 




Students were given two or three days to consider the study and decide whether they would 
take part in the survey. The exact time for the third visit depended on their curriculum of 
each class over two or three days. Except for Grade 12, students of Grades 10 and 11 had a 
self-study class every afternoon in all the chosen schools. In terms of Grade 12, Ning’an and 
Hailin high schools arranged self-study classes every evening from 7pm to 9pm; and 
students in No. 1, 2, 3 high schools had one self-study class every afternoon or every other 
day. I had confirmed the third visit time with the teachers during the second visit and let the 
students know. In Visit 2, when students had further queries about the survey, I provided 
information to them on that day, or else they were able to contact me directly afterwards. My 
contact details were given on the information sheet. I did not receive any emails or phone 
calls from students or their parents about the survey.  
 
Visit 3: I visited the included classes at the agreed date and time (Table 3-10). I identified 
those students who had decided to take part in the survey. No students indicated that they 
would not participate in the survey. They all wanted to read the questionnaires before their 
final decision. Then the participants were given the questionnaire and asked to complete it by 
themselves: I emphasised a number of points with approximately the following wording:  
 ‘First, we value your honest answers rather than correct ones, so please answer the 
questions honestly no matter how little or how much knowledge you have.  
 Second, do not turn to the next page until you finish the first page. Once you read the 
HPV information in Section 2, please do not change your answers in Section 1.  
 Third, please complete the questionnaire by yourself and do not look at other’s responses 
or chat with other students: please respect the privacy of your classmates 
 Fourth, HPV is not the same as HIV/AIDS, please do not get confused.  
 Fifth, students who live in the following places constitute urban residents: four districts of 
Mudanjiang city, Ning’an and Hailin county; students who live in the following places 
constitute rural residents: townships and villages in Mudanjiang, Ning’an, and Hailin’ 
 
I stayed in the classroom waiting for the students to complete the questionnaire and was 
therefore available to respond to any queries. I talked to the teachers and hoped that they 
would not be present in the classroom during the survey (I was concerned this might 
influence the validity of student responses). Most of the teachers agreed and left the 
classroom, while a small number of teachers stood in front of the classroom for a while and 
then left. No teacher observed the whole process of the survey. I observed the students and 
encouraged them to complete the survey in silence. Students were asked to put the completed 




The students’ participation was not confidential because students who took part in the survey 
were known by their teacher and the other students in the same class; there was no obvious 
way of avoiding this. Nevertheless the answers in the questionnaire were and will be kept 
strictly confidential. Students who declined to participate were not known by others. The 
classroom was spacious and every student had their own desk, seated in different lines and 
rows. Participants could not easily see the responses of other participants who were seated in 
a separate row. The questionnaire was anonymous - no identifying information was included. 
The completed questionnaires were stored initially in secure filing cabinets in offices at 
Mudanjiang Medical University, then transported back to the UK for secure storage at the 
University of Edinburgh. 
 
A number of further measures were undertaken to enhance the integrity of the questionnaire-
completion process and the validity of responses. These included measures to ensure the 
questionnaire was completed in private, protection of confidentiality, and clarification over 
the confusion between HPV and HIV, etc. For quality control purposes, I did not check for 
missing or invalid responses at Visit 3. In the data entry process using Epidata software, 
missing data were not recorded as any number, just left blank; but SPSS (the statistical 
software used for data analysis), included missing data in the descriptive analysis – these 
data were excluded from further comparisons. So the amount of missing data was known but 
was not analysed included a as variable.  
3.9 Data management  
3.9.1 Transport and storage of questionnaires  
Before visiting the high schools and after gaining ethical approval (early April), I printed out 
all the documents in Chinese at a printing facility in Mudanjiang Medical University. 
Completed questionnaires were stored in a locked cabinet in an office of the university once 
they were collected from schools. During the survey, nobody had the key to the cabinet. 
After finishing all the fieldwork in China, I sent all the questionnaires back to the Centre for 
Population Health Sciences, Edinburgh University, by registered mail (China Post), where I 
stored the questionnaires in a secure, locked filing cabinet to keep them confidential.  
3.9.2 Data coding  
Epidata Data Entry software (Epidata Association, http://www.epidata.dk) was used to code 
and enter data. First, a sample of the questionnaire was recorded in Epidata format (a ‘.qes’ 
file), which defined the variable names, types, and lengths, as well as the layout of the data 
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entry form for a file. To ensure consistency between database and questionnaires and avoid 
potential entry errors, the Chinese version of questionnaire was used in the Epidata. Variable 
names were generated (eg knldg1 and atttd2) - the same variable names were used in SPSS 
for analysis. Responses were recorded in a ‘.rec’ file as numbers, and the coding of 
responses is described in Table 3-11. For example, for knowledge questions: ‘True’ is 1, 
‘False’ is 2 and ‘Don’t know’ is 3. All missing data (participant chose not to respond) were 
coded accordingly. A check file (‘chk’file) was used to check the validity of data during data 
entry. Below are the settings made in Epidata for data entry; they also include ways to reduce 
manual errors via computer-based management prior to data entry.  
 
Field type: As only closed questions were included in the questionnaire, categorical fields 
were set for all the questions except age (numerical fields), where only numbers could be 
entered. 
 
Field length: determined how many characters could be entered in one field. 
 All the variables but age were categorical (the number of categories was 5), so only 1 
number could be entered in these fields.  
 For age, the anticipated age range was 16–19, which includes no numbers lower than 10 
or higher than 99, so 2 characters could be entered. 
 
 
Range/legal values: limited the values that could be entered in the field.  
 All the variables but age were categorical ones, so a legal value limit was set for these 
categorical fields. The input needed to match the specified list of values.  
 For example: Gender: 1=male, 2=female, so only 1 or 2 can be entered; Agreement: 
strongly disagree=1, somewhat disagree=2, somewhat agree=3, strongly agree=4, 
unsure=5, so only 1, 2, 3, 4 or 5 could be entered.  
 I set a range limit for age, which was from 10 to 99.  
 
Jumps: Jumps were used to move between two fields. Conditional jumps were used in the 
coding sheet; the first question in the questionnaire was a screening one, and if participants 
answered ‘yes’, they could go on to answer the following knowledge questions, otherwise, 




Finally, a database, based on the questionnaire, was generated (Figure 3-10 presents the 
database from Epidata). 
3.9.3 Data entry and checking 
All the data (3,788 questionnaires) was entered to the Epidata database by me first, and a 
colleague with data entry skills undertook a second entry of 10% of the data - 379 
questionnaires (these were selected randomly on the basis of a number sequence with regular 
a interval - 6, 16, 26 ... 3766, 3776, and 3786). All the data entry was conducted at the 
University of Edinburgh, and it took approximately three months (from June to August 2013) 
to complete the two entries. In order to reduce manual errors,, I set up a time limit for my 
single data entry, which was no more than three hours a day and five days a week. Double 
entry of 10% of the data was done by my colleague over two weeks. Questionnaires that had 
been entered into Epidata were again put in the locked filing cabinet in the office. 
 
Each questionnaire had 50 items, which meant that I need to enter 189,400 items in total. 10% 
of the data were checked automatically in Epidata. Below are the results of the data check:  
 Double entry: 69 errors from 34 questionnaires out of 758 questionnaires (combining the 
two data sets – my colleague’s ’s and mine) were found, and the overall discrepancy rate 
was 0.18% per field (item) (calculation equation: 69 errors / 18,950 items).  
 Single entry (first data entry by me): 23 errors from 42 questionnaires were found in 378 
questionnaires, and the error rate was 0.22% per field (item) (calculation equation: 42 
errors / 18,950 items)  
 Single entry (second data entry by my colleague): 27 errors from 11 questionnaires were 
found, and the error rate for the second data entry is 0.14% (calculation equation: 27 
errors / 18,950 items).  
 
The error rate (0.14%–0.22%) for single data entry was acceptable when compared with 
international studies (detailed discussion is addressed in Chapter 4).  
 
All the mistakes were typically mistyping or complete omission.  
3.10  Approach to data analysis 
In common with most questionnaire-based surveys, my data analysis was intended to 
produce simple frequencies for each of my questionnaire variable, and to look for 




Hence, I firstly used descriptive analysis to demonstrate the characteristics of respondents in 
terms of demographics, smoking, and schools, and also the proposed ‘dependent variables’: 
level of awareness, knowledge, acceptability, and attitudes. Note that I used some variables 
(such as knowledge) as both predictor and outcome variables (see below). Second, I used a 
simple measure of association (chi-square testing) to initially explore the relationship 
between predictor and outcome variables. Third, I used logistic regression to explore the 
association between multiple variables – this enabled me to take account of confounding 
effects. Outcome variables were categorical, and I used a multivariate logistic regression 
approach. Finally, to avoid multiple testing issues, I used factor analysis to transform the 
attitudinal variables before undertaking logistic regression to explore the association among 
them. Details of my analysis methods are described below.  
3.10.1 Analysis plan 
My main questions were:  
 what is the level of knowledge of, acceptability of, and attitudes towards HPV? 
 how do demographics affect knowledge of, acceptability of, and attitudes towards HPV? 
 what is the association between knowledge and acceptability, attitudes and acceptability, 
and knowledge and attitudes? 
 
My analytical techniques (and their associated research questions) were: 
 
Descriptive analysis (percentage displayed) 
 what are the characteristics of participants (age, gender, rurality, smoking, and school)? 
 what is the awareness of HPV and acceptability of HPV vaccination (age, gender, rurality, 
smoking, and school)? 
 what is the level of knowledge of HPV, cervical screening, and HPV vaccination?  
 what are the attitudes towards HPV, cervical screening, and HPV vaccination? 
 
Chi-square testing analysis (cross tabs) 
Participants were categorised into an aware/unaware of HPV subgroup, male/female 
subgroup, urban/rural subgroup, and a <18 / >=18 age subgroup. Results are shown by 
category. 
 what are the differences in demographics, attitudes, and acceptability between 
respondents who have heard of HPV and those who have not? 
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 what is the influence of age, gender, and rurality on the following variables?  
o knowledge level of HPV (population: people who knew of HPV) 
o perceived risk and severity of HPV and cervical cancer 
o attitudes to the potential stigma of HPV 
o perceived benefits of and barriers to vaccination  
o others’ influences on the acceptability of the vaccine 
 
Factor analysis—exploratory factor analysis 
What are the attitude patterns extracted from the attitudes items? 
 
Logistic regression analysis (outputs are expressed as odds ratios) 
What are the predictors for acceptability and knowledge? 
 Association between acceptability and attitudes (population: all respondents) 
 Association between attitudes and knowledge, acceptability and knowledge (population: 
people who know about HPV 
3.10.2 Statistical methods  
Descriptive analysis and chi-square testing 
Descriptive statistical analysis was used to summarise demographic characteristics. 
Categorical variables were presented as numbers and percentages (eg acceptability). 
Associations were initially identified using chi-square testing. As responses to attitude 
questions used a five-level Likert scale (strongly disagree, somewhat disagree, somewhat 
agree, strongly agree, unsure), the numbers in each box of the chi-square table were very 
likely to be less than 5 (which is too small for meaningful analyses). Accordingly, I 
regrouped the 5-Likert scale response options into three categories (disagree, agree, unsure) 




Two key steps were included in my factor analysis. First, I decided on how many factors 
could be extracted from attitudinal variables to achieve the best estimate of the original 
groupings of variables. Second, I decided on which individual variables could be included in 
the specific factor to find the variables most matched with the factor. . The eigenvalue is 
used to determine the number of factors extracted, and factor loadings determine the 
percentage of variance of the individual variable that can be explained by the factor. The 
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Varimax rotation model is used to determine how many factors are formulated, to achieve 
the best match between the factor and the grouping of variables (maximising the variance of 
a factor on the variables) - and to make the output more understandable.  
 
I chose principal component factor analysis [232, 233] to identify attitude patterns. This is a 
widely used method for factor extraction which extracts the maximum possible variance. To 
determine the number of factors, I considered potential candidate factors as those with an 
eigenvalue greater than 1.0. When a factor has eigenvalue smaller than 1.0, the factor’s 
explanatory power is lower than the power of the original variable, and the factor is assumed 
not to be the best estimate of the original grouping of variables [233]. Accordingly, factors 
with smaller eigenvalues (< 1.0) were removed. But the final included factors also depended 
on their importance in the context of my thesis topic.  
 
Individual variables that had 0.40 factor loadings were included in the factor [233]. In  factor 
analysis, ‘0.70 factor loadings’ describe a situation in which half of the variance of the 
individual variable can be explained by the factor [232, 233]. However, the 0.70 loading is a 
high standard, and most data may not meet this criterion, thus, ‘0.40 loadings’ serve as a 
commonly used standard [232] [233].  
 
Factors were finally recorded and saved as factor scores, which are continuous variables, for 
use as variables in the subsequent modelling. Factor scores were then categorised into 
quartiles according to the distribution of the subjects. Figure 3-11 shows the key elements of 
my factor analysis. 
 
Logistic regression 
Logistic regression analysis was used to determine the association between variables taking 
potential confounders into account – analyses included attitude (predictor) and acceptability, 
and attitude (predictor) and level of knowledge (low level and high level). Odds ratios (OR’s) 
were estimated between each quartile (except the lowest one) and the lowest quartile of each 
attitude pattern (predictor) with respect to the outcomes (acceptability or level of knowledge). 
The logistic regression model was also adjusted for age, gender, and rurality.  All analyses 
were two sided at the 2.5% level (p<0.025) as the statistically significant value.   
 
I undertook some data manipulation. For example, to examine the associations between 
knowledge level and predictor variables responses to knowledge questions were recorded as 
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scores. If the respondents chose the right answer, they would be given a score of 1; if they 
chose the wrong answer, they would be given a score of -1; if they didn’t know the answer, 
they would be given a score of 0. Theoretically, the lowest possible score for all the 
knowledge questions is -14, while the highest score is 14.  As it transpired, the lowest score 
was -6, and the highest was 14. The median was 6. I classified the responses into two 
categories: high level of knowledge (>6 score) and low level of knowledge (≤6 score). 
Finally, I categorised 222 respondents with a ‘high level of knowledge’ and 255 respondents 
with a ‘low level of knowledge’.  
 
Handling of the predictor variables 
In the initial analysis, I found that gender and rurality had an influence on knowledge and 
acceptability of HPV vaccination. In order to identify the influence of attitudinal variables 
(eg stigma, perceived barriers), adjustments for gender and rurality were made.  
 
Predictor variables including stigma, perceived barriers, and perceived risk were extracted as 
‘factors’ based on my factor analysis. Factor scores were recorded during this process. Factor 
scores were continuous variables and represented the ratings of participants’ responses. In 
order to easily estimate the associations, factor scores were categorised into quartiles 
according to the distribution of the study subjects. Thus, predictors extracted from the factor 
analysis were all categorical variables. 
 
Handling of the outcome variables 
Level of knowledge of HPV was recorded as ‘high score knowledge’ or ‘low score 
knowledge’ based on the number of ‘correct’ answers—so level of knowledge was a 
dichotomous outcome variable. Acceptability was recorded as one of three points on a Likert 
scale.  
3.10.3 Conclusion 
I used statistical methods to produce summary statistics and explore associations between 
variables. Of course, demonstration of statistical association does not imply causality; any 
demonstrated association needs to make sense. Hence, the discussion section of my results 
chapter explains more what the results mean and how reliable, or plausible, they might be.  
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3.11  Rationale for my chosen statistical methods 
3.11.1 Factor analysis (exploratory factor analysis) 
Two main issues occur in the process of analysing associations between a large number of 
similar variables. They are the main reasons why I undertook the factor analysis prior to the 
regression analysis. 
 
The first issue concerns the likely collinearity or multicollinearity within the variables. In 
order to demonstrate an association in a robust way, I wanted to use a regression model that 
gave valid results. Ideally, the best regression models have predictor variables that each 
correlate highly with the outcome variable rather than correlating with each other (or only 
minimal correlation). However, there were 20 questions generated from five concepts 
relating to attitudes towards HPV vaccination in the questionnaire. It is inevitable that these 
questions (variables) correlate in some ways. For example, questions like ‘Do you agree that 
people will think someone who is infected with HPV is likely to have been promiscuous?’ 
and questions like ‘Do you agree people are infected with HPV because they or their partners 
have been unfaithful?’ would have some kind of correlation, meaning that people who 
choose the ‘promiscuous’ opinion would also be more likely to believe the ‘unfaithful’ 
statement. And when the two are used to identify the association with the level of knowledge 
respectively, the result of each variable would be difficult to explain if it was affected by 
another in some way. Hence, when these variables are directly included in the statistical 
analysis, issues of collinearity may occur, or of multicollinearity, when three or more 
predictor variables share the same theme.  
 
The second issue relates to multiple testing. I aimed to analyse the association between 
attitudes and level of knowledge, and attitudes and the acceptability of HPV vaccines. Given 
that I have 20 variables relating to attitudes, theoretically, I should undertake more than 20 
tests to determine the associations. This inevitably produces multiple testing problems due to 
such a large number of association tests, and accordingly increases the probability of finding 
associations purely by chance.  
 
Therefore, to avoid issues of collinearity and multiple testing, I decided to use factor analysis 
prior to the association analysis, in which, by linear transformation, 20 variables could be 
combined into a smaller number of groups of variables. This process should ideally capture 
the meanings in the original uncombined variables as much as possible. The ‘number’ of 
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factors refer to the number of groups of original variables. Given that the attitude questions 
were generated based on the Health Belief Model (containing five constructs), theoretically, 
five factors (groups of variables) at least would be extracted via factor analysis. This may 
tackle the collinearity problems and reduce the multiple testing issues to some extent via 
decreasing the number of variables. 
3.11.2  Logistic regression 
I also sought, in my analysis, to examine associations between key variables using logistic 
regression techniques.  
 My key outcome variables were: 1) level of knowledge about HPV and 2) acceptability of 
HPV vaccine. 
 My key predictor variables were age, gender, rurality, perceived stigma, perceived risk, 
perceived benefits, perceived severity, and perceived barriers. 
 
Logistic regression analysis is used to identify the association between a ‘dependent’, or 
outcome variable and multiple independent variables – it seeks to tease out the independent 
contribution of independent variables on outcome. Two scenarios can be accommodated 
with regression methods: 
 The dependent variable is continuous; multiple linear regression is generally used.  
 The dependent variable is categorical (as is the case with my data); chi-square testing is 
appropriate in the first instance, then binary or multivariate logistic regression.  
In the presence of confounders which would influence the association between variables, 
logistic regression is usually used for adjustment.  
 
In terms of the dichotomous and multiple dependent variables, I used binary and multivariate 
logistic regression analysis respectively. In my survey, I used multivariate logistic regression 
to identify the relationship between predictors and level of knowledge, and predictors and 
acceptability. 
3.12  Ethics Review in UK and China 
The study underwent a rigorous ethics review at Edinburgh University – through the Centre 
for Population Health Sciences’s ethics panel. The feedback I received included issues over 
inclusion of questions about sexual activity, age group selection, the balance of how much 
information on HPV was given prior to completion of the questionnaire, and inclusion of 
individual socio-economic data in the questionnaire. There was some dialogue between my 
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study team (myself and my supervisors) and the ethics committee over pragmatic 
considerations, maintaining the integrity of international study comparisons, and the Chinese 
research environment (which is fundamentally different from the UK research environment - 
see Appendix 6, which provides the ethical documents. Following some modification of my 
protocol, ethical approval was obtained.  
 
I also needed ethical approval from a Chinese institution; with this in mind I established a 
dialogue over this project with an epidemiology professor (Professor Li Xiaoxia) in 
Mudanjiang Medical University - the local university in Mudanjiang city. She agreed to help 
us in the ethics review and the storage of questionnaires. She helped us to review the 
documents and submit them to the ethics committee of Mudanjiang Medical University – 
approval was duly granted. Professor Li provided extremely useful input on local 
implementation issues, highlighting levels of sexual health education in Mudanjiang city, 
and strategies for avoiding bias in questionnaire distribution. No further changes were 
suggested in terms of the content or structure of the questionnaire or conduct of the survey.  
3.13  Conclusion  
This chapter has described the methods I used in my questionnaire survey, including the 
development of the instrument, recruitment, data management, and analysis. I have given 
particular emphasis to the steps taken to ensure the sample is as representative of the target 
population as possible. I have acknowledge the limitations in the representativeness of my 
sample – nevertheless, while no sampling technique is perfect, I feel I have a sample from 
which implications for the wider Chinese population can reasonably be drawn. 
 
Development of the survey was strongly influenced by my literature review and discussions 
with my supervisors - and a statistician within the Centre for Population Health Sciences. I 
drew on theoretical frameworks in developing my survey (including the Health Belief 
Model), and used established techniques such as concurrent probing, and think-aloud 
interviewing in my cognitive testing. Data collection was a very significant task; it included 
sample size estimation, evaluation of the representativeness of Heilongjiang province, 
selection of schools, classes, and students, implementation of the survey and data coding, 
entry, and double checking.  
 
I am hopeful this process has produced results which are valid and meaningful – they are 
presented in the following chapter.    
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Pros  Cons  
Postal 
questionnaire 
 Affordable, the cost only consists of 
printing and distributing 
 Flexible, respondents have more time 
to think, and would give more a honest 
reply due to the absence of the 
interviewer 
 
 Poor response rate, only a very few 
people would be interested in filling out 
the questionnaire and mailing it back 
 Questions can be misunderstood 
 Inconvenient in China where many 
people live in communities that rarely 
use the postal box, so it is hard to reach 
people in the community by post 
Face to face 
administration 
in community 
 Researchers can clarify the doubt and 
ensure questions are properly 
understood  
 Respondents are randomly distributed, 
and there is no selection bias; 
 Time consuming: it will take a long time 
to reach a great many people 
 Expensive: it will cost much for the 
administration 
High school  Convenient, it could reach large 
amount of people in short time 
 Affordable, the cost only consists of 
printing 
 High response rate, when the 
questionnaire is distributed in class 
 Selection bias: this will ignore those 
adolescents who do not attend high 
schools, especially in rural regions 
 Social desirability bias: adolescents 
would response conforming to the social 
norms when the researchers are present 
College or 
university 
 Big sample size, it would reach a big 
sample size in short time 
 Affordable, the cost is low, only 
consist of printing 
 High response rate if distributed via 
class  
 Selection bias: this will ignore the young 
adults who do not attend college or 
university, especially those from rural 
areas 
 Social desirability bias 
Health centre/ 
hospital 
 Convenient, it’s easy to reach patients 
in the hospitals 
 Affordable, the cost is low 
Selection bias: patients who go to hospital 
would be those who care more about health 
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Table 3-2:  Comparison of Health Behaviour Theories 










One’s ability to 
perform the 
behaviour 
One’s risk if not 
engaged in the 
behaviour 
One made a firm 
commitment to 
































































HBM: Health Belief Model 
TRA: Theory of reasoned action 
TPB: Theory of Planned Behaviour 
SCT: Social Cognitive Theory 





Table 3-3:  Stages and elements for sample size estimation 
Research questions (rank) The primary objective What is the level of knowledge of HPV in the teenage participants 
The primary, secondary, 
and tertiary comparison 
of interest 
What is the association between gender and level of knowledge 
What is the association between the level of knowledge of HPV and the acceptability of vaccination 
What is the association between attitudes towards HPV and the acceptability of vaccination 
Main elements The outcome and 
predictor variables 
Outcome variables Predictor variables 
Knowledge Age, gender, rurality and smoking 
Attitudes Age, gender, rurality and smoking 
Awareness of HPV (those who know and those who do not) 
Knowledge level 
Acceptability  Age, gender, rurality and smoking 
Awareness of HPV (those who know and those who do not) 
Knowledge level 
Attitudes 
Parameter estimates  
(on which sample size 
based) 
Parameter symbols Parameter meanings 
α Significance level (probability of committing a type I error) 
Power (1- β) Probability of making a type II error 
p1, p2, q1, q2 Frequency of the outcome 
𝑝1 − 𝑝2 Difference in proportions of the outcome 
 r Ratio of larger group to smaller group 
Variability Potential variables will confound the association between predictors and outcomes 
Prior studies (Data on which 
I based my assumptions) 
Primary comparison Gender difference is 15%: 50% males know HPV causes cervical cancer, and 35% females do not 
Secondary comparison Acceptability difference is 15%: acceptability is 60% and 75% between people who have knowledge and those who do not 
Statistical tests used Test Role of test 
Chi-square test To identify age, gender, and rurality influence on knowledge, attitudes, and acceptability 
Logistic regression  To identify association between acceptability and knowledge, acceptability and attitudes, attitudes and knowledge 
Factor analysis To extract factors from 20 attitudinal variables 




Table 3-4:  Parameters that affect sample size estimation 





Indicators on which sample size 
calculation formula based 
Strength of the association Moderate Very small 
Frequency of the outcome Moderate Very small 
How precise I want to be 
(confidence level) 
Fairly precise Very precise 
How sure I want to be 
(statistical power) 
Fairly sure Very sure 
How much variation in the study population  
(potential confounding) 
Low variation High variation 
Response rate High rate Low rate 














1 Guangdong 10505 63.4  
2 Shandong 9637 48.3  
3 Henan 9388 37.7  
4 Sichuan 8050 38.7  
5 Jiangsu 7899 55.6  
6 Hebei 7241 43.0  
7 Hunan 6596 43.2  
8 Anhui 5968 42.1  
9 Hubei 5758 46.0  
10 Zhejiang 5463 57.9  
11 Guangxi 4645 39.2  
12 Yunnan 4631 34.0  
13 Jiangxi 4488 43.2  
14 Liaoning 4383 60.4  
15 Heilongjiang 3834 55.5  
16 Shaanxi 3743 43.5  
17 Fujian 3720 51.4  
18 Shanxi 3593 46.0  
19 Guizhou 3469 29.9  
20 Chongqing 2919 51.6  
21 Jilin 2749 53.3  
22 Gansu 2564 32.7  
23 Inner Mongolia 2482 53.4  
24 Shanghai 2347 88.6  
25 Xinjiang 2209 39.9  
26 Beijing 2019 85.0  
27 Tianjin 1355 78.0  
28 Hainan 877 49.1  
29 Ningxia 639 46.1  
30 Qinghai 568 41.9  
31 Tibet 303 23.8  
Reproduced from China Population Census 2010, China Statistics Yearbook 2012[149], and 





Table 3-6:  GDP of provinces in China in 2011  
Rankings of 
GDP per capita 
Province GDP per capita (RMB) GDP (100 million RMB) 
1 Tianjin 84337 11191.0 
2 Shanghai 82560 19195.7 
3 Beijing 80394 16011.4 
4 Jiangsu 61649 48604.3 
5 Zhejiang 58665 32000.1 
6 Inner Mongolia 57515 14246.1 
7 Liaoning 50299 22025.9 
8 Guangdong 50295 52673.6 
9 Shandong 47260 45429.2 
10 Fujian 46972 17410.2 
11 Jilin 38321 10530.7 
12 Chongqing 34500 10011.1 
13 Hubei 34131 19594.2 
14 Hebei 33571 24228.2 
15 Shaanxi 33142 12391.3 
16 Heilongjiang 32615 12503.8 
17 Ningxia 32392 2060.8 
18 Shanxi 30974 11100.2 
19 Hunan 29828 19635.2 
20 Xinjiang 29496 6474.5 
21 Henan 28981 27232.0 
22 Qinghai 28891 1634.7 
23 Hainan 28797 2515.3 
24 Sichuan 26133 21026.7 
25 Jiangxi 25884 11583.8 
26 Anhui 25340 15110.3 
27 Guangxi 25315 11714.4 
28 Tibet 20077 605.8 
29 Gansu 19517 5000.5 
30 Yunnan 18957 8751.0 
31 Guizhou 16413 5701.8 






Table 3-7:  Health care expenditure in provinces of China in 2010  










1 Beijing 1389.5 7.8 1 Beijing 867.9 9.8 
2 Tianjin 1273.4 8.6 2 Shanghai 738.9 7.5 
3 Jilin 1120.4 10.3 3 Zhejiang 609.1 7.9 
4 Liaoning 1018.4 8.3 4 Jilin 511.5 13.1 
5 Shanghai 1002.1 4.8 5 Heilongjiang 434.3 10.2 
6 Inner Mongolia 992.7 8.0 6 Inner Mongolia 416.9 10.5 
7 Zhejiang 984.6 5.9 7 Liaoning 409.6 9.6 
8 Chongqing 982.7 8.1 8 Ningxia 356.4 10.6 
9 Heilongjiang 978.8 10.2 9 Shaanxi 329.3 9.8 
10 Hebei 971.3 10.0 10 Jiangsu 323.0 5.6 
11 Guangdong 925.6 5.5 11 Xinjiang 316.6 10.7 
12 Ningxia 921.9 9.0 12 Shandong 301.6 6.8 
13 Shandong 885.2 7.4 13 Tianjin 299.8 7.0 
14 Henan 875.5 9.2 14 Qinghai 291.3 9.1 
15 Shaanxi 863.4 8.1 15 Hebei 289.3 8.6 
16 Jiangsu 808.4 6.1 16 Hunan 258.1 6.4 
17 Shanxi 789.9 8.4 17 Sichuan 258.1 6.2 
18 Hunan 784.7 7.2 18 Henan 242.9 7.2 
19 Gansu 746.8 8.4 19 Chongqing 242.6 7.7 
20 Anhui 716.9 7.0 20 Shanxi 240.9 7.3 
21 Yunnan 708.8 6.9 21 Hubei 236.3 6.3 
22 Qinghai 701.4 8.0 22 Jiangxi 232.8 6.6 
23 Hubei 694.6 6.7 23 Guangdong 232.0 4.6 
24 Xinjiang 684.0 7.3 24 Anhui 227.1 6.2 
25 Sichuan 648.3 6.0 25 Fujian 219.0 4.4 
26 Hainan 604.2 6.0 26 Guangxi 205.2 6.3 
27 Fujian 591.5 4.4 27 Yunnan 197.6 6.8 
28 Jiangxi 550.3 5.6 28 Gansu 180.1 6.5 
29 Guangxi 538.2 5.2 29 Guizhou 133.2 5.5 
30 Guizhou 535.4 5.9 30 Hainan 129.3 4.2 
31 Tibet 352.3 3.9 31 Tibet 71.5 3.0 
# Rankings based on the health care expenditure per capita 
*Proportion of health care expenditure in total consumption expenditure 





Table 3-8:  Standardised death rate of cervical cancer in provinces in China in 2004–
2005 [17] 
Rankings Province 
Standardised death rate of cervical 
cancer (per 100,000 population) 
1 Xinjiang 10.69 
2 Gansu 9.36 
3 Hunan 4.98 
4 Jiangxi 4.9 
5 Shaanxi 4.59 
6 Ningxia 4.21 
7 Guizhou 3.99 
8 Qinghai 3.9 
9 Shanxi 3.7 
10 Tibet 3.38 
11 Anhui 2.81 
12 Guangxi 2.77 
13 Henan 2.73 
14 Hainan 2.65 
15 Hubei 2.5 
16 Hebei 2.35 
17 Zhejiang 2.29 
18 Heilongjiang 2.12 
19 Tianjin 2.11 
20 Fujian 2.01 
21 Jilin 1.97 
22 Yunnan 1.78 
23 Guangdong 1.73 
24 Inner Mongolia 1.61 
25 Sichuan 1.53 
26 Liaoning 1.35 
27 Beijing 1.28 
28 Shandong 1.23 
29 Jiangsu 1.2 
30 Shanghai 1.04 





Table 3-9:  Overview of Heilongjiang province in China [17, 149, 223] 
 
 China  Heilongjiang 
province 
Similar conditions in other 
parts of China  
(31 provincial regions) 
Rank of Heilongjiang in China  
(31 provincial regions) 
Demography 
Population (million)  1,300M 38M 9 provinces (30-50M) Top 15th populated  
Proportion of rurality (%) 54% 44.5% 17 provinces (40-60%) Top 9th urbanised province 
Economic development 
GDP per capita (¥) 2011 32615 (median) 32,615 8 provinces (¥30,000-40,000)  Top 16th wealthy  
Household income (¥)  
(urban vs. rural) 2010 
18373 vs. 6604  
(median) 
15,696 vs.7,590 10 provinces (<¥18,000) Top 28th vs. Top 10th wealthy 
Health care 
Health expenditure per capita (¥)  
(urban vs. rural)  2010 
808 vs. 258  
(median) 
978 vs. 434 11 provinces (¥ 800-1,000) Top 9th vs. Top 5th most 
Out-of-pocket proportion in total 
consumption (%)  
(urban vs. rural) 2010 
6.4% vs. 8.4% 10.2% vs. 10.2% 3 provinces (>10%) vs.  
5 provinces (>10%) 
Top 2nd vs. Top 5th most 
Education 
Illiteracy rate (%) 2010 3.8% (median) 2.1% 16 provinces (1.7-4.0%) Top 8th least illiteracy  
Cervical cancer 




2.12/100,000 10 provinces (1.5-2.5) Top 14th low mortality  
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Table 3-10:  Timeline of the survey 
 
Time Visit  School  
Mar 20th – Apr 5th  1st visit  All five high schools 
Apr 8th –Apr 16th  2nd, 3rd, visit  Hailin high school 
Apr 18th – May 1st 2nd, 3rd, visit Ning’an high school 
May 2nd – May 8th  2nd, 3rd, visit  No. 3 high school 
May 9th – May 16th 2nd, 3rd, visit No. 2 high school 




Table 3-11:  Data coding for knowledge questions and responses 
 
 Codes for responses 
Knowledge questions’ 
responses 
True False Don’t know   









Very likely Unsure 











 1 2 3 4 5 
Demographic questions’ 
responses 
Male Female    









 1 2 3 4 5 




































Preparatory work / 
generating sample 
 
Ideally 15-18 year old teenagers 
5 public high schools, Mudanjiang 
city, Heilongjiang province 
Data handling and 
analysis  
 





5 schools, (3 visits of each school) 
3 grades,  
67 classes, 
















































Structure of questionnaire 
3 sections,  
1 information box, 
1 screening question, 
Categorical responses 
Refinement of draft questions 
Sources of questions Health behaviour theories:  
Health Belief Model 
Cognitive interview 





Figure 3-3:  Key elements of sample size estimation  
 
This is based on the secondary comparison of interest (other estimation of comparisons 





Logistic regression adjust for age, gender and rurality
Assumptions
α(two-sided)=0.025; β=0.80; p1=0.61; p2=0.75
Wish
To detect a 15% acceptability difference between people with knowledge and those without
Previous data
P1(acceptability of people who have 
knowledge)=0.60
P2(acceptability of people who do not)=0.75
Research question


































Figure 3-6:  Proportion of medical expenditure in total consumption expenditure in 




The measurement of health care expenditure proportion is categorised into five levels 
(lowest to highest) 
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Figure 3-7:  Proportion of medical expenditure in total consumption expenditure in 




The measurement of health care expenditure proportion is categorised into five levels 
(lowest to highest)  
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Figure 3-8:  Map of China: location of Heilongjiang province in China.  
 
 
The orange region refers to Heilongjiang province; the red region refers to Mudanjiang city. 
 




The red regions refer to the central regions of the city; number 7 refers to Hailin county; 
number 8 refers to Ning’an county.   
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Conduct of factor analysis 
Determine how many factors are 
extracted from variables 
Varimax rotation model 
Extract factors with 
Eigenvalue >1.0 
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4 Chapter 4 HPV and cervical screening survey: 
Results  
 
Chapter 3 described the methodology of my survey in Heilongjiang in China: in this chapter 
I present the results of that work.. I carried out a questionnaire-based survey and I report 
results based on summary data and analysis of the responses to each question in the 
questionnaire.  
 
The first question in the questionnaire was a screening question about HPV awareness, 
which served to identify participants who had heard of HPV, and those who had not. The 
participants were subsequently divided into two groups based on the response to that 
screening question: 1) those who had heard of HPV were requested to answer all three 
sections in the questionnaire: i.e. the knowledge, attitude, and background questions; 2) 
those who had not heard of HPV were requested to answer the last two sections: only the 
attitude and background questions. Hence, when it comes to the analysis, description of 
characteristics of participants, awareness, attitude and acceptability, and association between 
these variables are shown among all the respondents; description of knowledge level and the 
association of knowledge level with other variables are only provided for respondents who 
had heard of HPV. The number of participants for any individual result is presented on the 
top line of each table of results.   
 
Firstly, respondents’ characteristics are presented as numbers and percentages. Secondly, 
results of chi-square testing undertaken to identify any initial differences in awareness, 
knowledge, attitudes, and acceptability between urban and rural participants, males and 
females, and <18 and >=18 participants are presented. Thirdly, results of logistic regression 
are presented. Logistic regression was undertaken under the following circumstances: a. 
when a difference was required to be identified between two specific categories of variables 
that had more than two categories; b. when there was confounding of the association 
between variables, and adjustment was required. Tables of results for the chi-square testing 
are not all presented because of the further regression analysis between the same variables 
(details are provided in the chapter).  
4.1 Characteristics of participants 
In total, 67 classes from five high schools in Heilongjiang province were approached. Within 
these five schools, 24 classes were from Grade 10, 23 classes from Grade 11, and 20 classes 
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from Grade 12. The number of questionnaires distributed and returned in each school is 
provided in Table 4-1. No students asked to leave the classroom before the survey started. 
Students who declined to participate after they had read the questionnaire did not return the 
questionnaires. A total of 4,050 questionnaires were distributed, and 3,788 were returned. 
The overall response rate was 94.2%.  
 
The characteristics of the participants are presented in Table 4-2. Participants were aged 
between 14 and 22 years and 16–19-year-old students accounted for the majority: 3,460 
(91.3%). Over half were female: 2,060 (54.4%). A total of 740 (19.5%) participants were 
from rural areas and the remainder were from urban regions. Participants were equally 
distributed among the chosen five schools (approximately 20% from each school). Most of 
the students never smoked: 3,200 (84.5%) and 84 (2.2%) smoked every day.  
 
Some differences in age, gender, and rurality were found among questionnaire respondents 
(Table 4-3). More rural participants than urban participants were aged 18 years or older. 
Gender and age were found to be associated with smoking through chi-square testing, and 
multivariate logistic regression further identified that males (22.5%) were more likely to 
have smoked than females (7.4%); participants who were aged 18 years or older were more 
likely to smoke than those younger than 18 years. Age and gender of respondents were also 
found to be associated with participants’ schools. Hence, adjustments for age, gender, 
rurality, smoking, and school were needed when further analysis was undertaken because of 
the association between them. Tables 4-3 and 4-4 present these results of chi-square testing 
and logistic regression.  
4.2 Awareness of HPV  
Of all the participants (3,788), 499 (13.2%) reported that they were aware of HPV, meaning 
these students answered ‘Yes’ to the screening question ‘Have you heard of HPV?’ (Page 1 
of the questionnaire). As discussed in Chapter 3, it was important to identify the students 
who were already aware of HPV: these students answered the knowledge questions in the 
questionnaire. They also answered the attitude questions, and comparisons are made later in 
this chapter between those who were aware of HPV and those who were not.  
4.3 Knowledge of HPV and vaccination 
A total of 499 (13.2%) participants had heard of HPV, and only these respondents answered 
the subsequent knowledge questions. The level of knowledge of HPV infection and 
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vaccination among these participants is presented in Table 4-5 and missing data is also 
presented. Figure 4-1 presents knowledge levels in descending order in terms of the 
proportion of correct responses.  
 
I divided the levels of knowledge into three groups. If less than one third of respondents 
reported having knowledge of a given area it was viewed as a low-level of knowledge; 
between one-third and two-thirds was viewed as a moderate level; over two thirds was 
viewed as a high level. Details are presented in Figure 4-1.  
 
The high-level knowledge areas 
 ‘HPV vaccination is not 100% effective against cervical cancer’ (n=366, 73.3%) 
 ‘Cervical screening is still necessary after HPV vaccination’ (n=351, 70.3%) 
 The risk of multiple sexual partners for cervical cancer (n=343, 68.7%)  
 The asymptomatic nature of HPV infection (n=342, 68.5%) 
 
The moderate-level knowledge areas 
 ‘HPV infection may cause cervical cancer’ (n=327, 65.5%) 
 The sexually transmitted nature of HPV infection (n=290, 58.1%)  
 The condom role in the protection of HPV infection (n=199, 39.9%) 
 
The low-level knowledge areas 
 ‘Most HPV can be cleared without treatment’ (n=116, 23.2%)  
 ‘Poor personal hygiene can increase the risk of getting HPV’ (n=30, 6.0%) 
 
These results constituted a high-level overview of knowledge levels among participants who 
had heard of HPV (499, 13.2%).  Knowledge level was also examined by overall scores for 
correct responses among these participants. As discussed in Chapter 3, participants were 
divided into two groups: 222 (44.5%) participants had a high level of knowledge and 255 
(51.1%) had a low level of knowledge (22 participants missed answering some knowledge 
questions). Considering the multiple testing issues, high and low levels of knowledge among 
participants were used later in this chapter to identify the association with acceptability and 
attitudes instead of the level of knowledge of each question by participants.  
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4.4 Attitudes toward HPV and vaccination 
The attitudes questions were categorised into six categories based on the Health Belief 
Model.  These categories were perceived risk, perceived severity, perceived benefits, 
perceived barriers, other influences, and attitudes on stigma. Table 4-6 presents the attitudes 
towards HPV and vaccination among all the participants (n=3,788), i.e. including both those 
who had heard of HPV and those who had not. Questions related to the following issues 
were required to be answered only by females (2,060, 54.4%): personal perceived risk of 
cervical cancer, personal perceived impact of cervical cancer, personal perceived necessity 
of taking up cervical screening, and the recommended frequency of cervical screening. 
Males who answered these questions were excluded from the analysis.  
4.4.1 Overview of attitudes  
Areas of attitudes towards HPV vaccination were listed under headings according to Health 
Belief Model concepts. Response options of somewhat/strongly agree and somewhat/very 
likely in the questionnaire were combined together respectively to obtain an overview of 
attitudes among participants.  
 
Perceived risk of HPV infection, and cervical cancer 
Regarding the question ‘How likely the risk is that you will get HPV infection in the future?’, 
325 (8.6%) participants perceived their personal risk of HPV (those who chose somewhat 
likely and very likely options); for question ‘How likely the risk is that you will get cervical 
cancer in the future?’ 151 female participants (7.3%) perceived their personal risk of cervical 
cancer (somewhat and very likely).  
 
Perceived severity of HPV infection and cervical cancer 
Regarding the statements ‘HPV infection would be disruptive to my physical health/social 
life/sexual relationships’ over half of the participants agreed (strongly and somewhat agreed) 
with all these statements. For statements ‘Cervical cancer would be disruptive to my physical 
health/social life/sexual relationships’, over half of female participants agreed (strongly and 
somewhat agreed) with these. Data is presented by number and percentage.  
 The most worrying impact of HPV infection (n=2,721, 71.8%) and cervical cancer 
(n=1,674, 80%) was that on physical health 
 The second most worrying was the impact on sexual relationships by HPV infection 
(n=2,374, 62.7%), and by cervical cancer (n=1,285, 62.4%) 
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 The least worrying was the impact of HPV infection (n=2,091, 55.2%) and cervical 
cancer (n=1,182, 57.4%) on their social life.  
 
Perceived benefits of HPV vaccine  
A total of 2,968 (78.4%) participants believed the HPV vaccine could protect them from 
HPV infection, while 2,414 (63.7%) believed the vaccine could prevent cervical cancer. 
Only 542 (14.3%) participants agreed with the statement that the HPV vaccine would lead to 
people having more sexual partners. Regarding female participants, 1,684 (81.7%) knew it 
was still necessary to be screened after vaccination, and 548 (26.6%) agreed with the 
statement that the frequency of screening could be reduced after vaccination.  
 
Perceived barriers of HPV vaccine  
Regarding the statements ‘I am concerned that HPV vaccines have not been proved to be 
effective in preventing cervical cancer’, ‘I am concerned that HPV vaccines may have minor 
side effects such as fatigue or fever’, ‘I am concerned that HPV vaccines may have major 
side effects such as long term illness’, ‘I am worried that HPV vaccine costs too much’, and 
‘I trusted companies that make HPV vaccines’, participants presented the barriers 
(strongly/somewhat agreed with the statements) to HPV vaccines. The findings are described 
in descending order below. 
 The first barrier (n=2,707, 71.5%) was minor side effects such as fatigue or fever 
 The second barrier was the effectiveness of the HPV vaccine not having been proved 
(n=2,001, 52.8%)  
 Less than half of the participants worried about the cost of the vaccine (n=1698, 44.8%) 
and the major side effects of the vaccine (n=1,689, 44.6%).  
 1,295 respondents (26.5%) did not trust the companies that produce the HPV vaccine.  
 
Other influences on the acceptability of HPV vaccine  
Regarding the statements ‘I would be vaccinated if my friends/parents/doctors/school/public 
service ads recommend me to’, participants revealed whether they would be influenced by 
others (strongly/somewhat agreed with the statements) 
 The recommendation participants would be most likely to take was that of their parents 
(n=2,503, 66.1%).  
 Doctors and nurses’ recommendations ranked in second place (n=2,302, 60.7%).  
 1,746 respondents (46.1%) would take a school requirement into account when deciding 
whether to be vaccinated against HPV 
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 1,473 respondents (38.9%) would be likely to take their friends’ recommendations. 
 1,017 respondents (26.9%) would be influenced by public service health advertisements.  
 
Attitudes on the stigma of HPV infection  
Regarding the statements on stigma associated with  HPV infection (Table 4-6), I found the 
most commonly identified stigma was ‘if someone has HPV, people will gossip’ (n=1,911, 
50.5%), followed by ‘people will keep a social distance’ (n=1.363, 40%), ‘people would 
think the person is promiscuous’ (n=1,118, 29.5%). 643 respondents (17%) agreed with the 
statement that people who are infected with HPV are likely to have been infected as a result 
of them or their partners being unfaithful.  
4.4.2 Respondents’ uncertainty in attitudes towards the HPV vaccine 
A significant proportion of respondents were unsure whether they should accept the HPV 
vaccine in terms of the benefits, barriers, stigma, and other people’s opinions (Table 4-6). 
 
20–30% of the participants chose ‘Unsure’ option for the following statements 
 The worry of impact on sexual relationships by HPV infection (n=806, 21.3%) and by 
cervical cancer (n=472, 22.9%) 
 The effectiveness of the HPV vaccine (n=1049, 27.7%)  
 The major side effects of the HPV vaccine (n=1010, 26.7%)  
 The stigma of HPV infection in promiscuity (n=895, 23.6%), unfaithfulness (n=1070, 
28.2%), and social distance (n=830, 21.9%)  
 The recommendation from parents (n=774, 20.4%) and doctors (n=887, 23.4%) in terms 
of getting vaccinated 
30–40% of participants chose ‘Unsure’ option on if they should take the recommendation of 
 School (n=1130, 29.8%)  
 Friends (n=1322, 34.9%)  
 Public service health information advertisements (n=1313, 34.7%)  
Nearly 40% of participants were unsure if they should trust the drug companies (n=1479, 
39%). 
4.4.3 Summary of results of attitudes 
All the respondents (n=3,788) were requested to answer the attitude questions, including 
both those who had heard of HPV and those who had not, but missing data was found as well 
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(the numbers depended on the question). These results were used to identify the association 
between acceptability of the vaccine and level of knowledge, reported later in this chapter.  
4.5 Differences by age, gender, and rurality 
Differences in the awareness of HPV infection, knowledge of and attitudes towards HPV 
infection and vaccination, and acceptability of the HPV vaccine by age, gender, and rurality 
were initially explored by chi-square testing (Tables 4-7, 4-8 and 4-9). Further exploration 
was made by logistic regression in the areas of knowledge and attitude in those areas where 
differences were found (Tables 4-7, 4-8 and 4-9). In order to avoid insufficient statistic 
power caused by the very few responses in each of the categories when making comparisons, 
I combined attitude responses into three options ‘Disagree’, ‘Agree’, and ‘Unsure’. The 
influence of smoking was also examined.  
4.5.1 Awareness of HPV 
Regression analysis was performed to identify the influence of age, gender, and rurality on 
the awareness of HPV (Table 4-9). Differences in terms of rurality were found between 
people who had heard of HPV and those who had not: students from rural areas had lower 
awareness (4.5%) of HPV than those from urban areas (15.3%) (OR=0.33, 95% CI=0.22-
0.49, P<0.001). No differences of age and gender were found in the awareness of HPV 
(P=0.411).  
 
Among participants who smoked every day (n= 20, 23.8%) (OR=2.09, 95% CI=1.25-3.49, 
P=0.005) and those who used to smoke and had given up (n= 21, 23.6%) (OR=2.17, 95% 
CI=1.27-3.68, P=0.004) were more likely to have heard of HPV compared to those who had 
never smoked (n = 404, 12.6%). (Table 4-9).  
4.5.2 Knowledge of HPV infection and vaccination 
Regression analysis was carried out and differences in gender and rurality were found in one 
area of knowledge of HPV and vaccination. The comparisons were made between those who 
reported knowing about HPV, and those who did not. (Table 4-7 and Figures 4-2).   
 
More males than females, and more rural than urban participants knew 
 ‘Condom use lowers the risk of HPV infection’ (49% vs. 32.7%), (60.6% vs. 39.3%) 
 
Smoking was not found to be associated with knowledge levels (Table 4-9). 
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4.5.3 Attitudes towards HPV infection and vaccination 
Regression analysis was made using the reference group ‘Disagree’ in the areas of attitude in 
which differences were found by chi-square testing. Differences according to gender were 
found in the following areas of attitude below (Table 4-8).  
More females than males  
 Perceived the physical health impact of HPV infection (74.2% vs. 69.6%) 
 Were concerned about the effectiveness of HPV vaccines (53.8% vs. 52.7%) 
 Worried about the HPV vaccine’s minor side effects (73.5% vs. 69.3%)   
 Would be influenced by their parents (67.7% vs. 64.3%) 
 
More males than females 
 Believed the HPV vaccine would lead to people having more sexual partners (21.7% vs. 
8.8%)   
 Worried about the cost of the vaccine (48.9% vs. 41.7%) 
 Trusted the drug companies (38.9% vs. 30.6%) 
 Would be influenced by friends and TV advertisements. 
 
To summarise, females were more likely to understand the potential health implications of 
HPV infection, worry about the side effects of HPV vaccines, and be influenced by parents. 
Males were more concerned with the cost of the vaccine, the vaccine leading to people 
having more sexual partners and be influenced by friends and TV advertisements.  
 
No significant differences in attitudes towards HPV infection and vaccination were found by 
rurality and age. There were not significant differences in attitudes towards stigma about 
HPV infection by age, gender and rurality.  
4.5.4 Acceptability of the HPV vaccine 
The general acceptability (those who are likely to accept the HPV vaccine) was 68% among 
all the participants, including both those who had heard of HPV and those who had not.  
 
In terms of demographics, differences in gender were found in the acceptability of HPV 
vaccines. More females (n= 1431, 69.5%) than males (n=1110, 66.3%) were likely to accept 
the HPV vaccine (OR=1.69, 95%CI=1.38-2.07, P<0.001). No differences in age or rurality 




The acceptability of HPV vaccines was not found to be different between participants who 
had heard of HPV and those who had not. There was no association between smoking and 
acceptability (Table 4-9). 
4.6 Predictors for the acceptability, awareness, and 
knowledge of HPV 
4.6.1 Factor analysis results 
The result of Bartlett’s Test (P<0.001) confirmed the assumption that the 20 attitude 
variables had some correlations between them. Therefore, it is appropriate to use factor 
analysis to explore these further.  
 
First, five factors had an eigenvalue greater than 1.0 (determining the number of factors to be 
retained) and were derived from the analysis. The cumulative variance explained by these 
five factors was 60.07%. Second, variables that had more than 0.40 loadings under the 
specific factor were included in this extracted factor (Table 4-10).  
 
Two items were excluded for the following reasons (data is not shown in the table). 
 The item ‘Having an HPV vaccination may lead to people having more sexual partners as 
they think their risk of disease is reduced’ was excluded because its loadings under the 
five factors were all less than 0.40 and thus it could not be explained by the five factors. 
 The item ‘I trust the company that make HPV vaccines’ was excluded. Because it could 
not be categorised and explained by any factors, although its loading for factor 1 was 0.58 
(greater than 0.40).  
 
The remaining variables were categorised into five factors (Table 4-10). 
 Factor 1 (Items 1–5): named other influences, explained 29.68% of the total variance.  
 Factor 2 (Items 6–9): named stigma, explained 10.24% of the total variance.  
 Factor 3 (Items 10–13): named perceived barriers, explained 7.32% of the total variance.  
 Factor 4 (Items 14–16): named perceived severity, explained 7.13% of the total variance.  
 Factor 5 (Items 17–18): named perceived benefits, explained 5.70% of the total variance.  
 
The factor score for each attitudinal factor was calculated by summing the frequencies of the 
option in the responses weighted by their factor loadings. Factor scores were based on the 
participants’ rating of responses to the respective factors, and higher scores reflect a higher 
rating of responses to a given factor. Factor scores were saved in SPSS and were not 
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displayed in the analysis. In order to clearly understand the rating, I first translated the rating 
of responses into this order in SPSS: Unsure, Strongly disagree, Somewhat disagree, 
Somewhat agree, Strongly agree. Hence, higher rating meant ‘Somewhat agree’ and 
‘Strongly agree’. Then, I used quartiles to categorise the five factors’ scores. These quartiles 
were used as independent variables in the logistic regression. The lowest quartile was my 
reference group, which was close to ‘Unsure’ and ‘Strongly disagree’ responses and highest 
quartiles, level 4, close to ‘Somewhat agree’ and ‘Strongly agree’ options.  
4.6.2 Predictors for the acceptability of HPV vaccines 
Based on the data analysis, four positive predictors of the acceptability of HPV vaccines 
were found. The higher factor scores participants had, the more likely it was that they would 
be influenced by others, perceive the severity of HPV, perceive the benefits of HPV vaccines, 
etc. (Tables 4-11). No negative positive predictors were found.  
 Other influences on the acceptability of HPV vaccines (positive): Compared to the 
participants who were not likely to accept HPV vaccines, those who were likely to be 
vaccinated would be more influenced by other people, such as friends, parents, and 
doctors (OR=3.89, 95%CI=2.75-5.49, P<0.001).  
 Perceived severity of HPV infection and cervical cancer (positive): Participants who were 
likely to accept HPV vaccine were more likely perceive HPV infection as a serious issue 
(OR: 2.53, 95% CI: 1.87-3.42, P=0.002).  
 Perceived benefits of the HPV vaccine (positive): Participants who were likely to be 
vaccinated were more likely perceive HPV infection as beneficial (OR: 1.54, 95% CI: 
1.17-2.03, P=0.002). 
 High level of knowledge of HPV infection and vaccination (positive): Participants who 
were likely to be vaccinated were more likely to have a high level of knowledge.  (OR: 
2.43, 95% CI: 1.39-4.25, P=0.002) 
4.6.3 Predictors for the awareness of HPV 
One positive predictor was found for the awareness of HPV (Table 4-11).  
 Other influences (positive):  Participants who had heard of HPV were more likely to be 
influenced by others on the acceptability of HPV vaccines (OR=1.66, 95%CI=1.24-2.20, 
P=0.001).   
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4.6.4 Predictors for the knowledge of HPV and vaccination 
High and low levels of knowledge were used to make comparisons in terms of age, gender, 
rurality, and smoking. No differences were found (Table 4-11). One negative and one 
positive predictor of knowledge level were found: attitudes on stigma and the perceived 
severity of HPV (Table 4-11). 
 Stigma about HPV-infected people (negative): participants who had a high level of 
knowledge of HPV and cervical cancer were less likely to have stigmatising attitudes 
towards HPV infection (e.g. People would gossip about those who had the HPV infection) 
(OR: 0.48, 95% CI: 0.27-0.84, P=0.011).  
 Perceived severity of HPV infection (positive): participants with a high level of 
knowledge of HPV and cervical cancer were more likely to perceive the severity of HPV 
infection (e.g. HPV infection would be disruptive to my physical health) (OR: 2.91, 
95%CI: 1.66-5.13, P<0.001).   
4.7 Summary of results 
4.7.1 Key findings 
Awareness and knowledge of HPV and vaccination 
An overall low level of awareness of HPV (13.1%) was found. However, among those who 
did report knowing about HPV, low, moderate to high levels of knowledge were identified 
among participants for individual knowledge items.  
 
Attitudes towards HPV infection and vaccines 
Over two thirds of participants worried about the health impacts of HPV infection and 
cervical cancer, but the perceived personal risk of HPV infection, and of cervical cancer was 
low (8.6% in all the respondents and 7.3% in females respectively)  
 
Approximately two thirds of participants believed the HPV vaccines to be effective in 
preventing cervical cancer. A high proportion of female participants (81.7%) were aware of 
the need for cervical screening after vaccination.  
 
The most commonly reported barrier (over two thirds of respondents) to HPV vaccine was 
concern about side effects (many of them minor). Less than half of the participants worried 
about the cost of the vaccine. Students were most likely to accept the recommendation of 
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their parents about whether or not to accept the vaccine (66.1%). The most identified stigma 
relating to HPV infection was ‘if someone has HPV infection, people will gossip’ (50.5%). 
 
High levels of acceptability (63.2-80.6%) for the HPV vaccine were found irrespective of the 
age, gender, and rurality of participants, or their levels of awareness and knowledge of HPV 
infection and vaccination. 
 
Differences by in age, gender, and rurality 
Differences in response were found by age, gender, and depending on rural or urban location 
of the student.  Rural participants had lower awareness, and females were more likely to be 
willing to accept the vaccine if it were to be available. Differences in terms of gender existed 
in knowledge levels and attitudes, but no pattern was found, and whether males or females 
had more knowledge or were more likely to perceive barriers or be influenced by others 
depended on the specific topic.  
 
Predictors for acceptability and knowledge of HPV vaccines 
The significant positive predictors for acceptability were the influence of others, perceived 
severity of HPV infection, perceived benefits of the HPV vaccine, and the level of 
knowledge. This meant that the more participants were influenced by others, the greater they 
perceived the severity of HPV infection and the benefits of the vaccine to be, and the higher 
their level of knowledge, the more likely they were to accept the HPV vaccine. No 
significant negative predictor was found.  
 
The significant positive predictor of knowledge was perceived severity. The significant 
negative one was attitudes on stigma. 
4.7.2 Interpretation of results  
Missing data 
There was missing data in the question responses. The proportion of missing data was less 
than 2% in each question relating to knowledge, background, and attitude to stigma, and less 
than 1% in the other attitude questions. The structure and format of the questionnaire may 
have contributed to this difference in the proportion of missing data (Appendices 4 and 5). 
As the questionnaire was printed double-sided, and Pages 2 and 3 (including most of the 
attitude questions, but not those relating to stigma) were inside, Pages 1 and 4 (including the 
questions on knowledge, background, and stigma) may have appeared to the participants to 
195 
 
be the covers of the questionnaire. Hence, some participants might have failed to answer the 
questions on the ‘cover’.  
 
No missing data was found in three variables— whether rural or urban, awareness of HPV, 
and name of high school. First, regarding whether rural or urban (the first issue mentioned), I 
explained this item a few times prior to students filling in the questionnaires in case that they 
did not understand which regions should be defined as urban and which ones as rural. As 
soon as I made this point, the students probably all filled in the question as I indicated. 
Second, question about HPV awareness was the first in the questionnaire. All the students 
were required to answer it as they had to find out which of the subsequent parts they should 
fill in next. Third, the school name was marked in all the questionnaires once they were 
collected from each school; hence, no missing data was found here. 
 
Demographics of participants 
The oldest and youngest participants: Students usually go to school at 6 or 7 years old, and 
high school education starts from Grade 10 to Grade 12. So, high school students aged 16–19 
years old were the potential recipients of my survey. Given that students from rural regions 
usually go to school one to three years later than students from urban areas, older 
participants were mostly found in rural regions, and it was not unexpected that some 
participants were older than 19 years. Two of the participants were 14, which may have been 
because of personal or family reasons. But as expected, most participating students (91.3%) 
were aged between 16 to 19 years old at the time of the survey.  
 
The proportion of participants from rural regions: As three of the high schools are located in 
the urban regions of Mudanjiang city and they only recruit students from among the 
residents of the city, no rural students attend these schools. The other two schools have 
almost the equal number of urban and rural students. Hence, approximately 20% of the 
participants in my survey were rural students. 
 
The awareness of HPV and the acceptability of the HPV vaccine 
The low level of awareness of HPV is not surprising  in terms of the study location 
(Mudanjiang city in North China), the lack of sexual health education in high school, and the 





It is difficult to interpret the high acceptability of the HPV vaccine irrespective of 
demographics, socio-economic conditions, health care, and educational factors. But it might 
be helpful to consider why willingness to take up the HPV vaccination is higher in this 
Chinese population than among people in other countries where the HPV vaccine has been 
introduced and promotion programmes have started. Some reasons below might explain the 
hypothetical high acceptability of the HPV vaccine.  
 
Lack of detailed thought: The low level of awareness and perceived risk (less than 10% for 
HPV infection) suggested even though they did not know what HPV was or whether they 
were at risk, they were still willing to be vaccinated. This might because they have not 
thought hard about this choice. 
 
Prevention of the serious disease of cancer: Cancer is a serious disease and may lead to death 
in a short period, even when treated properly. The fact that cervical cancer can be prevented 
by the vaccine might give people a hope to prevent this cancer. Moreover, the high level of 
perceived severity of HPV infection and of cervical cancer may partly explain the high 
acceptability of the HPV vaccine in that it is needed to prevent a disease that would generate 
a serious health impact in the future.   
 
Only a few hypothetical scenarios were presented: I have not created several hypothetical 
scenarios of acceptability in terms of a varied level of cost. One reason for this is that I am 
not sure which factor (i.e. cost or side effects) is ranked highest among Chinese teenagers’ 
perceived barriers to the HPV vaccine. Furthermore, it is not possible to list all the potential 
barriers under the question of ‘How likely would you be to accept the HPV vaccine?’, as too 
many choices might lead to weaker statistical power and more bias. Hence, the perceived 
barriers were examined independently and later added to the analysis of predictors of 
acceptability of HPV vaccine to see their influence.  
 
Knowledge of HPV infection and cervical cancer 
Influence of traditional Chinese culture 
Nearly three-quarters of my participants understood that the HPV vaccination was not 100% 
effective and that cervical screening was still necessary after vaccination. Zhao’s study [201], 
carried out in mainland China in 2012, reported that 4.5%–10.8% of 15–19-year-old women 
had experienced sexual activity. Further, it is estimated that less than 10% of female students 
would have the opportunity to get cervical screening, and those who finally received 
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screening would be much less. This suggested that most teenagers in China would not know 
what cervical screening was. Possible reasons for this unexpectedly high level of knowledge 
are presented below.  
 
The conservative attitude of Chinese people: Chinese people tend to think neutrally and 
conservatively. Participants might think that any kind of vaccination is not absolutely 
effective and that even people who got the vaccine might still have a chance of suffering 
from the illness. Moreover, as a result of the vaccinations participants have already received 
(e.g. hepatitis B), they may know that very few vaccinations provide lifelong immunity for 
human bodies. That cervical cancer could be prevented by vaccination is a new concept, and 
it will take time to prove its effectiveness and for people to believe it. Hence, suspicion 
might exist amongst adults as well as teenagers.  
 
The influence of Chinese social norms: China has a long history of the feudal system, 
resulting in the deeply rooted social perspective that people, especially women, are not 
supposed to have more than one sexual partner or initiate sexual activity prior to marriage. 
Thus, having multiple sexual partners and engaging in sexual activity at an early age may be 
viewed as going against social norms. Moreover, the question ‘Having multiple sexual 
partners increases the chance of getting cervical cancer’ seems like a negative statement, and 
would lead participants give answers that were correct in terms of social and moral standards, 
though I tried my best to make the question look more neutral and less challenging to 
Chinese social norms. 
 
Areas of lower knowledge 
A small proportion of respondents (less than 10%) correctly answered the knowledge 
question that ‘Poor personal hygiene can increase the risk of getting the HPV infection’ is 
false. This may because the statement seems common sense that personal hygiene would 
affect the risk of people getting any disease, regardless of the kind of infection, such as 
hepatitis B and some respiratory infections. However, sexually transmitted infection differs 
from other infections, which would not be infected through sharing toilet or be protected by 
good habits of hand-washing. Hence, sexual health education is suggested.  
 
The self-healing feature of the HPV infection, a more specialised but necessary knowledge 
item, was known by approximately one quarter of participants. This suggested that some 
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specialised sexual health education is needed in the future, to both increase self-protection 
and reduce anxiety among people. 
 
Approximately one third of the participants knew that condoms could be used for the 
prevention of sexually transmitted diseases. A higher level of knowledge could have 
expected. HIV health education and promotion programmes are very common in China 
among high school and college students, and one of the most repeatedly emphasised aspects 
of the programme is the role of condoms in the prevention of sexually transmitted disease. 
58.1% of the participants knew that HPV could be sexually transmitted, but only one third of 
them were aware of the use of condoms in preventing this. This suggested students might 
lack real understanding of preventive knowledge in terms of sexually transmitted infections.  
 
Incorrect responses 
Two knowledge statements were incorrectly answered by over 70% of participants. These 
were: ‘HPV vaccination is 100% effective against cervical cancer’ and ‘Regular cervical 
screening is not necessary after HPV vaccination’. The correct answer for both questions 
was ‘False’. The conservative attitude of Chinese people discussed earlier in this chapter 
might explain the incorrect responses to these two items.  
 
Uncertainties in interpreting the results 
The appropriate recipient of the HPV vaccine: Two-fifths the participants knew that HPV 
vaccine targeted people who were not sexually active. This result was unexpected, as no 
HPV vaccine promotion campaign is available in China to inform the public of whom the 
HPV vaccine targets, when the best time for vaccination, etc is. Therefore, I have 
reservations about this result.  
 
The asymptomatic feature of the HPV infection: Over two thirds of participants knew that 
HPV infection was asymptomatic. This revealed a higher level of knowledge among 
participants even than ‘the sexually transmitted nature of HPV infection’ (58.1%) and ‘HPV 










Attitudes towards HPV, cervical cancer, and vaccination 
Low level of perceived risk of HPV and cervical cancer 
Below are the probable reasons for the low levels of perceived risk. 
 
Lack of sexual experience among young teenagers: Few Chinese high school students have 
sexual experience (4.5–10.8% [60]; the percentage is close to the percentage of perceived 
risk) and they would, thus, not have a clear understanding of the likelihood of getting the 
HPV infection through sexual activity.  
 
Lack of ability to translate the knowledge into estimating the risk of HPV infection: Nearly 
half of the students already knew that HPV was a common sexually transmitted infection, 
but had not realised the risk. Knowing a fact is one thing; applying that knowledge to 
estimate susceptibility to HPV infection, or the relationship between HPV infection and 
potentially developing cervical cancer is another. Many factors are involved in the process of 
estimation, e.g. the confidence in their health, the understanding of the risky sexual 
behaviours, etc.  
 
Furthermore, the mature health care system in urban regions may make participants (80% of 
participants are urban students) less likely to realise the risk. Further, occurrence of cervical 
cancer in adults may further reduce the risk that young teenagers would perceive.  
 
Perceived barriers to the HPV vaccine 
As expected, the effectiveness and safety of the HPV vaccine were the most commonly 
reported barriers. Cost was not the biggest barrier for the young Chinese teenagers. This may 
be because such teenagers have not started to earn their own money and thus have not had 
the opportunity to make decisions concerning whether they need to pay and how much they 
would pay. Thus, their views may not be treated seriously in terms of payment for the 
vaccine. But their attitudes, to some extent, might play a role in the decision-making of their 
parents.  
 
Trust in drug companies is another reported barrier. One third of the participants reported 
low trust in drug companies, and even more (39%) were unsure (chose ‘Unsure’ option in 
the responses) about them. The weakness of the question is that it did not state whether the 
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drug company was an external (i.e. international) one or an internal (Chinese) company. 
Participants might have given very different answers to the question if this were clarified, as 
the Chinese people tend to have much more faith in Western pharmaceutical companies in 
terms of technology and quality of production.  
 
Other influences on the acceptability of the HPV vaccine 
Young teenagers (two-thirds in my survey) chose parents as the most trustworthy source of 
information for advice concerning whether to get or not to get HPV vaccination, and the 
opinions of doctors ranked in second place. Young teenagers relied more on their parents for 
decision-making; this may because they were largely dependent on their parents financially 
and educationally, and trust their care for them.  
 
Attitudes on stigma of HPV infection 
Chinese people tended to have a low level of awareness of the need to protect privacy in 
public spaces, which might partly be because of the lack of facilities for personal space 
caused by a large population base and poverty. Hence, it is easier for people to find out 
private information about others. Moreover, sexually transmitted infections may not be well 
understood in China, and people might gossip. My survey, nevertheless, found that the 
stigma surrounding HPV infection was not huge (less than half participants reported stigma 
associated with HPV infection), and this may suggest that the increasing openness in China 
is leading to a reduction in stigmatising attitudes towards people with sexually transmitted 
infections. This may be partly attributed to the efforts that have been made nation-wide 
increasing awareness of HIV infection, and treating AIDS patients in a humane way. 
However, the stigma may have been underestimated as a result of the lack of awareness of 
the HPV infection among participants; my study did not examine this possibility.  
 
The weakness in these questions was that I did not clarify whether other people in their 
social group were knowledgeable about the HPV infection. Therefore it is difficult to predict 
whether an increase in people’s knowledge about the disease would lead to an increase in 
psychological pressure in social situations for those infected with HPV.  
 
Predictors for acceptability and knowledge level 
Predictors derived from factor analysis highlighted the three main concepts of the Health 
Belief Model: perceived severity of HPV infection, perceived effectiveness (benefits) of the 
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HPV vaccine, and perceived barriers to the HPV vaccine. Another two predictors were other 
influences on accepting the HPV vaccine, and stigmatising attitudes on HPV infection.  
 
In deciding whether to accept the HPV vaccine, young teenagers would be influenced by 
their parents and doctors, the perceived severity of HPV infection and of cervical cancer, as 
well as the perceived benefits of the HPV vaccine. The results suggested that they would be 
more likely to get vaccinated if they knew that HPV infection and cervical cancer had a 
negative impact on their health and that the HPV vaccine was effective. In terms of 
knowledge level, a possible explanation is that the more they knew about HPV infection, 
cervical cancer, and the HPV vaccine, the more likely it was that they would know about the 
perceived severity and benefits, and in turn the more likely they would be to accept the HPV 
vaccine.  
 
Differences in knowledge and attitude by age, rurality and gender  
Differences between the knowledge of rural and urban participants was found with regard to 
protective role of condoms for HPV infection. However, because the knowledge questions 
were answered only by participants who had heard of HPV, only a small number of rural 
students (around 35) had heard of HPV, and fewer than 5 rural students gave certain 
response option (eg true, false, or unsure), statistic power could not be achieved with such an 
insufficient sample size. For example, difference in knowledge by rurality found in the area 
of condom role and surprisingly rural participants presented higher knowledge level. The big 
range of 95% confidence interval (1.41-7.04) for this odds ratio (odds of rural participants’’ 
knowledge in contrast to urban participants’) indicates the limitation in the reliability of the 
result. Further, the unbalanced proportion rate between rural and urban participants limits the 
generalisability of the results. Differences in rurality need to be reassessed by studies with a 
better-balanced distribution of urban and rural participants. No difference by rurality was 
found in terms of attitudes. 
 
Gender-based differences in the knowledge of HPV and vaccination depended on the 
specific topic. No conclusion can be easily drawn that whether one gender had more 
knowledge overall than the other. Regarding attitudes, male students were more concerned 
with the vaccine’s cost and its potential impact on number of sexual partners. In contrast, 
female students cared more about the potential health impact of the vaccine and its side 
effects. Parents, doctors, and schools all played important roles in the acceptance of HPV 
vaccines, and females expressed more dependence on their parents’ views, while males 
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reported greater reliance on their friends’ views. These results provided useful information 
on what needs to be included and emphasised in future HPV vaccination campaigns.  
 
No differences were found in areas of knowledge and attitudes by age. 
4.7.3 Methodological issues and comparison with other studies 
Sampling 
Selection bias 
One-province study: It was not a multi-centre study, which may compromise the 
generalisability of the sample to wider population in China. The interpretation of results 
needs to be cautious due to the specific geographical location—the most northeastern 
province in China, ranked in the middle of China in terms of economy and population. My 
findings may reflect the teenagers’ perceptions in some middle-developed inland provinces.  
 
Nevertheless, they may not be applicable to the following regions:  
 Four municipalities 
 Eastern coastal provinces  
 Five autonomous regions (education and health care resources are relatively limited)  
 
Study of only one age group (teenagers): My study did not investigate all population groups 
who would be involved in introduction of the HPV vaccine in China, for example young 
adults (18-26 year old, the likely population in college), parents, and health professionals. 
However, it does provide among the first evidence from Chinese teenagers—the majority of 
the potential recipients—whose views are poorly understood to date. Teenagers in my survey 
expressed worries about the side effects, concerns about potential increased sexual behaviour 
following HPV vaccination, and their susceptibility to cervical cancer, etc. Existing data on 
mainland Chinese teenagers is limited, and few conclusions can be drawn. One reason for 
this lack of published data reporting the knowledge and attitudes of Chines teenagers might 
be uncertainty regarding how much influence the views of teenagers would actually have on 
the introduction of the HPV vaccination in the country.  
 
‘Good’ student perspective: My study used a convenience sampling method, which included 
participants who are among the top 60–75% of students in the city, and provided views from 
the perspective of a ‘good’ student. The participants—‘good’ students preparing themselves 
for future studies at university, may be over-represented, and my findings may not represent  
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about the views of  less able students. However, of the groups engaged in the vaccination 
programme, the ‘good’ high school students are the group most likely to influence their peers, 
exerting their influence through universities and schools.  
 
No family background data (e.g. socio-economic factors): ‘Good’ students usually come 
from well-educated families, and their parents are more likely to have a strong economic 
capacity. But the exclusion of private, international, and vocational schools in the 
recruitment for the study would have helped to ensure a relatively balanced range of family 
backgrounds—neither excessively wealthy nor overly poor. No family background questions 
were asked in the questionnaire, because participants were too young to provide accurate 
family income information.  
 
Sampling methods in other similar studies 
Similar studies on the knowledge of and attitudes towards HPV vaccines have mostly been 
quantitative ones and questionnaire-based surveys [123, 124, 187, 201]. Some were 
interview or focus group studies [198, 209]. In terms of the population background, some 
studies were school-based [123, 209], some were hospital- or clinic-based [187, 201], and 
some were community-based [124, 198]. All of them were cross-sectional studies due to 
research priority, cost, and feasibility.  
 
Response rate 
Non-responders to the survey 
The overall response rate was 94.2% (4,050 student were approached, and 3,788 
questionnaires were returned). For ethical and logistical reasons, I was unable to access 
students who did not return the questionnaires and find out the characteristics of such 
students. However, given the small number of non-responders (5.8%) it is unlikely that even 
outlier responses from these non-participants would have influenced the overall results 
Moreover, I had anticipated a response rate of approximately 90%, and sample size 
calculations were based on this response rate. 
 
Response rate in other similar studies 
The high response rate might be related to the sampling method. A systematic review among 
European adolescents reported a high response rate for classroom-completed questionnaire 






Quality of the instrument 
Validity of the questionnaire 
No internationally-validated questionnaires on knowledge of and attitudes towards HPV are 
available. The questionnaire in my survey was self-designed, based on both the Western and 
Chinese-language literature. The draft questionnaire was refined by cognitive interviews 
with 10 Chinese students aged 21–24 years old, based in Edinburgh. The cognitive 
interviews improved internal validity by measuring the comprehension of the questionnaire, 
refining the wording and the format. It helped me to examine whether the questionnaire 
measured what I really wanted it to and not something else. But it may also have reduced the 
external validity of the questionnaire, as it used teenager-friendly language, applied 
particularly to teenagers at public high schools in middle-developed provinces in China 
(assuming the potential participants had a traditional secondary education in China).  
 
Moreover, there are challenges in choosing specific wording for some  questions, as there 
may be no translation to convey  exactly the same meaning in a different cultural and 
linguistic l setting. For example, the words “promiscuous”, and “gossip” have similar words 
in the  Chinese language (see Appendix 5), but with differing degrees of positive and 
negative connotations (eg. still negative, but more neutral in Chinese than in English). Hence, 
issues in translation and culture need to be taken into account when the Chinese language 
findings are reported in English. . Yu and colleagues have highlighted common features 
of translating across cultural and language barriers, i.e. maintaining the original 
intent of the questionnaire, optimising the cultural relevance of the concepts, and 
comprehensibility of the translated questionnaire. They emphasise the importance of 
literal and cultural adaptation rather than simple word translation in maintaining 
equivalence of concepts. [234] 
 
Health Belief Model 
I used the Health Belief Model in the development of attitude questions. It has clear benefits 
in identifying behaviours such as emotional and psychological thinking, but it also has some 
recognised limitations. For example, the Health Belief Model does not sufficiently account 
for a person's attitudes, beliefs, or other individual determinants that dictate a person's 
acceptance of a health behavior. There is also concern that it does not take into account 
behaviors that are performed for non-health related reasons such as social acceptability, or 
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sufficiently allow for environmental or economic factors that may prohibit or promote the 
recommended action. Critically for my survey, there are concerns that the Health Belief 
Model assumes that everyone has access to equal amounts of information on the illness or 
disease. There have also been concerns expressed about its use in traditional, non-Western 
populations [235]. 
 
To address these gaps, I added questions examining demographic factors, and stigma, and 
provided summary information about HPV in the questionnaire itself.  
 
The Health Belief Model was developed in the Western setting, but it does have some utility 
in exploring attitudes among Chinese populations. The most detailed analysis of the 
applicability of the Health Belief Model in a Chinese population is that of Lai and Cheng 
who compared the variables benefits and barriers in the Health Belief Model among Hong 
Kong Chinese adults and adolescents in response to an imaginary flu outbreak and a 
hypothetical vaccine [236].  They concluded that the health belief model variables on 
prevention intention had some applicability for adolescents but less so for adults in their 
study populations.   
 
Other researchers have also drawn on the Health Belief Model in studies exploring attitudes 
and understanding of a range of health behaviours among the Chinese population, both 
Mainland and Hong Kong. Some examples include: Lau et al examined acceptability of HPV 
vaccines and perceptions of HPV among men who have sex with men in Hong Kong [237]; 
Yue and colleagues found that the Health Belief Model was reliable in predicting medication 
adherence in an adult Chinese population [238]; Li and colleagues developed a survey 
questionnaire based on the Health Belief Model to examine factors associated with 
willingness for HIV testing among Chinese women [239].  
 
Despite the limitations noted above, I am confident that use of the Health Belief Model was 
appropriate to inform the objective of my research, aiming to explore health understanding 
and attitudes that had not previously been systematically explored in the Chinese population. 
Nonetheless, it is important that future research draws on other theories of health behaviours 
to deepen understanding of factors influencing these attitudes and behaviours. There is also 
scope for a more detailed examination of the applicability of Health Belief Model constructs 




Completeness of questionnaire 
There were between none and 75 missing data items (0–2.0%) for different questions. The 
question on age had the highest level of non-response (75 non-responders). The question on 
participant gender, the questions of attitudes to stigma each had 52-53 non-responders. The 
other knowledge and attitude questions had no more than 35 non-responders. It is not 
feasible to have enough statistical power to analyse their characteristics because of the small 




I used Epidata for data entry, and it has clear benefits that prevent more errors from 
occurring.  
 The layout of the database was operator-friendly—easy, straightforward, and highlighted 
coding areas.  
 The format of the database looked exactly the same as the questionnaire on which the 
original data was collected. It minimised the potential complications in finding the exact 
field at each data entry.  
 The double-check function in Epidata allowed me to set a limit for each field and restrict 
the database to accept only a few specific numbers for each variable. Immediate detection 
and correction of problems with data was carried out as data was entered. It substantially 
minimised the potential errors made during data entry, such as mistyping or range errors.  
 
Epidata also has some limitations: a. Questionnaire files cannot exceed 999 lines of text; b. 
Epidata was not designed to be operated by multiple users. Only one person can modify a 
file at one time. But as the database I used did not exceed 100 lines of text and there was no 
need for more than two operators working at the same time, the limitations did not affect 
data entry.  
 
Another method to minimise the error rate was double data entry. Double data entry can 
enhance the data quality, but it also substantially increases the cost and time of data entry. 
For these reasons, only 10% of the overall data was selected for double entry in Epidata. 
Compared with 198,400 data fields in total in my questionnaire, double data entry was only 
completed for 10% of them (19,840 data fields), having the potential to have less error (0.22% 
vs. 0.14% per data field respectively) due to a decreased amount of data entry work. But still, 
the single data entry error rate was not high compared with international health studies (see 
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below). The limitation was that I could not ensure the other the 90% of the single entry data 
was completely accurate, which might undermine the validity of the data.  
 
Data entry in previous studies 
A few studies have reported the error rate of single data entry, which ranged from 0.04% to 
0.34% per field. As no golden rule for the acceptable error rate exists, one way to assess my 
survey would be through comparison with similar studies discussed below (systematic 
review or meta-analysis have not been found in this area). Errors were determined by many 
factors: data field type (numeric or categorical), data field amount, data entry program, etc.  
 The Coronary Artery Risk Development in Young Adults study in 1992 [240] 
o The single data entry error rate was 0.22% per field.  
o The sample size was 717 with 474,164 fields in the database (the dietary form, 
questions including serving size and amount, frequency in day, week or month, etc.).  
o A precoded screen was developed for data entry. No further information on the data 
entry program was reported.  
 The Continuous Hyperfractionated Accelerated Radiotherapy Trials in 1994 [241]  
o The error rate of single data entry was 0.15% per field.  
o The sample was 44 patients with around 16,277 fields in the database.  
o The data entry manager was not mentioned. 
 A recent clinical study in 2012  
o The error rate for single data entry was 0.04% based on Optical Mark Recognition 
automated forms processing [242].  
o The sample size was 398, and 21,608 data fields were in the database.  
o Epidata was used for data entry.  
 A 2003 study [243] 
o The single data entry error rate was 0.34% per field.  
o The sample size was 560 and there were 104,720 fields in the database.   
o Data was entered by Microsoft Access. 
 
The database in my survey had 198,400 data fields, and the single data entry error rate was 
0.22%, which comparable with previous reported studies.   
 
Data analysis 
The use of factor analysis in the attitude section may lead to information being lost by 
grouping some sets of variables together. There was also a degree of subjectivity in deciding 
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how many factors to include, which should be excluded, and how to categorise variables into 
different groups. But as the Health Belief Model was applied to generate attitude questions 
based on the five concepts, questions dealing with the same concept would have similar 
characteristics and responses. Thus, this would facilitate the extraction of factors and 
increase the exactness and practicality of the factors.  
 
Data analysis methods used in other similar studies 
Factor analysis is widely used in dietary pattern studies based on cultural background and 
diet preference [244]. It was also used in identifying stigma related to sexually transmitted 
diseases [218]. Despite the extraction of factors, researchers translated factor scores into 
quartiles, and then comparisons were made by logistic regression between the newly 
identified factors (dietary patterns and different levels of stigma, recoded as quartiles) and 
relevant variables, such as disease or health-seeking behaviours.  
 
My survey is the first study I am aware of that uses factor analysis to find predictors of 
acceptability of HPV vaccines based on the Health Belief Model. I aimed to explore specific 
attitudes towards HPV vaccines (i.e. concerns about cost, side-effects, and risk), but I also 
wanted to find predictors of the acceptance of HPV vaccines from different emotional or 
psychological perspectives (such as perceived barriers and perceived effectiveness). 
4.7.4 Comparisons with other studies 
I compare my findings with studies carried out in Asian and Western countries below. To 
provide context, the issues below may affect the reliability of comparisons.  
 
1) The status of the HPV vaccine (i.e. introduced or not, free or not) 
 Studies prior to and after HPV vaccination may present different knowledge and attitudes 
[245, 246] 
 The health insurance coverage would influence the acceptability of the vaccine [245, 247] 
2) Disparity in demographics (gender, ethnicity, cultural background, etc.) 
 
In the Asia-Pacific area, three countries (Australia [84], Singapore [84] and Malaysia [245]) 
introduced the HPV vaccine free of charge for recipients in 2006–2010. It is included in their 
National Immunization Programmes and the uptake is high (over three-quarters) [84]. A few 
countries and regions (e.g. Japan [247], South Korea [246], Hong Kong [248]) marketed the 
vaccine in 2006–2010, but the potential recipients had to order or request it in private health 
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centres and meet the cost ($240–$500) on their own. The uptake of the vaccination is 
estimated at less than 10% in these Asia-Pacific regions, but unavailable and incomplete 
population data may also contribute to the low uptake [85].  
 
Findings consistent with my survey 
Findings consistent with those of my survey were found in previous studies carried out in 
China and other Asian and Western regions. These included: a low level of awareness of 
HPV, a high level of acceptability of HPV vaccines, and attitudes towards stigma and the 
influence of other people.  
 
Low level of HPV awareness 
Chinese adult women: Li’s study carried out among 14–59-year-old Chinese women 
between 2005 and 2007 reported a low level of awareness (15.5%) [124]. It can be viewed as 
a robust study —a multi-centre, population-based questionnaire survey including rural 
regions which employed non-randomised cluster sampling and quota sampling methods. 
However, survey respondents were mostly adult women, and the low level of awareness 
might be attributed to the following features of the study: the early study period and the 
proportion of rural population (50%).  
 
Chinese young adults: Two multi-centre Chinese studies [128] (surveyed in 2011–2012) 
explored the awareness of HPV in young adults (college students aged 18–22 years), and one 
study included approximately 50% males [129]. Low levels of awareness were found (14.3% 
in males, 7.2% in females). Both studies were conducted in urban regions of developed cities 
in China (some were the capital of a province). 
 
Hong Kong Chinese teenagers: No other literature has been found that reported on 
knowledge and attitudes towards HPV infection among mainland Chinese teenagers. There 
are comparable studies among teenagers in Hong Kong. An HPV awareness level of 0% was 
found in 13–20-year-old girls in a focus group study in 2008 after HPV vaccines had been 
marketed in 2006 in Hong Kong [209]. This extremely low level of awareness may be 
explained by the early date of the research and the features of focus group. It might also be 
attributed to a similar culture to that of mainland China, in which females are supposed to be 
conservative regarding sexual issues and may be too shy to state in front of a group that they 




Other Asian teenagers and young adults: Awareness regarding HPV was reported to be 21.7% 
among female university students ( mean age 21.5 years) in Malaysia in 2010 [249] after 
HPV vaccinations were introduced.  
 
High level of acceptability of the vaccine 
Chinese adult women: Zhao’s study, carried out in China in 2012, reported that the 
acceptability of HPV vaccination was 77% for women aged 15–59 years [201]. Li’s study in 
2009 found it to be 84.6% among 14–59-year-old Chinese women [124]. Kwan’s study in 
2008 found that the acceptability of HPV vaccination was 88% among Chinese women in 
Hong Kong [208]. 
 
Other Asian teenagers and young adults: Oh’s study, carried out in South Korea [198] in 
2010, (HPV vaccination was marketed in Korea in 2010) found the acceptability was 55.5% 
among adult women, and higher, 77%, for their daughters.  
 
Predictors for the acceptability of HPV vaccine 
Li’ s study in China in 2009 reported [124] that for adult women, recommendations from 
doctors or nurses and hospital lecturers (46.2% to 55.6%.) were the major influences on 
accepting the HPV vaccine. This suggests that parents of teenagers in China would be open 
to recommendations of health professionals. The findings of my survey suggested that the 
recommendations Chinese teenagers would be most likely to take were those of their parents 
or doctors.  
 
Brewer’s systematic review, carried out in 2007 in the United States, also identified 
predictors for the acceptability of the HPV vaccine [121]. Higher perceived effectiveness 
(benefits), school requirements, and physician recommendation were associated with higher 
HPV vaccine acceptability. Higher perceived barriers were associated with lower HPV 
vaccine acceptability [121]. These were all similar to my findings, although a higher 
perceived severity of HPV infections was not related to greater vaccine acceptability[121]. 
 
Attitudes on stigma about HPV infection 
Kwan’s study carried out in Hong Kong in 2012 examined stigma about HPV infection 
among health professionals, including doctors, nurses, and smear-taking trainees, and thus 
might not comparable to the respondents of my survey [187]. The most commonly identified 
stigma was ‘women are infected because they have more than 1 sexual partner’ (32%). 
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Similarly, 29.5% of participants in my survey believed that people infected with HPV were 
promiscuous, and 17% of participants agreed that the partners of those infected with HPV 
infected had been unfaithful. 
 
Stigma about HPV infection was negatively associated with the level of knowledge of HPV 
in both my study, and the Hong Kong study [187]. However, no evidence was found that 
stigma could be reduced by imparting knowledge to the recipients. Further studies are 
needed to find out what kind of knowledge is most effective in decreasing stigma associated 
with HPV.  
 
 
Findings that differed from my results 
However, there are some difference between findings in the Chinese and English literature 
and the findings of my survey. These included a higher level of awareness and knowledge of 
HPV and vaccination, a lower level of acceptability of the HPV vaccine, and different 
attitudes towards the HPV vaccination.  
 
Moderate to high level of HPV awareness 
Chinese adult women: In some recent multi-centre studies a moderate to high level of HPV 
awareness has been found (25.1% in a study on parents in 2013; 36% in a study on urban 
women in 2012) [123, 201]. A reason for this might be that the participants in both studies 
were from urban regions or even the capital of a province, where people are more likely to 
have a high level of education, income, and access to health care [123, 201].  
 
Hong Kong Chinese teenagers: A moderate level of awareness of HPV (44%) was found in 
teenage girls in 2011. The research period (my survey was carried out in 2014, 3 years later) 
and method (self-administered questionnaire) might partly explain the difference between 
the awareness level among Hong Kong teenagers and that found in my survey [250]. The 
different levels of sexual health education and HPV vaccination campaign may also 
contribute to the difference in the awareness of HPV. Further studies are suggested to 
explore the issue.  
 
Taiwanese young adults: An awareness level of HPV of 49% was found in 17–36-year-old 




Moderate level of acceptability of the vaccine 
Young adults in West Asian countries: Ortashi’s study carried out in 2012 in United Arab 
Emirates showed the acceptability of the vaccine was 46% among male university students 
(mean age: 21±1.5 years) [252]. 
 
Young adults in Western countries: It was 48% for young adults in the Netherlands in 2008 
(age range 18–25 years; 91% were born in the Netherlands) [253]. A lower acceptability was 
found in the US—34% among young adults in 2008 (age range 18–32 years; 85.5% were 
white)[254].  
 
Chinese parents of adolescents: 36.2% of the parents wanted to vaccinate their child in a 
2013 multi-centre Chinese study [123]. Nearly 50% of the parents were wealthy, and 42.4% 
of them had higher than senior high school education. An explanation for the moderate 
acceptability provided in the study was that caution and hesitation regarding vaccination 
acceptance may be more emphasised among highly educated parents, as they may be 
exposed to a wider variety of environment and be influenced by more factors (eg pros and 
cons). However, further studies in China are needed on this issue concerning the education 
level and acceptability of HPV vaccination.  
 
High level of knowledge 
Young adults in Western countries: The knowledge that HPV is sexually transmitted is 
common among some Western young adults: 86–92% of 17–25-year-old students in the UK 
[255] in 2009, and 64.9% of 18–26-year-old Italian women [206] in 2012. 74.1% of them 
knew that HPV may cause cervical cancer [206]. The HPV vaccine was introduced to Italy 
in 2007 for girls aged 11. However, 4-8% of Chinese teenagers (30-60% of HPV-awarded 
respondents knew) in my survey had this knowledge.  
 
Difference in gender in awareness and knowledge 
A university-based study in 18–25-year-old Dutch young adults showed that females (17.7%) 
were more aware of HPV than males (12.1%) [253] and females (41.6%) answered more 
questions correctly than males (21.7%) in terms of HPV-related knowledge[248]. My survey 
had inconsistent results: no significant gender difference was identified in the awareness of 
HPV (14.6% vs. 12.4%).  
 
Perceived risk of HPV and cervical cancer 
213 
 
The perceived risk of HPV among adult Korean men and women is 17.3% and 21.6% 
respectively [198], higher than that in my survey (8.6%).  
 
Perceived benefits of the HPV vaccine 
Compared to the 63.7% of participants who agreed that HPV vaccines would help avoid 
cervical cancer in my survey, 82.5% of Philippines [199] women (18–52 years old) believed 
the HPV vaccine could offer protection against cervical cancer in 2010. But in Sweden [200], 
only 6.3% of women aged 18–30 years old perceived the benefits after four years of the 
vaccine being approved for use. The reason for this low level of perceived benefit was not 
clear.  
 
Perceived barriers to the HPV vaccine 
Asian adult women: [198] 0.8–5.2% of Korean women were concerned by the adverse 
events of vaccination. 37.0% and 27.5% of Philippines women [199] worried about fatigue 
and long-term illness. Compared with the worry (71.5% worried about minor side effects) 
identified in my survey, Chinese people demonstrated more doubts about the side effects of 
the vaccine than other Asians. 
 
Willingness to pay US$300 for the vaccine 
Only 4% of adult males and females aged over 20 in Korea were willing to pay more than 
US$300 [198] and 28% Canadians aged 26-30 year old would want to pay US$300 for the 
three-dose vaccines. Zhang’s study [123] in 2013 found 11.6% of Chinese parents  of young 
adolescents were willing to pay more than CNY¥500. 
 
Trust in drug companies 
Very few Chinese teenagers (34.2%) in my survey trusted pharmaceutical companies. In 
Philippines [199], 87.4% of women trusted the companies that manufacture the vaccines. But 
comparison was difficult to make as neither of the studies mentioned whether the companies 
were national or international (i.e. Western pharmaceutical companies). 
4.8 Conclusion 
This questionnaire survey is among the first carried out among Chinese teenagers regarding 
their attitudes towards HPV vaccines based on the Health Belief Model; it was also among 
the first to identify positive/negative factors affecting the acceptability of HPV vaccines, and 
to explore HPV-related stigma among Chinese teenagers. Similarities as well as differences 
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are found compared to results of similar work in the international literature. In contrast with 
teenagers in many other countries, I found that the Chinese teenagers in my survey had a low 
level of awareness and knowledge of HPV and cervical cancer, and conservative attitudes 
towards sexually transmitted infections. This may reflect the impact of traditional Chinese 
culture, social recognition, and acceptability on teenagers.  
 
Based on the methodological limitations of the survey in terms of sampling and 
questionnaire design, further studies should explore more to fill in the gaps.  
 Although this study in Heilongjiang province does provide evidence that will be likely be 
broadly representative of similar provinces located in central regions of China, multi-
centre population-based studies among teenagers across China would be more 
representative.  
 Participants in the survey were limited to public high school students. Vocational and 
private school students, who account for a significant proportion of the total number of 
students, also need to be studied.  
 Social-economic questions and questions about family background were not included in 
the questionnaire because of pragmatic considerations and the response burden, but if 
applicable, further studies would need to identify the influences of social-economic status 




Box.  Summary of findings in the questionnaire survey in China 
Knowledge and attitude 
Overall, this survey identified a low level of awareness of HPV infection and a high level of 
acceptability of HPV vaccine in the survey population. 
 
The attitudes towards HPV infection and vaccination (including Health Belief Model constructs 
and stigma) 
 The biggest worry (concerning both HPV infection, and cervical cancer) is health impact 
(72-80%) 
 The greatest concern is minor side effects (72%) 
 The most significant recommendation would be taken from their parents (66%) 
 The biggest stigma is concern about gossip from others (51%) 
  
Predictors for the acceptability of HPV vaccine  
 Facilitators: Others’ influences, perceived severity of HPV infection and cervical cancer,  
  perceived benefits of HPV vaccine, high knowledge level of HPV infection 
and cervical cancer 
Predictors for knowledge of HPV infection and vaccination 
 Positive: perceived severity of HPV infection and cervical cancer 
 Negative: stigma on HPV-infected people 
Predictors for the awareness of HPV infection 
 Positive: other influences on accepting HPV vaccines 
 
Differences by responder characteristics 
Gender  
 Females had a higher level of acceptability of HPV vaccine 
 Females were more concerned about the health impact, side effects, and parents’ opinions 
 Males were more concerned about the HPV vaccine leading to more sexual partners, cost of 
vaccination 
 Males had more trust in drug companies 
 Males had more knowledge about condoms protecting against  HPV infection 
 
Rurality  
 Rural residents had lower level of awareness 
 
Gaps 
The gap with other Asian and Western countries 
 Countries and regions that have included the vaccination into national programmes 
 Countries and regions that have introduced the vaccination, but paid for by the recipients  
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Table 4-1:  Selection and distribution of participants among five high schools 
 
School  Number of 
classes  
Number of 







No. 1 high school 13 5,4,4 776 723 
No. 2 high school 14 5,5,4 844 767 
No. 3 high school 13 5,4,4 782 757 
Ning’an high school 13 4,5,4 792 742 
Hailin high school 14 5,5,4 846 799 





Table 4-2:  Characteristics of participants 
 
Characteristic Number  Percentage %  
No. of participants   No. of  approached 4050  
  No. of respondents 3788 92.2% 
Age   14 2 0.1 
   15 67 1.8 
   16 519 13.7 
   17 1261 33.3 
   18 1195 31.5 
   19 485 12.8 
   20 175 4.6 
   21 7 0.2 
   22 2 0.1 
   Missing  75 2.0 
Gender   Male 1676 44.2 
   female 2060 54.4 
   Missing  52 1.4 
Residence   Urban  3048 80.5 
   Rural  740 19.5 
   Missing  0 0 
High school   No.1 high school 722 19.1 
   No.2 high school 767 20.2 
   No.3 high school 757 20.0 
   Hailin high school 799 21.1 
   Ning’an high school 743 19.6 
   Missing  0 0 
Smoking   Never 3200 84.5 
   Once or twice 223 5.9 
   Used to smoke, given up 89 2.3 
   Sometimes 131 3.5 
   Everyday 84 2.2 














N (%) N (%) N (%) N (%) N (%) N (%) 
No. of participants 3048 (80.5) 740 (19.5)  1676 (44.2) 2060 (54.4)     
          
Age group   <0.001*   0.575   - 
  < 18 1591 (52.7) 258 (37.3)  837 (50.3) 1012 (49.4)  - - - 
  >= 18 1430 (47.3) 434 (62.7)  826 (49.7) 1038 (50.6)  - - - 
Gender   0.671   -   - 
  Male 1363 (45.0) 313 (44.1)  - - - - - - 
  female 1664 (55.0) 396 (55.9)  - - - - - - 
Residence   -   0.671   - 
  Urban  - - - 1363 (81.3) 1664 (80.8)  - - - 
  Rural  - - - 313 (18.7) 396 (19.2)  - - - 
High school      0.007*   <0.001* 
  No. 1  722 (23.7) 0  351 (20.9) 371 (18.0)  427 (23.1) 295 (15.8)  
  No. 2  767 (25.2) 0  343 (20.5) 424 (20.6)  427 (23.1) 340 (18.2)  
  No. 3  757 (24.8) 0  340 (20.3) 410 (19.9)  383 (20.7) 367 (19.7)  
  Hailin  379 (12.4) 420 (56.8)  357 (21.3) 414 (20.1)  166 (9.0) 587 (31.5)  
  Ning’an  423 (13.9) 320 (43.2)  285 (17.0) 441 (21.4)  446 (24.1) 275 (14.8)  
Smoking   0.187   <0.001*   <0.001* 
  Never 2610 (81.6) 590 (18.4)  1294 (77.5) 1905 (92.6)  1639 (88.6) 1549 (83.1)  
  Once or twice 177 (79.4) 46 (20.6)  139 (8.3) 84 (4.1)  94 (5.1) 129 (6.9)  
  Used to, given up 73 (82.0) 16 (18.0)  63 (3.8) 26 (1.3)  36 (1.9) 53 (2.8)  
  Sometimes 96 (73.3) 35 (26.7)  100 (6.0) 31 (1.5)  52 (2.8) 77 (4.1)  
  Everyday 68 (81.0) 16 (19.0)  73 (4.4) 11 (0.5)  28 (1.5) 55 (3.0)  
By Chi-square testing, * P<0.025.  





Table 4-4:  Difference of gender and age in smoking habits 
Smoking  Male (ref.) 
N (%) 
Female N (%) P value AOR (95% CI) <18 (ref.)  
N (%) 
>=18 N (%) P value AOR (95% CI) 
Never (ref.) 1294 (77.5) 1905 (92.6)  1.00 1639 (88.6) 1549 (83.1)  1.00 
Once or twice 139 (8.3) 84 (4.1) <0.001* 0.40 (0.31-0.54) 94 (5.1) 129 (6.9) 0.007* 1.47 (1.11-1.94) 
Used to, given up  63 (3.8) 26 ( 1.3) <0.001* 0.28 (0.18-0.44) 36 (1.9) 53 (2.8) 0.029 1.62 (1.05-2.50) 
Sometimes 100 (6.0) 31 (1.5) <0.001* 0.20 (0.13-0.30) 52 (2.8) 77 (4.1) 0.018* 1.56 (1.08-2.24) 
Everyday 73 (4.4) 11 (0.5) <0.001* 0.10 (0.05-0.19) 28 (1.5) 55 (3.0) 0.001* 2.19 (1.37-3.49) 
*P<0.025. 
bAOR: adjusted odds ratio; 95%CI: 95% confidence interval. 





Table 4-5:  Knowledge level of HPV and vaccination among respondents who had heard of HPV  








HPV May cause cervical cancer (T) 327 (65.5) 52 (10.4) 113 (22.6) 7 (1.4) 
Can be cleared without treatment (T) 116 (23.2) 267 (53.5) 109 (21.8) 7 (1.4) 
Can last years without treatment (T) 342 (68.5) 46 (9.2) 102 (20.4) 9 (1.8) 
Can be sexually transmitted (T) 290 (58.1) 74 (14.8) 125 (25.1) 10 (2.0) 
Is an uncommon sexually transmitted infection in China (F) 212 (42.5) 129 (25.9) 148 (29.7) 10 (2.0) 
The risk of HPV Can be lowered by condom use (T)  199 (39.9) 134 (26.9) 156 (31.3) 10 (2.0) 
Can be increased by poor personal hygiene (F) 30 (6.0) 406 (81.4) 54 (10.8) 9 (1.8) 
Can be increased by having multiple sexual partners (T) 343 (68.7) 35 (7.0) 114 (22.8) 7 (1.4) 




Cervical screening can effectively prevent cervical cancer (T) 342 (68.5) 63 (12.6) 82 (16.4) 12 (2.4) 
Regular cervical screening is not necessary after HPV vaccination (F) 351 (70.3) 61 (12.2) 79 (15.8) 8 (1.6) 
HPV test can identify women who are at increased risk of cervical cancer 
(T) 
296 (59.3) 54 (10.8) 141 (28.3) 8 (1.6) 
HPV vaccination is 100% effective against cervical cancer (F) 366 (73.3) 41 (8.2) 84 (16.8) 8 (1.6) 
HPV vaccination are most useful for those who already have had sex (F) 206 (41.3) 73 (15.6) 212 (42.5) 8 (1.6) 





Table 4-6:  Attitudes towards HPV infection and vaccination among all the participants 






Very likely  Unsure  Missing 
How likely is the 
perceived risk of… 
HPV infection in the future 1219 (32.2) 1198 (31.6) 298 (7.9) 27 (0.7) 1039 (27.4) 7 (0.2) 
Cervical cancer in the future  531 (25.8) 644 (31.3) 134 (6.5) 17 (0.8) 718 (34.9) 16 (0.8) 








Unsure Missing  
HPV would be 
disruptive to… 
(perceived severity) 
Physical health 127 (3.4) 444 (11.7) 2197 (58.0) 524 (13.8) 492 (13.0) 4 (0.1) 
Social life 228 (6.0) 860 (22.7) 1650 (43.6) 441 (11.6) 605 (16.0) 4 (0.1) 
Sexual relationships 175 (4.6) 425 (11.2) 1760 (46.5) 614 (16.2) 806 (21.3) 8 (0.2) 
Cervical cancer  would 
be disruptive to 
(perceived severity) 
Physical health (Female) 45 (2.2) 117 (5.7) 1178 (57.2) 469 (22.8) 240 (11.7) 11 (0.5) 
Social life (Female) 86 (4.2) 436 (21.2) 883 (42.9) 299 (14.5) 346 (16.8) 10 (0.5) 
Sexual relationships (Female) 70 (3.4) 223 (10.8) 955 (46.4) 330 (16.0) 472 (22.9) 10 (0.5) 
If vaccinated, HPV 
vaccines…  
(perceived benefits) 
Will help avoid HPV infection 66 (1.7) 161 (4.3) 2541 (67.1) 427 (11.3) 585 (15.4) 8 (0.2) 
Will help avoid cervical cancer 82 (2.2) 479 (12.6) 2091 (55.2) 323 (8.5) 776 (20.5) 37 (1.0) 
No longer necessary to be screened for cervical cancer (F)  435 (21.1) 1249 (60.6) 112 (5.4) 21 (1.0) 238 (11.6) 5 (0.2) 
May need less frequent screening for cervical cancer (F) 245 (11.9) 972 (47.2) 518 (25.1) 30 (1.5) 279 (13.5) 16 (0.8) 
May lead to having more sexual partners as the risk of disease is reduced 1289 (34.0) 1362 (36.0) 440 (11.6) 102 (2.7) 561 (14.8) 34 (0.9) 
I am concerned that 
HPV vaccines … 
(perceived barriers)  
Not have been proved effective to prevent cervical cancer 104 (2.7) 604 (15.9) 1806 (47.7) 195 (5.1) 1049 (27.7) 30 (0.8) 
May have minor side effects such as fatigue or fever 72 (1.9) 273 (7.2) 2363 (62.4) 344 (9.1) 724 (19.1) 12 (0.3) 
May have major side effects such as long term illness 160 (4.2) 910 (24.0) 1408 (37.2) 281 (7.4) 1010 (26.7) 19 (0.5) 
Cost too much and don’t want to pay such a high cost 326 (8.6) 955 (25.2) 1258 (33.2) 440 (11.6) 800 (21.1) 9 (0.2) 
Trust the companies that make HPV vaccines 228 (6.0) 776 (20.5) 1175 (31.0) 120 (3.2) 1479 (39.0) 10 (0.3) 
I would be vaccinated 
if these people 
recommend me to 
(Other influences) 
Friends  169 (4.5) 815 (21.5) 1321 (34.9) 152 (4.0) 1322 (34.9) 9 (0.2) 
Parents  112 (3.0) 392 (10.3) 2088 (55.1) 415 (11.0) 774 (20.4) 7 (0.2) 
Doctors or nurses  149 (3.9) 442 (11.7) 1895 (50.0) 407 (10.7) 887 (23.4) 8 (0.2) 
School requirement 238 (6.3) 663 (17.5) 1519 (40.1) 227 (6.0) 1130 (29.8) 11 (0.3) 
Public service ads on TV or internet  478 (12.6) 977 (25.8) 897 (23.7) 120 (3.2) 1313 (34.7) 3 (0.1) 
Attitudes on stigma People will think that someone who is infected with HPV is a person who 
is promiscuous 
320 (8.4) 1402 (37.0) 939 (24.8) 179 (4.7) 895 (23.6) 53 (1.4) 
If someone has HPV infection, people will gossip 269 (7.1) 844 (22.3) 1685 (44.5) 226 (6.0) 712 (18.8) 52 (1.4) 
People are infected as they/their partners have been unfaithful 411 (10.9) 1611 (42.5) 487 (12.9) 156 (4.1) 1070 (28.2) 53 (1.4) 
One should keep a social distance from those who are infected with HPV 280 (7.4) 1263 (33.3) 1170 (30.9) 193 (5.1) 830 (21.9) 52 (1.4) 
F means these questions were only required to be answered by female students.  
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Table 4-7:  Knowledge of HPV and vaccination: Gender, rurality, and age impact 
Knowledge Male (ref.)  





AORb (95% CI) 
By logistic regression 
Condom use lowers the risk of HPV 
infection 
    
  Don’t know  59 (24.5) 97 (39.1)  
1.00 
  Incorrect  64 (26.6) 70 (28.2)  
  Correct 118 (49.0) 81 (32.7) <0.001* 0.56 (0.38-0.82)** 
Poor personal hygiene can increase the 
risk of getting HPV infection 
    
  Don’t know  35 (14.5) 19 (7.6)  
1.00 
  Incorrect  191 (79.3) 215 (86.3)  
  Correct 15 (6.2) 15 (6.0) 0.049* 0.95 (0.44-2.04) 
Early age at first sexual intercourse can 
increase the risk of getting HPV infection 
    
  Don’t know  75 (31.0) 81 (32.5)  
1.00 
  Incorrect  38 (15.7) 17 (6.8)  
  Correct 129 (53.3) 151 (60.6) 0.007* 1.31 (0.90-1.91) 
HPV vaccination are most useful for 
those who already have had sex (F) 
    
  Don’t know  89 (36.8) 123 (49.4)  
1.00 
  Incorrect  46 (19.0) 27 (10.8)  
  Correct 107 (44.2) 99 (39.8) 0.005* 0.61 (0.36-1.06) 






AORb (95% CI) 
By logistic regression 
Condom use lowers the risk of HPV 
infection 
    
  Don’t know  148 (32.5) 8 (24.2)  
1.00 
  Incorrect  129 (28.3) 5 (15.2)  
  Correct 179 (39.3) 20 (60.6) 0.049* 3.15 (1.41-7.04)** 






AORb (95% CI) 
By logistic regression 
Poor personal hygiene can increase the 
risk of getting HPV infection 
    
  Don’t know  35 (14.8) 19 (7.5)  
1.00 
  Incorrect  189 (79.7) 216 (85.7)  
  Correct 13 (5.5) 17 (6.7) 0.037* 1.27 (0.60-2.68) 
 
 *P<0.025 by chi-square, meaning there is difference in the distribution of responses;  
F means the correct answer is false. 
bAOR: adjusted odds of females/rural/>=18 participants who correctly answered the area of 
knowledge in contrast to those who did not (including both those who chose responses of 
‘Don’t know’ and ‘Incorrect’) by multivariate logistic regression; 95%CI: 95% confidence 
interval. 












AORb (95% CI) 
By logistic regression 
If I had an HPV infection, it would have 
a serious impact on my physical health 
    
  Disagree  281 (16.8) 274 (13.3)  
1.00 
  Unsure 229 (13.7) 256 (12.4)  
  Agree 1165 (69.6) 1527 (74.2) <0.01* 1.23 (1.06-1.43)** 
Having an HPV vaccination may lead to 
people having more sexual partners as 
they think their risk of disease is reduced 
    
  Disagree  1029 (62.3) 1581 (77.0)  
1.00 
  Unsure 264 (16.0) 291 (14.2)  
  Agree 358 (21.7) 180 (8.8) <0.001* 0.36 (0.29-0.44) ** 
I am concerned that HPV vaccines have 
not been proved effective in prevention 
of HPV and cervical cancer 
    
  Disagree  344 (20.8) 355 (17.3)  
1.00 
  Unsure 438 (26.5) 595 (29.0)  
  Agree 870 (52.7) 1105 (53.8) 0.016* 1.08 (0.95-1.24) ** 
I am concerned that HPV vaccines may 
have side effects such as fatigue or fever 
    
  Disagree  181 (10.8) 160 (7.8)  
1.00 
  Unsure 332 (19.9) 384 (18.7)  
  Agree 1156 (69.3) 1511 (73.5) 0.002* 1.22 (1.06-1.42) ** 
I am worried that the HPV vaccine costs 
too much (¥2000) and I don’t want to 
pay such a high cost for the vaccine 
    
  Disagree  553 (33.1) 711 (34.6)  
1.00 
  Unsure 300 (18.0) 489 (23.8)  
  Agree 817 (48.9) 857 (41.7) <0.001* 0.76 (0.67-0.87) ** 
I trust the companies that make HPV 
vaccines 
    
  Disagree  462 (27.7) 533 (25.9)  
1.00 
  Unsure 558 (33.4) 895 (43.5)  
  Agree 649 (38.9) 629 (30.6) <0.001* 0.70 (0.61-0.80) ** 
I would get vaccinated if my parents 
recommend me to do so 
    
  Disagree  264 (15.8) 236 (11.5)  
1.00 
  Unsure 334 (20.0) 429 (20.9)  
  Agree 1075 (64.3) 1391 (67.7) <0.001* 1.19 (1.03-1.37) ** 
I would get vaccinated if doctors or 
nurses recommend me to do so 
    
  Disagree  316 (18.9) 271 (13.2)  
1.00 
  Unsure 361 (21.6) 510 (24.8)  
  Agree 997 (59.6) 1274 (62.0) <0.001* 1.09 (0.96-1.25) 
I would get vaccinated if there is a school 
requirement for me to be vaccinated 
    
  Disagree  468 (28.0) 424 (20.7)  
1.00 
  Unsure 451 (27.0) 658 (32.1)  
  Agree 754 (45.1) 970 (47.3) <0.001* 1.12 (0.98-1.29) 
*P<0.025 by chi-square, meaning the there is difference in the distribution of responses; 
**p<0.025 by logistic regression.  
bAOR: adjusted odds of females who agreed the attitudinal statement in contrast to those 
who did not (including both those who chose responses of ‘Disagree’ and ‘Unsure) by 
multivariate logistic regression; 95%CI: 95% confidence interval. 
Adjusted for age, gender, rurality, and schools 
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AORb (95% CI) 
By logistic regression 
People are infected because they or 
their partners have been unfaithful 
    
  Disagree  909 (54.4) 1107 (53.8)  1.00 
  Unsure 437 (26.2) 631 (30.7)  
  Agree 325 (19.4) 318 (15.5) 0.001* 0.81 (0.68-0.97) 
If I had an HPV infection, it would 
be disruptive to my sexual 
relationship(s) 
    
  Disagree  285 (17.1) 304 (14.8)  1.00 
  Unsure 310 (18.6) 481 (23.4)  
  Agree 1075 (64.4) 1273 (61.9) <0.001* 0.91 (0.79-1.04) 
I would get vaccinated if my 
friends  recommend me to do so 
    
  Disagree  459 (27.4) 511 (24.9)  1.00 
  Unsure 501 (29.9) 804 (39.2)  
  Agree 714 (42.7) 738 (35.9) <0.001* 0.80 (0.70-0.92) ** 
I would get vaccinated if public 
service ads on TV or internet 
recommend it 
    
  Disagree  664 (39.6) 771 (37.5)  1.00 
  Unsure 523 (31.2) 770 (37.4)  
  Agree 488 (29.1) 517 (25.1) <0.001* 0.84 (0.72-0.97) ** 
How likely is the risk that you will 
be getting HPV in the future 
    
  Unlikely (ref.) 1107 (66.2) 1281 (62.2)  1.00 
  Unsure 399 (23.9) 619 (30.1)  
  Likely 165 (9.9) 158 (7.7) <0.001* 0.83 (0.65-1.05) 
*P<0.025 by chi-square, meaning the there is difference in the distribution of responses; 
**p<0.025 by logistic regression.  
bAOR: adjusted odds of females who agreed the attitudinal statement in contrast to those 
who did not (including both those who chose responses of ‘Disagree’ and ‘Unsure) by 
multivariate logistic regression; 95%CI: 95% confidence interval. 








Table 4-9:  Results of logistic regression: differences by age, gender, rurality and smoking in the acceptability of the HPV vaccine, awareness of HPV 
and knowledge level of HPV infection and vaccination. 
 Likely to be vaccinated Had heard of HPV(the screening question) Had high level of knowledge 
N (%)a AORb (95% CI) P- value N (%)a AORb (95% CI) P- value N (%)a AORb (95% CI) P- value 
Age <18 (ref.) 1222 (66.1) 1.00  241 (13.0) 1.00  104 (45.2)   
>=18 1302 (70.0) 1.21(0.99-1.47) 0.068 257 (13.8) 1.16(0.95-1.40) 0.143 117 (47.6) 1.15(0.80-1.67) 0.477 
Gender Male (ref.) 1110 (66.3) 1.00  244 (14.6) 1.00  111 (47.2)   
Female 1431 (69.5) 1.69(1.38-2.07) <0.001* 255 (12.4) 0.92(0.76-1.12) 0.411 111 (45.9) 0.87(0.60-1.27) 0.476 
Rurality Urban (ref.) 2068 (67.9) 1.00  466 (15.3) 1.00  206 (46.2)   
Rural 507 (68.9) 0.77(0.56-1.04) 0.090 33 (4.5) 0.33(0.22-0.49) <0.001* 16 (51.6) 1.80(0.81-3.98) 0.148 
Smoking Never (ref.) 2150 (67.3) 1.00  404 (12.6) 1.00  187 (48.6) 1.00  
Once or twice 170 (76.6) 1.32 (0.86-2.03) 0.206 30 (13.5) 1.09 (0.73-1.63) 0.686 9 (32.1) 0.56 (0.24-1.29) 0.173 
Used to, given up 63 (70.8) 0.88 (0.49-1.58) 0.676 21 (23.6) 2.09 (1.25-3.49) 0.005* 8 (38.1) 0.63 (0.25-1.56) 0.315 
 Sometimes 91 (69.5) 1.04 (0.62-1.76) 0.876 23 (17.6) 1.62 (1.01-2.61) 0.048 10 (43.5) 0.81 (0.34-1.95) 0.640 
 Everyday 59 (70.2) 0.97 (0.52-1.80) 0.921 20 (23.8) 2.17 (1.27-3.68) 0.004* 7 (36.8) 0.62 (0.23-1.64) 0.330 
Had heard 
of HPV  
No (ref.) 2221 (67.6) 1.00  - - - - - - 
Yes 354 (71.2) 0.85(0.72-1.25) 0.698 - - - - - - 
Knowledge 
level  
Low (ref.) 160 (63.2) 1.00   - - - - - - 
High 179 (80.6) 2.43(1.39-4.25) 0.002* - - - - - - 
aN means the number of respondents likely to be vaccinated/had heard of HPV/had high level of knowledge and (%) means the proportion in each category 
(e.g. the proportion of respondents who had heard of HPV in all the never-smoke respondents). 
Multivariate logistic regressions were performed. *P<0.025 
bAOR: adjusted odds ratio; 95%CI: 95% confidence interval 




Table 4-10:  Results of factor analysis on attitudes towards HPV vaccine 
Extraction Method: Principal Component Analysis.  
Rotation Method: Varimax with Kaiser Normalization. 





1 2 3 4 5 
1. I would get vaccinated if my friends recommend me to do so 0.782 - - - - 
2. I would get vaccinated if my parents recommend to do so 0.715 - - - - 
3. I would get vaccinated if doctors or nurses recommend me to do so 0.740 - - - - 
4. I would get vaccinated if there is a school requirement for me to be vaccinated 0.775 - - - - 
5. I would get vaccinated if public service ads on TV or internet recommend it 0.706 - - - - 
6. People will think that someone who is infected with HPV is a person who is promiscuous - 0.769 - - - 
7. If someone has HPV infection, people will gossip - 0.770 - - - 
8. People are infected because they or their partners have been unfaithful - 0.811 - - - 
9. One should keep a social distance from those who are infected with HPV - 0.524 - - - 
10. I'm concerned that HPV vaccines have not been proved effective in prevention of HPV and 
cervical cancer 
- - 0.740 - - 
11. I'm concerned that HPV vaccines may have side effects such as fatigue or fever - - 0.651 - - 
12. I'm concerned that HPV vaccines may have major side effects such as long term illness - - 0.746 - - 
13. I'm worried that HPV vaccine costs too much - - 0.663 - - 
14. If I had an HPV infection, it would have a serious impact on my physical health - - - 0.799 - 
15. If I had an HPV infection, it would be disruptive to my social life - - - 0.846 - 
16. If I had an HPV infection, it would be disruptive to my sexual relationship - - - 0.779 - 
17. If someone is vaccinated with HPV vaccine, this will help them avoid HPV infection - - - - 0.847 
18. If someone is vaccinated with HPV vaccine, this will help them avoid cervical cancer - - - - 0.843 
Eigenvalues 5.94 2.05 1.46 1.43 1.14 
Variance (%) 29.68 10.24 7.32 7.13 5.70 
Cumulative Variance (%) 29.68 39.92 47.24 54.37 60.07 
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Table 4-11:  The attitudinal predictors for acceptability of HPV vaccines, HPV awareness and knowledge 
Attitudes Quartile Likely to be vaccinated 
(N=) 
Had heard of HPV  
(N=) 
Had high level of knowledgea 
(N=) 
AORb (95% CI) P- value AORb (95% CI) P- value AORb (95% CI) P- value 
Other influences  1 (ref.) 1.00   1.00  1.00  
2 0.85 (0.65-1.11) 0.230 1.27 (0.94-1.71) 0.118 1.21 (0.67-2.21) 0.527 
3 1.49 (1.12-1.98) 0.006* 1.65 (1.24-2.20) 0.001* 1.16 (0.66-2.06) 0.602 
4 3.89 (2.75-5.49) <0.001* 1.66 (1.24-2.20) 0.001* 1.65 (0.94-2.89) 0.079 
Perceived barriers  1 (ref.) 1.00   1.00  1.00  
2 1.26 (0.93-1.71) 0.137 1.22 (0.92-1.63) 0.172 2.28 (1.28-4.04) 0.005* 
3 1.15 (0.85-1.56) 0.351 1.37 (1.04-1.82) 0.028 1.72 (0.98-3.01) 0.060 
4 0.75 (0.56-0.99) 0.045 1.34 (1.01-1.78) 0.041 1.34 (0.76-2.37) 0.317 
Perceived severity  1 (ref.) 1.00   1.00  1.00  
2 1.65 (1.26-2.16) <0.001* 1.07 (0.82-1.39) 0.623 2.38 (1.40-4.04) 0.001* 
3 1.81 (1.38-2.38) <0.001* 0.91 (0.69-1.20) 0.494 2.39 (1.39-4.12) 0.002* 
4 2.53 (1.87-3.42) <0.001* 0.77 (0.58-1.02) 0.071 2.91 (1.66-5.13) <0.001* 
Perceived benefits  1 (ref.) 1.00   1.00  1.00  
2 2.01 (1.53-2.64) <0.001* 1.39 (1.05-1.84) 0.023* 1.31 (0.75-2.30) 0.346 
3 2.12 (1.61-2.79) <0.001* 1.52 (1.15-2.01) 0.004* 1.53 (0.89-2.64) 0.126 
4 3.01 (2.22-4.08) <0.001* 1.07 (0.80-1.44) 0.654 1.84 (1.02-3.32) 0.043 
Stigma about 
HPV infection 
1 (ref.) - - 1.00  1.00  
2 - - 1.28 (0.98-1.69) 0.075 1.20 (0.72-2.02) 0.486 
3 - - 1.04 (0.78-1.38) 0.793 1.57 (0.91-2.71) 0.104 
4 - - 1.06 (0.80-1.40) 0.711 0.48 (0.27-0.84) 0.011* 
 
Multivariate logistic regressions were performed between acceptability of HPV vaccines and attitudes, awareness of HPV and attitudes, knowledge 
level and attitudes. *P<0.025. 
bAOR: adjusted odds ratio; 95%CI: 95% confidence interval. 
Adjusted for age, gender, rurality and schools, and awareness, smoking 
a: respondents had knowledge > 6 scores; 1: the lowest quartile; 4: the highest quartile; 
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Figure 4-1:  Knowledge level of HPV and cervical cancer  
 
 
F means the correct answer is false; T means the correct answer is true.  















0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0
Poor personal hygiene increases the risk of HPV infection (F)
Most HPV can be cleared without treatment (T)
Condom lowers the risk of HPV infection (T)
HPV vaccine are most useful for those who have already had sex (F)
HPV is an uncommon sexually transmitted infection in China (F)
Earlier sexual activity can increase the risk of HPV infection (T)
HPV can be sexually transmitted (T)
HPV test can identify women who are at risk of cervical cancer (T)
HPV may cause cervical cancer (T)
HPV infection can last years without symptoms (T)
Cervical screening can effectively prevent cervical cancer (T)
Multiple sexual partners increases the chance of cervical caner (T)
Regular cervical screening is not necessary after HPV vaccination (F)
HPV vaccination is 100% effective against cervical cancer (F)
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* indicates significant difference of knowledge level between males and females 
F means the correct answer is false; T means the correct answer is true. 
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Poor personal hygiene increase the risk of HPV infection (F)
Most HPV infections can be cleared without treatment (T)
Condom use lowers the risk of HPV infection (T)*
HPV vaccines are most useful for those who alread have had sex (F)
HPV is an uncommon sexually transmitted infection in China (F)
HPV infection can be sexually transmitted (T)
Earlier sexual activity increase the risk of HPV infection (T)
HPV test identify women who are at risk of cervical cancer (T)
Multiple sexual partners increases the chance of cervical cancer (T)
HPV may cause cervical cancer (T)
Cervical screening can effectively prevent cervical cancer (T)
Sometimes, a HPV infection can last years without symptoms (T)
Regular cervical screening is not necessary after HPV vaccination (F)







5 Chapter 5 Discussion and implications 
5.1 Introduction 
My thesis has examined an important element of any future strategy to reduce the burden 
from cervical cancer in China—the knowledge, attitudes, and beliefs of young people in 
relation to HPV vaccination and cervical cancer screening. I have emphasised in my thesis 
that cervical cancer is the fourth most common cancer in women worldwide, and the fourth 
most common in Chinese women. Further, there is an ongoing upward trend in the incidence 
of cervical cancer and HPV prevalence in China over the last decade [16].  
 
Two major strategies for prevention of cervical cancer are available worldwide: cervical 
screening and HPV vaccination. HPV vaccination, which has been licenced and introduced 
in over 120 countries since 2006, is expected to prevent up to 70% of cervical cancer cases 
— it is widely viewed as a cost-effective prevention strategy. However, in China, no national 
cervical cancer prevention programmes have been established. Many factors contribute to 
this, including China’s large geographic area and diverse population, and a lack of 
prioritisation of cervical screening. Hence, comprehensive but tailored prevention 
programmes need to be developed which include education, HPV vaccination, and cervical 
screening. Awareness and knowledge of HPV infection and vaccination—factors that would 
affect the acceptability of HPV vaccination in China—have not, to date, been thoroughly 
examined in China.  
 
The primary aim of my thesis was to identify knowledge levels about HPV and vaccination 
and the attitudinal facilitators and barriers that would influence the introduction of HPV 
vaccination. Hence, I undertook a systematic review and a questionnaire survey, as described 
in Chapters 2, 3, and 4. In this chapter, I summarise my findings, examining methodological 
issues, and describe the main contributions of my thesis to the area of cervical cancer control 
in China. I include some recommendations for future research and examine some of the 
many factors which need to be taken into account if HPV vaccination is to be successfully 
introduced in China.  
5.1.1 Summary of key outputs from my thesis 
Chapter 2 described the methodology and results of the systematic review. Chapter 3 
presented the methodology for my questionnaire survey, and Chapter 4 provided the results 
of my survey.  
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5.1.2 Summary of key outputs from my systematic review 
My systematic review is the first exercise of its kind that I am aware of: it examines and 
synthesises research on knowledge of and attitudes towards HPV vaccination in the Chinese 
literature from various regions across China and among different population groups, 
including teenagers, adults, health professionals, and racial groups (such as Uyghur people). 
 
Forty-seven studies were identified in my search. There were three key findings:  
1) There are variations between different demographics and geographical areas in terms of 
awareness and knowledge of HPV infection, and the acceptability of HPV vaccination, 
suggesting the potential for health inequalities in more deprived regions (where there are less 
health care facilities and personnel). 
2) There are many factors which would affect the acceptability of HPV vaccines.  
3) There are significant issues in the quality of Chines studies when compared with 
international studies (this is discussed further in section 5.3 in this chapter).  
 
A similar pattern in terms of demographics and location was identified in the awareness and 
knowledge of HPV infection and cervical cancer: for example, low levels of awareness of 
HPV (<10% of respondents in the included studies) were found among survey populations in 
West China, among underserved populations (Uyghur women and rural women), and among 
younger people (teenagers), while moderate levels of awareness of HPV (approximately 30% 
of respondents in the included studies) were found among young adults and urban adult 
women. In addition, differing patterns in acceptability of the vaccine were found: health 
professionals who had higher levels of awareness (>80%) and knowledge of HPV and 
cervical cancer (>80%) had a lower level of acceptability (<30%) of the HPV vaccine (for 
their daughters); people in North China who had  a moderate level (about 30%) of awareness 
and knowledge of HPV and cervical cancer had a higher level acceptability (>70%) of the 
HPV vaccine for both themselves and their daughters.  
 
It is important to note, however, that there are only a limited number of studies in each 
category and the fair or poor quality of these studies limits the confidence that can be placed 
in these results. Few studies (eight in total) examined factors affecting the acceptability of 
HPV vaccines: the cost of the vaccine, who would provide the vaccine, the source of the 
vaccine, and the acceptable age of vaccination were the most commonly examined factors. 
These studies suggest that the majority of respondents would be willing to pay up to ¥100 
($16) for the vaccine (>80% of respondents in the included studies), and would be willing to 
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accept vaccines offered by the government (>55% of respondents in the included studies). 
Issues regarding the safety and effectiveness of HPV vaccines were examined in the included 
studies, but it is difficult to draw a definite conclusion because of the small number of 
studies (four) examining these topics, as well as the diverse populations and different 
wording of the questions included in these studies.  
5.1.3 Summary of key outputs from my survey 
My questionnaire survey differed from most previously published studies in China on this 
topic in that it developed a theory-based questionnaire to explore attitudes towards HPV 
vaccines among Chinese teenagers. It is also among the first to examine facilitators and 
barriers to the acceptability of HPV vaccines and HPV-related stigma among a school-age 
Chinese population.   
 
There were three key findings:  
1) low levels of awareness of HPV despite high levels of acceptability of HPV vaccination; 
varying levels of knowledge of HPV and cervical cancer (low, moderate, and high);  
2) there are many predictors for the acceptability of HPV vaccines (e.g. perceived 
effectiveness of HPV vaccine; perceived barriers to HPV vaccine)  
3) gender and age have a significant effect on awareness, knowledge, and attitudes 
 
I found that the Chinese teenagers in my survey had a low level of awareness of HPV and 
high levels of acceptability of HPV vaccination. These results were consistent with findings 
in my systematic review. Attitudes towards sexually transmitted infections differed from 
those typically seen in Western literature, and may be explained by traditional Chinese 
culture and prevailing social norms. 
 
I found both facilitators and barriers to acceptance of HPV vaccination among Chinese 
teenagers.  
 
Four facilitators were found. These were:  
 recommendations from parents and doctors 
 perceived severity of HPV infection and of cervical cancer—the greater the physical, 




 perceived benefits of HPV vaccine—the more effective respondents perceived HPV 
vaccination to be, the more likely they were to be vaccinated 
 high levels of knowledge of HPV and cervical cancer.  
 
Females reported higher levels of acceptability of HPV vaccines, and they were more 
concerned than males about the health impact of HPV infection and of cervical cancer, the 
side effects of vaccination, and the opinions of their parents. Males were more concerned 
about the cost of vaccination and the prospect of HPV vaccination leading to higher levels of 
sexual activity. Males also had more trust in drug companies and more knowledge of 
preventive measures such as condom use.  
5.2 Methodological issues 
In critiquing my findings I need to examine some key methodological issues, principally: 1) 
my search strategy and the critical appraisal and synthesis of results in my systematic review; 
and 2) the study design, instrument development, and analytical issues concerning data from 
my questionnaire survey. These issues inevitably affect the external and internal validity of 
my findings and reveal the strengths and weaknesses of the key outputs from my thesis. 
5.2.1 Methodological issues in my systematic review 
As with all systematic reviews, there are limitations which must be recognised. The search 
strategy had limitations with respect to the time period covered, languages included, and the 
locations of included studies. Searches of the databases (CNKI and Wanfang databases) 
selected for my systematic review were carried out in December in 2012; since that date 
there have been newly published Chinese-language publications (2013–2015) added to these 
two databases examining knowledge of and attitudes towards HPV and vaccination. Further, 
these more recent studies included more geographical regions, and broader areas of attitudes 
were explored. I will include this more recent evidence in the peer-reviewed paper based on 
this section.  
 
Moreover, I did not include English literature and studies carried out in Hong Kong and 
Taiwan for the following reasons: English-language papers were mostly included in English-
language systematic reviews, and studies carried out in Taiwan and Hong Kong were 
published either in English language or in Traditional Chinese language—a different written 
Chinese language from the Simplified Chinese language used in Mainland China databases 
like CNKI. Hence, the external validity of my review might be limited, but it provides 
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valuable results that summarise the findings of surveys in Chinese-language literature carried 
out in Mainland China; international researchers may have only limited opportunity to access 
these findings.  
 
Critical appraisal was carried out on included studies in order to assess their internal validity. 
I chose an existing quality assessment tool and modified it to better suit my review.  There 
are obvious implications of using quality assessment tools developed in the context of 
western literature in reviews of papers in a different language and from a different culture. 
However, there is no gold standardised tool and I chose the quality assessment tool I 
believed to me the most appropriate for my review. As more and more scientific literature is 
produced in China, it is likely that quality assessment tools designed to reflect local literature 
will emerge. For the time being the only choice is to use western-developed tools, while 
trying to examine carefully whether their criteria seem appropriate for Chinese literature. 
 
Based on the quality assessment, some of the included studies in my review were not of high 
quality, especially the surveys carried out in West China and among ethnic minority and 
teenage populations. A number of factors may contribute to this poorer quality of 
publications: 1) the different level of required quality for the journals in which these studies 
were published; 2) the lack of commonly applied standardised guidelines in performing and 
reporting studies, in contrast to much published research in Western literature; 3) the limited 
academic resources and network in the research institutes where these studies were carried 
out. Despite these issues, one strength of my review is that its quality assessment report is 
among the first to critically appraise Chinese-language studies carried out in Mainland China 
and thus may offer some insights for Chinese researchers to perform and publish higher-
quality studies.  
 
I used a narrative synthesis approach to describe my findings, displaying summaries of key 
findings in tables and graphs. For some items of interest only a few studies were available in 
which relevant data was reported (for example, people’s concerns about the safety and 
effectiveness of HPV vaccines were reported in only four studies, carried out among 
different subgroups—health professionals, urban adults, and adult women, and using 
different wording in the questions (see Chapter 2)). Further discussion of the systematic 
review is provided later in this chapter (5.4) 
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5.2.2 Methodological issues in my survey 
The external validity of my survey may be limited because of the selection of the location 
and participants. Although my survey was carried out in one province—Heilongjiang—the 
results could be generalised to some inland provinces in China, because of the similar 
demography, economy, and education level between them. Obviously, a larger sample size 
and random sampling might yield greater statistical power to achieve more accurate national 
estimates. I used a non-probability sampling method—convenience sampling—due to the 
availability of and easy access to the selected participants. It may be less representative than 
random or cluster sampling, but careful study design regarding the selection of classes, 
grades, and schools (inclusion/exclusion criteria applied) and the recruitment of participants 
may, to some extent, reduce the selection bias. Further, although I have made comparisons 
between knowledge and attitudes according to rurality, care should be taken in interpreting 
these results. There was a disproportionate participation rate of urban to rural participants in 
my survey, and because of this, my selected schools are not representative of the rest of the 
province with respect to rural/urban ratio.   
 
My survey used a questionnaire designed specifically for this study to explore the issues of 
HPV vaccination in the school-age population. Hence, my study instrument had not been 
validated prior to my research. However, I consider I took reasonable measures to ensure the 
quality of my questionnaire; questions were generated based on western and Chinese 
literature review, and the wording of the questionnaire was refined by cognitive interviews in 
order to obtain more valid and reliable questions. I also invested considerable effort in 
designing questions, and forms of wording which were culturally and linguistically 
appropriate for my study setting.  
 
I used a theory-based approach (the Health Belief Model) to formulate the questions in my 
questionnaire. As I’ve discussed the HBM might be limited in terms of the model’s 
constructs and the model’s application in my study setting. However, after reviewing 
available models, I considered the HBM to be the most appropriate for my study setting – its 
basic constructs seemed understandable to school-age children in China. A degree of caution 
is, nevertheless, necessary, as concepts such as fear, anxiety and vulnerability sometimes 
don’t translate well between cultures. 
 
One concern in questionnaires of this nature is multiple testing: there is no standardized 
correction to decrease the possibility of finding significant results by chance. In my analyses, 
237 
 
I used the Bonferroni correction—the simplest and most conservative approach—to correct 
the observed p value significance level. Two main analyses of the hypothesis were 
performed:  I sought to correct for multiple testing by dividing the p value by two hypothesis 
tests, and the new level of significance was 0.025. But for each analysis of the hypothesis, 14 
tests were performed. If the Bonferroni correction was used for the 14 tests, then the new 
significant level of p value would be 0.004. Considering the significant level for sample size 
estimation and that a larger sample size would have been required if I had used this very 
small significant level (a sample approximately six times larger when using a p value of 
0.004 compared to 0.025), I did not apply this very small significant level because of the 
logistical issues in accessing such a big sample size and the limited information p value 
could provide (see below for interpretation), but care should be taken to interpret these 
findings appropriately. Moreover, the odds ratio was calculated and presented close to p 
value in the tables, providing more information on the results—the size of the difference of 
proportions that p value cannot present.  
 
Confounding factors were selected based on the systematic literature review and prior 
association analysis from which significant association was found with outcome variables. 
Thus, age, gender, rurality, school, and smoking were included and adjusted in the 
multivariate logistic regression analysis. The majority of confounding effects could be 
minimised. However, unmeasured confounding factors (e.g. family income) or unknown 
ones may still exist and cannot be ruled out.  
5.3 Main contributions of my thesis  
The main contributions of my thesis can be divided into two categories—contemporary 
evidence relating to the Chinese population, and methodological considerations for future 
research. In relation to evidence, four areas of results from my thesis (see below 5.3.1–5.3.4) 
may contribute to the evidence base; for methodological considerations, I have developed a 
quality assessment tool and a theory-based questionnaire suitable for use in China.  
5.3.1 Systematically synthesising the evidence in Chinese literature 
The first contribution of my thesis is in providing synthesised evidence about knowledge of 
and attitudes towards HPV infection and vaccination from Chinese-language literature. 
Findings of academic research are mostly reported in English-language peer-reviewed 
publications, and although some Chinese-language literature is available online, such as 
CNKI, it cannot be easily understood by international researchers because of the language 
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barrier. Hence, my review provides an important and, I hope, useful contribution to this field 
by systematically synthesising and presenting the results from the Chinese-language 
literature and in this way providing detailed evidence from Chinese populations that is 
largely absent from English-language literature. Variation in the standard of reporting in 
Chinese academic journals leads to limited and heterogeneous evidence; however, my 
review is still of importance, as it provides contemporary evidence from Chinese-language 
literature as well as suggesting potential areas for future research. The findings from my 
review may have some relevance for those provincial regions and populations that have not 
yet been included in academic studies, although I recommend that research in these 
provinces and communities is carried out.  
5.3.2 Estimating the awareness and knowledge of HPV and vaccination 
among school-age Chinese 
Based on my understanding of the literature (as outlined in Chapters 1 and 2), as far as I am 
aware, my survey is one of the first to estimate the awareness and knowledge of HPV 
infection and of cervical cancer among high-school-age Chinese in North China. Similarly, it 
is one of the first to examine factors relating to HPV vaccination in a school-age Chinese 
population, and to examine differences by gender and age (younger and older than 18 years) 
regarding  knowledge of HPV and vaccination in Mainland China. My survey was a 
localised one, but the results may be generalised to similar populations in selected inland 
provinces (e.g. Henan) in Mainland China. 
5.3.3 Identifying the factors that would facilitate or hinder the 
acceptability of HPV vaccination in Chinese 
Again, according to my understanding of the literature (as outlined in Chapters 1 and 2), my 
survey is among the first to examine the acceptability of HPV vaccines among a high-
school-age Chinese population in Mainland China. It is also among the first to explore the 
facilitators and barriers to HPV vaccination, based on the behavioural theory of the Health 
Prediction Model, in this population. Examples include whether the younger generation have 
perceptions of the importance (risk or severity) of cervical cancer and whether their 
perceptions of the effectiveness of HPV vaccination might influence their vaccination 




5.3.4 Identifying the stigma in HPV infection among school-age 
Chinese in Mainland China 
Stigma about HPV infection has been explored in Chinese women in Hong Kong, but to date 
it had not been reported from Mainland Chinese populations. My survey is among the first to 
examine stigmatising attitudes towards HPV infection among the younger generation in 
contemporary Mainland China. I found that although younger generations in my survey 
population in China are less likely to conform to the traditional social norms (e.g. abstinence 
before marriage), pressure from peers, parents, and the entire societal environment would 
still have a great influence on their perceptions and behaviours. 
5.3.5 Developing a quality assessment tool to critically appraise 
observational studies in Chinese literature 
I have developed a quality assessment tool for observational studies in Chinese literature, 
adapted from previously published tools, and my review was the first one I am aware of to 
assess the quality of Chinese-language studies in the area of knowledge of and attitudes 
towards HPV and vaccination, based on this refined critical appraisal checklist. The tool may 
be of use for critical appraisal of observational studies in Chinese literature.  
5.3.6 Developing a theory-based questionnaire of knowledge of and 
attitudes towards HPV and vaccination 
I have developed a theory-based questionnaire examining various aspects of knowledge of 
and attitudes towards HPV infection and vaccination. I used teenager-friendly Chinese 
language in the questionnaire, and it may be appropriate for use in future surveys examining 




5.4 Recommendations for future research 
5.4.1 Recommendations for areas of future research 
Though the cervical cancer burden (both incidence and mortality) in China is close to the 
average of high-income countries, the difference between the minimum and maximum age-
standardised incidence is much larger - an 8-fold difference has been reported [256]. This 
may be because of the disparities between geographical regions in China, as well as its 
diverse populations. However, these reported rates may also be due to the uncertainty of the 
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reliability of estimated rates. Hence, research on how to accurately measure national 
estimates of incidence and mortality by population and region is needed to offer information 
for decision making on adopting HPV vaccination. 
 
My review and survey have highlighted the need for more studies looking at facilitators and 
barriers to HPV vaccination (including the influence of stigma related to HPV infection). My 
study also suggested further studies are needed in China among potential recipients—
teenagers and young adults—in various geographical regions.  
 
Critically, neither my survey nor other studies carried out in China to date have examined the 
system-level financial constraints for HPV vaccines—the type and coverage of health 
insurance that participants receive, and how this might influence the affordability of HPV 
vaccines. Evidence suggests that the reimbursement rate of HPV vaccines by health 
insurance in countries where the vaccine is not covered by any health insurance was 
positively associated with acceptability of the vaccine [257]. Thus, further research is 
required in China on the acceptability and potential uptake of HPV vaccine in relation to 
health insurance coverage and reimbursement for the vaccine.  
 
As described, my review focused on Chinese-language literature. Ideally, the next step will 
be to compare and combine results from both Chinese and English literature to obtain greater 
insights into the factors affecting HPV infection and vaccination, and cervical screening, in 
China. Similarly, a review of literature from Chinese populations from Mainland China, 
Hong Kong, and Taiwan may be of interest to researchers and policy makers.  
 
5.4.2 Recommendations on methodological issues 
The wide diversity of populations and geographic regions within China creates difficulties in 
obtaining accurate national estimates of knowledge of and attitudes towards HPV 
vaccination. Most studies in China were localised ones—many were based in one provincial 
site—and although a few multi-centre (more than two provincial sites) studies have been 
carried out in China recently, the potential representativeness of wider populations was not 
well stated and this requires further exploration. Some provincial regions have not been 
included in surveys in either Chinese- or English-language literature, and the available 
evidence would not be sufficient to represent estimates in these areas and thereby guide 




I suggest the use of standardised protocols, rigorous tools for collecting information, and 
rigorous analysis methods, which may help to obtain reliable and consistent data and 
facilitate synthesising cumulative evidence, thereby improving the quality of research. 
5.5 Considerations for the introduction of HPV vaccination in 
China 
The introduction of HPV vaccination is a complex process, requiring decision making by 
and involvement of multi-level stakeholders. Some issues need to be considered prior to 
implementing prevention programmes for cervical cancer (HPV vaccination alone, or a 
combination of vaccination and screening). Burchett 2012 [258] has identified nine criteria 
for decision making when adopting new vaccines in a country. I will use the identified 
criteria as reference to divide the considerations into seven parts (5.6.1-5.6.7) to see what the 
facilitators or barriers are to the introduction of HPV vaccination. My review and survey 
may provide some insight in terms of perceptions of cervical cancer and of the effectiveness 
of HPV vaccination by the public and related considerations. I will also address these issues 
from global health perspective.  
5.5.1 The importance of cervical cancer in China  
A number of factors will likely affect the significance placed on cervical cancer prevention 
(and detection) in China in coming decades. They include: 1) health priority; 2) disease 
burden; and 3) perceptions of importance in terms of the perceived risk and severity of 
cervical cancer. I will discuss these three issues in detail in the global context below. 
 
 
Health priority and disease burden 
WHO has recommended Millennium Development Goals (MDGs) [259] regarding global 
health, which outlined eight health areas that all countries should try to address, especially 
low- and middle-income countries. These areas are mostly related to high disease burden and 
serious threat to human health, including child health, immunization, maternal health, 
infectious disease, etc. [259]. Good progress has been made in these areas during the past 
decade: however, as the demographic transition is ongoing, the global map of disease is 
changing and there has been a shift in the disease burden from infectious disease to non-




China is considered to be a middle-income country and has been striving to achieve MDGs 
according to WHO guidelines over the past couple of decades, particularly with respect to 
improving child and maternal health, and infectious disease. For example, China has had an 
established National Immunisation Plan since 2007 [100], currently providing 14 vaccines 
free of charge: 11 to all children and 3 to susceptible people in the country [100]. However, 
because of the shift in disease burden towards NCDs and the fact that the majority of poor 
people live in rural regions, China may have to face a double burden of infectious disease 
and NCDs. A global report showed that over 70% of poor people worldwide live in middle-
income countries rather than low-income countries, and, like other middle-income countries, 
China may experience a similar situation.  
 
It is unlikely that cervical cancer — ranked in fourth place among NCDs in women in China 
— will be prioritised as quickly as infectious diseases (such as measles), which pose an 
immediate, serious physical threat and the potential for a great population impact. Compared 
to the vaccines included in the national routine immunisation programmes [100], HPV 
vaccines are the only ones aiming to prevent a non-infectious disease—cervical cancer in 
adult women, and with oral or anal cancer in adult men. Regarding the potential recipients of 
HPV vaccination—teenagers—it is a population that has not been included in the national 
immunisation programmes in China, which may constitute another barrier to implementing 
vaccination.  
 
Perceptions of the importance of cervical cancer  
Findings in my study suggested a low level of perceived risk and severity of cervical cancer 
among Chinese teenagers and a lack of specialised knowledge of the prevention of cervical 
cancer among Chinese health professionals. They suggest that at an individual level many 
people are unaware of the threat of cervical cancer and the importance and possibility of 
preventing it.  
5.5.2 Characteristics of HPV vaccines  
There are two main issues: 1) the effectiveness of HPV vaccines; and 2) the safety of HPV 
vaccines.  
 
Effectiveness of HPV vaccines  
Evidence noting that the short-term population impact of HPV vaccines has been 
demonstrated in Western countries (Australia, the US, New Zealand, Denmark, Germany, 
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and Sweden) in terms of HPV infection, genital warts, and cervical lesions [261]; this was 
described in Chapter 1. As cancer development may take several decades, the long-term 
effect of the vaccine remains to be seen. However, two main factors may affect the ability to 
obtain evidence of the effectiveness of HPV vaccines in China. First, evidence of the short-
term effect of HPV vaccines in Western countries may not act as reference for Chinese 
people because of Chinese regulations. The Chinese State Food and Drug Administration 
requires external drug companies to perform clinical trials in Mainland China among 
Mainland Chinese prior to licensing their products. Phase III clinical trials by GSK and Merk 
had finished in Mainland China by 2013, and two Chinese drug companies are currently 
carrying out clinical trials[93]. Second, another barrier is the endpoint of the trials in China, 
which is the precancerous cervical lesions rather than persistent HPV infection - the 
recommended endpoint from WHO [262]. However, it may take decades to get significant 
results of precancerous lesions in clinical trials in Mainland Chinese population due to the 
late start of trials of HPV vaccines in China, although preliminary evidence has been found 
in Australia [75], Scotland [76] and Denmark [77]. Thus, evidence of the effectiveness of 
HPV vaccines has not been available in Chinese people according to the Chinese regulations 
and the endpoint used.   
 
Safety of HPV vaccines 
Evidence suggests there was not a significant difference in vaccine-related serious adverse 
events between the vaccine and control groups [72]. Minor side effects occurred, such as 
pain and swelling, but this was usually of short duration [72]. Similarly, clinical evidence 
regarding safety is required to be gathered from Chinese people, according to Chinese 
regulations.  
5.5.3 Vaccine delivery 
I will address issues around the delivery of HPV vaccines in the following three parts: 1) age; 
2) gender; 3) location of vaccination. As the strategy of vaccination would greatly influence 
these delivery issues (detailed are described below), the discussion here may offer some 
information for decision making.  
 
Age  
Given the fact that HPV vaccine to those who are already sexually active have not been 
proved effective and may lead to a waste of resources, people prior to sexual debut are 
recommended as appropriate recipients for HPV vaccination [4]. A Chinese study has been 
244 
 
carried out to estimate the average age of sexual debut and found that 15 years old would be 
the ideal vaccination age given the estimated age of sexual debut [60, 94]. However, 
uncertainty about the accuracy of this estimation resulting from the diverse population and 
large geographical area of China may limit the effectiveness of implementation of HPV 
vaccination. According to the experiences of Hong Kong and Taiwan, researchers and policy 
makers need to consider whether it is necessary in China to widen the age-range of potential 
recipients from teenagers to adults (as has been done Hong Kong and Taiwan) when the 
vaccine is not free of charge. [248] 
 
Gender  
Males were not recommended for HPV vaccination in some Asian countries and regions 
[245, 247, 248] (described late in this chapter), but many of these countries are not large, and 
have less diverse populations than China. Thus, researchers and policy makers in China may 
need to refer to the strategies adopted in other countries, for example, US. The 
considerations may include whether it is necessary to include males in the vaccination 
programme in China to achieve a high level of effectiveness when the coverage for girls is 
not high (e.g. US.). It may also need to consider whether it is necessary and feasible in China 
to target a high-risk group (men who have sex with men) with the aim of reducing anal or 
oral cancer. 
 
Location of vaccine delivery 
The location of delivery of HPV vaccination in China may depend on who are the intended 
recipients are and whether the vaccine is free. If it was not free and was offered at the 
recipient’s request, clinic and hospitals might be appropriate sites for delivery. However, if it 
was free, according to the experience of Asian countries, school-age girls aged 16-18 years 
(ideally) might be the priority cohort, rather than younger or older age groups and boys. Thus, 
school-based vaccination programmes might be more accessible and achieve a high uptake 
more easily than community-based health facilities.  
5.5.4 Acceptability of HPV vaccines  
The findings of my survey suggest that the acceptability of HPV vaccines is high in school-
age Chinese, but results from the systematic review suggest that parental acceptability is 
lower, at least among health professionals. However, these the generalizability of these 
findings is limited as these levels of acceptability were not assessed under various scenarios 
of cost, safety, effectiveness, etc. Hence, I will consider the influential factors in the 
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acceptability of HPV vaccines that were identified in my survey here. They include: 1) 
perceptions of the effectiveness of HPV vaccines; 2) perceptions of the safety of HPV 
vaccines; 3) the distrust of drug companies; 4) the stigma of HPV vaccination.  
 
Perceptions of effectiveness of HPV vaccines  
The findings of my survey suggested that perceived effectiveness was the second most 
commonly perceived barrier (over half) among my school-age population, and one study in 
my systematic review [163] reported that approximately half of health professionals did not 
believe in the effectiveness of the vaccine. Hence, my findings may suggest that preparatory 
work is needed prior to implementing HPV vaccination. 
 
Perceptions of the safety of HPV vaccines 
The findings of my survey identified the risk of minor side effects as the most common 
perceived barrier (three-quarters) to HPV vaccination among the school-age young people in 
my survey population. Females and the older respondents (>=18) were more concerned 
about the side effects of HPV vaccines. This relatively high level of worry about safety 
(much higher than neighbouring countries, such as South Korea and Philippines) might be 
related to the highly publicised adverse events of other vaccines in China in recent years. 
The most influential was the adverse effects of HBV vaccination in Hunan in 2013 [257]. 
Two children were reported to have died; later it was confirmed that the deaths were not 
related to the injection of the HBV vaccine, but anxiety about vaccination among parents 
hindered them from allowing their children to be vaccinated in the future. If HPV 




Distrust of drug companies  
Only one third of the school-age Chinese young people in my survey trusted drug companies, 
which was much lower than other countries, such as Philippines (85%) [199]. This low level 
of trust in drug companies may also be related to the adverse events around vaccination that 
have occurred in China in the last couple of years (see the example of events surrounding 
HBV vaccination described above). This distrust may affect the introduction and 
implementation of HPV vaccines in China, especially when international (e.g. GSK) and 
national (Chinese) drug companies are marketed roughly at the same time, but are priced 




Stigma in relation to HPV vaccination  
My survey suggested that stigma might be caused by the fact that HPV vaccines are for a 
sexually transmitted infection. The most commonly identified stigma in my school-age 
sample was ‘People will gossip about those who get the HPV infection’, followed by ‘Keep 
a social distance from those who have got HPV infection’.  Furthermore, stigma also existed 
among males who were more concerned than females that HPV vaccines would lead to 
people having more sexual partners. However, whether stigma surrounding HPV vaccination 
would occur in the society as a whole or among a specific population may largely depend on 
how the government defined the vaccine when it was introduced and how the vaccination 
campaign was implemented.  
 
To summarise, perceptions of effectiveness and safety, distrust of drug companies, and 
stigma surrounding HPV vaccination may be barriers to the acceptability of HPV vaccines; 
however, there are also some facilitators that have a strong influence on the decisions of both 
recipients and policy makers. Evidence showed technical agencies like WHO and United 
Nations Children's Fund (UNICEF) play an important role in health promotion [258]. The 
example of tobacco control in Beijing has demonstrated this. WHO Beijing office has 
successfully worked together with Beijing Municipal Government to pass a new law, making 
‘all indoor public places in Beijing 100% smoke-free from 1 June 2015’ [264]. Hence, it 
offers an example of how a health intervention can be introduced in China, one that might 
provide lessons for the introduction of the HPV vaccination in China.  
5.5.5 System issues regarding HPV vaccination 
Burchett’s 2012 [258] study found that when  adopting a new vaccine nationally, high-
income countries were more concerned about safety and acceptability issues, and low- and 
middle-income countries were more likely to examine health system weaknesses and 
financial constraints. However, these factors might all occur concurrently in China: China 
has a large geographical area and diverse population and is experiencing both economic and 
demographic transition and facing issues in both poor and wealthy regions, similar to both 
low-income and high-income countries in the world. Hence, apart from the acceptability of 







An ideal national cervical cancer prevention programme should have the following 
components [5, 58] (details stated in Chapter 1, summarised here): 1) primary prevention 
(e.g. sexual education including condom use, and introduction of HPV vaccination); 2) 
secondary prevention (cervical screening); 3) a monitoring system, offering sustainable 
infrastructure to monitor, evaluate, and supervise the vaccination programme. However, 
there is no primary care system in China, and the already overburdened hospitals in big cities 
and shortages of gynaecologists and cytologists in rural regions might hinder the 
introduction of a national vaccination programme. The lack of a national surveillance system 
and infrastructure for the vaccination of teenagers would be another system-level barrier. 
Vaccination administration is important to ensure the effectiveness and safety of vaccines; 
the events surrounding HBV vaccination in Hunan was an example demonstrating the 
insufficient training for technicians and the lack of infrastructure for monitoring. Hence, 
prior to the introduction of HPV vaccines, a complete and sustainable system must be 
established.  
 
Reduction of disparities  
If the HPV vaccine is not included in the national immunisation plan free to the whole 
population in China when it is introduced, health inequalities for HPV vaccine uptake, and 
ultimately for cervical cancer rates, may emerge. The findings in my study suggested 
differing levels of knowledge and attitude by age, gender, and rurality, which suggest that 
future prevention interventions — e.g. raising awareness or skill building — should be 
tailored to the specific population to increase the acceptability and efficacy of the 
intervention, thereby reducing the likelihood of disparities emerging. For example, use of 
teenager-friendly language in the materials of the health education curriculum should be 
encouraged. Ethnic and social disparity may be introduced by a free but not nationally 
implemented vaccination strategy - the likely strategy for HPV vaccination in China in the 
near future. Hence, the needs of underserved populations should be highlighted as well. The 
findings of my study suggested that these people (e.g. Uyghur and rural people) were more 
likely to have less knowledge of HPV and cervical cancer, and to be more concerned with 
cost. Thus, educational intervention may also have to be culturally sensitive, for example, the 
use of Uyghur-language materials. I listed the potential highlighted population based on the 
findings of my study; they would include, but not be restricted to: 1) ethnic minority 
populations; 2) teenagers younger than 18 years old; 3) female students in high school and 
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college; 4) rural residents; 5) teenage children of adult immigrants from rural regions in big 
cities; 6) teenage immigrants from rural regions in big cities; 7) people living in West China. 
5.5.6 Financial constraints 
Financial constraints exist at both individual and system levels.  
 
Individual-level 
Compared to the safety and effectiveness of HPV vaccines, cost was viewed as less of a 
perceived barrier by my survey participants. But in my systematic review of the Chinese 
literature, cost was the most examined issue relating to HPV vaccines. Evidence showed the 
average affordable out-of-pocket cost of HPV vaccines for the individual was less than $50 
for each vaccinated person, which was also viewed as a cost-effective price in China [91]. 
Hence, based on the affordable out-of-pocket cost by individual Chinese [91], the 
government would subsidize up to 80% (($300-50)/$300) of the cost if three-dose HPV 
vaccines were introduced in China at full cost - approximately $300—by GSK or Merck. 
However, cost would be reduced if a two-dose HPV vaccine was licenced for instead of a 
three-dose schedule in China.  
 
System-level 
At system level, the cost of HPV vaccination should include cost of the vaccine itself and the 
cost of administration—storage, transport, monitoring, and supervision[265]. From a health 
economic perspective, the cost described in my survey and review referred to out-of-pocket 
costs for vaccination, not those covered by health insurance. Until the end of 2014, most 
eastern Asian countries and regions—Japan, South Korea, Taiwan, etc.—have not included 
HPV vaccination in their national routine programmes, and the likely recipients have to pay 
the entire cost on their own [240-242]; situations in these neighbouring countries and regions 
may greatly influence HPV vaccination implementation in China—probably to a greater 
extent than those of Western countries. However, if payment for the HPV vaccine was 
entirely out-of-pocket, it might lead to greater disparities between underserved people and 
wealthy people. 
5.5.7 How might HPV vaccination be introduced in China? 
Three main strategies of HPV vaccination exist worldwide [245-248, 266]. They are:  
1) national free programmes, adding to national immunisation systems (i.e. UK, Australia, 
US, Singapore, Malaysia) [84]  
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2) a national partially subsidised programme, in which recipients pay for a proportion (i.e. 
France, 35% no reimbursement) [84]  
3) a programme not covered by any health insurance (i.e. Hong Kong, Taiwan, Japan, Korea) 
[267]  
 
So, what would be the most likely approach in China? A few issues should be taken into 
account; they include the age and gender of the recipients, the delivery venue, and health 
insurance coverage. The strategies for HPV vaccination in neighbouring countries/regions, 
which are likely to influence China, are:  
 Malaysia: free of charge for 13-year-old Malaysian girls since 2010 at schools or clinic; 
the uptake in 2011 was 87.1% in 13-year-old girls [245].  
 Japan: offered since 2010 (some regions subsidise the whole cost, while others ask for 
$500) and the recommended age is 13–16 years; however, from June 2013, the HPV 
vaccine was no longer recommended by the government due to its side effects [247].  
 South Korea: licensed in 2007 and recommended for 15–17-year-old girls and 9–15-
year-old boys in 2010. It was not covered by national health insurance and was offered 
for $360 for the completion of three doses [246]. 
 Hong Kong: introduced in 2006, Gardasil was for 9–45-year-old females; Cervix was for 
10–45-year-old females. Recipients had to pay $300 for three doses in a private clinic 
[248].    
 Taiwan: introduced in 2011, Gardasil was for 9–26-year-old females; Cervix was for 10–
25-year-old females. Recipients had to pay $350 for three doses in a clinic or hospital 
[251].  
 Vietnam: Recipients had to pay $240 for three doses. Cervarix was for 10–25-year-old 
women, and Gardasil for 9–26 year-old-women [266].  
 
None of these countries have included males in HPV vaccination programmes, and Hong 
Kong, Taiwan, and Vietnam offered the vaccines for both teenagers and adults. Older adult 
women have also been recommended for vaccination in Hong Kong.  
 
China seems likely to develop a strategy which is tailored for its own unique circumstances. 
It is an incredibly diverse country, with distinct geographical regions and racial groups. 
There are significant financial constraints, and at present there is not a great willingness to 
roll out a national programme. However, given worldwide trends, it seems likely that such a 
programme will be introduced at some point in the future—either through a one-off initiative 
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or through incremental change. When this happens, attitudes, knowledge, and practices (such 
as those demonstrated in my thesis) will have an important influence on implementation. In 
particular, they highlight the need for appropriate educational and awareness-raising 
strategies to address knowledge deficits and attitudinal barriers. It is my hope that the 
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Appendix 1:  Summary of included studies in the systematic review 
  






Study setting Study instrument Age 
(years) 
Study population Main result 
Chen J et 
al 
Zhejiang 2010 123 Urban 
hospital-based 
Telephone 
interview with HPV 
positive women at 
home  
17-79 HPV positive 
women who took the 
HPV test from 
March to April in 
2010 at one hospital 
69.92% of the participants knew about HPV infection 
and the relationship with cervical cancer; these 
participants showed panic and anxiety on the results. 
Cui B  Liaoning 2010 1160: 660 











by the trained 
researchers 
15-59 Outpatients, 
inpatients and female 
relatives of the 
patients in seven 
urban hospitals; 
women residents in 
the selected villages 
17.6% urban residents and 17.2% rural residents had 
heard of HPV; 9.2% urban and 5.8% rural residents 
knew HPV caused cervical cancer; 8.0% urban and 
10.6% rural residents had heard of HPV vaccine; age, 
education was the factors that influenced the 
knowledge; 3.8% urban and 2.0% rural residents 
thought vaccine was targeted to the women who do 
not have sex before; 68.2% urban and 63.8% rural 
residents were willing to be vaccinated; safety and 
efficacy were the barriers of vaccination for urban 
residents. Rural residents worried about cost and 
thought they didn't’ have the risk for being infected.  






conducted by the 
trained researchers 
40-95 Women residents in 
three communities in 
Shijingshan district 
from April 7th to 18th 
in 2008 
16.3% of the participants knew about HPV infection, 
6.68% know the relationship between HPV and 
cervical cancer; 65.34% perceived high risk to be 
infected by HPV.  
Fan XF et 
al 
Xinjiang 2011 242 Not available Questionnaire filled 
in at  the same time  
at one place  by the 
participants 
28-60 Women with low 
medical insurance 
21.9% of the participants knew about HPV as the risk 
factor for cervical cancer; 25.4% of the participants 
know HPV can be sexually transmitted; there is 
significant difference on the knowledge between 
HPV positive and negative women.  
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Study setting Study 
instrument 
Age (years) Study population Main result 







19-72 Women outpatients 
selected from a hospital 
within one year 
23.6% of the participants had heard of HPV; 
56.83% of the participants knew HPV can cause 
cervical cancer; 88.05% of the participants were 
willing to be vaccinated; safety and source of the 
vaccine were the main concerns of the vaccine; 
worrying to be infected by HPV and suffered by 
genital warts were the reasons for being vaccinated; 
55.41% accept the vaccine offered by government; 
46.57% expect the government cover all cost.  



















50 in rural 
areas 
782 women from urban 
hospitals, 650 women 
from rural hospitals 
within six months 
39.1% urban and 27.1% rural residents had heard of 
HPV; 23.7% urban and 15.7% rural residents had 
heard of HPV vaccine; newspaper and television 
were the main source of obtaining the knowledge; 
previous screening history, age, education and 
economic condition were correlated with the 
knowledge; 65.4% urban and 57.1% rural residents 
thought married women should be vaccinated;  





30-59 Rural women from 
Linxiang district in 
Yunnan province 
2.91% of women knew HPV is the cause of cervical 
cancer.  
Guzhanuer 
A et al 







90%  Uighur men were 
from rural regions, 
10%  Uighur men were 
from urban regions in 
Hetian district 
0% of men knew HPV, and 0% knew HPV is the 
cause of cervical cancer. 0% knew HPV vaccine.  
Gulinuer A 
et al 
Xinjiang 2006 248 Urban hospital 
-based 
Questionnaire 




20-65 Women outpatients 
between March and 
June in 2006 at Bozhou 
hospital in Xinjiang 
2.42% of the participants knew about HPV 
infection; 7.26% of the participants knew the risk 
factors of cervical cancer; there was no ethnicity 
difference on the knowledge between Han and 










Study setting Study instrument Age 
(years) 
Study population Main result 
Guzhalinu
er A et al 




in at five hospitals by 
the gynaecologists 
23-76 Uyghur Cervical 
cancer patients in five 
hospitals in Xinjiang  
No participants knew about HPV infection; 1.3% of the 
patients knew the risk factors of cervical cancer.  
Huang GF 
et al 




in at the selected 
hospital  by the 
participants 
20-58 Women during a 
certain time period at 
the selected hospital 
32.14% of the participants were willing to be vaccinated; 
aged 30-50 participants were more likely to be vaccinated 
than aged 20-30 participants.  














in at 14 hospitals in 
seven regions of 
China  by the 
participants 
18-82 Women outpatients 
and health 
professionals at 14 
hospitals from 2007 
to 2009 
32.85% women had heard of HPV and 89.62% health 
professionals knew HPV caused cervical cancer; 72.31% 
women and 69.77% health professionals were willing to be 
vaccinated; that the vaccine hasn’t been promoted in large 
scale is the barrier for not being vaccinated; 56.21% 
women tend to receive the vaccine offered by the 
government.   
He X et al  Henan 2009 2102 College-
based 
Questionnaire filled 
in during class 
supervised by the 
trained researchers 
16-26 1093 female and 1009 
male students from 
two universities in 
2010 
43.0% students had heard of HPV; 69.2% students knew 
HPV can be sexually transmitted; female students had less 









in at one place 
supervised by trained 
researchers 
20-65 Women residents in 
one community of 
Hong Kou district of 
Shanghai city in 2010 
34.1% of the participants knew HPV can cause cervical 
cancer; there was significant difference on the knowledge 
between screening group and non-screening group.  




in at the selected 
hospitals  by the 
participants 
19-69 Outpatients and 
inpatients selected 
from 3 hospitals from 
Sep to Dec in 2007 
46.2 of the participants had heard of HPV; 52.9% of the 
participants knew HPV can cause cervical lesions;  






conducted by the 
trained researchers 
15-54 Women residents in 
Zhanlanlu community 
of Beijing city from 
June of 2006 to June 
of 2007 
30.7% of the participants had heard of HPV, 51.78% of 
them knew HPV was related to cervical cancer; 75.91% of 
the participants were willing to be vaccinated; that the 
vaccine hasn’t been promoted in large scale is the barrier 
for not being vaccinated; 55.77% participants tend to 










Study setting Study instrument Age 
(years) 
Study population Main result 




filled in at one 
place in the 
community by the 
participants 
18-60 Women residents in 
one community in 
Baoan district of 
Shenzhen city 
30.9% of the participants knew HPV causes cervical 
cancer; 54.9% of the participants knew HPV can be 
sexually transmitted; there was significant difference 
on knowledge of HPV between screening women and 
non-screening women. 




filled in at one 
place supervised 
by the trained 
researchers 
20-50 Women residents in 
Nanpu community 
of Wenzhou city  
7.5% of the participants had heard of HPV; 11.5% 
knew HPV can be sexually transmitted; 13% knew 
HPV causes genital warts; 21.5% knew that HPV can 
cause cervical cancer; the knowledge increased after 
health promotion intervention 





filled in at one 
place 
36.6±9.6 Doctors and 
government 
officials 
88.8% and 78.8% doctors had heard of HPV and knew 
HPV is the cause of cervical cancer, so did 43.8% and 
30% government officials; 51.3% doctors and 27.5% 
officials had heard of HPV vaccine; over half of them 
thought CDC should be the vaccination centre; 12.5% 
doctors and 5% officials thought women who never 
had sex before would be the target population for the 
vaccines; 81.3% doctors and 73.8% officials would 
like to be vaccinated; 78.8% doctors and 81.3% 
officials would like their daughter to be vaccinated; 
Li CT et al Xinjiang 2011 960 Not available Questionnaire 
filled by the 
participants 
themselves 
20-39 Women residents in 
Tianshan district in 
Urumqi city 
11.0% of women knew about HPV. 58.9% of women 
said they would wait to be vaccinated until others get 
the vaccine; 33.3% won’t take vaccine now; 89.3-
100% thought the efficacy and safety is most 
important; 47.9% thought the protection time is 
important; 89.0% can’t accept 3000 yuan for 
vaccination; 62.3% would accept imported vaccines; 















Study population Main result 
Liu ZH 
et al 







filled in during 
class 
14-18 High school male 
and female students 
in Xiangtan city 
10.1% had heard of HPV; 9.1% had heard of HPV vaccine; 
18.6% knew HPV causes cervical cancer; 16.3% knew HPV 
is sexually transmitted; 20.9% knew men can also infected 
with HPV; the knowledge were mostly from TV& 
radio(59.3%), internet(57.0%), rarely from parents(25.6%), 
health professionals(20.9%); those with good school 
performance had higher knowledge of HPV. 
Long 











>18 Medical testing 
major students from 
selected college 
74.2% junior students, 21.9% sophomore and 3% freshmen 
had heard of HPV; 81% of them knew HPV can be sexually 
transmitted; 10.9% had heard of HPV vaccine.  
Ma D et 
al 




filled in at the 
selected 
hospital 
20-54 49 doctors and 149 
nurses from selected 
hospital in 
Tangshan city 
91.8% doctors and 77.2% nurses had heard of HPV; 87.8% 
doctors and 67.1% nurses knew HPV is sexually transmitted; 
81.6% doctors and 50.3% nurses knew persistently infected 
with high-risk HPV is the cause of cervical cancer; 53.1% 
doctors and 38.9% nurses knew HPV 16/18 is related to 
cervical cancer; 18.4% doctors and 12.1% nurses knew HPV 
infection could be cleared spontaneously; 53.1% doctors and 
44.3% nurses had heard of HPV vaccine; 59.6-65.8% them 
worried about the safety and efficacy; over 70% them thought 
both men and women should be vaccinated; 36.7% doctors 
and 47.0% nurses thought HPV vaccine would increase high-
risk sexual behaviour; over 65% of them thought government 
should pay for the vaccine; 90% of them would like to pay 
less than 200 yuan; 23.4% doctors and 34.8% nurses would 
like to be vaccinated; over 55% of them suggested the target 
population should be people over 18 years; less than half of 














Study population Main result 
Ma D et 
al 



















from a selected 
community and 
women outpatients 
from a selected 
hospital 
33% of the community women knew HPV causes cervical 
cancer and so did 24.2% of women in the hospital; 29% of 
the community women knew that HPV can be sexually 
transmitted and so did 14.8% of women in the hospital.  
Ren CL 
et al 




18-58 Han, Uighur and 
Hui women were 
equally distributed 
20.6% Han, 5.2% Uighur and 11.5% Hui knew HPV is the 
cause of cervical cancer, and there is significant difference 
among different ethnicities; 13.8% Han, 2.4% Uighur and 
3.4% Hui knew condom could prevent HPV infection.  
Song D  Shanxi  2007 957 Village-
based 
Questionnaire 




15-54 Women from 26 
villages in 
Xiangyuan county 
in Shanxi province 
5.9% of the participants had heard of HPV; 34.61% of the 
participants knew HPV can cause cervical cancer; 96.5% 
of the participants were willing to be vaccinated;  source 
and safety of the vaccine were the main concerns; 60.7% 
of the participants accept the vaccine offered by large 
medical companies; 67.2% expect the government covered 
all the cost the vaccine;  








21-60 Women from one 
hospital in Dalian 
from Feb to Mar in 
2010 
23.9% of the participants knew HPV can cause cervical 
cancer; 20.3% of the participants knew HPV can be 
sexually transmitted;  














20-60 Women residents 
from three selected 
villages and women 
outpatients from a 
selected hospital 
13.3% of the participants knew HPV causes cervical 
cancer. 
Wang 
HQ et al 




filled in  at the 
four selected 
hospitals  
20-53 Obstetricians and 
Gynaecologists 
from four hospitals 
in Tangshan city 
92.2% had heard of HPV, knew that HPV can be sexually 
transmitted; 34.3% knew HPV infection can be cleared 
automatically; 83.7% of the participants knew HPV causes 
cervical cancer; 34.2% of the participants had heard of 











Study setting Study instrument Age 
(years) 
Study population Main result 
Wen LZ 
et al 
Xinjiang 2009 400 Urban 
hospital-based 
Questionnaire filled 
in  at the selected 
hospital by the 
participants 
22-48 Women 
outpatients at one 
hospital selected 
from Jan to June 
in 2009 
45% of the participants had heard of HPV; 30% of the 
participants knew HPV was related to cervical cancer; 7.5% 
of the participants had heard of HPV vaccine; The knowledge 
increased after health promotion intervention.  
Wang QL 
et al 
Sichuan 2010 886 Village-based Interview-
administrated 
questionnaire 





from 3 counties in 
north Sichuan 
mountain areas 
0.2% of the participants knew the relationship between HPV 
and cervical cancer.  
Wu Y  Zhejiang 2010 489 Not available Questionnaire filled 
in at one place by 
the participants 
>15 Women residents 
in Hangzhou city 
28.83% of the participants had heard of HPV; 47.85% of the 
participants were willing to be vaccinated; 82% of the 
participants accepted the vaccine offered by the government; 
concerned about the source of the vaccine and side effect 
were the barriers.  
Wang 
XM et al 








25-73 341 urban women 
residents and 1928 
rural women 
residents 
50.7% urban residents and 34.6% rural residents would like to 
pay for some amount of the price of the vaccine; around 60% 
of them would like to pay less than 100 yuan; 
Xiamixin






in at the selected 
hospitals by the 
gynaecologists  
23-85 Uighur cervical 
cancer patients 
selected from five 
hospitals from Jan 
of 2004 to Jul of 
2006 
No participants had heard of HPV or HPV vaccines, knew 
HPV causes cervical cancer, and knew HPV can be sexually 
transmitted.  
Xiao W et 
al 
Beijing 2008 368 Urban 
hospital-based 
Questionnaire filled 
in  at the selected 




selected from one 
hospital from Jan 
to Apr in 2008 
45.81% of the participants had heard of HPV; 72.75% of the 
participants were willing to be vaccinated; the barrier are that 
they didn’t perceive the risk to be HPV infected and worried 
the vaccine hasn’t been promoted in large scale; 70.97% of 
the participants tend to accept the vaccine offered by the 
government; 61.51% would take the vaccine from the 














Study population Main result 
Xing 
YX et al 
Qinghai 2009 200 Not available Questionnaire 
filled in by local 
doctors 
18-63 136 Tibetan women 
residents and 64 Han 
women population 
1.56% Han and 2.2% Tibetan had heard of HPV; the 











filled in at one 
place supervised 
by researchers 
25-54 Women residents 
from four districts of 
city, four districts of 
inner suburbs and 
four districts of outer 
suburbs 
26.9% of the participants knew that HPV is the risk 















filled in at one 
place supervised 
by the trained 
researchers 
15-59 640 urban women 
residents from 
selected hospitals and 
1026 rural women 
from selected villages 
from Jun to Nov in 
2009 
19.87% of the participants had heard of HPV; 62.84% 
of the participants knew HPV causes cervical cancer; 
urban residents had better knowledge than rural 
residents; 15.43% of the participants had heard of HPV 
vaccine; 76.71% of the participants were willing to be 
vaccinated 
Xie Y et 
al  






30-59 Women residents 
from 3 counties in 
August in 2010 
0.8% of the participants had heard of HPV. 
Ye JR et 
al 
Guangdong 2010 1120 Village-based Questionnaire 
filled in at one 
place 
23-51 560 married women 
from two villages 
3.7% knew HPV; 3.2% knew HPV is related to 
cervical cancer;2.6% knew HPV vaccine;  
Zhang 










18-54 Women patients 
selected from one 
hospital from Dec of 
2006 to Sep of 2007 
28% of the participants knew the mode of transmission 
of HPV; 11% of the participants knew the relationship 
between HPV and cervical cancer; the knowledge 












Study setting  Study instrument Age 
(years) 
Study population Main result 
Zhao DJ 
et al 




filled in at one 
place supervised 
by the trained 
researchers 
16-54 Women residents 
in two selected 
communities in 
Shanghai 
20.6% of the participants had heard of HPV; age, education, 
profession were the factors that influenced the awareness; 
66.1% of the participants were willing to be vaccinated; 
53.64% of the participants would like their daughter to be 
vaccinated; the barriers were that participants didn’t perceive 
the risk of being infected, the vaccine hasn’t been promoted in 
large scale, concerned about the source of the vaccine. 65% 
receive the vaccine offered by the government.  
Zhou JY 
et al 










filled in at one 
place supervised 
by the trained 
researchers 
30-59 Women residents 
in the both urban 
and rural 
communities from 
Apr to Dec in 
2008 
15.8% of the participants knew that HPV infection causes 
cervical cancer. 
Zhou 
LX et al  





















There was difference between women selected from 
community and hospital on the awareness of HPV, HPV 
vaccine; they were 36.12%, 12.13% of community women 
and 46.46%, 22.57% of hospital women. Knowledge of HPV 
causes cervical cancer was significantly different, 14.28% of 
community women and 27.82% of hospital women.  
Zhou Y 
et al  







filled in during 
class 
17-21 Fresh students 
from the selected 
college 
17.87% of the participants had heard of HPV; 62.16% of the 
participants knew HPV infection can be asymptomatic; 
29.73% knew HPV can be sexually transmitted; 86.49% knew 
HPV may lead to cervical cancer.  
Zhou Y 
et al 
Hunan 2009 2293: 1428 






filled in the 
dormitory  
17-25 Students from 
selected college 
20.5% males and 17.0% females had heard of HPV, there is 
significant difference between males and females; senior 
students knew more about HPV than other grades; TV, radio 
and magazines are the main source (74.1%) of HPV 
information, internet is another important source (17.2%); 
students rarely get HPV information from friends (4.1%) and 
















Study population Main result 
Zhou Y et 
al 






17-59 Women residents 
in the selected 
county in Shanxi 
province 
11.8% of the participants had heard of HPV; age, 
education, profession were the factors that influenced the 
awareness; 69.5% knew HPV may cause cervical cancer, 
40.7% knew HPV may cause genital warts; 25% had 
heard of HPV vaccine; 82% would like to be vaccinated; 






Appendix 2:  summary of excluded studies in the systematic review 
 
Study Title Exclusion reasons 
Ao MH Research and Evaluation of Opportunistic Cervical Cancer Screening Knowledge, attitudes and acceptance are not discussed 
Bao LH et al  The risk factors and prevention of cervical cancer  It’s a general review 
Cui LQ The clinical analysis of 53 cervical cancer women Knowledge, attitudes and acceptance are not discussed 
Cheng HE HPV -16 E6 gene expression study on cervical cancer CaSki cell Knowledge, attitudes and acceptance are not discussed 
Cao YH A study of etiology and determinants of cervicitis Knowledge, attitudes and acceptance are not discussed 
Cao SD  The study on the mechanism of thrombin-induced nausea conversion of human bronchial 
epithelial cells 
Knowledge, attitudes and acceptance are not discussed 
Cao JP et al  health education of patients with condyloma It’s a general review 
Chen BC et al Antiviral drug and its intellectual property rights in China It’s a general review 
Chen S et al Treatment and nursing of condyloma acuminata with pregnancy Knowledge, attitudes and acceptance are not discussed 
Cui F et al The relationship between HPV subtypes and cervical lesions among women in Hongkou 
district in Shanghai 
Knowledge, attitudes and acceptance are not discussed 
Cheng SX  The relationship between high risk HPV infection in cervical cancer and p16, PTEN protein 
expression 
Knowledge, attitudes and acceptance are not discussed 
Cheng YX et 
al 
Therapeutic Effect of Herbal Compound Including Arsenic and Its Effect on Human 
Papilloma Virus Load in Patients with Chronic cervicitis 
Knowledge, attitudes and acceptance are not discussed 
Chen HB et al  HPV infection and relationship with Cervical epithelial hyperplasia Knowledge, attitudes and acceptance are not discussed 
Chen GD et al The application value of high risk HPV DNA detection in the high-grade cervical squamous 
intraepithelial lesions screening and follow-up treatment 
Knowledge, attitudes and acceptance are not discussed 
Chen JX et al A study on the diagnosis significance of direct immunofluorescence on Condyloma 
Acuminatum 
Knowledge, attitudes and acceptance are not discussed 
Chen RL  The expression of PIK3CA gene in cervical lesions and the relationship with HPV infection  Knowledge, attitudes and acceptance are not discussed 
Chen SZ et al  Screening of cervical cancer associated genes and bioinformatic analysis Knowledge, attitudes and acceptance are not discussed 
Chen YN  The relationship between PCNA, COX-2 and Cervical squamous cell carcinoma 
Microvessel density 
Knowledge, attitudes and acceptance are not discussed 
Chen Q Preparation on RBC blood group monoclonal antibodies and genetically engineered 
antibody 
Knowledge, attitudes and acceptance are not discussed 
Dai ZL et al  Study on the correlation between HPV and cervical cancer early lesions Knowledge, attitudes and acceptance are not discussed 
Du LB Glucocorticoid induces chemoresistance by modulating the regulatory pathway involved E6, 
P53 and miR-145 in cervical cancer 
Knowledge, attitudes and acceptance are not discussed 




Study Title Exclusion reasons 
Ding GC Detection of Human Papillomavirus in Single Esophageal and Gastric Cardia Cancer and 
Concurrent Esophageal and Gastric Cardia Cancers from the Same Patient and Studies on 
Alternations of p53, p16, p21~(WAF1), MDM2 at High-incidence Area in Henan 
Knowledge, attitudes and acceptance are not discussed 
Fan JN et al Study on high risk HPV DNA detection and cytology test among rural women in Haiyang Knowledge, attitudes and acceptance are not discussed 
Fei HL An Evaluation of Five Screening Methods for the Early Detection of Cervical Neoplasia and 
Cervical Cancer 
Knowledge, attitudes and acceptance are not discussed 
Fang J et al  The implication of cervical abnormal cytology in pregnancies outcomes Knowledge, attitudes and acceptance are not discussed 
Feng YL  Analysis of Cervical Cancer Screening among Women in XingHuaLing District, TaiYuan, 
ShanXi Province 
Can’t extract information on knowledge, attitude and 
acceptance 
Feng SW et al The application of partnership-based health education in the first visit of Cervical 
intraepithelial neoplasia patients 
Knowledge, attitudes and acceptance are not discussed 
Guan WW et 
al 
Analysis the psychological state and nursing strategy of newly diagnosed HPV positive 
outpatients 
Knowledge, attitudes and acceptance are not discussed 
Gao K et al  The application of VIA in screening of cervical disease among women workers Knowledge, attitudes and acceptance are not discussed 
Gu Xiaofen A survey on cervical cancer screening and KAP situation Can’t extract information on knowledge, attitude and 
acceptance 
Guo XQ et al The discovery of HIV and its great significance It’s a general review 
Guo Y The Association between Epithelial Proliferation and Intraepithelial Infiltrating 
Inflammatory Cells and the Detection of HPV Infection in Esophageal Carcinoma High-risk 
Population 
Knowledge, attitudes and acceptance are not discussed 
Gao D Epidemiological Features of Warts in Patients from Shenyang, and Clinical Observation on 
the Effect of Local Thermotherapy 
Knowledge, attitudes and acceptance are not discussed 
Gao SJ et al  Retrospective analysis of High-grade squamous intraepithelial lesions and Microinvasive 
Loop electrosurgical excision procedure  
Knowledge, attitudes and acceptance are not discussed 
Gao N Mechanism of Boningmycin on anti-tumor and anti-human papillomavirus Knowledge, attitudes and acceptance are not discussed 
Huang JY The association between XRCC1, MGMT SNP and cervical cancer susceptibility Knowledge, attitudes and acceptance are not discussed 
Huang HS Woman s and Doctor s Knowledge, Attitudes and Beliefs about HPV Vaccination in Macau Not in mainland China 
Hao XG The Epidemiological Investigation of Condyloma in Chang Zhi Area Knowledge, attitudes and acceptance are not discussed 
Hu YJ  HPV type detection by Pyrosequencing and HPV 16 Methylation status and cervical cancer-
causing effect 
Knowledge, attitudes and acceptance are not discussed 
He L The Application of Rapid Pathologic Examination in the Diagnosis and Treatment of 
Cervical Lesions 




Study Title Exclusion reasons 
Hu SY Research on etiology and prevention and control of cervical cancer Knowledge, attitudes and acceptance are not discussed 
Jin YC  The expression of HPV, NFKB in Ovarian cancer tissues and relationship study Knowledge, attitudes and acceptance are not discussed 
Jin W Clinical observation of Treatment of recurrent genital warts by autologous warts embedded 
combined topical imiquimod method 
Knowledge, attitudes and acceptance are not discussed 
JanM A et al Price is not the only obstacle Not a research report 
Jiang R  The clinical test study on Nakejia treating in high-risk HPV infection Knowledge, attitudes and acceptance are not discussed 
Jiang XM A Study on the Relationship between hr HPV, L1 Protein, p16 Protein and Cervical Lesions 
and Their Diagnostic Value in Clinic 
Knowledge, attitudes and acceptance are not discussed 
Kong Y  The expression of hTERC gene and HPV types and the clinical application Knowledge, attitudes and acceptance are not discussed 
Kong L Functional research on RbSp48 of HPV caused cervical cancer Knowledge, attitudes and acceptance are not discussed 
Liang YM The review of  human finger length ratio It’s a general review 
Liang XN et 
al 
The clinical value of high risk HPV Auxiliary liquid-based thin-film cytology in cervical 
screening 
Knowledge, attitudes and acceptance are not discussed 
Liu J Studies on regulating roles of Hes1/Hes5 and their signal pathway in cerivical carcinoma 
cell differentiation 
Knowledge, attitudes and acceptance are not discussed 
Li YY Geographic analysis on HPV 58 type Knowledge, attitudes and acceptance are not discussed 
Liu YZ Study on white lesions of vulva lesions cyclin D1, CDK4, p21 and Cell proliferation index 
and the clinical observation of Chinese traditional medicine  
Knowledge, attitudes and acceptance are not discussed 
Liu ZH et al  Study on the health promotion and information need of HPV infection It’s a general review 
Liu KJ Epidemiology and molecular biology study of risk factors on Uigur and Han cervical cancer 
in Xinjiang 
Knowledge, attitudes and acceptance are not discussed 
Liu XT The information analysis in the tumor vaccine area Knowledge, attitudes and acceptance are not discussed 
Liu X  The expression of human harf-wing gene and HPV in cervical cancer and  cervical 
intraepithelial neoplasia 
Knowledge, attitudes and acceptance are not discussed 
Liu R HBC and HPV16L1 carrier influenza generic vaccine research Knowledge, attitudes and acceptance are not discussed 
Liu AL Stady on the Clinical Application of TERC Amplification of the Exfoliated Cervical 
Epithelial Cells Detected by FISH 
Knowledge, attitudes and acceptance are not discussed 
Li XL  Relationship among HPV Infection, FHIT Deletion and Lung Cancer in Nonsmoking 
Female 
Knowledge, attitudes and acceptance are not discussed 
Lin CL et al  High risk HPV detection in Cervical intraepithelial neoplasia and cervical cancer screening Knowledge, attitudes and acceptance are not discussed 




Study Title Exclusion reasons 
Lin WY  The Application of Modified Reid s Colposcopic Index on Screening of Cervical Neoplasia Knowledge, attitudes and acceptance are not discussed 
Liang JN et 
al 
The clinical value of high risk HPV aided Liquid-based thin-film cytology in the cervical 
screening 
Knowledge, attitudes and acceptance are not discussed 
Lu XF  The expression and implication of hWAPL gene in cervical intraepithelial neoplasia and 
Cervical squamous cell carcinoma 
Knowledge, attitudes and acceptance are not discussed 
Lv LL et al  The relationship between infection and cervical cancer Knowledge, attitudes and acceptance are not discussed 
Lv FB et al The diagnosis value of TCT correlated with Electronic colposcopy in the cervical lesions Knowledge, attitudes and acceptance are not discussed 
Lu MG et al HIV interpretation It’s not  a research report 
Li SH et al The analysis of female sexual transmitted disease test results Knowledge, attitudes and acceptance are not discussed 
Luo WM et 
al 
Clinical research of TCT, colposcopy for early stage cervical cancer screening  in  the 
primary hospital 
Knowledge, attitudes and acceptance are not discussed 
Li L et al The application of HPV self-sampling in the cervical cancer screening Knowledge, attitudes and acceptance are not discussed 
Li RZ et al  Early detection and treatment on cervical screening Knowledge, attitudes and acceptance are not discussed 
Li XD et al  The effect of Local hyperthermia on HPV infection in Epidermis Langerhans cell function 
activity 
Knowledge, attitudes and acceptance are not discussed 
Li YB  Study on Commercial sex workers’  sexually transmitted infections and related risk factors Knowledge, attitudes and acceptance are not discussed 
Li L  The clinical analysis of Cervical cytology of atypical glandular cells and the correlation with 
HPV detection 
Knowledge, attitudes and acceptance are not discussed 
Li L et al The diagnostic value of atypical glandular cells with other conditions for adenocarcinoma in 
situ 
Knowledge, attitudes and acceptance are not discussed 
Li XJ et al A clinical research on high-risk HPV-DNA testing in screening of cervical disease Knowledge, attitudes and acceptance are not discussed 
Li Y  The correlation research on HPV infection and cervical lesions Knowledge, attitudes and acceptance are not discussed 
Li L et al Research progress on the HPV vaccine awareness and acceptance in the world It’s a general review 
Li Q et al Study on the way of cervical cancer screening in urban community of China Knowledge, attitudes and acceptance are not discussed 
Li RK Effect of Sevoflurane with Propofol on Stress Response during One Lung-ventilation Knowledge, attitudes and acceptance are not discussed 
Lu Q et al A Study on Human Paplillowmarivus Infection Rate of Suscepitble Person in Shenzhen Knowledge, attitudes and acceptance are not discussed 
Lu MG  HIV interpretation for the College Entrance Examination Not a research report 
Liu HM et 
al  
2341 pregnancy women cervical screening and postpartum follow up Knowledge, attitudes and acceptance are not discussed 
Liu H et al High risk HPV infection of retired women in Gaoqiao community Knowledge, attitudes and acceptance are not discussed 
Liu YJ  The expression pattern of P16INK4a, Ki67 in Cervical intraepithelial lesions and the 
correlation with HPV infection 
Knowledge, attitudes and acceptance are not discussed 




Study Title Exclusion reasons 
Liu Q  The study on anti-inflammatory effects of vaginal contraceptive suppository Knowledge, attitudes and acceptance are not discussed 
Liu CY et al Study on cervical cancer screening by high risk HPV second-generation Hybrid Capture test Knowledge, attitudes and acceptance are not discussed 
Min QH et al Evaluation of Liquid-based Thin-layer Cytological Test and HPV21 Subtype Gene 
Detection for Cervical Cancer Screening Using ROC Curve Analysis 
Knowledge, attitudes and acceptance are not discussed 
Nan Y  The TSPAN-1 protein expression and relationship with Ki-67 and CD105 in Cervical 
squamous cell carcinoma 
Knowledge, attitudes and acceptance are not discussed 
Pruitt SL et al Knowledge of cervical dysplasia and human papillomavirus among women seen in a 
colposcopy clinic 
Can’t extract information on knowledge, attitudes and 
acceptance 
Pu HO et al The diagnostic value of Colposcopy of cytology and tumor inherent fluorescence diagnostic 
apparatus on cervical lesions 
Knowledge, attitudes and acceptance are not discussed 
Qiao WJ et al Relevant factors analysis of HPV infection among women Knowledge, attitudes and acceptance are not discussed 
Qiu ZL et al Analysis of children genital warts infection Knowledge, attitudes and acceptance are not discussed 
Ren CL Difference and cluster analysis of uterine cervix cancer gene expression profiling of Uygur Knowledge, attitudes and acceptance are not discussed 
Sun P Relationship between Nasal inverted papilloma and human papillomavirus subtypes Knowledge, attitudes and acceptance are not discussed 
Shi XM The clinical significance of the serum C-reactive protein in patienst with Lung cancer Knowledge, attitudes and acceptance are not discussed 
Shi YY  The relationship between high-risk HPV infection and cervical lesions  
Shi JF  The epidemiological research on HPV infection and cervical cancer on Shenzhen women Knowledge, attitudes and acceptance are not discussed 
Su S  The expression and implication of Sfrp-1, Wnt-1 gene in cervical cancer and Precancerous 
lesions 
Knowledge, attitudes and acceptance are not discussed 
Su YY  The expression of RASSF1A gene and HPV 16 infection in cervical lesions Knowledge, attitudes and acceptance are not discussed 
Sun XP  Local hyperthermia efficacy in common warts of hand and foot Knowledge, attitudes and acceptance are not discussed 
Sun ZH Psychological Research on Women Infected Genital Human Papillomavirus Knowledge, attitudes and acceptance are not discussed 
Sun HL  Clinical Significance of HPV Test in Examination of Cervical Diseases Knowledge, attitudes and acceptance are not discussed 
Shen H Epidemiological Studies of AIDS among STD Clinic Attendants and Sex Workers in Jiading 
District 
Knowledge, attitudes and acceptance are not discussed 
Shi J et al Looking for the ultimate invisible culprit It’s not a research report 
Shu YH et al Acetate experiments for the screening of cervical lesions Knowledge, attitudes and acceptance are not discussed 
Song XR et al HPV and cervical cancer It’s a general review 
Song JM et al  HPV 16 L1 Gene Immunization Evaluation and Comparative Study of different 
immunization schemes and ways  
Knowledge, attitudes and acceptance are not discussed 




Study Title Exclusion reasons 
Song YR et al Etiological factors in younger patients with cervical carcinoma Knowledge, attitudes and acceptance are not discussed 
Sui S et al The application and significance of opportunistic screening for cervical cancer Knowledge, attitudes and acceptance are not discussed 
Shen YH et al Study on HPV infection of cervical cancer high incidence rate region in Shanxi Knowledge, attitudes and acceptance are not discussed 
Shen H et al A Study on HIV,HSV-2,HPV,Syphilis and Risk Factors Among STD Clinic 
Attendants in Jiading District,Shanghai 
Knowledge, attitudes and acceptance are not discussed 
Tang YF et al The evaluation of cervical LEEP biopsy correlated with HPV 16,18 and TCT testing 
for CIN1 
Knowledge, attitudes and acceptance are not discussed 
Tong XJ et al The correlation study on high risk HPV infection and cervical lesions Knowledge, attitudes and acceptance are not discussed 
Wang W et al Impact of HPV infection on adolescent and young adult women It’s a general review 
Wang J et al HPV types distribution and study on gene chip technology in cervical screening  
Wang SM et al Controlled Research on Mental Intervention Effects for the HPV Positive Patients Knowledge, attitudes and acceptance are not discussed 
Wang DL et al  Analysis of cervical cancer screening among 4866 rural women Knowledge, attitudes and acceptance are not discussed 
Wang SM et al Control study on HPV-positive patients with psychological intervention Knowledge, attitudes and acceptance are not discussed 
Wang QX et al Clinical Consideration in Analysis and Management on Atypical Glandular Cells of 
Cervical Cytology 
Knowledge, attitudes and acceptance are not discussed 
Wang CH et al  The implementation of cervical cancer health  education on childbearing age women Knowledge, attitudes and acceptance are not discussed 
Wang DH et al How can people stay away from cervical cancer It’s not a research report 
Wang JD et al  Analysis on cervical cytology ASC-US patients and influencing factors Knowledge, attitudes and acceptance are not discussed 
Wang Y Study on the Vaginal Microflora and the Associated Disease by PCR-DGGE Knowledge, attitudes and acceptance are not discussed 
Wang Q Value of Visual Inspection with Acetic Acid and Logu s Iodine on Primary Screening 
for Cervical Cancer and Its Precancerous Lesions 
Knowledge, attitudes and acceptance are not discussed 
Wang Q  The correlation research on HPV infection and CIN Knowledge, attitudes and acceptance are not discussed 
Wang BZ New discovering on the secretory form and transporting route of phlypeptide 
hormones of pancreatic islets and its relationship to type2 diabet4ew mellitus 
Knowledge, attitudes and acceptance are not discussed 
Wang XQ Effects o flocal hyperthermia on promoting apoptosis and proinflammatory cytokines 
of HPV infected keratinocytes 
Knowledge, attitudes and acceptance are not discussed 
Wang XW Roles of HPV infection in P53, PCNA in Laryngeal carcinoma Knowledge, attitudes and acceptance are not discussed 
Wang L Studies on B-sitosterol inhibit Cervical cancer SiHa cell lines and mechanism Knowledge, attitudes and acceptance are not discussed 
Wu RF et al HPV infection and CIN prevalence among different professional women in Shenzhen Knowledge, attitudes and acceptance are not discussed 
Wu RF et al The prevalence of HPV infection and Cervical intraepithelial neoplasia and the 
evaluation of cervical cancer screening 
Knowledge, attitudes and acceptance are not discussed 




Study Title Exclusion reasons 
Wu YP et al Roles of liquid-based cytology and/or HPV DNA test in cervical cancer screening Knowledge, attitudes and acceptance are not discussed 
Wu YZ et al  Review of the therapeutic vaccine It’s a general review 
Wu JP et al The analysis of 8463 cases of cervical cancer Knowledge, attitudes and acceptance are not discussed 
Wu GZ Mutation Site Analysis of Telomerase Inhibitor PinX1 Gene in Cervical Carcinomaand 
the Effects of HPV16E6 on PinX1 
Knowledge, attitudes and acceptance are not discussed 
Wu YZ et al Review of the therapeutic vaccine It’s a general review 
Wu C et al  The clinical analysis of Resection margin status by Cervical loop electrosurgical excision 
procedure 
Knowledge, attitudes and acceptance are not discussed 
Wu XJ  The gene expression and the implication of KCC1 upgraded by IGF-2 through Erk1/2 
MAPK and PI3K/AKT gene in cervical cancer cell 
Knowledge, attitudes and acceptance are not discussed 
Wu XY  Women hrHPV infection and relationship between virus and cervical lesions Knowledge, attitudes and acceptance are not discussed 
Wu LJ Expression of Fhit Protein and Its Correlation with Human Papillomavirus Infection in 
Cervical Lesions 
Knowledge, attitudes and acceptance are not discussed 
Xu ZL The expression and clinical significance of the CD105 in cervical cancer serum and tissue Knowledge, attitudes and acceptance are not discussed 
Xiao W  HPV infection and cervical cancer development study Knowledge, attitudes and acceptance are not discussed 
Xiao B  Six errors sexual attitudes It’s not a research report 
Xin WJ et al Optical system design of Human blood and tissue cell analyzer Knowledge, attitudes and acceptance are not discussed 
Xue JY  Preliminary optimization of the HPV virus particle vaccine preparation process Knowledge, attitudes and acceptance are not discussed 
Ye J et al HPV epidemiological investigation and the role of cervical cancer risk factors in the HPV 
screening 
Knowledge, attitudes and acceptance are not discussed 
Yu JM et al Analysis of female cervical lesions TCT and TBS detection in Meicheng area.  Knowledge, attitudes and acceptance are not discussed 
You XR et al Clinical analysis of 968 cases of cervical diseases Knowledge, attitudes and acceptance are not discussed 
Yu LM et al Study on cervical cancer risk factors Knowledge, attitudes and acceptance are not discussed 
Yu LM et al The analysis of cervical cancer etiology and the trend of young age Knowledge, attitudes and acceptance are not discussed 
Yu HR et al The establishment of the virus carcinogenic doctrine Knowledge, attitudes and acceptance are not discussed 
Yao YQ The Expression and Significance of VEGF, VEGFR-1 and VEGFR-2 in Condyloma 
Acuminatum 
Knowledge, attitudes and acceptance are not discussed 
Yan Y  The study on vitamin A acid cream associated with human interferon ointment in the 
treatment of flat warts 
Knowledge, attitudes and acceptance are not discussed 
Yang J The relationship between KDR, TSP-1 and Cervical squamous cell carcinoma 
Angiogenesis  
Knowledge, attitudes and acceptance are not discussed 




Study Title Exclusion reasons 
Yang X The expression of RUNX3 cervical cancer and its proliferation effect on Hela Knowledge, attitudes and acceptance are not discussed 
Yang HY Experimental studies of pelvic endometriosis by Chinese medicine treatment Knowledge, attitudes and acceptance are not discussed 
Zhao P DNA vaccine preparation of HLA specific HCMV Tandem epitopes of adenovirus and 
evaluation of immune effects 
Knowledge, attitudes and acceptance are not discussed 
Zhao FH et al Research on a variety of cervical cancer screening programs  Knowledge, attitudes and acceptance are not discussed 
Zhao XL  Study on association  between DNMTI and DAPK and in vitro inhibition 
of DNMT1 expression 
Knowledge, attitudes and acceptance are not discussed 
Zhao FH Cervical cancer screening methods and strategies Knowledge, attitudes and acceptance are not discussed 
Zhang JF et al Research on HPV 16 Gastrointestinal gene vaccine Knowledge, attitudes and acceptance are not discussed 
Zhang W The review of interferon in the treatment of cervical cancer and precancerous lesions It’s a general review 
Zhang X The prevalence of HPV infection and CIN in Shenyang city  Knowledge, attitudes and acceptance are not discussed 
Zhang YB et al  High school biology knowledge links Not a research report 
Zhang JH et al The detection of cervical cancer in high risk women  Knowledge, attitudes and acceptance are not discussed 
Zhang JM et al  Diagnosis and differential diagnosis of Precancerous lesions of the uterine squamous 
cell carcinoma 
Knowledge, attitudes and acceptance are not discussed 
Zhang RZ et al Research progress on the health education of cervical cancer patients It’s a general review 
Zhang WJ et al Clinical features and prognostic analysis of young women with cervical cancer Knowledge, attitudes and acceptance are not discussed 
Zhang X et al HPV infection and Chinese medicine treatment on women in Shenyang city Knowledge, attitudes and acceptance are not discussed 
Zhang JL Investigation research of the Uygur women cervical lesions and the HPV 16 infection in 
Xinjiang Ka Shi sharp Tao le townshiop 
Knowledge, attitudes and acceptance are not discussed 
Zhou YB et al Research on HPV 16 L1 gene and Recombinant adenovirus vaccine Knowledge, attitudes and acceptance are not discussed 
Zhou N Survey of Prevalence and Behavioral Risk Factors for AIDS/STD Among Female Sex 
Workers in Tianjin 
Knowledge, attitudes and acceptance are not discussed 
Zhang RZ et al Health education progress of cervical cancer patients It’s a general review 
Zhao DJ et al  The prevalence study on the HPV infection and the risk factors of the community female 
population in Shanghai 
Knowledge, attitudes and acceptance are not discussed 
Zheng GQ et al The study on Artificial vaginoplasty by Sigmoid Knowledge, attitudes and acceptance are not discussed 
Zhou QZ et al The correlation between genital tract HPV infection and cervical lesions among 
Shenzhen women. 
Knowledge, attitudes and acceptance are not discussed 
Zhu YS et al An analysis of risk factors of cervical carcinoma and cervical intraepithelial neoplasia Knowledge, attitudes and acceptance are not discussed 
Zhan HY et al The value for Cervical conization lesions residues after endocervical curettage surgery 
and HPV testing 





Study Title Exclusion reasons 
Zhou KZ et al The relationship between HPV infection and cervical lesions among women in Shenzhen Knowledge, attitudes and acceptance are not discussed 
Zhou WY et al The nursing of cervical intraepithelial neoplasia with LEEP conization Knowledge, attitudes and acceptance are not discussed 
Zhao SP et al Prevalence of cervical intraepithelial neoplasia and its risk factors among rural minority 
married women 
Knowledge, attitudes and acceptance are not discussed 
Zhang XL et al Effect of psychological intervention on the life quality of patients with cervical human 
papillomavirus infection after treatment 
Knowledge, attitudes and acceptance are not discussed 
Zhang XL et al The influence of psychological intervention on the quality of marital in the CIN Ⅰ patients 
with human papilloma virus 
Knowledge, attitudes and acceptance are not discussed 
Zhang GY et al   Rat orthotopic small bowel transplantation model established by Three casing vascular 
anastomosis 
Knowledge, attitudes and acceptance are not discussed 
Zhang GY et al The clinical analysis of Vulvar intraepithelial neoplasia  Knowledge, attitudes and acceptance are not discussed 
Zhang YM Comparison of detection methods and clinical implications of pregnancy-related Cervical 
intraepithelial neoplasia 
Knowledge, attitudes and acceptance are not discussed 
Zhang WJ et al Clinical features and prognostic analysis of young women with cervical cancer Knowledge, attitudes and acceptance are not discussed 
Zheng GH et al thepathogen distribution of 16-20 year-old female reproductive tract infection Knowledge, attitudes and acceptance are not discussed 
Zhao DQ HPV-related test illustration Not a research report 
Zhu YS et al The analysis of cervical cancer and precancerous lesions related risk factors Knowledge, attitudes and acceptance are not discussed 
Zhou L et al Analysis on prevalence status and high risk factors of female cervical diseases in Changchun Knowledge, attitudes and acceptance are not discussed 
Zhou XR et al  Quality analysis of cervical cytology diagnosis Knowledge, attitudes and acceptance are not discussed 
Zhou JY et al Analysis of influencing factors on compliance with colposcopy in cervical cancer screening 
project in Daxing District, Beijing City 
Knowledge, attitudes and acceptance are not discussed 
Zhang JM et al Precancerous lesions and differential diagnosis of cervical squamous cell carcinoma Knowledge, attitudes and acceptance are not discussed 
 Sexually transmitted diseases are not necessarily sexually transmitted It’s not a research report 
Zhang YL et al The clinical analysis of prevalence of HPV infection in cervical cancer patients Knowledge, attitudes and acceptance are not discussed 
Zhang SH et al  CYP1A1 gene polymorphism and the relationship between HPV infection and Cervical 
squamous cell carcinoma 
Knowledge, attitudes and acceptance are not discussed 
Zhang WY et al  The relationship between high risk HPV and the severity of cervical cancer Knowledge, attitudes and acceptance are not discussed 
Zhang N  The study on Proliferation and apoptosis factors in Pseudo-condyloma and genital warts Knowledge, attitudes and acceptance are not discussed 
Zhang J  The study on HPV infection in cervical tissue and local immune state Knowledge, attitudes and acceptance are not discussed 
Zhang HP  The expression and implication of Livin and Smac in the genital warts tissue Knowledge, attitudes and acceptance are not discussed 
Zhang LJ et al  The clinical implication of high risk HPV detection in high degree of cervical intraepithelial 
neoplasia 
Knowledge, attitudes and acceptance are not discussed 
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The quality assessment of Chen J study (13 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (17-79), gender (women), and sample size (123 participants) of 
the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected during two months in 2010 in one selected hospital and the HPV 
positive outpatients were selected to do the telephone interview. But the study didn’t mention who 
conducted the telephone interview.  
3. Were there specific inclusion/exclusion criteria for all groups? No. The inclusion criteria were HPV positive outpatients. There were no exclusion criteria.  
4. Was the study population served as a probability sample? 
No. The study didn’t mention the sampling method they used. The sample was collected in one 
hospital from March to April in 2010, it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The participation rate was 100%. The study didn’t report any inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection, the way through which health information delivered were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive and bivariate statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. χ2 test was used in the data analysis.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct any multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess confounding like demographic, socio-economic, or other factors.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 100% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to correct 
controllable variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No. The researcher didn’t mention other potential bias or unmeasured confounders such as ethnicity, 
occupation and so on.  
286 
 
The quality assessment of Cui B study (20 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (15-59), gender (women), and sample size (1160 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in seven selected hospital and the selected villages. The study 
use cluster sampling method to approach participants. 
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. The inclusion is women aged between 15-59 years old who are able to behave normally.  
4. Was the study population served as a probability sample? 
Yes. The study used cluster sampling method. The sample was collected from seven hospitals 
and selected villages, it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate and inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Knowledge of HPV infection, HPV vaccine, knowledge difference by education, and the 
targeted population were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive and bivariate statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. Descriptive analysis, χ2 test and spearman correlation were used in the data analysis.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct any multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed confounding like educational level, urban/rural residence. 
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 96.7% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study conducted stratification by educational level and urban/rural residence to 
correct controllable variables.  
17. Did the researchers describe all potential bias or 
unmeasured confounders 
Yes. The researcher mentioned ethnicity, occupation as potential bias.  
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The quality assessment of Fu FH study (14 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (40-95), gender (women), and sample size (2952participants) of 
the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected during twelve days in April in 2008 in three selected communities in 
Shijingshan district. The study was conducted by the trained researchers through face to face interview.   
3. Were there specific inclusion/exclusion criteria for all groups? No. The inclusion criteria were women over age 40. There were no exclusion criteria.  
4. Was the study population served as a probability sample? 
No. The study didn’t mention the sampling method they used. The sample was collected in three 
communities in April in 2008, it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate and inappropriate groups of participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Knowledge of HPV infection, the awareness difference among different age and education were 
provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive and bivariate statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. χ2 test was used in the data analysis.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct any multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed confounding like demographic factors, such as age, education level.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 98.4% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to correct 
controllable variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No. The researcher didn’t mention other potential bias or unmeasured confounders such as ethnicity, 
occupation and so on.  
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The quality assessment of Fan XF study (11 scores) 
 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (28-60), gender (women), and sample size (242 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? No. The study didn’t mention by whom, when, where and how the sample was collected.   
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The exclusion criteria were women who conducted hysterectomy. The inclusion criteria 
were women aged 28-60 with low medical insurance.  
4. Was the study population served as a probability sample? 
No. The study didn’t mention the sampling method they used. Little is known about how the 
sample was collected, so it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate and inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection, the risk factors of cervical cancer were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive and bivariate statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. t test was used in the data analysis.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct any multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study didn’t assess confounding like demographic factors, socio-economic factors.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 97.6% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to correct 
controllable variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No. The researcher didn’t mention other potential bias or unmeasured confounders such as 
ethnicity, occupation and so on.   
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The quality assessment of Fan BJ study (17 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (19-72), gender (women), and sample size (962 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected from January to December in 2008 in the outpatients 
department of Liaoning cancer hospital.  
3. Were there specific inclusion/exclusion criteria for all groups? No. There were no inclusion/exclusion criteria.  
4. Was the study population served as a probability sample? 
Yes. The study used random cluster sampling method. The sample was collected in one 
hospital in 2008, it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate and inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Knowledge of HPV infection, HPV vaccine, the willingness to be vaccinated were 
provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive and bivariate statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. T test was used in the data analysis.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct any multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed confounding like demographic factors, such as education level.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 96.2% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study was stratified by educational level to correct controllable variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No. The researcher didn’t mention other potential bias or unmeasured confounders such as 
ethnicity, occupation and so on.  
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The quality assessment of Feng SW study (22 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (18-50), gender (women), and sample size 
(1432participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected from March to August in 2010 in selected hospitals in 
Hangzhou and Lishui. The study was conducted by the trained researchers.   
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The inclusion criteria were women who had normal communication ability. The exclusion 
criteria were age <18 or >50, ever had cervical disease, ever had psychiatric disease and so on.  
4. Was the study population served as a probability sample? Yes. The study used cluster sampling method and it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, and 
etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection, attitude toward HPV vaccine were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
Yes. The study conducted test-retest reliability test, calculate Cronbach α when assessing the 
questionnaires. The Cronbach α was 0.87, the test-retest reliability was 0.63-0.93.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive, bivariate statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. T test, χ2 test, linear regression was used in the data analysis.  
11. Were multiple comparisons taken into consideration? 
Yes. It conducted multivariate correlation analysis to analyse education, age and economic 
status was correlated with knowledge of HPV infection. 
12. Was modelling and multivariate techniques appropriate? Yes. The multivariate correlation analysis was appropriate.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed confounding like urban/rural residence.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study N/A. The study didn’t mention how many enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study was stratified by urban/rural residence to correct controllable variables. It also 
conducted multivariate analysis to adjust demographic factors.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
Yes. The researcher mention other potential bias such as age, education and economic status 
and so on.  
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The quality assessment of Gao L et al study (17 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (30-59), gender (women), and sample size (2648 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected during five months in 2008 in Linxiang District in Yunnan. 
The sample of rural women was collected by the researchers in CDC by using questionnaires.   
3. Were there specific inclusion/exclusion criteria for all groups? 
No. The inclusion criteria were rural women who are volunteers to join in the study. There 
were no exclusion criteria.  
4. Was the study population served as a probability sample? 
No. The study didn’t mention the sampling method they used. The sample was collected in 
one district during four months in 2008, so it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
Yes. The participants were all volunteers The study didn’t report any inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Knowledge of HPV infection, the awareness difference among different ethnicity and 
education were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive and bivariate statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. Latent classes analysis and latent class model was used in the data analysis.  
11. Were multiple comparisons taken into consideration? Yes. It conducted multivariate analysis, latent classes analysis.  
12. Was modelling and multivariate techniques appropriate? Yes.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? 




15. Did at least 80% of enrolled participants complete the study N/A. The study didn’t report the percentage of enrolled participants.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study conducted stratification by ethnicity and education to correct controllable 
variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
Yes. The researcher mentioned other potential bias or unmeasured confounders such as 
ethnicity, education, age, marital status and so on.  
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The quality assessment of Guzhanuer A study (12 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described gender (men), and sample size (560 participants) of the study 
population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected during three months in 2008 in Hetian District in Xinjiang. The 
sample of men was collected through their wives who joined in the cervical screening program.   
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. The inclusion criteria were men who are husbands of women taking part in the cervical screening 
in the study. There were no exclusion criteria.  
4. Was the study population served as a probability sample? 
No. The study didn’t mention the sampling method they used. The sample was collected in one 
district during three months in 2008, so it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The participants were all volunteers. The study didn’t report any inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Knowledge of HPV infection, the awareness difference among different education were 
provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive and bivariate statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? No. The study didn’t mention any statistical analysis.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed confounding like demographic factors, such as, education level.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study N/A. The study didn’t report the percentage of enrolled participants.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study conducted stratification by education to correct controllable variables.  
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No. The researcher didn’t mention other potential bias or unmeasured confounders. 
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The quality assessment of Gulinuer A study (15 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample size 
justification)? 
Yes. The study well described the age (20-65), gender (women), and sample size (248 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected during four months in 2006 in Bozhou hospital in Xinjiang. 
The sample of women outpatients were collected by the doctors by using questionnaires.   
3. Were there specific inclusion/exclusion criteria for all groups? No. The inclusion criteria were women outpatients. There were no exclusion criteria.  
4. Was the study population served as a probability sample? 
No. The study didn’t mention the sampling method they used. The sample was collected in 
one hospital during four months in 2006, it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The participation rate was 100%. The study didn’t report any inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Knowledge of HPV infection, the awareness difference among different occupation 
and education were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive and bivariate statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. χ2 test was used in the data analysis.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct any multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? 
Yes. The study assessed confounding like demographic factors, such as occupation, 
education level.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study N/A. The study didn’t report the percentage of enrolled participants.  
16. Did the researchers correct for controllable variables to limit bias 
appropriately  
Yes. The study conducted stratification by occupation and education to correct controllable 
variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No. The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Guzhalinuer A study (10 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (23-76), gender (women), and sample size (400 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in five selected hospitals in Xinjiang. The questionnaire 
was filled by the doctors.   
3. Were there specific inclusion/exclusion criteria for all groups? No. The inclusion criteria were Uighur women. There were no exclusion criteria.  
4. Was the study population served as a probability sample? 
No. The study didn’t mention the sampling method they used. The sample was collected 
in five selected hospitals, so it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The participation rate was 100%. The study didn’t report any inappropriate groups 
of participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection, the risk factors of cervical cancer were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing 
the questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? No. The study didn’t report which statistical test was conducted in the data analysis.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct any multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? No. The study didn’t report the power calculation.  
14. Was there an assessment of confounding? 
No. The study didn’t assess confounding like demographic factors, socio-economic 
factors. .  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study N/A. The study didn’t report the percentage of enrolled participants.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No. The researcher didn’t mention other potential bias or unmeasured confounders such 
as ethnicity, occupation and so on.  
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The quality assessment of Huang GF study (14 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample size 
justification)? 
Yes. The study well described the age (20-58), gender (women), and sample size (196 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
No. The sample was collected in 2008. But the study didn’t mention where, by whom and 
how the sample was collected.  
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The inclusion criteria were women aged 20-58. The exclusion criteria were women who 
had hysterectomy, pelvic radiation therapy, who were in menstrual period and pregnancy.  
4. Was the study population served as a probability sample? 
No. The study didn’t mention the sampling method they used. The study didn’t mention 
where and how the sample was collected, so it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. The willingness of women to be vaccinated were provided 
7. Was the measurement method valid? N/A. The questions were not provided in the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive and bivariate statistical analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. χ2 test was used in the data analysis.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct any multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed confounding like demographic factors, such as age.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study N/A. The study didn’t report the percentage of enrolled participants.  
16. Did the researchers correct for controllable variables to limit bias 
appropriately  
Yes. The study conducted stratification by using different age group to correct controllable 
variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No. The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of He M study (18 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample size 
justification)? 
Yes. The study well described the age (18-82), gender (women), and sample size (9865 
women outpatients and 780 health professionals) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in 14 selected hospitals in seven regions of China from 2007 
to 2009. The questionnaire was filled in by the participants.   
3. Were there specific inclusion/exclusion criteria for all groups? No. There were no inclusion/exclusion criteria.  
4. Was the study population served as a probability sample? 
Yes. The study conducted multi-centre clinical survey to collect sample. The sample was 
collected in 14 selected hospitals, it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Knowledge of HPV infection, the willingness to be vaccinated, the appropriate age for 
vaccination were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and multivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. The study conducted descriptive analysis, χ2 test and logistic regression.  
11. Were multiple comparisons taken into consideration? Yes. It conducted multivariate analysis, such as logistic regression.  
12. Was modelling and multivariate techniques appropriate? Yes.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? 




15. Did at least 80% of enrolled participants complete the study N/A. The study didn’t report the percentage of enrolled participants.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study conducted multivariate analysis to correct controllable variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
Yes. The researcher mentioned age, education, income and sex debut as potential bias.  
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The quality assessment of He X study (17 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (16-26), gender (male and female), and sample size 
(1009 male and 1093 female students) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in two colleges. The questionnaire was filled in by the 
participants supervised by the trained researchers.   
3. Were there specific inclusion/exclusion criteria for all groups? No. There were no inclusion/exclusion criteria.  
4. Was the study population served as a probability sample? 
Yes. The study used stratified cluster sampling to collect sample. The sample was 
collected in two selected colleges, it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Knowledge of HPV infection, the way through which they get the health information 
were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. The study conducted descriptive analysis and χ2 test.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed confounding like demographic factors, such as gender.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 96.5% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study was stratified by gender to correct controllable variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders. 
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The quality assessment of Jiang SY study (19 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample size 
justification)? 
Yes. The study well described the age (20-65), gender (women), and sample size (944 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in one community of Hongkou district. The questionnaire 
was filled in by the participants supervised by the trained researchers.   
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The inclusion criteria were women aged between 20 and 65. The exclusion criteria 
were women who never had sex experience, who had hysterectomy.  
4. Was the study population served as a probability sample? 
Yes. The study used random cluster sampling to collect sample. The sample was collected 
in one community of Hongkou district, it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Awareness of HPV infection were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. The study conducted descriptive analysis and χ2 test.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? 
Yes. The study assessed confounding like screening status, stratified by screening women 
and non-screening women.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 94.4% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study was stratified by screening status to correct controllable variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders. 
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The quality assessment of Lu KN study (16 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (19-69), gender (women), and sample size (104 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected from inpatients and outpatients in three Beijing hospitals 
from September to December in 2007.  
3. Were there specific inclusion/exclusion criteria for all groups? No. There is no specific inclusion/exclusion criteria.  
4. Was the study population served as a probability sample? No. The study used convenience sampling to collect sample. It wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Awareness of HPV infection and knowledge of cervical cancer were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. The study conducted descriptive analysis and χ2 test.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? 
Yes. The study assessed confounding like educational status, stratified by high level 
education women and low level education women.  
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 94.5% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study was stratified by education status to correct controllable variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders. 
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The quality assessment of Li J 2008 study (19 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample size 
justification)? 
Yes. The study well described the age (15-54), gender (women), and sample size (1013 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in Zhanlanlu community of Beijing city from June 2006 to June 
2007. The interview-administrated questionnaire was conducted by the trained researchers.   
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The inclusion criteria were women aged between 15 and 54. The exclusion criteria. were 
women who was in pregnancy, who had hysterectomy, who had pelvic radiation therapy and etc.  
4. Was the study population served as a probability sample? 
Yes. The study used cluster sampling to collect sample. The sample was collected in one 
community of Beijing city, it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, and 
etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection, the willingness of being vaccinated were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. The study conducted descriptive analysis and χ2 test.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? 




15. Did at least 80% of enrolled participants complete the study No. The study didn’t mention what the percentage of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study was stratified by age, marriage, occupation and education to correct controllable 
variables.  
17. Did the researchers describe all potential bias or unmeasured 
confounders 
Yes.  The researcher mentioned age, marriage, occupation and education as all the potential bias.  
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The quality assessment of Li JM study (19 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (18-60), gender (women), and sample size (304 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in one community of Baoan district of Shenzhen city. The 
questionnaire was filled in by the participants.   
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The inclusion criteria were women aged between 18 and 65. The exclusion criteria. were 
women who had never sex experience, who had hysterectomy, and etc.  
4. Was the study population served as a probability sample? 
Yes. The study used random cluster sampling to collect sample. The sample was collected in 
one community of Baoan district of Shenzhen city, it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection, the risk factors of cervical cancer were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. χ2 statistical test were used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed confounding like screening status.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study 
No. The study didn’t mention what the percentage of the enrolled participants complete the 
study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study was stratified by screening status, like screening women and non-screening 
women.   
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Li XP study (11 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (20-50), gender (women), and sample size (300 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in Nanpu community of Wenzhou city. The questionnaire 
was filled in by the participants.   
3. Were there specific inclusion/exclusion criteria for all groups? No. There were no inclusion/exclusion criteria.   
4. Was the study population served as a probability sample? 
No. The study didn’t mention the sampling method. The sample was collected in one 
community of Wenzhou city, it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. The study conducted descriptive analysis and χ2 test. 
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study 
N/A. The study didn’t mention what the percentage of the enrolled participants complete 
the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
303 
 
The quality assessment of Li J 2011 study (16 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample size 
justification)? 
Yes. The study well described the age (36.5+9.6), gender (women and men), and sample 
size (160 participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in Nanpu community of Wenzhou city. The questionnaire 
was filled in by the participants.   
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The inclusion criteria were health professionals in hospitals and rural clinic, 
government officials.  There is not specific criteria to age and gender. 
4. Was the study population served as a probability sample? 
Yes. The study used convenient, cluster and random sampling method. The sample was 
collected in one city of Dalian city and one county, it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Knowledge of HPV infection, attitude and acceptability of HPV vaccines were 
provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. The study conducted descriptive analysis and χ2 test. 
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes.  90.9-94.1% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study stratified by education level to correct controllable variables. 
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Li CT et al study (17 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample size 
justification)? 
Yes. The study well described the age (20-39), gender (women), and sample size (960 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
No. The sample was collected in Tianshan community of Urumqi city. But it didn’t mention 
from which setting the sample was specifically collected and when. 
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The study included women who had normal cognition, excluded women who had 
Hysterectomy history and pelvic radiation therapy.   
4. Was the study population served as a probability sample? 
No. Cluster sampling method was used. But it didn’t mention where the sample collected. It 
wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. The study conducted descriptive analysis and χ2 test. 
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study stratified the participants by age.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study 
N/A. The study didn’t mention what the percentage of the enrolled participants complete the 
study.  
16. Did the researchers correct for controllable variables to limit bias 
appropriately  
Yes. The study conducted stratification by age to correct controllable variables. 
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Liu ZH et al study (17 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (14-18), gender (boys and girls), and sample size 
(848 participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in one high school in Xiangtan city. Five classes were 
randomly selected from three grades in the high school.  
3. Were there specific inclusion/exclusion criteria for all groups? No. There were no inclusion/exclusion criteria.   
4. Was the study population served as a probability sample? Yes. The study used stratified cluster sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study report the participation rate was 94.2%, which is a high rate.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection was provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study 
8. Was the measurement method reliable? Yes. The Cronbach α was 0.86 and the test-retest reliability was0.81.  
Data analysis 
9. Did the researchers conduct statistical testing? 
Yes. Descriptive statistical and variance analysis, multiple linear regression were 
conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. Variance analysis, multiple linear regression were used.  
11. Were multiple comparisons taken into consideration? Yes. It conducted multiple linear regression.  
12. Was modelling and multivariate techniques appropriate? Yes.  
13. Was the power calculation provided? Yes. p<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 94.2% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Long XE study (9 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (>18), gender (not speficify), and sample size (286 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
No. The sample was collected in one college. There wasn’t specific sampling frame for 
the study population 
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. There were no inclusion/exclusion criteria.   
4. Was the study population served as a probability sample? No. The study didn’t mention the sampling method, and it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection and HPV vaccine were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical was conducted in the study.  
10. Did the researchers report which statistical tests were used? No. The study didn’t report which kind of statistical test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? No. The power calculation wasn’t provided.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 90.5 of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Ma D et al 2012study (16 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (20-54), gender (women and men), and sample size 
(198 participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in one hospital of Tangshan city in May 2011 including both 
doctors and nurses. 
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. The study didn’t mention any inclusion and exclusion criteira.  
4. Was the study population served as a probability sample? 
No. The study didn’t mention the sampling method. The sample was collected in one 
hospital of Tangshan city, it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection and attitude of HPV vaccine were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? Yes. The study didn’t calculate Cronbach α when assessing the questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. The study conducted descriptive analysis and χ2 test. 
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed confounding by stratifying the sample by doctors and nurses.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
Yes. The study showed 99% of the enrolled participants completed the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study conducted stratification to correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Ma D 2010 study (18 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (16-56), gender (women), and sample size (249 participants) 
of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in one community and one hospital outpatient department of Beijing 
city. The questionnaire was filled in by the participants.   
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. The inclusion criteria were women aged 16-56. The exclusion criteria were women who had 
hysterectomy.  
4. Was the study population served as a probability sample? 
No. The study used the convenience sampling method to collect data. The sample was collected in 
one community and one hospital of Beijing city, it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? Yes. The study calculated Cronbach α when assessing the questionnaires. The Cronbach α was 0.72.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. The study conducted descriptive analysis and t test. 
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? 
Yes. The study assessed confounding by stratifying the sample by community women and women 
outpatients.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
N/A. The study didn’t mention what the percentage of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study conducted stratification to correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Ren CL et al study (15 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (18-58), gender (women), and sample size (1005 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
No. The sample was collected Malan district in Xinjiang. There wasn’t specific sampling 
frame for the study population 
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The inclusion criteria were women with normal cognition, no pregnant, no 
hysterectomy or pelvic radiation therapy.   
4. Was the study population served as a probability sample? 
No. The study mentioned where the sample was collected, but with no sampling method, 
and it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. χ2 statistical test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study No. The study didn’t mention what percentage of participants completed the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study conducted stratification by ethnicity to correct controllable variables. 
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Song D study (15 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (20-54), gender (women), and sample size (957 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
Yes. The sample was collected in one county. 5-year is defined as one group including 125 
women. 
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. The inclusion criteria were women aged 20-54, women having normal cognition, no 
pregnant, no hysterectomy or pelvic radiation therapy.   
4. Was the study population served as a probability sample? No. The study didn’t mention the sampling method, and it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, and 
etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection and attitude and acceptability of HPV vaccine were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate tests were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive test and х
2
 test were used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P≦0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assess education level and cervical cancer history as confoundings.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
Yes. 95.7 of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to correct 
controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
311 
 
The quality assessment of Sun J 2010 study (18 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (21-60), gender (women), and sample size (301 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in the outpatients department of one hospital in Dalian city 
from February to March.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. The inclusion criteria were women with normal cognition, had sexual behaviour.   
4. Was the study population served as a probability sample? No. The study used convenient sampling method, and it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection and HPV vaccine were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study 
8. Was the measurement method reliable? 
Yes. The study conducted reliability test and calculate Cronbach α which is 0.843, and 
pearson correlation is 0.831 when assessing the questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and linear regression was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. F statistical test, t test and pearson correlation was used.  
11. Were multiple comparisons taken into consideration? Yes. It conducted multivariate analysis, multivariate linear regression.  
12. Was modelling and multivariate techniques appropriate? Yes.  
13. Was the power calculation provided? Yes. P ≦0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 97.1 of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Shi YY study (19 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (20-60), gender (women), and sample size (1200 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in one hospital, one community, and two villages by using 
cluster sampling.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. The inclusion criteria were women residents who aged 20-60, had no cervix operation, 
not pregnancy, and had no pelvic radiation therapy.    
4. Was the study population served as a probability sample? Yes. The study conducted cluster sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Risk factors for cervical cancer was provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis and χ2 test were used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study identified age as the confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
Yes. 95.7%of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study stratified by age to correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Wang HQ study (17 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (20-53), gender (women), and sample size (257 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
Yes. The sample was collected from four hospitals. The participants were gynaecologists 
and obstetricians. The study didn’t mention who collected the sample.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. There were no inclusion/ exclusion criteria.    
4. Was the study population served as a probability sample? Yes. The study conducted random sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection and acceptance of HPV vaccine were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis and χ2 test were used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study identified age and education level as the confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
Yes. 85.7% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study stratified by education level correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention any other potential bias.  
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The quality assessment of Wen LZ study (11 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (22-48), gender (women), and sample size (400 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected in the outpatient department of one hospital from Jan to 
June in 2009 by researchers.  
3. Were there specific inclusion/exclusion criteria for all groups? No. There were no inclusion/ exclusion criteria.    
4. Was the study population served as a probability sample? No. The study didn’t mention the sampling method, and it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection and awareness of HPV vaccine were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study 
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing 
the questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical and bivariate analysis was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. Descriptive analysis and χ2 test were used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study 
N/A. The study didn’t mentions what was the percentage of the enrolled participants 
complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Wang QL study (12 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including 
sample size justification)? 
Yes. The study well described the age (20-70), gender (women), and sample size (886 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
Yes. The sample was collected in three counties in north mountain areas in Sichuan 
province by researchers.   
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. There were no inclusion/ exclusion criteria.    
4. Was the study population served as a probability sample? Yes. The study used cluster sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection was provided 
7. Was the measurement method valid? Yes. The questions were provided for the study and fulfil the objective of the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical was conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? No. The study didn’t mention the power calculation.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
N/A. The study didn’t mentions what was the percentage of the enrolled participants 
complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Wu Y study (15 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including 
sample size justification)? 
Yes. The study well described the age (>15), gender (women), and sample size (489 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
No. The study didn’t mention the specific sampling frame.   
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. There were no inclusion/ exclusion criteria.    
4. Was the study population served as a probability sample? Yes. The study used random sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection, the acceptance of HPV vaccine were provided 
7. Was the measurement method valid? Yes. The questions were provided for the study and fulfil the objective of the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing 
the questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis and χ2 were used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed age, education level as confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
Yes. 97.8% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study conducted stratification to correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention any other potential bias.  
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The quality assessment of Wang XM et al study (18 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including 
sample size justification)? 
Yes. The study well described the age (>25), gender (women), and sample size (2269 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
Yes. The urban women were collected from physical examination centre and rural women 
were collected from cervical screening program during July and September, 2010.   
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. The exclusion criteria were women with history of hysterectomy and pelvic radiation 
therapy.    
4. Was the study population served as a probability sample? Yes. The study used cluster sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection, the acceptance of HPV vaccine were provided 
7. Was the measurement method valid? Yes. The questions were provided for the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis and χ2 were used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed socio-economic status as confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
N/A. The study didn’t mention what percentage of participants completed the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study conducted stratification to correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention any other potential bias.  
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The quality assessment of Xiamixinuer A study (14 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (23-85), gender (women), and sample size (245 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected from inpatients department of five hospitals in Xinjiang 
province from Jan in 2004 to Jul in 2006.  
3. Were there specific inclusion/exclusion criteria for all groups? 
No. The inclusion criteria were cervical cancer inpatients aged 23-85. There were no 
exclusion criteria    
4. Was the study population served as a probability sample? No. The study didn’t mention the sampling method, and it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection and awareness of HPV vaccine were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. Descriptive analysis was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? No. The study didn’t mention the power calculation.  
14. Was there an assessment of confounding? Yes. The study assessed educational level and occupation as confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study 
N/A. The study didn’t mention what was the percentage of the enrolled participants 
complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study conducted stratification to correct controllable variables. 
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Xiao W study (15 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including 
sample size justification)? 
Yes. The study well described the age (21-74), gender (women), and sample size (368 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
Yes. The sample was collected from outpatients department in one hospital in Beijing from 
Jan to Apr in 2008.   
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. There were no inclusion/ exclusion criteria.    
4. Was the study population served as a probability sample? No. The study didn’t mention the sampling method, and it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection, the acceptance of HPV vaccine were provided 
7. Was the measurement method valid? Yes.  The questions were provided and could represent and fulfil the objectives of the study .  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis and χ2 were used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed health intervention as confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
Yes. 97.4% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study stratified by health intervention to correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention any other potential bias.  
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The quality assessment of Xing YX et al study (14 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (18-63), gender (women), and sample size (200 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
Yes. The sample was collected from Yushu district in Qinghai from June to August in 2009.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. The study didn’t have specific inclusion/exclusion criteria.   
4. Was the study population served as a probability sample? No. The study didn’t mention the sampling method.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection and cervical cancer were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical was conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis and χ2 test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed educational level as confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
N/A. The study didn’t mention what percentage of participants completed the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study used stratification to correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
321 
 
The quality assessment of Xu CY study (16 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (25-54), gender (women), and sample size (6339 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected from 137 communities of 12 districts in Beijing from Mar 
in 2007 to Sep in 2008.  
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The inclusion criteria were women residents who aged 25-54, who had no cervical 
surgery, who had no pelvic radiation therapy, who had no pregnancy.   
4. Was the study population served as a probability sample? Yes. The study used multi-stage cluster sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Risk factor of cervical cancer was provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical was conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. Descriptive analysis was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.01 is statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 99.8% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Xu LN study (20 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (15-59), gender (women), and sample size (1666 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The sample was collected from two urban districts and one rural county from Jun 
to Nov in 2009.  
3. Were there specific inclusion/exclusion criteria for all groups? Yes. The inclusion criteria were women aged 15-59 with normal cognition.    
4. Was the study population served as a probability sample? Yes. The study used cluster sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Awareness and knowledge of HPV infection and HPV vaccine, acceptance of HPV 
vaccine were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing 
the questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? 
Yes. Descriptive statistical analysis and multivariate analysis were conducted in the 
study.  
10. Did the researchers report which statistical tests were used? Yes. Descriptive analysis, χ2test, logistic regression analysis was used.  
11. Were multiple comparisons taken into consideration? Yes. It conducted multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? Yes.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed urban/rural residence as confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 96.5% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
Yes. The study was stratified by urban/rural residence to correct controllable variables. 
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Xie Y study (16 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (30-59), gender (women), and sample size (2000 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? Yes. The sample was collected from three counties in Chengdu in August of 2008.  
3. Were there specific inclusion/exclusion criteria for all groups? 
Yes. The inclusion criteria were women residents who aged 30-59, who had no cervical 
surgery, who had no pelvic radiation therapy, who had no pregnancy.  .    
4. Was the study population served as a probability sample? Yes. The study used cluster sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection was provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. Descriptive analysis, χ2test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. 99.4% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to limit 
bias appropriately  
No. The study didn’t conduct randomization or stratification to correct controllable 
variables. 
17. Did the researchers describe all potential bias or unmeasured 
confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Ye JR study (16 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including 
sample size justification)? 
Yes. The study well described the age (20-60), gender (women), and sample size (1120 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
Yes. The sample was collected from one hospital and two villages in Dalingshan County 
from Jan in 2010 to Jan in 2011.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. The inclusion criteria women, who aged 20-60 and lived in Dalingshan County more 
than three years, had no history of cervical surgery.    
4. Was the study population served as a probability sample? Yes. The study the stage cluster sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection was provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis, χ2test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
Yes. The study showed 100% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Zhang LJ study (13 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including 
sample size justification)? 
Yes. The study well described the age (18-54), gender (women), and sample size (100 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
Yes. The sample was collected from one hospital in Shenzhen from Dec in 2006 to Sep in 
2007.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. The inclusion criteria were HPV positive women, who aged 18-54. The exclusion 
criteria were women who have any mental disorders or cognitive impairment.    
4. Was the study population served as a probability sample? No. The study didn’t mention the sampling method, and it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection was provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis, χ2test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
No. The study didn’t mention what was the percentage of the enrolled participants complete 
the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias or unmeasured confounders.  
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The quality assessment of Zhao DJ study (14 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (16-54), gender (women), and sample size (997 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
Yes. The sample was collected from two communities in one district of Shanghai.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. There were no inclusion/exclusion criteria.  
4. Was the study population served as a probability sample? Yes. The study used cluster sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection and acceptance of HPV vaccine were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis, χ2test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed age, education level and occupation as confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
N/A. The study didn’t mention what was the percentage of the enrolled participants 
complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher mentioned age, education level and occupation as other potential bias.  
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The quality assessment of Zhou JY study (15 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including 
sample size justification)? 
Yes. The study well described the age (30-59), gender (women), and sample size (2000 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study 
population? 
No. The sample was collected from one district of Beijing. The study didn’t mention when 
and who conducted the sampling process.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. The inclusion criteria were women residents who aged 30-59, who had no cervical 
surgery, who had no pelvic radiation therapy, who had no pregnancy. 
4. Was the study population served as a probability sample? Yes. The study used multi-stage cluster sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or 
all-volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Knowledge of HPV infection and risk factors for cervical cancer were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis, χ2test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.01 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
Yes. 97.8% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher mentioned age, education level and occupation as other potential bias.  
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The quality assessment of Zhou LX study (15 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (16-55), gender (women), and sample size (752 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
No. The sample was collected from one community and one outpatient department of one 
hospital. The study didn’t mention when and who conducted the sampling process.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. The inclusion criteria were women residents who aged 16-55, who had no cervical 
surgery, who had no pelvic radiation therapy, who had no pregnancy. 
4. Was the study population served as a probability sample? Yes. The study used random sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, 
and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Awareness and knowledge of HPV infection and HPV vaccine were provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis, χ2test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
Yes. 96.4% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher mentioned age, education level and occupation as other potential bias.  
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The quality assessment of Zhou Y 2010 study (12 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (17-21), gender (male and female), and sample size 
(207 participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? Yes. The sample was collected from one college; the students were the freshmen in 2009.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. There were no inclusion/exclusion criteria.  
4. Was the study population served as a probability sample? No. The study didn’t mention the sampling method, and it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Awareness and knowledge of HPV infection were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis, χ2test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? No. The study didn’t assess any confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
Yes. 97.6% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization, stratification or statistical adjustment to 
correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher mentioned age, education level and occupation as other potential bias.  
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The quality assessment of Zhou Y et al 2012 study (17 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (17-25), gender (women and men), and sample size 
(2293 participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? 
Yes. The participants were collected from four grades of Nanhua university during Mar 9th 
and 11th in 2009. The researcher went to the dormitory of the university to collect data. 
3. Were there specific inclusion/exclusion criteria for all 
groups? 
Yes. There were no inclusion/exclusion criteria.  
4. Was the study population served as a probability sample? Yes. The study used random sampling method, and it was a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of 
participants, and etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? Yes. Awareness and knowledge of HPV infection were provided 
7. Was the measurement method valid? 
Yes. The questions were provided and could represent and fulfil the objectives of the 
study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were used? Yes. Descriptive analysis, χ2test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed gender and education level as the confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the study Yes. The study showed 96.3% of the enrolled participants complete the study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
Yes. The study was stratified by gender and education level to correct controllable 
variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention other potential bias.  
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The quality assessment of Zhou Y 2011 study (10 scores) 
 Questions  Reasons 
Description 
1. Was the study population well described (including sample 
size justification)? 
Yes. The study well described the age (15-59), gender (women), and sample size (500 
participants) of the study population. 
Sampling 
2. Was there specific sampling frame for the study population? No. The study didn’t mention when, where and who conducted the sampling process.  
3. Were there specific inclusion/exclusion criteria for all 
groups? 
No. There were no inclusion/exclusion criteria.  
4. Was the study population served as a probability sample? No. The study didn’t mention the sampling method, and it wasn’t a random sampling.  
5. Was there other selection bias (low participation rate, or all-
volunteer sample, or inappropriate control)? 
No. The study didn’t report any low participation rate, inappropriate groups of participants, and 
etc.  
Measurement 
6. Was the primary/ secondary outcomes clearly defined? 
Yes. Awareness and knowledge of HPV infection and acceptance of HPV vaccine were 
provided 
7. Was the measurement method valid? Yes. The questions were provided and could represent and fulfil the objectives of the study.  
8. Was the measurement method reliable? 
N/A. The study didn’t conduct reliability test or calculate Cronbach α when assessing the 
questionnaires.  
Data analysis 
9. Did the researchers conduct statistical testing? Yes. Descriptive statistical analysis and bivariate analysis were conducted in the study.  
10. Did the researchers report which statistical tests were 
used? 
Yes. Descriptive analysis, χ2test was used.  
11. Were multiple comparisons taken into consideration? No. It didn’t conduct multivariate analysis.  
12. Was modelling and multivariate techniques appropriate? N/A.  
13. Was the power calculation provided? Yes. P<0.05 was statistical significant.  
14. Was there an assessment of confounding? Yes. The study assessed occupation and education level as the confounding.   
Interpretation 
of results 
15. Did at least 80% of enrolled participants complete the 
study 
No. The study didn’t mention what was the percentage of the enrolled participants complete the 
study.  
16. Did the researchers correct for controllable variables to 
limit bias appropriately  
No. The study didn’t conduct randomization or stratification to correct controllable variables. 
17. Did the researchers describe all potential bias or 
unmeasured confounders 
No.  The researcher didn’t mention any other potential bias.  
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Appendix 4:  Questionnaire-English language 
Knowledge of and attitudes towards HPV vaccine among 
Chinese teenagers 
 
Thank you for agreeing to complete this questionnaire. Remember that this questionnaire 
is COMPLETELY CONFIDENTIAL, so please say exactly what your views are.  
  
All the questions can be answered by ticking a box. Please try to answer all questions. 
The questionnaire will be approximately 15-20 minutes to complete.  Please do NOT 
turn to the next page until you finish completing page 1. 
 
Have you ever heard of the Human Papillomavirus (HPV)? (NOTE: HPV is NOT the 
same as HIV/AIDS) 
□ Yes (please complete Section 1, below) 
□  No (please go to Section2,, on page 2) 
 
Section 1: What known about HPV infection, cervical screening and 
HPV vaccines  
Here are some statements about HPV and cervical cancer: do you think they are true 
or false? (Please tick as the example given below) 
Statement True False Don’t 
know 
About HPV infection 
HPV may cause genital warts (example)     √   
HPV may cause cervical cancer    
Most HPV infections can be cleared without treatment    
Sometimes, a HPV infection can last years without symptoms    
HPV infection can be sexually transmitted    
Condom use lowers the risk of HPV infection    
HPV is an uncommon sexually transmitted infection in China    
Poor personal hygiene can increase the risk of getting HPV infection     
Having multiple sexual partners increases the chance of getting 
cervical cancer 
   
Early age at first sexual intercourse can increase the risk of getting 
HPV infection 
   
About cervical screening 
Cervical cancer screening can effectively prevent cervical cancer    
The human papillomavirus test can identify women who are at 
increased risk of cervical cancer 
   
About HPV vaccination 
Regular cervical screening is not necessary after HPV vaccination    
HPV vaccination is 100% effective against cervical cancer    
The HPV vaccines are most useful for those who already have had sex    
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Section 2: Attitudes and Beliefs about HPV infection and acceptability of the vaccine 















Part 1: Attitude towards HPV infection and cervical cancer (Please answer the question 1 to 8, please tick one box only on each line)  
 









1 How likely is it you will get HPV infection in the future?       
2 How likely is it you will get cervical cancer in the future (female only)?      









3 If I had an HPV infection, it would have a serious impact on my physical health      
4 If I had an HPV infection, it would be disruptive to my social life      
5 If I had an HPV infection, it would be disruptive to my sexual relationship(s)      
6 If I had cervical cancer, it would have a serious impact on my physical health (female only)      
7 If I had cervical cancer, it would be disruptive to my social life (female only)      
8 If I had cervical cancer, it would be disruptive to my sexual relationship(s) (female only)      
 
 Human papillomavirus (HPV) is a common infection. It gets the name because it can cause papillomatosis in skin or mucosa, such as common warts or 
genital warts and has nothing to do with nipple or breast. People can get HPV infection by sexual activity or by skin-to-skin contact. Both men and 
women could be infected with HPV.  
 HPV infection is very common among young men and women, but 70 percent of infections will be get rid of by their own immune system in 1 year. 5-
10 percent of infected women are at risk of developing cervical cancer. Cervical cancer is a common female cancer - each year there are over 75,000 
new cases in China.   
 The risk factors for cervical cancer are multiple sexual partners, having sexual activity at early age, early pregnancy, multiple pregnancies, smoking, 
and long term use of oral contraceptives. The protective factors are cervical screening, vaccination, and condom use. 
 HPV vaccines are available and help to improve the body’s ability to fight HPV infections, and ultimately prevent some cervical cancers  
 The best suitable people to receive the HPV vaccines are teenagers who are never been exposed to HPV infections 
 prevent some cervical cancers and genital warts.  
 The most suitable people to receive the HPV vaccines are teenagers who are never been exposed to HPV infections 
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Part 2: Attitude towards HPV vaccination (Please answer the question 9 to 24, please tick one box only on each line. Please think carefully before 
answering the following questions) 









9 How likely is it you would accept an offer of vaccination against HPV infection and cervical 
cancer if the vaccine was offered to you now 
     









10 If someone is vaccinated with HPV vaccine, this will help them avoid HPV infection      
11 If someone is vaccinated with HPV vaccine, this will help them avoid cervical cancer       
12 If I have a HPV vaccination, it is no longer necessary to be screened for cervical cancer (female 
only) 
     
13 If I have a HPV vaccination, it may be appropriate to have less frequent screening for cervical 
cancer (female only) 
     
14 Having an HPV vaccination may lead to people having more sexual partners as they think their 
risk of disease is reduced 
     
15 I am concerned that HPV vaccines have not been proved effective in prevention of HPV and 
cervical cancer 
     
16 I am concerned that HPV vaccines may have side effects such as fatigue or fever.       
17 I am concerned that HPV vaccines may have major side effects such as long term illness.      
18 I am worried that the HPV vaccine costs too much (CNY￥2000) and I don’t want to pay such a 
high cost for the vaccine 
     
19 I trust the companies that make HPV vaccines      
20 I would get vaccinated if my friends  recommend me to do so      
21 I would get vaccinated if my parents recommend me to do so      
22 I would get vaccinated if doctors or nurses recommend me to do so      
23 I would get vaccinated if there is a school requirement for me to be vaccinated      
24 I would get vaccinated if public service ads on TV or internet recommend it      
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Part 3 Attitudes towards those with HPV infection  
 
24. People will think that someone who is infected with HPV is a person who is 
promiscuous 
Strongly disagree   somewhat disagree    somewhat agree     strongly agree   unsure     
      □                □              □              □          □ 
25. If someone has HPV infection, people will gossip 
Strongly disagree   somewhat disagree    somewhat agree     strongly agree   unsure     
 □                □              □              □          □ 
26. People are infected because they or their partners have been unfaithful 
Strongly disagree   somewhat disagree    somewhat agree     strongly agree   unsure     
      □                  □                   □                □            □ 
27. One should keep a social distance from those who are infected with HPV 
Strongly disagree   somewhat disagree   somewhat agree     strongly agree       unsure     
      □                  □                   □                □            □ 
Section 3:  Questions about you (Please remember all your answers are 
CONFIDENTIAL. We will not share your response with others) 
1. What is your gender?   
□ Male □ Female 
2. What is your age? 
            _________ 
3. Which school are you studying? 
□ Mudanjiang No.1 high school □ Mudanjiang No. 2 high school 
□ Mudanjiang No.3 high school □ Ning’an high school
□ Hailin high school 
4. Where do you live? 
□ city                         □ countryside 
5. Which of the following best describes you?  
 
PLEASE TICK ONE BOX ONLY 
I have never tried smoking    □ 
I have only tried smoking once or twice  □ 
I used to smoke but I have given up  □  
I smoke some days    □ 
I smoke every day     □ 
 
Thank you very much for taking part in the questionnaire survey and your answers are 
kept strictly CONFIDENTIAL! 
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Appendix 5:  Questionnaire- Chinese language 
 







你听说过人乳头瘤病毒吗 (HPV)? （请勿将 HPV 与 HIV 混淆，HIV 是艾滋病毒） 
□ 听说过 （请继续回答第一部分内容） 





有关知识问题 对 错 不知道 
关于人乳头瘤病毒（HPV） 
人乳头瘤病毒（HPV）可导致生殖器疣 (范例)     √   
人乳头瘤病毒（HPV）可导致宫颈癌    
大多数人乳头瘤病毒（HPV）感染，在没有治疗的情况下
可自行消退 
   
有时，人乳头瘤病毒（HPV）可无症状持续数年    
人乳头瘤病毒（HPV）可通过性途径传播    
使用避孕套可降低感染人乳头瘤病毒（HPV）的风险    
人乳头瘤病毒（HPV）在中国是非常少见的性传播疾病    
不良的个人卫生习惯可增加感染人乳头瘤病毒（HPV）的
风险 
    
拥有多个性伴侣将增加患宫颈癌的机会    
过早的开始性生活可增加感染人乳头瘤病毒（HPV）的风
险 
   
关于宫颈癌筛查 
宫颈癌筛查可有效的预防宫颈癌发生    
人乳头瘤病毒（HPV）测试能够识别处于患宫颈癌危险性
较高的妇女 




   
人乳头瘤病毒（HPV） 疫苗对预防宫颈癌 100% 有效    
人乳头瘤病毒（HPV）疫苗对已经有过性行为的人最有效    

















1 关于 HPV 感染的态度 
 (请回答 1-8 单选题，每题选择一个最适合的答案) 
 题目 非常不可能 不可能 可能 非常可能 不确定 
1 与同龄人相比，你将来感染 HPV 的可能性有多大？      
2 与同龄人相比，你将来患宫颈癌的可能性有多大？（女生回答）      
 你是否同意以下说法 非常不同意 不同意 同意 非常同意 不确定 
3 如果我感染了 HPV，它对我的健康危害很大      
4 如果我感染了 HPV，它将很大的影响我的社交生活      
5 如果我感染了 HPV，它将很大的影响我与性伴侣的关系      
6 如果我患宫颈癌，它对我的健康危害很大（女生回答）      
7 如果我患宫颈癌，它将很大的影响我的社交生活（女生回答）      
8 如果我患宫颈癌，它将很大的影响我与性伴侣的关系（女生回答）      
 人乳头瘤病毒（HPV）是常见的病毒感染，其得名是由于 HPV 可导致皮肤或粘膜的乳头状瘤样增生，如寻常疣（俗称瘊子）
和生殖器疣，与人的乳头或乳腺无关。HPV 可通过性，皮肤接触等途径传播。男性和女性都有可能无症状感染 HPV。 
 HPV 感染在年轻的男性和女性中非常常见，但 70%感染者在 1 年内可通过自身免疫清除病毒。5-10%的 HPV 长期感染者将有
可能患宫颈癌。宫颈癌是常见的女性肿瘤，每年中国有超过 75,000 新发病例。 
 感染 HPV 及患宫颈癌的危险因素有：过早性生活，多个性伴侣，早育，多产，吸烟，长期口服避孕药等。其保护因素有：接
种疫苗，使用避孕套，进行宫颈癌筛查。 
 HPV 疫苗已研制出来，可帮助机体对抗 HPV 感染，预防宫颈癌和生殖器疣。 
 HPV 疫苗最适宜的接种对象是那些没有感染 HPV 的青少年。 
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2 关于 HPV 疫苗的态度 
  
(请回答 9-24 单选题， 每题选择一个最适合的答案，在您回答前请仔细思考) 
 
 题目 非常不可能 不可能 可能 非常可能 不确定 
9 如果现在有 HPV 疫苗预防人乳头瘤病毒（HPV）感染和宫颈癌，你打
算接种 HPV 疫苗的可能性有多大 
     
 你是否同意以下说法 非常不同意 不同意 同意 非常同意 不确定 
10 如果有人接种 HPV 疫苗，那可帮助他/她预防 HPV 感染      
11 如果有人接种 HPV 疫苗，那可帮助她预防宫颈癌      
12 如果我接种 HPV 疫苗，就没有必要进行宫颈癌筛查      
13 如果我接种 HPV 疫苗，有必要减少宫颈癌筛查的次数      
14 接种 HPV 疫苗会使人们拥有更多的性伴侣，因为大家认为患病（HPV
感染及宫颈癌）风险降低了 
     
15 我担心 HPV 疫苗在预防 HPV 感染和宫颈癌方面不是十分有效      
16 我担心 HPV 疫苗有轻微的副作用，如疲劳或发烧       
17 我担心 HPV 疫苗有严重的副作用，如长期患病      
18 HPV 疫苗太贵（约 2000元人民币），我不想负担高额费用去接种疫苗      
19 我信任生产疫苗的公司      
20 如果我的朋友建议我接种疫苗，我会去接种      
21 如果我的父母建议我接种疫苗，我会去接种      
22 如果医生或护士建议我接种疫苗，我会去接种      
23 如果学校有要求接种此疫苗，我会去接种      
24 如果电视或者网络上的公益广告建议我接种疫苗，我会去接种      
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3 对感染人乳头瘤病毒（HPV）的态度  
26. 人们会认为 HPV 感染者是性行为不检点的人 
非常不同意              不同意              同意                  非常同意          不确定 
     □                □          □           □           □ 
27. 如果有人感染 HPV 病毒，别人会说闲话 
非常不同意              不同意              同意                  非常同意          不确定 
     □                □         □           □           □ 
28. 被感染 HPV 的人，是因为他自己或者性伴侣不忠诚 
非常不同意              不同意              同意                  非常同意           不确定 
     □                □          □          □           □ 
29. 最好对 HPV 感染者保持距离  
非常不同意              不同意              同意                  非常同意           不确定 
     □                □          □          □           □ 
第三部分: 关于你的问题 
1. 你的性别是? 
□ 男性 □ 女性 
 
2. 你的年龄是?  _____________         
 
3. 你吸烟吗? 
□ 从来不吸  □ 有时候吸烟




□ 牡丹江市第一中学  □ 牡丹江市第二中学
□ 牡丹江市第三中学                                     □ 宁安市高级中学
□ 海林市高级中学
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Appendix 6:  Ethical approval in China-Chinese language 
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Invitation to take part in a questionnaire survey 
 
Knowledge of and attitudes towards HPV vaccine among 
Chinese teenagers 
 
You are being invited to take part in a research study that I’m carrying out as part of my PhD 
studies at the University of Edinburgh in the United Kingdom.  
 
My project is looking at issues relating to the potential future introduction of the HPV 
vaccine among teenagers in China (HPV stands for Human Papillomavirus: it is linked to 
different types of cancers, and a vaccine has been developed to protect people from this 
virus).  
 
I am in China from April to May 2013 to try to better understand the awareness and attitudes 
of teenagers like you in Heilongjiang province towards the HPV vaccine. I am asking you to 
complete a short questionnaire. Your responses will help influence decisions about the future 
introduction of the HPV vaccine in China.  
 
Everyone’s responses will be anonymous. You are asked to give answers to the questions in 
the questionnaire by yourself. No one will know what your responses are. We want to find 
out the honest views of people your age, even if you think you don’t know much about HPV. 
 
Your participation in this survey is voluntary and you may stop your participation at any 
time. The questionnaire will take about 15-20 minutes to fill out, and would be completed 
during a self-study course in your class. All information in the questionnaires will remain 
completely confidential. 
 
Please read the information sheet for further information, and if you are willing to help 





DU WANG, PhD Student 
Centre for Population Health Sciences, University of Edinburgh 
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这项研究是探讨为中国青少年引进 HPV 疫苗的可行性（HPV 是人乳头瘤病毒，目前
已有疫苗可以用来预防这种病毒的感染）。 
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Information sheet for questionnaire survey 




You have been invited to take part in a research study. Before you decide whether or not to 
take part, please read this information sheet carefully as it explains the purpose of the study 
and what we’d be asking you to do if you agree to take part. You may talk to others about the 
study if you wish. Please ask the researcher Du Wang if there is anything that is not clear, or 
if you would like more information.  
 
What is the purpose of the study? 
Ms Du Wang is a PhD student at the Centre for Population Health Sciences at the University 
of Edinburgh. , is examining issues relating to the potential future introduction of the HPV 
vaccine among teenagers in China (the Human Papillomavirus vaccine can protect against 
many cases of cervical cancer). One part of the project is a questionnaire survey among 
teenagers in China to try to better understand the awareness and attitudes of teenagers 
towards the HPV vaccine: this questionnaire survey is being carried out in the spring of 2013.  
The questions are similar to those used in other surveys in China, and among teenagers in 
other countries. The results of the survey will give valuable information about introducing 
the HPV vaccine in China: help draft the materials to initiate health educational campaigns 
on HPV vaccines that best meets the information needs of young people in China.   
 
Why have I been invited? 
Adolescents aged from 15-18 years old in Mudanjiang city and Ning’an and Hailin County 
in Heilongjiang province are being asked to take part. You are a student at a high school in 
these three regions of Heilongjiang province where this study is being conducted and so you 
are invited to take part.  
 
What will happen to me if I take part in? 
The study will be conducted at your school by the researcher, Du Wang. Du Wang will 
explain in class why and how she will conduct the survey and what you are expected to do. 
You will be given an invitation letter with this information sheet. Please read these: if you 
want you can discuss them with your parents or family if you want to take part in the survey. 
Two or three days later Du Wang will visit your school again. In a self-study course, if you 
consent to participate, you will be given a questionnaire to complete (expected to take 15-20 
minutes). The whole process will be kept completely anonymous. You’ll be asked to put 
your completed questionnaire into a box so that nobody can see how you respond to the 
questions. Because the questionnaire is anonymous, your personal information will not be 
known by others. You are able to withdraw from the study at any time without giving a 
reason. Du Wang will stay in the classroom to ensure students are able to complete the 
questionnaire in silence. 
 
The questions in the questionnaire comprise three sections:  
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 section 1, knowledge of HPV infection and vaccines (questions asked like “what are the 
risk factors of HPV infection?” and etc.)  
 section 2, attitudes towards HPV infection and vaccines (questions asked like “how 
likely is it you will get HPV infection in the future?” etc.) 
 section 3, background characteristics. (questions include age, gender, regional 
characteristic of schools and self-reported lifestyle) 
 
Are any medicines or treatments involved in this study? 
No, this is simply a questionnaire study where we will ask for your knowledge and attitude 
of HPV vaccination. 
 
What are the possible risks of taking part in? 
There are no risks to taking part. Your responses will be kept completely confidential, and 
will not be shared with other students or school staff.  Nobody will know how you respond 
to any of the questions. 
 
What are the possible benefits of taking part in? 
There are no direct benefits to you in taking part. However, your answers will help health 
workers to better understand the awareness and attitudes of teenagers, and help shape health 
education and health promotion about the HPV vaccine for teenagers in China in the future.  
 
Will my taking part in the study be kept confidential? 
Yes. Your teacher and classmates will know if you take part in the survey, but all your 
responses in the questionnaire will be kept confidential. Because while you are completing 
the questionnaire, the researcher will stay in the classroom to ensure that participants will not 
look across other participants’ form or chat with other students around. Once you finish your 
questionnaire, you will put your completed questionnaire into a box so that the head teacher, 
your classmates and researcher will not know how you respond in the questionnaire.  
 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time. If you do withdraw, we will use the 
information already collected up to that point only with your consent. If you do not consent, 
we will destroy the questionnaire received from you.  
 
Who is carrying out this study? 
This study is being undertaken as part of a PhD research project for Ms DU WANG at The 
University of Edinburgh’s Centre for Population Health Sciences (contact details below).  
 
What should I do now? 
If you decide that you would like to take part in this study, please fill in the consent form and 
return it to the researcher when she visits your class again.  
 
I want to know more about the study before I decide 
If you would like more information about the study, you can speak to Ms DU WANG who is 
responsible for the study. Mobile: 13810186592 or duwang84@gmail.com or D.Wang-
8@sms.ed.ac.uk   
 
WE WILL ADD THE CONTACT DETAILS OF A NOMINATED PERSON FROM 
MUDANJIANG MEDICAL UNIVERSITY 
 
THANKS FOR READING THIS INFORMATION SHEET 
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关于 HPV 疫苗的知识和态度，此研究将在 2013 年春天开展。调查的结果将会为中国
引进 HPV 疫苗提供宝贵信息。 
 
为什么我要参加? 






















影响 HPV 疫苗接种的影响因素，从而帮助我们更好的设计并实施学校的健康教育。  
 
 






















duwant84@gmail.com or D.Wang-8@sms.ed.ac.uk。 
 
 
 
非常感谢您阅读此信息卡！ 
 
 
 
